: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

C49 + CC Journal Club

For more information, please refer to our special emails from April 13 and May 19.

Bladder Cancer, January 2024
Free Subscription

Abstracts
Retrieve all available abstracts of the following 3153 articles:
HTML format

Single Articles

GRIVAS P, Koshkin VS, Chu X, Cole S, et al
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
Eur Urol Oncol. 2023 Dec 27:S2588-9311(23)00288.
Abstract

WANG T, Ding G, Wang X, Cui Y, et al
Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy.
Arch Med Res. 2023;55:102927.
Abstract

LIU P, Cai L, Yu R, Cao Q, et al
Significance of Normalized Apparent Diffusion Coefficient in the Vesical Imaging-Reporting and Data System for Diagnosing Muscle-Invasive Bladder Cancer.
J Magn Reson Imaging. 2023 Dec 28. doi: 10.1002/jmri.29208.
Abstract

ELBAEK SK, Andreasen TG, Taber A, Young-Halvorsen K, et al
Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer.
Eur Urol Open Sci. 2023;58:37-46.
Abstract

Retraction: Kinesin family member 3A stimulates cell proliferation, migration, and invasion of bladder cancer cells in vitro and in vivo.
FEBS Open Bio. 2023 Dec 27. doi: 10.1002/2211-5463.13756.
Abstract

XIA Y, Liu X, Ma B, Huang T, et al
Development and validation of a novel nomogram model for predicting the survival of patients with T2-4a, N0-x, M0 bladder cancer: a retrospective cohort study.
Am J Clin Exp Urol. 2023;11:500-515.
Abstract

SHATKOVSKAYA O, Kaidarova D, Ongarbayev B, Sagi M, et al
Five-year overall survival of patients with advanced bladder cancer in Kazakhstan: OSURK registry study.
Am J Clin Exp Urol. 2023;11:542-548.
Abstract

SHIN JH, An JH, Park SM, Lim GH, et al
Changes in Urinary Exosomal Nuclear Matrix Protein-22 in Dogs With Urothelial Carcinoma: A Pilot Study.
In Vivo. 2024;38:190-195.
Abstract

CHEN YH, Chen CT, Wu HP
Effect of Danshen for improving clinical outcomes in patients with bladder cancer: a retrospective, population-based study.
Front Pharmacol. 2023;14:1260683.
Abstract

ZHANG N, Qu X, Zhang X, Sun X, et al
Immunotherapy-Induced Hypophysitis Following Treatment With Tislelizumab in an Elderly Patient With Bladder Cancer and Prostate Cancer: A Case Report.
Cureus. 2023;15:e51015.
Abstract

NAM W, Chae HK, Jung Y, Kang H, et al
HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer.
Front Immunol. 2023;14:1301510.
Abstract

PFISTER C, Gravis G, Flechon A, Chevreau C, et al
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Lancet Oncol. 2023 Dec 21:S1470-2045(23)00587.
Abstract

MERTENS LS, van der Heijden MS
Accelerating neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Lancet Oncol. 2023 Dec 21:S1470-2045(23)00626.
Abstract

KALWA PL, Walz S, Granai M, Fend F, et al
Differentiation of bladder cancer with water flow elastography (WaFE).
J Mech Behav Biomed Mater. 2023;150:106319.
Abstract

ZAMEER U, Shaikh W
A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval.
Tumori. 2023 Dec 23:3008916231221508. doi: 10.1177/03008916231221508.
Abstract

WANG X, Liu M, Stevinson C, Dai YB, et al
Effect of a Single Light-intensity Walking Session on Sleep Quality of Patients with Bladder Cancer: A Randomized Cross-Over Study.
Semin Oncol Nurs. 2023 Dec 22:151571. doi: 10.1016/j.soncn.2023.151571.
Abstract

LOZAR T, Wang W, Gavrielatou N, Christensen L, et al
Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review.
Viruses. 2023;15:2320.
Abstract

MARCHENKO IV, Trushina DB
Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems.
Pharmaceutics. 2023;15:2724.
Abstract

SILVA A, Felix A, Cerqueira M, Goncalves CS, et al
Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer.
Pharmaceutics. 2023;15:2688.
Abstract

KUAN FC, Li JM, Huang YC, Chang SF, et al
Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial-Mesenchymal Transition and Stemness Properties.
Int J Mol Sci. 2023;24:17610.
Abstract

VIEIRA DE SOUSA T, Guedes de Pinho P, Pinto J
Metabolomic Signatures of Treatment Response in Bladder Cancer.
Int J Mol Sci. 2023;24:17543.
Abstract

ALONSO JCC, de Souza BR, Reis IB, de Arruda Camargo GC, et al
OncoTherad((R)) (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway.
Int J Mol Sci. 2023;24:17535.
Abstract

RUSSO P, Marino F, Rossi F, Bizzarri FP, et al
Is Systemic Immune-Inflammation Index a Real Non-Invasive Biomarker to Predict Oncological Outcomes in Patients Eligible for Radical Cystectomy?
Medicina (Kaunas). 2023;59:2063.
Abstract

MASTROIANNI R, Iannuzzi A, Ragusa A, Tuderti G, et al
Health Related Quality of Life in Patients with Bladder Cancer Receiving a Radical Cystectomy.
Cancers (Basel). 2023;15:5830.
Abstract

SCHEIPNER L, Zurl H, Altziebler JV, Pichler GP, et al
Charlson-Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023;15:5770.
Abstract

YE Y, Luo Z, Qiu Z, Cao K, et al
Radiomics Prediction of Muscle Invasion in Bladder Cancer Using Semi-Automatic Lesion Segmentation of MRI Compared with Manual Segmentation.
Bioengineering (Basel). 2023;10:1355.
Abstract

LONE Z, Benidir T, Wood A, Campbell RA, et al
Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology.
Urol Oncol. 2023 Dec 21:S1078-1439(23)00471.
Abstract

HOUSSIAU H, Pairet G, Dano H, Seront E, et al
The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy.
Curr Oncol. 2023;30:10550-10555.
Abstract

RAN S, Yang J, Hu J, Fang L, et al
Identifying Optimal Candidates for Trimodality Therapy among Nonmetastatic Muscle-Invasive Bladder Cancer Patients.
Curr Oncol. 2023;30:10166-10178.
Abstract

BISWAS A, Sahoo S, Riedlinger GM, Ghodoussipour S, et al
Transcriptional state dynamics lead to heterogeneity and adaptive tumor evolution in urothelial bladder carcinoma.
Commun Biol. 2023;6:1292.
Abstract

HEIDRICH V, Mariotti ACH, Inoue LT, Coser EM, et al
The bladder microbiota is not significantly altered by intravesical BCG therapy.
Urol Oncol. 2024;42:22.
Abstract

YE J, Chen Z, Pan Y, Liao X, et al
The Prognostic Value of Preoperative Naples Prognostic Score in Upper Tract Urothelial Carcinoma Patients after Radical Nephroureterectomy.
Nutr Cancer. 2024;76:80-88.
Abstract

MCELREE IM, Belzer A, Mott SL, Packiam VT, et al
Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma.
Urol Oncol. 2024;42:20.
Abstract

ARON M, Chandrashekar DS, Canete-Portillo S, Brimo F, et al
Nested and Large Nested Subtypes of Urothelial Carcinoma of the Upper Urinary Tract: A Multi-institutional Study.
Mod Pathol. 2023;36:100333.
Abstract

JACOB JM, Woldu SL, Linehan J, Labbate C, et al
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors.
Urol Oncol. 2024;42:20.
Abstract

LIU C, Cong Y, Chen L, Lv F, et al
Hsa_circ_0001583 fuels bladder cancer metastasis by promoting staphylococcal nuclease and tudor domain containing 1-mediated MicroRNA decay.
Neoplasia. 2024;47:100963.
Abstract

POMPA IR, Qi D, Ghosh A, Goldberg SI, et al
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States.
Bladder Cancer. 2023;9:345-353.
Abstract

WANG EY, Armas-Phan M, Meng MV, Loeb S, et al
Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life.
Bladder Cancer. 2023;9:323-326.
Abstract

YONESE I, Numao N, Inamura K, Yoneoka Y, et al
A case of neoadjuvant chemotherapy-resistant muscle-invasive bladder cancer that markedly responded to pembrolizumab before conversion radical cystectomy.
IJU Case Rep. 2023;7:64-67.
Abstract

AOKI T, Furuya R, Fukasawa M, Nozawa M, et al
Bladder cancer with urinary diversion by a sigmoid colon conduit after transverse colon stoma.
IJU Case Rep. 2023;7:46-49.
Abstract

GHOSH I, Dey Ghosh R, Mukhopadhyay S
Identification of genes associated with gall bladder cell carcinogenesis: Implications in targeted therapy of gall bladder cancer.
World J Gastrointest Oncol. 2023;15:2053-2063.
Abstract

MA J, Hu J, Zhao L, Wu Z, et al
Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment.
BMC Urol. 2024;24:6.
Abstract

CHEN X, Feng X, Chen Y, Huang F, et al
CT findings and clinical characteristics in distinguishing renal urothelial carcinoma mimicking renal cell carcinoma from clear cell renal cell carcinoma.
BMC Urol. 2024;24:4.
Abstract

CHATTERJEE D, Mou SI, Sultana T, Hosen MI, et al
Identification and validation of prognostic signature genes of bladder cancer by integrating methylation and transcriptomic analysis.
Sci Rep. 2024;14:368.
Abstract

NUNES SP, Morales L, Rubio C, Munera-Maravilla E, et al
Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer.
Cell Death Discov. 2024;10:1.
Abstract

HUANG G, Xiong H, Li S, Zhu Y, et al
The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis.
J Cancer Res Clin Oncol. 2024;150:5.
Abstract

SHAH D, Young K
Exploring Pembrolizumab-Induced Myocarditis, Myositis, and Myasthenia Gravis: A Comprehensive Literature Review and Case Presentation on Bladder Cancer.
Cureus. 2023;15:e49867.
Abstract

PENG T, Xiong K, He Z, Cheng S, et al
Acyl-coenzyme A: cholesterol acyltransferase inhibitor avasimibe suppresses tumorigenesis and induces G1-phase cell-cycle arrest by activating PPARgamma signaling pathway in bladder cancer.
J Cancer. 2024;15:370-382.
Abstract

ZHAO Y, Lin S, Zeng W, Lin X, et al
JS-K activates G2/M checkpoints through the DNA damage response and induces autophagy via CAMKKbeta/AMPKalpha/mTOR pathway in bladder cancer cells.
J Cancer. 2024;15:343-355.
Abstract

TAN M, Pan Q, Yu C, Zhai X, et al
PIGT promotes cell growth, glycolysis, and metastasis in bladder cancer by modulating GLUT1 glycosylation and membrane trafficking.
J Transl Med. 2024;22:5.
Abstract

GAO HY, Liu GJ, Qiu YR
Siglec-15 regulates cell proliferation, migration and invasion in bladder cancer.
Asian J Surg. 2024 Jan 1:S1015-9584(23)02105.
Abstract

UM PK, Praharaj M, Lombardo KA, Yoshida T, et al
Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist.
bioRxiv. 2023 Dec 15:2023.12.15.571740. doi: 10.1101/2023.12.15.571740.
Abstract

PALMBOS P, Wang Y, Jerome N, Kelleher A, et al
TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesion.
Res Sq. 2023 Dec 12:rs.3.rs-3697712. doi: 10.21203/rs.3.rs-3697712.
Abstract

FURUYA H, Sakatani T, Tanaka S, Murakami K, et al
Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms.
J Transl Med. 2024;22:8.
Abstract

LU M, Li Y, Hu D, Yu J, et al
Hepatoid adenocarcinoma in ureter with next-generation sequencing: A case report and literature review.
BMC Med Genomics. 2024;17:7.
Abstract

WEI W, Liu K, Huang X, Tian S, et al
EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance.
J Exp Clin Cancer Res. 2024;43:2.
Abstract

FENG Y, Huang Z, Song L, Li N, et al
PDE3B regulates KRT6B and increases the sensitivity of bladder cancer cells to copper ionophores.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jan 2. doi: 10.1007/s00210-023-02928.
Abstract

LIU J, Gao Y, Song C, Liao W, et al
Immunotherapeutic prospects and progress in bladder cancer.
J Cell Mol Med. 2024 Jan 2. doi: 10.1111/jcmm.18101.
Abstract

WEI Y, Zhuang Y, Zhang Y, Luo L, et al
Role of heat shock protein 70 in silibinin-induced apoptosis in bladder cancer.
J Cancer. 2024;15:79-89.
Abstract

TANG D, Yan Y, Li Y, Li Y, et al
Targeting DAD1 gene with CRISPR-Cas9 system transmucosally delivered by fluorinated polylysine nanoparticles for bladder cancer intravesical gene therapy.
Theranostics. 2024;14:203-219.
Abstract

PYUN JH, Son NH, Ko YH, Kim SW, et al
The Long-Term Impact of 5-alpha Reductase Inhibitors on the Development of Bladder Cancer and the Need for Radical Cystectomy: A Nationwide Observational Study.
World J Mens Health. 2024 Jan 2. doi: 10.5534/wjmh.230137.
Abstract

YAO Z, Yang H, Liu X, Jiang M, et al
Preliminary study on the role of the CSMD2 gene in bladder cancer.
Heliyon. 2023;10:e22593.
Abstract

LIM KY, Chu K, Rajarubendra N, Huang J, et al
Patterns of chemotherapy use in muscle-invasive bladder cancer in a tertiary centre.
Bladder (San Franc). 2023;10:e21200013.
Abstract

LI J, Liu J, Wang H, Ma J, et al
Single-cell analyses EMP1 as a marker of the ratio of M1/M2 macrophages is associated with EMT, immune infiltration, and prognosis in bladder cancer.
Bladder (San Franc). 2023;10:e21200011.
Abstract

FERNANDES CN, Vale L, Sousa JV, Lopes TA, et al
Surgeon experience in second-look transurethral resection of bladder cancer - a prospective study.
Actas Urol Esp (Engl Ed). 2023 Dec 29:S2173-5786(23)00143.
Abstract

KITAMURA K, Nonami T, Muto S, Horie S, et al
Small cell bladder carcinoma treated with nivolumab as adjuvant maintenance therapy.
BMJ Case Rep. 2023;16:e257402.
Abstract

OMER ME, Mustafa M, Ali N, Abd Rahman NH, et al
Non-Mixture Cure Model Estimation in Bladder Cancer Patients: A Novel Approach with Exponentiated Weibull Exponential Distribution.
Asian Pac J Cancer Prev. 2023;24:4167-4177.
Abstract

GAO Z, Qi N, Qin X, Li Z, et al
The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single-center study based on propensity score matching.
Cancer Med. 2023;12:22071-22080.
Abstract

ZHANG C, Huang MN, Shan JQ, Hu ZJ, et al
Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells.
Biochem Biophys Res Commun. 2024;691:149314.
Abstract

NAKAMOTO T, Yoshida T, Katayama S, Ohe C, et al
ASO Visual Abstract: Development and Validation of a Preoperative Nomogram for Endoscopic Management Decision Making in Upper Urinary Tract Urothelial Carcinoma.
Ann Surg Oncol. 2024;31:1416-1417.
Abstract

SHI K, Zhou J, Li M, Yan W, et al
Pan-cancer analysis of PLAU indicates its potential prognostic value and correlation with neutrophil infiltration in BLCA.
Biochim Biophys Acta Mol Basis Dis. 2024;1870:166965.
Abstract

CHEN J, Tang Y, Liu H, Sun G, et al
The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response.
Cancer Med. 2023;12:22370-22380.
Abstract

GRIVAS P, Grande E, Davis ID, Moon HH, et al
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
ESMO Open. 2023;8:102050.
Abstract

NAKAMOTO T, Yoshida T
ASO Author Reflections: Endoscopic Management of Upper Urinary Tract Urothelial Carcinoma: A Preoperative Nomogram.
Ann Surg Oncol. 2024;31:1412-1413.
Abstract

NAKAMOTO T, Yoshida T, Katayama S, Ohe C, et al
Development and Validation of a Preoperative Nomogram for Endoscopic Management Decision Making in Upper Urinary Tract Urothelial Carcinoma.
Ann Surg Oncol. 2024;31:1393-1401.
Abstract

MORIZANE S, Nakane K, Tanaka T, Zennami K, et al
Comparison of perioperative outcomes and complications between intracorporeal, extracorporeal, and hybrid ileal conduit urinary diversion during robot-assisted radical cystectomy: a comparative propensity score-matched analysis from nationwide multi-i
Int J Clin Oncol. 2024;29:64-71.
Abstract

KAGAWA H, Urabe F, Kiuchi Y, Katsumi K, et al
Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study.
Int J Clin Oncol. 2024;29:55-63.
Abstract

DING M, Liu Z, Li W, Wang T, et al
Robot-assisted partial cystectomy for the treatment of inflammatory myofibroblastic tumor of urinary bladder: A case report.
Asian J Surg. 2024;47:681-682.
Abstract

VANDENBUSSCHE CJ, Heaney CD, Kates M, Hooks JJ, et al
Urinary IL-6 and IL-8 as predictive markers in bladder urothelial carcinoma: A pilot study.
Cancer Cytopathol. 2024;132:50-59.
Abstract

ZHOU H, Pan Y, Xu M, Wang S, et al
Intracavitary Chemotherapy after kidney-Sparing Therapy for Upper Tract Urothelial Carcinoma: A Meta-Analysis.
Urol J. 2023;20:369-378.
Abstract

LUO Z, Jiao B, Zhao H, Huang T, et al
Comparison of different prediction tools for the risk of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a propensity-matched analysis.
Clin Transl Oncol. 2024;26:136-146.
Abstract

KAO CC, Lai CR, Lin YH, Chen TM, et al
GW4064 inhibits migration and invasion through cathepsin B and MMP2 downregulation in human bladder cancer.
Chem Biol Interact. 2024 Jan 10:110869. doi: 10.1016/j.cbi.2024.110869.
Abstract

WANG H, Liu J, Tang R, Hu J, et al
Deciphering the significance of anoikis in bladder cancer and systematic analysis of S100A7 as a potential therapeutic target.
Eur J Med Res. 2024;29:52.
Abstract

YUAN H, Mao X, Yan Y, Huang R, et al
Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer.
J Transl Med. 2024;22:48.
Abstract

WANG Y, Tang Y, Liu Z, Tan X, et al
Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer.
Sci Rep. 2024;14:1216.
Abstract

TAKEUCHI H, Nakata W, Matsuse M, Tsujimura G, et al
Preoperative Immunonutrition Significantly Reduced Surgical Site Infection After Urinary Diversion for Invasive Bladder Cancer: A Retrospective Cohort Study.
Clin Genitourin Cancer. 2023 Dec 13:S1558-7673(23)00269.
Abstract

XIA Y, Ma BB, Liu X, Xu DF, et al
Explore the prognostic influence of the treatment sequence of TURBT-chemotherapy combination for patients with localized muscle-invasive bladder cancer.
Asian J Surg. 2024 Jan 11:S1015-9584(24)00014.
Abstract

GAN Z, Abudurexiti A, Hu X, Chen W, et al
E2F3/5/8 serve as potential prognostic biomarkers and new therapeutic direction for human bladder cancer.
Medicine (Baltimore). 2024;103:e35722.
Abstract

YANG R, Rac G, Felice MD, Pahouja G, et al
Robotic versus open radical cystectomy for bladder cancer: evaluation of complications, survival, and opioid prescribing patterns.
J Robot Surg. 2024;18:10.
Abstract

HUANG Q, Li Z, Liu C
Prognostic Value of Fatty Acid Metabolism-related Genes in Patients with Bladder Cancer.
Recent Pat Anticancer Drug Discov. 2024;19:328-341.
Abstract

A BUENO AP, Clark O, Turnure M, Moreira ES, et al
Treatment patterns in metastatic bladder cancer in Japan: results of the CancerMPact((R)) survey 2020.
Future Oncol. 2024 Jan 12. doi: 10.2217/fon-2023-0197.
Abstract

ZHANG W, Yu L, Chang Z, Xiong H, et al
BCG immunotherapy promotes tumor-derived T-cell activation through the FLT3/FLT3LG pathway in bladder cancer.
J Cancer. 2024;15:623-631.
Abstract

DU W, Guo K, Wang P, Zhong J, et al
HSPB8 Facilitates the Oncogenesis and Advancement of Bladder Cancer via Activation of HSP27.
J Cancer. 2024;15:645-658.
Abstract

ZHANG P, Yang Q, Chen X, Chen X, et al
CENPW knockdown inhibits progression of bladder cancer through inducing cell cycle arrest and apoptosis.
J Cancer. 2024;15:858-870.
Abstract

RICHTERS A, Robbrecht DGJ, Meijer RP, van der Heijden AG, et al
Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort.
Eur Urol Open Sci. 2023;59:50-54.
Abstract

YI J, Ma X, Ying Y, Liu Z, et al
N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the mir-128-3p/MAPK1 axis.
Cancer Lett. 2024 Jan 9:216613. doi: 10.1016/j.canlet.2024.216613.
Abstract

ZANG PD, Angeles A, Dorff TB, Pal SK, et al
Immuno-Oncology Advances in Genitourinary Cancers.
Am Soc Clin Oncol Educ Book. 2024;44:e430428.
Abstract

ZHOU H, Cui X, Zhu L, Xu Z, et al
circPVT1 Inhibits the Proliferation and Aids in Prediction of the Prognosis of Bladder Cancer.
Pharmgenomics Pers Med. 2024;17:1-11.
Abstract

TUO Z, Feng D, Jiang Z, Bi L, et al
Unveiling clinical significance and tumor immune landscape of CXCL12 in bladder cancer: Insights from multiple omics analysis.
Chin J Cancer Res. 2023;35:686-701.
Abstract

REYNOLDS T, Riddick G, Meyers G, Gordon M, et al
Results Obtained from a Pivotal Validation Trial of a Microsatellite Analysis (MSA) Assay for Bladder Cancer Detection through a Statistical Approach Using a Four-Stage Pipeline of Modern Machine Learning Techniques.
Int J Mol Sci. 2023;25:472.
Abstract

LASOTA M, Jankowski D, Wisniewska A, Sarna M, et al
The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer.
Int J Mol Sci. 2023;25:269.
Abstract

REYNOLDS T, Bertsche K, Moon D, Moon C, et al
Qualification of the Microsatellite Instability Analysis (MSA) for Bladder Cancer Detection: The Technical Challenges of Concordance Analysis.
Int J Mol Sci. 2023;25:209.
Abstract

LEE SY, Lee YH, Kim TM, Ha US, et al
Longitudinal Transcription Profiling of Bladder Cancers Dictate the Response to BCG Treatment and Disease Progression.
Int J Mol Sci. 2023;25:144.
Abstract

QURESHI TA, Chen X, Xie Y, Murakami K, et al
MRI/RNA-Seq-Based Radiogenomics and Artificial Intelligence for More Accurate Staging of Muscle-Invasive Bladder Cancer.
Int J Mol Sci. 2023;25:88.
Abstract

LAUFER M, Perelman M, Segal G, Sarfaty M, et al
Low Alanine Aminotransferase as a Marker for Sarcopenia and Frailty, Is Associated with Decreased Survival of Bladder Cancer Patients and Survivors-A Retrospective Data Analysis of 3075 Patients.
Cancers (Basel). 2023;16:174.
Abstract

SUN Y, Liu X, Tong H, Yin H, et al
SIRT1 Promotes Cisplatin Resistance in Bladder Cancer via Beclin1 Deacetylation-Mediated Autophagy.
Cancers (Basel). 2023;16:125.
Abstract

LV Y, Liu Z, Deng L, Xia S, et al
Hesperetin promotes bladder cancer cells death via the PI3K/AKT pathway by network pharmacology and molecular docking.
Sci Rep. 2024;14:1009.
Abstract

MANKAN AK, Mankan N, de Las Heras B, Ramkissoon SH, et al
Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy.
Adv Ther. 2024 Jan 10. doi: 10.1007/s12325-023-02758.
Abstract

PYRGIDIS N, Volz Y, Ebner B, Kazmierczak PM, et al
The effect of hospital caseload on perioperative mortality, morbidity and costs in bladder cancer patients undergoing radical cystectomy: results of the German nationwide inpatient data.
World J Urol. 2024;42:19.
Abstract

CHEN CY, Chang CH, Yang CR, Hsieh KL, et al
Prognostic factors of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma.
World J Urol. 2024;42:22.
Abstract

KIM K, Byun YJ, Zheng CM, Moon S, et al
COL6A1 expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype.
Investig Clin Urol. 2024;65:94-103.
Abstract

LI X
Editorial for "Significance of Normalized Apparent Diffusion Coefficient in the Vesical Imaging-Reporting and Data System for Diagnosing Muscle-Invasive Bladder Cancer".
J Magn Reson Imaging. 2024 Jan 10. doi: 10.1002/jmri.29233.
Abstract

WU Z, Wang D, Zhang Y, Zhang Z, et al
SPP1 mRNA determination based on molecular beacon for the recurrence prognosis of bladder cancer.
Transl Androl Urol. 2023;12:1834-1844.
Abstract

SHEN J, Chen C, Chen Z, Gong P, et al
CCL5 promotes the proliferation and metastasis of bladder cancer via the JAK2/STAT3 signaling pathway.
Transl Androl Urol. 2023;12:1845-1858.
Abstract

ZHU MR, Hong HX, Cheng JR, Tang J, et al
Risk Factors Analysis and Pathogen Distribution of Urinary Tract Infection in Patients Undergoing Cutaneous Ureterostomy After Radical Cystectomy for Bladder Cancer.
Biol Res Nurs. 2024 Jan 9:10998004241226948. doi: 10.1177/10998004241226948.
Abstract

BAHLINGER V, Branz A, Strissel PL, Strick R, et al
Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Histopathology. 2024 Jan 9. doi: 10.1111/his.15130.
Abstract

CHEN YT, Tu WJ, Ye ZH, Wu CC, et al
Integration of the cancer cell secretome and transcriptome reveals potential noninvasive diagnostic markers for bladder cancer.
Proteomics Clin Appl. 2024 Jan 9:e2300033. doi: 10.1002/prca.202300033.
Abstract

GEETHA SD, Chavarria HD, Abdelwahed M, Kataria N, et al
Granulomatous myocarditis arising from intravesical Bacillus Calmette-Guerin therapy leading to death diagnosed by postmortem examination: a case report.
J Med Case Rep. 2024;18:12.
Abstract

KRAL M, Kurfurstova D, Hartmann I, Studentova H, et al
Ewing's sarcoma of the urinary bladder - the urologic and pathologic differential diagnosis and current therapeutic options.
Klin Onkol. 2023;37:314-319.
Abstract

FURRER MA, Soliman C, Wuethrich PY
Meticulous initial clinical and pathological staging with standardized long-term follow-up after radical cystectomy is required to validate and improve overall prognostic performance in patients undergoing neoadjuvant chemotherapy for bladder cancer.
Minerva Urol Nephrol. 2024 Jan 9. doi: 10.23736/S2724-6051.23.05563.
Abstract

JINDAL D, Suresh PK, Sreeram S, Holla R, et al
Immunohistochemical expression of androgen receptors in urothelial carcinoma of urinary bladder. Is it significant? Experience from coastal India.
Arch Ital Urol Androl. 2023;95:11514.
Abstract

SHI S, Peng G, Luo L, Li D, et al
Predictive nomograms for risk and prognostic factors in metastatic bladder cancer: a population-based study.
Transl Cancer Res. 2023;12:3284-3302.
Abstract

SHI H, Tan Z, Duan B, Guo C, et al
LASS2 enhances chemosensitivity to cisplatin by inhibiting PP2A-mediated beta-catenin dephosphorylation in a subset of stem-like bladder cancer cells.
BMC Med. 2024;22:19.
Abstract

DAHM P, Maisch P, Lane GI
Response to letter to the editor on the systematic review "Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer".
World J Urol. 2024;42:11.
Abstract

STEINBERG GD, Shore ND, Redorta JP, Galsky MD, et al
CREST: phase III study of sasanlimab and Bacillus Calmette-Guerin for patients with Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder cancer.
Future Oncol. 2024 Jan 8. doi: 10.2217/fon-2023-0271.
Abstract

LV F, Xiong Q, Qi M, Dai C, et al
Unraveling neoantigen-associated genes in bladder cancer: An in-depth analysis employing 101 machine learning algorithms.
Environ Toxicol. 2024 Jan 8. doi: 10.1002/tox.24123.
Abstract

CHENG Z, Ye F, Liang Y, Xu C, et al
Blood lipids, lipid-regulatory medications, and risk of bladder cancer: a Mendelian randomization study.
Front Nutr. 2023;10:992608.
Abstract

INTERNATIONAL BR
Retracted: Susceptibility Loci in SLC15A1, UGT1A3, and CWC27 Genes Associated with Bladder Cancer in the Northeast Chinese Population.
Biomed Res Int. 2023;2023:9767851.
Abstract

OZTURK H, Karapolat I
Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer.
World J Clin Cases. 2023;11:8447-8457.
Abstract

CHAUHAN SS, Kumar N, Rana F
Xanthogranulomatous Cholecystitis Mimicking Gall Bladder Cancer: a Diagnostic Dilemma and Review of Literature.
Indian J Surg Oncol. 2023;14:796-799.
Abstract

TASHIRO Y, Teishima J, Sakata H, Mita Y, et al
Ureteral obstruction following transurethral resection of bladder cancer within the Hutch's diverticulum.
Int Cancer Conf J. 2023;13:45-48.
Abstract

SU WT, Chen JY, Sun JB, Huang QI, et al
Fatty acid metabolism-related molecular subtypes and a novel model for predicting prognosis in bladder cancer patients.
J Biosci. 2024;49:11.
Abstract

DEMA V, Croitor A, Floruncut A, Dema S, et al
Incidental carcinoma of the prostate in cystoprostatectomy specimens - is it always a toothless lion?
Rom J Morphol Embryol. 2023;64:501-507.
Abstract

LI R, Nocera L, Rose KM, Raggi D, et al
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
Eur Urol Oncol. 2024 Jan 5:S2588-9311(23)00296-1. doi: 10.1016/j.euo.2023.
Abstract

YANG Y, Yang B, Xu J, Liu J, et al
Prostate cancer was detected after radical resection of bladder cancer.
Asian J Surg. 2024 Jan 5:S1015-9584(23)02075.
Abstract

FREITAS NR, Vieira PM, Tinoco C, Anacleto S, et al
Multiple mask and boundary scoring R-CNN with cGAN data augmentation for bladder tumor segmentation in WLC videos.
Artif Intell Med. 2024;147:102723.
Abstract

LI K, Huang Z, Xie G, Huang B, et al
Transcriptomic insights into UTUC: role of inflammatory fibrosis and potential for personalized treatment.
J Transl Med. 2024;22:24.
Abstract

SHUAI Y, Zhang H, Liu C, Wang J, et al
CLIC3 interacts with NAT10 to inhibit N4-acetylcytidine modification of p21 mRNA and promote bladder cancer progression.
Cell Death Dis. 2024;15:9.
Abstract

ZHANG F, Yao Z, Zhang B
Genetically proxied intestinal microbiota and risk of bladder cancer.
Int J Surg. 2024 Jan 4. doi: 10.1097/JS9.0000000000001019.
Abstract

HADJI M, Rashidian H, Marzban M, Rezaianzadeh A, et al
Unveiling an Association between Waterpipe Smoking and Bladder Cancer Risk: A Multicenter Case-Control Study in Iran.
Cancer Epidemiol Biomarkers Prev. 2024 Jan 5. doi: 10.1158/1055-9965.EPI-23-0773
Abstract

LIAO RS, Ruan HT, Jang A, Huynh M, et al
Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons.
Am Soc Clin Oncol Educ Book. 2024;44:e430336.
Abstract

MIAO Z, Li J, Zeng S, Lv Y, et al
Endoplasmic Reticulum-Targeting AIE Photosensitizers to Boost Immunogenic Cell Death for Immunotherapy of Bladder Carcinoma.
ACS Appl Mater Interfaces. 2024;16:245-260.
Abstract

GRANDE E, Arranz JA, De Santis M, Bamias A, et al
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Lancet Oncol. 2024;25:29-45.
Abstract

SIEFKER-RADTKE AO, Desai M
Evolution of front-line immunotherapy for metastatic urothelial cancer.
Lancet Oncol. 2024;25:2-3.
Abstract

BAMIAS A, Davis ID, Galsky MD, Arranz JA, et al
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Lancet Oncol. 2024;25:46-61.
Abstract

MILLER EJ, Galsky MD
Precision Medicine in Urothelial Carcinoma: Current Markers to Guide Treatment and Promising Future Directions.
Curr Treat Options Oncol. 2023;24:1870-1888.
Abstract

WANG X, Zeng M, Ju X, Lin A, et al
Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients.
Br J Surg. 2024;111:znad377.
Abstract

BACHERT SE, Di J, Zhang S, Short HE, et al
TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?
Hum Pathol. 2024;143:42-49.
Abstract

RAN P, Zhou W, Zhang X, Lv J, et al
FDG PET/CT in a Case of Primary Lymphoma of the Ureter.
Clin Nucl Med. 2023 Nov 17. doi: 10.1097/RLU.0000000000004976.
Abstract

LOBO J, Tenace NP, Canete-Portillo S, Carneiro I, et al
Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Histopathology. 2024;84:507-514.
Abstract

VARMA M, Comperat E, van der Kwast T
Head-to-head: how many categories for grading urothelial carcinoma?
Histopathology. 2024;84:421-428.
Abstract

STOCKEM CF, Galsky MD, van der Heijden MS
Turning up the heat: CTLA4 blockade in urothelial cancer.
Nat Rev Urol. 2024;21:22-34.
Abstract

LI K, Qi L, Tang G, Xu H, et al
Epigenetic Regulation in Urothelial Carcinoma.
Curr Mol Med. 2024;24:85-97.
Abstract

YANG W, Liu J
Regarding the role of HER2 overexpression on the survival in muscle-invasive bladder cancer.
Int J Surg. 2024 Jan 18. doi: 10.1097/JS9.0000000000001091.
Abstract

ASDEMIR A, Ozgur A
Molecular mechanism of anticancer effect of heat shock protein 90 inhibitor BIIB021 in human bladder cancer cell line.
Naunyn Schmiedebergs Arch Pharmacol. 2024.
Abstract

WEI D, Liu Y, Yuan Y, Li Y, et al
Molecular map of cGAS-STING pathway-related genes in bladder cancer: the perspective toward immune microenvironment and prognosis.
Aging (Albany NY). 2024;15.
Abstract

JIANG LJ, Guo SB, Zhou ZH, Li ZY, et al
Snai2-mediated upregulation of NADSYN1 promotes bladder cancer progression by interacting with PHB.
Clin Transl Med. 2024;14:e1555.
Abstract

KOHUT-JACKSON A, Orf J, Barresi D, Davaro F, et al
Age related trends in the utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer.
Urol Oncol. 2024 Jan 17:S1078-1439(24)00007.
Abstract

ERMAN A, Kamensek U, Peskar D, Veranic P, et al
Establishment of Mouse Orthotopic Urinary Bladder Tumor Model and Its Analysis by Light and Electron Microscopy.
Methods Mol Biol. 2024;2773:33-49.
Abstract

ZUPANCIC D, Romih R
Urinary Bladder Cancer Induced by N-Butyl-N-(4-Hydroxybutyl)-Nitrosamine.
Methods Mol Biol. 2024;2773:25-32.
Abstract

OZDEMIR SANCI T, Terzi E, Oz Bedir BE, Gumustas M, et al
Effect of herniarin on cell viability, cell cycle, and Erk protein levels in different stages of bladder cancer cells.
Chem Biodivers. 2024 Jan 18:e202301645. doi: 10.1002/cbdv.202301645.
Abstract

LIU Y, Zhang J, Chen H, Zhang W, et al
Urinary microbiota signatures associated with different types of urinary diversion: a comparative study.
Front Cell Infect Microbiol. 2024;13:1302870.
Abstract

OZGUN G, Yaras T, Akman B, Ozden-Yilmaz G, et al
Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells.
Cancer Gene Ther. 2024 Jan 17. doi: 10.1038/s41417-024-00725.
Abstract

WARRICK J
Molecular Subtypes of Bladder Cancer: Component Signatures and Potential Value in Clinical Decision-making.
Adv Anat Pathol. 2024 Jan 18. doi: 10.1097/PAP.0000000000000430.
Abstract

KHOR V, Fahmy O, Lee CKS, Khairul-Asri MG, et al
Guillain-Barre Syndrome following intravesical Bacillus Calmette-Guerin therapy for bladder cancer: a rare and intriguing case report.
Cent European J Urol. 2023;76:311-314.
Abstract

DYBOWSKI B
Local solutions to shorten treatment delays in bladder cancer. Results of a survey among CEJU authors.
Cent European J Urol. 2023;76:280-282.
Abstract

INTERNATIONAL BR
Retracted: Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis.
Biomed Res Int. 2024;2024:9869348.
Abstract

INTERNATIONAL BR
Retracted: The Use of BT-ESD Technology under General Intravenous Anesthesia in the Treatment of Nonmuscle Invasive Bladder Cancer and the Effect of PI3K/Akt Signaling Pathway on Tumor Recurrence.
Biomed Res Int. 2024;2024:9815062.
Abstract

WARAICH TA, Khalid SY, Ali A, Kathia UM, et al
Comparative Outcomes of Radical Cystectomy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Cureus. 2023;15:e50646.
Abstract

YIN G, Zheng S, Zhang W, Dong X, et al
Classification of bladder cancer based on immune cell infiltration and construction of a risk prediction model for prognosis.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024.
Abstract

ZHANG HH, Zhang AQ, Peng P, Huang L, et al
USP5 facilitates bladder cancer progression by stabilizing the c-Jun protein.
Cancer Cell Int. 2024;24:32.
Abstract

MASONE MC
Urinoids - a new tool to study bladder cancer.
Nat Rev Urol. 2024 Jan 16. doi: 10.1038/s41585-024-00853.
Abstract

IKARASHI D, Kitano S, Tsuyukubo T, Yamashita M, et al
Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer.
Sci Rep. 2024;14:1442.
Abstract

ZHAO L, Li J, Xue Z, Wang J, et al
Exosomal noncoding RNAs as noninvasive biomarkers in bladder cancer: a diagnostic meta-analysis.
Clin Transl Oncol. 2024 Jan 16. doi: 10.1007/s12094-023-03374.
Abstract

CHAMIE K, Chang SS, Kramolowsky EV, Gonzalgo ML, et al
Quality of Life in the Phase 2/3 Trial of N-803 Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
Urol Pract. 2024 Jan 16:101097UPJ0000000000000517.
Abstract

LIEDBERG F, Hagberg O, Aljabery F, Gardmark T, et al
Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey.
Scand J Urol. 2024;59:19-25.
Abstract

YANG H, He P, Luo W, Liu S, et al
circRNA TATA-box binding protein associated factor 15 acts as an oncogene to facilitate bladder cancer progression through targeting miR-502-5p/high mobility group box 3.
Mol Carcinog. 2024 Jan 16. doi: 10.1002/mc.23677.
Abstract

OKATO A, Utsumi T, Ranieri M, Zheng X, et al
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
J Clin Invest. 2024;134:e169241.
Abstract

ESCOBAR GIL T, Borja Montes OF, Sheikh AB
Unraveling Bacillus Calmette-Guerin (BCG) Therapy Side Effects in Bladder Cancer: A Tale of Triumph Over Treatment Challenges.
Cureus. 2023;15:e50498.
Abstract

SIMO C, Serra-Casablancas M, Hortelao AC, Di Carlo V, et al
Urease-powered nanobots for radionuclide bladder cancer therapy.
Nat Nanotechnol. 2024 Jan 15. doi: 10.1038/s41565-023-01577.
Abstract

AY A, Alkanli N, Cevik G
Determination of the Roles of Endothelial Nitric Oxide Synthase 4VNTR (4a/b), G894T, T786C Gene Variations in the Bladder Cancer Development.
Indian J Clin Biochem. 2024;39:92-100.
Abstract

WANG Z, Wang Y, Wang S, Ran Q, et al
Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series.
Ann Med Surg (Lond). 2023;86:245-251.
Abstract

ZEHRA M, Fatima T, Hanif A, Raufi N, et al
Nadofaragene: a new era of precision medicine for bladder cancer.
Ann Med Surg (Lond). 2023;86:7-10.
Abstract

CHEN JQ, Salas LA, Wiencke JK, Koestler DC, et al
Matched analysis of detailed peripheral blood and tumor immune microenvironment profiles in bladder cancer.
Epigenomics. 2024;16:41-56.
Abstract

RUSSO AE, Memon A, Ahmed S
Bladder Cancer and the Urinary Microbiome-New Insights and Future Directions: A Review.
Clin Genitourin Cancer. 2024 Jan 9:S1558-7673(23)00281.
Abstract

LI M, Yu J, Ju L, Wang Y, et al
USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer.
Cell Death Dis. 2024;15:44.
Abstract

ZHOU L, Du K, Dai Y, Zeng Y, et al
Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer.
J Transl Med. 2024;22:55.
Abstract

AMIRI Z, Hasani A, Abedini F, Malek M, et al
Urease-Powered Black TiO(2) Micromotors for Photothermal Therapy of Bladder Cancer.
ACS Appl Mater Interfaces. 2024 Jan 13. doi: 10.1021/acsami.3c11772.
Abstract

TSIKOPOULOS I, Papadopoulos DI, Anastasiou D, Karatzas A, et al
Vesical fungal bezoars on post-TURBT scar tissue causing obstruction and mimicking urothelial carcinoma.
BMJ Case Rep. 2024;17:e257132.
Abstract

ZHUANG Y, Cai Q, Hu X, Huang H, et al
Elevated serum CA199 levels in patients suffering type 2 diabetes vs. various types of cancer.
BMC Endocr Disord. 2024;24:9.
Abstract

ZHOU Z, Xiong L, Yao K, Ma H, et al
Extraperitonealization of the ileal conduit decreases the risk of parastomal hernia: A single-center, randomized clinical trial.
Cell Rep Med. 2024;5:101343.
Abstract

LAMBERTINI L, Di Maida F, Cadenar A, Nardoni S, et al
Stentless florence robotic intracorporeal neobladder (FloRIN), a feasibility prospective randomized clinical trial.
Eur J Surg Oncol. 2024;50:107259.
Abstract

TAJIMA Y, Shibasaki F, Masai H
Cell fusion upregulates PD-L1 expression for evasion from immunosurveillance.
Cancer Gene Ther. 2024;31:158-173.
Abstract

HOU J, Huang H, Xie J, Yu W, et al
KLHDC7B as a novel diagnostic biomarker in urine exosomal mRNA promotes bladder urothelial carcinoma cell proliferation and migration, inhibits apoptosis.
Mol Carcinog. 2024;63:286-300.
Abstract

CONCI N, Tassinari E, Tateo V, Rosellini M, et al
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
Mol Diagn Ther. 2024;28:37-51.
Abstract

MCGREGOR BA, Sonpavde GP, Kwak L, Regan MM, et al
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
Ann Oncol. 2024;35:91-97.
Abstract

SIEFKER-RADTKE AO, Matsubara N, Park SH, Huddart RA, et al
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Ann Oncol. 2024;35:107-117.
Abstract

XU S, Huang J
Machine learning algorithms predicting bladder cancer associated with diabetes and hypertension: NHANES 2009 to 2018.
Medicine (Baltimore). 2024;103:e36587.
Abstract

MARTINS EP, Vieira de Castro J, Fontes R, Monteiro-Reis S, et al
Relevance of HOTAIR rs920778 and rs12826786 Genetic Variants in Bladder Cancer Risk and Survival.
Cancers (Basel). 2024;16:434.
Abstract

DESPONDS E, Croci D, Wosika V, Hadadi N, et al
Immuno-Transcriptomic Profiling of Blood and Tumor Tissue Identifies Gene Signatures Associated with Immunotherapy Response in Metastatic Bladder Cancer.
Cancers (Basel). 2024;16:433.
Abstract

GARG H, Bhandari M, Dursun F, Liss MA, et al
A comparative analysis of radical cystectomy with perioperative chemotherapy, chemoradiation therapy, or systemic therapy in patients with clinically advanced node-positive bladder cancer (cN2/N3).
Front Oncol. 2024;13:1157880.
Abstract

WANG K, Xiao W, Zeng Q
Curcumin Inhibits Bladder Cancer by Inhibiting Invasion via AKT/MMP14 Pathway.
Discov Med. 2024;36:71-81.
Abstract

LU J, Hong H, Xiong Z, Zhang Y, et al
Development and preliminary validation of a PROS scale for Chinese bladder cancer patients with abdominal stoma.
Sci Rep. 2024;14:2187.
Abstract

SU Z, You L, He Y, Chen J, et al
Multi-omics reveals the role of ENO1 in bladder cancer and constructs an epithelial-related prognostic model to predict prognosis and efficacy.
Sci Rep. 2024;14:2189.
Abstract

KOPENHAFER L, Thompson A, Chang J, Sikirica S, et al
Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey.
Urol Oncol. 2024 Jan 24:S1078-1439(24)00015.
Abstract

MONTORSI F, Moschini M, Salonia A, Gandaglia G, et al
Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guerin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized
Eur Urol Focus. 2024 Jan 24:S2405-4569(24)00005.
Abstract

FUKUSHIMA H, Takao S, Furusawa A, Valera Romero V, et al
Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer.
Cancer Lett. 2024 Jan 23:216606. doi: 10.1016/j.canlet.2023.216606.
Abstract

WOOLBRIGHT BL, Xuan H, Ahmed I, Rajendran G, et al
Aging induces changes in cancer formation and microbial content in a murine model of bladder cancer.
Geroscience. 2024 Jan 25. doi: 10.1007/s11357-024-01064.
Abstract

TRIPATHI S, Bhirud DP, Singh M, Singh V, et al
Early port site and peritoneal metastasis following robot-assisted radical cystectomy: a rare case report.
J Cancer Res Clin Oncol. 2024;150:32.
Abstract

SUN R, Zhang M, Yang L, Yang S, et al
Preoperative CT-based deep learning radiomics model to predict lymph node metastasis and patient prognosis in bladder cancer: a two-center study.
Insights Imaging. 2024;15:21.
Abstract

YANG J, Ji Z, Gao F, Wu J, et al
Cigarette smoking combined with genetic variation regulates the m(6) A methylation of CRNKL1 and is associated with bladder cancer risk.
Environ Toxicol. 2024 Jan 25. doi: 10.1002/tox.24138.
Abstract

TRUONG TH, Nguyen DH, Dinh KN, Thai MS, et al
Urethral Recurrence After Cystectomy and Orthotopic Bladder Reconstruction: A Rare Case of Recurrent Bladder Cancer After 12 Years and Review of the Literature.
Clin Med Insights Case Rep. 2024;17:11795476231224188.
Abstract

ENOMOTO T, Okada H, Tomita H, Iinuma K, et al
Glycocalyx analysis of bladder cancer: three-dimensional images in electron microscopy and vicia villosa lectin as a marker for invasiveness in frozen sections.
Front Cell Dev Biol. 2024;11:1308879.
Abstract

WEN F, Lin T, Zhang P, Shen Y, et al
RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
Front Oncol. 2024;13:1233196.
Abstract

TAK S, Han G, Leem SH, Lee SY, et al
Prediction of anticancer drug resistance using a 3D microfluidic bladder cancer model combined with convolutional neural network-based image analysis.
Front Bioeng Biotechnol. 2024;11:1302983.
Abstract

OSSOLINSKI K, Ruman T, Copie V, Tripet BP, et al
Metabolomic profiling of human bladder tissue extracts.
Metabolomics. 2024;20:14.
Abstract

SAVIN Z, Mano R, Lazarovich A, Rosenzweig B, et al
Assessing the Impact of Percutaneous Nephrostomy Presence on Neoadjuvant Treatment Quality in Patients With Muscle Invasive Bladder Cancer.
Clin Genitourin Cancer. 2024 Jan 6:S1558-7673(24)00004.
Abstract

MCFADDEN J, Tachibana I, Adra N, Collins K, et al
Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy.
Urol Oncol. 2024 Jan 23:S1078-1439(23)00487.
Abstract

RAMOS P, Mateus A, Manso M, Botelho F, et al
Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?
Urol Oncol. 2024 Jan 23:S1078-1439(24)00010.
Abstract

WAN S, Li KP, Wang CY, Yang JW, et al
Immunologic Crosstalk of Endoplasmic Reticulum Stress Signaling in Bladder Cancer.
Curr Cancer Drug Targets. 2024 Jan 23. doi: 10.2174/0115680096272663231121100515
Abstract

MOHAMED SHARAF R, Essam Eldin-Shibel P, Abd-El-Moeze NA
Immunohistochemical Expression of Vitamin D Receptor (VDR) in Urinary Bladder Squamous Cell Carcinoma.
Turk Patoloji Derg. 2024;1.
Abstract

ABOU CHAKRA M, Packiam VT, Duquesne I, Peyromaure M, et al
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand Now?
Expert Opin Pharmacother. 2024 Jan 24. doi: 10.1080/14656566.2024.2310073.
Abstract

WANG W, Huang G, Lin H, Ren L, et al
Corrigendum: Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis.
Front Oncol. 2024;13:1216134.
Abstract

HUANG S, Huang Y, Li C, Liang Y, et al
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis.
Front Immunol. 2024;14:1332213.
Abstract

ZHAO C, Qi L, Chen M, Liu L, et al
[Retracted] microRNA?195 inhibits cell proliferation in bladder cancer via inhibition of cell division control protein 42 homolog/signal transducer and activator of transcription?3 signaling.
Exp Ther Med. 2023;27:78.
Abstract

OUANES Y, Chaker K, Yaich S, Foued D, et al
Predictive factors of bladder tumor recurrence after radical treatment of upper urinary tract cancer.
Tunis Med. 2023;101:356-361.
Abstract

CAI Q, Huang Y, Ling J, Kong L, et al
Radiomics nomogram for predicting disease-free survival after partial resection or radical cystectomy in patients with bladder cancer.
Br J Radiol. 2024;97:201-209.
Abstract

SU Z, Wei J, Yuan X
Giant cell-rich solitary fibrous tumour of the urinary bladder: case report of an unusual histological variant and literature review.
Diagn Pathol. 2024;19:20.
Abstract

WEN F, Lin T, Zhang P, Zeng H, et al
Bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer (HOPE-04): study protocol for a single-arm, prospective, phase II trial.
BMJ Open. 2024;14:e076663.
Abstract

CHANG YC, Wu YY, Tsan DL, Yap WK, et al
Dose-Escalated Radiation Therapy as Primary Treatment for Residual Bladder Cancer After Transurethral Resection.
Adv Radiat Oncol. 2024;9:101302.
Abstract

ALCANTARA MB, Tang WS, Wang D, Kaniowski D, et al
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
Front Immunol. 2024;14:1274781.
Abstract

GONG Y, Cheng Y, Zhang J, Bao ML, et al
Role of Additional MRI-Based Morphologic Measurements on the Performance of VI-RADS for Muscle-Invasive Bladder Cancer.
J Magn Reson Imaging. 2024 Jan 23. doi: 10.1002/jmri.29184.
Abstract

KOCHERGIN M, Fahmy O, Asimakopoulos A, Theil G, et al
Photodynamic Therapy: Current Trends and Potential Future Role in the Treatment of Bladder Cancer.
Int J Mol Sci. 2024;25:960.
Abstract

SHAN KS, Dalal S, Thaw Dar NN, McLish O, et al
Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers.
Int J Mol Sci. 2024;25:849.
Abstract

TATSUTA T, Ito J, Yamamoto K, Sugawara S, et al
Sialidase NEU3 Contributes to the Invasiveness of Bladder Cancer.
Biomedicines. 2024;12:192.
Abstract

LIU J, Tian C, Qiao J, Deng K, et al
m6A Methylation-Mediated Stabilization of LINC01106 Suppresses Bladder Cancer Progression by Regulating the miR-3148/DAB1 Axis.
Biomedicines. 2024;12:114.
Abstract

JEONG MS, Mun JY, Yang GE, Kim MH, et al
Exploring the Relationship between CLPTM1L-MS2 Variants and Susceptibility to Bladder Cancer.
Genes (Basel). 2023;15:50.
Abstract

UZELAC M, Xin R, Chen T, John D, et al
Urinary Microbiome Dysbiosis and Immune Dysregulations as Potential Diagnostic Indicators of Bladder Cancer.
Cancers (Basel). 2024;16:394.
Abstract

VERMA S, Swain D, Kushwaha PP, Brahmbhatt S, et al
Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.
Cancers (Basel). 2024;16:246.
Abstract

SUZUKI S, Gi M, Komiya M, Obikane A, et al
Evaluation of the Mechanisms Involved in the Development of Bladder Toxicity following Exposure to Occupational Bladder Cancer Causative Chemicals Using DNA Adductome Analysis.
Biomolecules. 2023;14:36.
Abstract

PORSERUD A, Karlsson P, Nygren-Bonnier M, Aly M, et al
The feasibility of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer, prior to the CanMoRe trial.
Pilot Feasibility Stud. 2024;10:12.
Abstract

MOUSAVIAN AH, Shafiee G, Sheidaei A, Balajam NZ, et al
The 15-year national trends of urinary cancers incidence among Iranian men and women; 2005-2020.
Int J Equity Health. 2024;23:13.
Abstract

OUYANG W, Xu R, Yao H, Jiang S, et al
Urinary DNA methylation-based risk stratification model to triage patients for repeat transurethral resection of bladder tumours.
Clin Transl Med. 2024;14:e1549.
Abstract

VOLBERG C, Urhahn F, Pedrosa Carrasco AJ, Morin A, et al
End-of-Life Care Preferences of Patients with Advanced Urological Malignancies: An Explorative Survey Study at a Tertiary Referral Center.
Curr Oncol. 2024;31:462-471.
Abstract

LIU T, Ul-Haq W, Tang Q, Li W, et al
Novel integrated Omics based computational approach for drug repurposing for non-muscle invasive bladder cancer (NMIBC).
J Biomol Struct Dyn. 2024 Jan 21:1-11. doi: 10.1080/07391102.2024.2302343.
Abstract

TOMIYAMA E, Fujita K, Nonomura N
[?. Urinary Liquid Biopsy in Bladder Cancer- Current Status and Issues].
Gan To Kagaku Ryoho. 2024;51:40-44.
Abstract

TANIGUCHI A, Hirakawa K, Mayama I
[INFECTIOUS AORTITIS-RELATED MORTALITY AFTER ILEAL NEOBLADDER SUBSTITUTION IN A PATIENT WITH DIABETES MELLITUS].
Nihon Hinyokika Gakkai Zasshi. 2023;114:26-29.
Abstract

KITA S, Yamakawa M, Kono R, Soumiya K, et al
[NONRISING BLADDER PARAGANGLIOMA SUCCESSFULLY TREATED BY THE OPEN BLADDER SURGERY: A CASE REPORT].
Nihon Hinyokika Gakkai Zasshi. 2023;114:16-20.
Abstract

WANG F, Zhang G, Xu T, Ma J, et al
High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor.
J Exp Clin Cancer Res. 2024;43:24.
Abstract

FU S, Tan Z, Shi H, Chen J, et al
Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.
NPJ Precis Oncol. 2024;8:14.
Abstract

LIU H, Wang X, Wu G, Wu J, et al
PRPF19 could serve as a prognostic biomarker for patients with bladder cancer: A comprehensive analysis by integrating bulk and single-cell sequencing.
Asian J Surg. 2024 Jan 19:S1015-9584(24)00115.
Abstract

ASHLEY S, Choudhury A, Hoskin P, Song Y, et al
Radiotherapy in metastatic bladder cancer.
World J Urol. 2024;42:47.
Abstract

TYSON MD
Single incision robotic cystectomy and urinary diversion.
World J Urol. 2024;42:45.
Abstract

GALSKY MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, et al
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Nat Med. 2024 Jan 19. doi: 10.1038/s41591-024-02814.
Abstract

MESSINA E, Proietti F, Laschena L, Flammia RS, et al
MRI for risk stratification of muscle invasion by upper tract urothelial carcinoma: a feasibility study.
Eur Radiol Exp. 2024;8:9.
Abstract

SHI J, Zhang K, Xiao T, Yang J, et al
Exposure to disinfection by-products and risk of cancer: A systematic review and dose-response meta-analysis.
Ecotoxicol Environ Saf. 2024;270:115925.
Abstract

SAHETIA KM, Dave VN, Pal M, Menon S, et al
Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
Indian J Cancer. 2023;60:575-577.
Abstract

JI J, Liu T, Yao Y, Liu W, et al
Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 cases.
Neoplasia. 2024;47:100961.
Abstract

MOLLICA V, Tassinari E, Santoni M, Marchese PV, et al
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
Pathol Res Pract. 2024;253:155008.
Abstract

COBAN G, Yildiz P, Sahin N, Ersoz C, et al
CD47 expression in urothelial carcinoma and its correlation with histopathological findings.
Indian J Cancer. 2023;60:458-463.
Abstract

COPUR S, Yildiz AB, Covic A, Kanbay M, et al
Is there any robust evidence showing that SGLT2 inhibitor predisposes to cancer?
Eur J Clin Invest. 2024;54:e14131.
Abstract

ZHAO S, Li Y, Xu J, Shen L, et al
APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Neurol Res. 2023 Nov 26:1-16. doi: 10.1080/01616412.2023.2287340.
Abstract

LI X, Zhang L, Hu S, Liu D, et al
Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System.
Clin Pharmacol Ther. 2024;115:256-268.
Abstract

DAI YN, Yi-Wen Yu E, Zeegers MP, Wesselius A, et al
The Association between Dietary Inflammatory Potential and Urologic Cancers: A Meta-analysis.
Adv Nutr. 2023 Nov 3:100124. doi: 10.1016/j.advnut.2023.
Abstract

WU Y, Cai D, Fan J, Meng C, et al
An accurate diagnostic approach for urothelial carcinomas based on novel dual methylated DNA markers in small-volume urine.
Chin Med J (Engl). 2024;137:232-234.
Abstract

PACHECO RR, Pacheco R, Cooley C, Kaufman R, et al
Diffuse Carbonic Anhydrase 9 and GATA3 Expression in Fumarate Hydratase Deficient Renal Cell Carcinoma - A Case Report and Immunoprofile Review.
Int J Surg Pathol. 2024;32:145-149.
Abstract

CAO Q, Goldenberg M, Aron M, Wang T, et al
Urinary Bladder "Melanosis": A Case Report and Review of the Literature.
Int J Surg Pathol. 2024;32:104-108.
Abstract

WANG H, Liu J, Lou Y, Liu Y, et al
Identification and preliminary analysis of hub genes associated with bladder cancer progression by comprehensive bioinformatics analysis.
Sci Rep. 2024;14:2782.
Abstract

LOTAN Y, Agarwal P, Black P, Dickstein R, et al
Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.
Urol Oncol. 2024 Feb 1:S1078-1439(24)00020-6. doi: 10.1016/j.urolonc.2024.
Abstract

YU J, Cai L, Chen C, Zou Y, et al
A novel predict method for muscular invasion of bladder cancer based on 3D mp-MRI feature fusion.
Phys Med Biol. 2024 Feb 2. doi: 10.1088/1361-6560.
Abstract

ZHAO ZY, Cao Y, Wang HL, Liu LY, et al
A risk model based on lncRNA-miRNA-mRNA gene signature for predicting prognosis of patients with bladder cancer.
Cancer Biomark. 2024 Jan 8. doi: 10.3233/CBM-230216.
Abstract

SEGEL JE, Wong WG, Kaag M, Joshi M, et al
Relationship Between Availability of Urologists and Primary Care Providers and Stage of Diagnosis for Invasive Urinary Bladder Cancer.
Urol Pract. 2024 Jan 15:101097UPJ0000000000000503.
Abstract

BOSTANCI E, Kirkik D, Kalkanli Tas S, Uyeturk U, et al
Genetic insights into bladder cancer: the impact of SIRT1 gene polymorphism.
Nucleosides Nucleotides Nucleic Acids. 2024.
Abstract

WEI Z, Liu H, Xv Y, Liao F, et al
Development and validation of a CT-based deep learning radiomics nomogram to predict muscle invasion in bladder cancer.
Heliyon. 2024;10:e24878.
Abstract

YU J, Ge S
PRPF19 functions in DNA damage repair and gemcitabine sensitivity via regulating DDB1 in bladder cancer cells.
Cytotechnology. 2024;76:85-96.
Abstract

MONSHAUGEN I, Luna L, Rhodes J, Kristiansen FIS, et al
Depletion of the m1A writer TRMT6/TRMT61A reduces proliferation and resistance against cellular stress in bladder cancer.
Front Oncol. 2024;13:1334112.
Abstract

BLACK PC, Eigl BJ
The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast.
Adv Ther. 2024 Feb 2. doi: 10.1007/s12325-023-02763.
Abstract

LOBO N, Duan Z, Sood A, Tan WS, et al
Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?
Eur Urol Oncol. 2024 Jan 31:S2588-9311(24)00036.
Abstract

PORRECA A, Di Nicola M, Lucarelli G, Dorin VM, et al
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database.
Urol Oncol. 2024 Jan 31:S1078-1439(24)00003.
Abstract

ABE M, Hiraki H, Tsuyukubo T, Ono S, et al
The clinical validity of urinary pellet DNA monitoring for the diagnosis of recurrent bladder cancer.
J Mol Diagn. 2024 Jan 30:S1525-1578(24)00012.
Abstract

XU Y, Sun X, Liu G, Li H, et al
Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
Front Immunol. 2024;14:1301157.
Abstract

YANG H, Ma L, Deng W, Fu B, et al
Prognostic biomarker DARS2 correlated with immune infiltrates in bladder tumor.
Front Immunol. 2024;14:1301945.
Abstract

INTERNATIONAL EM
Retracted: Preoperative Nutritional Risk Assessment for Predicting Complications after Radical Cystectomy plus Urinary Diversion for Bladder Cancer.
Emerg Med Int. 2024;2024:9849523.
Abstract

NARDELLI C, Aveta A, Pandolfo SD, Tripodi L, et al
Microbiome Profiling in Bladder Cancer Patients Using the First-morning Urine Sample.
Eur Urol Open Sci. 2023;59:18-26.
Abstract

CHEN S, Sun G, Chen X, Salgado T, et al
Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study.
BMC Urol. 2024;24:25.
Abstract

GROBET-JEANDIN E, Lenfant L, Pinar U, Parra J, et al
Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases.
Nat Rev Urol. 2024 Jan 31. doi: 10.1038/s41585-023-00842.
Abstract

MARIAPPAN P, Johnston A, Trail M, Hamid S, et al
Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2024 Jan 30:S2588-9311(24)00037.
Abstract

LV HX, Wang D, Zhou FH
Definition of the prognosis value of urine extracellular vesicles ZNF540 in bladder cancer based on GEO database.
Asian J Surg. 2024 Jan 30:S1015-9584(24)00109.
Abstract

LI F, Zhang H, Huang Y, Li D, et al
Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer.
Drug Resist Updat. 2024;73:101059.
Abstract

LI P, Wang W, Zhu B, Wang Y, et al
PRDX2 regulates stemness contributing to cisplatin resistance and metastasis in bladder cancer.
Environ Toxicol. 2024 Jan 31. doi: 10.1002/tox.24153.
Abstract

YAN Q, Zeng P, Huang S, Tan C, et al
[RBMX overexpression inhibits proliferation, migration, invasion and glycolysis of human bladder cancer cells by downregulating PKM2].
Nan Fang Yi Ke Da Xue Xue Bao. 2024;44:9-16.
Abstract

DONG L, Feng M, Kuczler MD, Horie K, et al
Tumour tissue-derived small extracellular vesicles reflect molecular subtypes of bladder cancer.
J Extracell Vesicles. 2024;13:e12402.
Abstract

LIU Z, Du D, Zhang S
Integrated bioinformatics analysis identifies a Ferroptosis-related gene signature as prognosis model and potential therapeutic target of bladder cancer.
Toxicol Res (Camb). 2024;13:tfae010.
Abstract

WANG J, Tan J, Zhang Y, Zhou L, et al
circCD2AP promotes epithelial mesenchymal transition and stemness in bladder cancer by regulating FOXQ1/USP21 axis.
iScience. 2023;27:108447.
Abstract

BAHLBURG H, Reicherz A, Reike M, Bach P, et al
A prospective evaluation of quality of life, psychosocial distress, and functional outcomes two years after radical cystectomy and urinary diversion in 842 German bladder cancer patients.
J Cancer Surviv. 2024 Jan 30. doi: 10.1007/s11764-024-01535.
Abstract

DEMIR R, Koc S, Ozturk DG, Bilir S, et al
Artificial intelligence assisted patient blood and urine droplet pattern analysis for non-invasive and accurate diagnosis of bladder cancer.
Sci Rep. 2024;14:2488.
Abstract

IIDA K, Naiki T, Etani T, Nagai T, et al
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
Sci Rep. 2024;14:2520.
Abstract

MISHRA P, Jiongming L, Jianhe L, Kewei F, et al
Prostate Cancer among Patients Undergoing Radical Cystoprostatectomy for Bladder Cancer in the Department of Urology in a Tertiary Care Centre.
JNMA J Nepal Med Assoc. 2023;61:782-786.
Abstract

CHEN ZL, Jia KP, Zheng Y, Zhang N, et al
Electrocardiographic characteristics of bladder cancer patients receiving preoperative chemotherapy combined with immunotherapy.
Ann Noninvasive Electrocardiol. 2024;29:e13107.
Abstract

NIE Z, Guo N, Peng Y, Gao Y, et al
Author Correction: Duality of the SVIL expression in bladder cancer and its correlation with immune infiltration.
Sci Rep. 2024;14:2369.
Abstract

ZHU S, Zhao H
Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes.
Front Pharmacol. 2024;14:1326627.
Abstract

SCHNEIDER AK, Domingos-Pereira S, Cesson V, Polak L, et al
Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.
Front Immunol. 2024;14:1335326.
Abstract

JIANG S, Yang X, Lin Y, Liu Y, et al
Unveiling Anoikis-related genes: A breakthrough in the prognosis of bladder cancer.
J Gene Med. 2024;26:e3651.
Abstract

SU H, Liu Z, Zhang C, Deng Z, et al
Exploration of the prognostic effect of costimulatory genes in bladder cancer.
J Gene Med. 2024;26:e3655.
Abstract

HUANG WQ, Zhang L, Fu S, Shi GZ, et al
[Mesonephric-like adenocarcinoma of the female urinary bladder associated with endometriosis: report of a case].
Zhonghua Bing Li Xue Za Zhi. 2024;53:201-203.
Abstract

ZHU C, Fang X, Liu X, Jiang C, et al
Squalene monooxygenase facilitates bladder cancer development in part by regulating PCNA.
Biochim Biophys Acta Mol Cell Res. 2024;1871:119681.
Abstract

BAUST JM, Corcoran A, Robilotto A, Katz AE, et al
Evaluation of a New Cystoscopic Cryocatheter and Method for the In Situ Destruction of Bladder Cancer: Preliminary In vivo Study.
J Endourol. 2024 Jan 27. doi: 10.1089/end.2023.0635.
Abstract

SU Y, Chen H, Yao L, Dai H, et al
The relationship between the expression of lncRNA MALAT1 and clinical features and prognosis in bladder cancer: A meta-analysis.
Cell Mol Biol (Noisy-le-grand). 2023;69:166-171.
Abstract

LUMKUL L, Jantaree P, Jaisamak K, Wongkummool W, et al
Combinatorial Gene Expression Profiling of Serum HULC, HOTAIR, and UCA1 lncRNAs to Differentiate Hepatocellular Carcinoma from Liver Diseases: A Systematic Review and Meta-Analysis.
Int J Mol Sci. 2024;25:1258.
Abstract

JO A, Joh HM, Bae JH, Kim SJ, et al
Plasma-Activated Media Produced by a Microwave-Excited Atmospheric Pressure Plasma Jet Is Effective against Cisplatin-Resistant Human Bladder Cancer Cells In Vitro.
Int J Mol Sci. 2024;25:1249.
Abstract

MAO Q, Liu H, Wu J, Cui Y, et al
Prognostic significance of lncRNA AL354919.2 in bladder cancer.
Asian J Surg. 2024 Jan 25:S1015-9584(24)00099.
Abstract

LIN YH, Tsai HY, Juang HH
Re: Christopher D. Gaffney, Andrew Katims, Neeta D'Souza, Marc A. Bjurlin, Richard S. Matulewicz. Bladder Cancer Carcinogens: Opportunities for Risk Reduction. Eur Urol Focus 2023;9:575-8.
Eur Urol Focus. 2024 Jan 25:S2405-4569(24)00006.
Abstract

SORIA F, Gontero P
Reply to Marco Moschini, Francesco Montorsi, Andrea Salonia, Giorgio Gandaglia and Alberto Briganti's Letter to the Editor Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guerin (BCG)
Eur Urol Focus. 2024 Jan 25:S2405-4569(24)00004.
Abstract

ZHANG HP, Liang RX, Lin XY, Xue ES, et al
Application of contrast-enhanced ultrasound in diagnosis and grading of bladder urothelial carcinoma.
BMC Med Imaging. 2024;24:26.
Abstract

MANNEH KOPP R, Galanternik F, Schutz FA, Kater F, et al
Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma.
JCO Glob Oncol. 2024;10:e2300244.
Abstract

LIU Y, Qi P, Chen G, Lang Z, et al
Nanoreactor based on single-atom nanoenzymes promotes ferroptosis for cancer immunotherapy.
Biomater Adv. 2024;157:213758.
Abstract

REN Y, Liu T, Li S, Ma X, et al
An iodine?labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.
Int J Pharm. 2024;651:123756.
Abstract

WANG CS, Lee YC, Jhan JH, Li WM, et al
MicroRNA-299-3p inhibits cell proliferation, motility, invasion and angiogenesis via VEGFA in upper tract urothelial carcinoma.
J Gene Med. 2024;26:e3616.
Abstract

SUN Y, Lu Z, Taylor JA, Au JLS, et al
Quantitative image analysis of intracellular protein translocation in 3-dimensional tissues for pharmacodynamic studies of immunogenic cell death.
J Control Release. 2024;365:89-100.
Abstract

KLEMM J, Laukhtina E, Shariat SF
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients.
Nat Rev Clin Oncol. 2024;21:87-88.
Abstract

RICCHETTI G, Grimaldi A, Agricola E, Slavich M, et al
Cardiac metastasis from urothelial carcinoma: a stealthy precursor.
Eur Heart J Cardiovasc Imaging. 2024;25:e92.
Abstract

WEI W, Wu D, Zhang Z, Liu J, et al
Comparison of DNA methylation and cytology tests in urine to detect upper tract urothelial carcinoma: A paired-design diagnostic study.
Am J Clin Pathol. 2024;161:115-121.
Abstract

BANDEIRA M, Dourado E, Lopes F, Tenazinha C, et al
Reactive arthritis as a rare complication of intravesical bacillus Calmette-Guerin treatment: Report of two cases.
Int J Rheum Dis. 2024;27:e14862.
Abstract

OLIVER-KRASINSKI JM, Bidot S, Ingram JW, O'Toole KM, et al
Noninvasive Papillary Urothelial Carcinoma of the Bladder: An Institutional Experience Focusing on Tumors With Borderline Features.
Arch Pathol Lab Med. 2024;148:223-229.
Abstract

CHEN X, Yin Y, He Y, Meng F, et al
The prognostic significance and clinical relevance of stem cell characteristic in bladder cancer.
Heliyon. 2024;10:e24858.
Abstract

SONG Z, Gui S, Xiao S, Rao X, et al
A novel anoikis-related gene signature identifies LYPD1 as a novel therapy target for bladder cancer.
Sci Rep. 2024;14:3198.
Abstract

BAO R, Qu H, Li B, Cheng K, et al
Bibliometric analysis of immunotherapy for bladder cancer: A correspondence.
Hum Vaccin Immunother. 2024;20:2313287.
Abstract

LIU K, Wang L, Peng J, Lyu Y, et al
Drug-Loaded Bacillus Calmette-Guerin Bacteria for Immuno-Chemo Combo Therapy in Bladder Cancer.
Adv Mater. 2024 Feb 8:e2310735. doi: 10.1002/adma.202310735.
Abstract

NINA NINA DG, Robeldo TA, Silva AD, Dos Santos Goncalves VS, et al
[6]-Shogaol Induces Apoptosis of Murine Bladder Cancer Cells.
Cell Physiol Biochem. 2024;58:49-62.
Abstract

CHANG KC, Hung SF
Re: Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer. Yanagisawa T, Sato S, Hayashida Y, Okada Y, Fukuokaya W, Iwatani K, et al. J Urol Oncol. 2023;41(12):484.e7-484.e15.
Urol Oncol. 2024 Feb 6:S1078-1439(24)00018-8. doi: 10.1016/j.urolonc.2024.
Abstract

KOOL R, Dragomir A, Kulkarni GS, Marcq G, et al
Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis.
Eur Urol Oncol. 2024 Feb 6:S2588-9311(24)00040-3. doi: 10.1016/j.euo.2024.
Abstract

BUKAVINA L, Davis L, Helstrom E, Magee D, et al
Population Estimates of Ovarian Cancer Risk in a Cohort of Patients with Bladder Cancer.
Eur Urol Focus. 2024 Feb 6:S2405-4569(24)00015-4. doi: 10.1016/j.euf.2024.
Abstract

REIS H, Paner GP
Glandular Lesions of the Urinary Bladder: Diagnostic and Molecular Updates.
Adv Anat Pathol. 2024;31:88-95.
Abstract

LI J, Huang C, Xiong T, Zhuang C, et al
Erratum: A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells In Vitro: Erratum.
Int J Biol Sci. 2024;20:1088-1089.
Abstract

AKAN S, Atmaca MC
[Guillain-Barre syndrome caused by intravesical instillation of Bacillus Calmette-Guerin].
Ideggyogy Sz. 2024;77.
Abstract

SONG J, Wu Y, Chen Z, Zhai D, et al
Clinical significance of KRT7 in bladder cancer prognosis.
Int J Biol Markers. 2024 Feb 6:3936155231224798. doi: 10.1177/03936155231224798.
Abstract

GUO CC, Lee S, Lee JG, Chen H, et al
Molecular profile of bladder cancer progression to clinically aggressive subtypes.
Nat Rev Urol. 2024 Feb 6. doi: 10.1038/s41585-023-00847.
Abstract

CHENG L, Wang C, Sun Q
Teaching NeuroImage: Metastatic Urachal Carcinoma in the Extraocular Muscles Mimicking Oculomotor Paralysis.
Neurology. 2024;102:e209191.
Abstract

WANG J, Jiang Z, Wang K, Zheng Q, et al
Construction of a necroptosis-related lncRNA signature for predicting prognosis and revealing the immune microenvironment in bladder cancer.
Aging (Albany NY). 2024;16.
Abstract

WANG W, Shan D, Wang G, Mao X, et al
Elafibranor emerged as a potential chemotherapeutic drug for non-muscle invasive bladder cancer.
Cell Insight. 2024;3:100149.
Abstract

ZHOU H, Li R, Liu J, Long J, et al
Characterization and verification of CAF-relevant prognostic gene signature to aid therapy in bladder cancer.
Heliyon. 2024;10:e23873.
Abstract

TRECARTEN SJ, Svatek RS
Supplementary selenium and vitamin E in non-muscle-invasive bladder cancer.
Nat Rev Urol. 2024 Feb 5. doi: 10.1038/s41585-024-00859.
Abstract

JIANG M, Chen R, Hu B, Xiong S, et al
FATP2 activates PI3K/Akt/mTOR pathway by inhibiting ATF3 and promotes the occurrence and development of bladder cancer.
Cell Signal. 2024;117:111087.
Abstract

ONDER RO, Aslan S, Bekci T
Prevalence of Bladder Cancers Incidentally Detected During Multiparametric MRI Scans of the Prostate Gland and the Clinical Significance of Scoring Them According to VI-RADS: A Pictorial Single-Centre Study.
J Belg Soc Radiol. 2024;108:7.
Abstract

MYERS AA, Kamat AM, Kilbert A, Galsky MD, et al
Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panel.
J Immunother Cancer. 2024;12:e008508.
Abstract

LUO Y, Li Q, Liao Z, Luo Z, et al
Unusual case of retroperitoneal hematoma and duodenal ulcerative bleeding after nephrectomy: Case report.
Medicine (Baltimore). 2024;103:e33765.
Abstract

KOSHIISHI H, Yoshimura T, Konno T, Fujie T, et al
[A Case Report of Metachronous Multiple Cancers Including Triple Lung Cancers, Gastric Cancer, and Double Urothelial Cancers].
Gan To Kagaku Ryoho. 2023;50:1656-1658.
Abstract

YOU X, Zhu C, Yu P, Wang X, et al
Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy.
Biomed Pharmacother. 2024;171:116152.
Abstract

KOSHKIN VS, Kumar V, Kline B, Escobar D, et al
Initial Experience with (68)Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
J Nucl Med. 2024 Jan 11:jnumed.123.266390. doi: 10.2967/jnumed.123.266390.
Abstract

TRIPATHI N, Fortuna GG, Gebrael G, Dal E, et al
Predictors of response to neoadjuvant therapy in urothelial cancer.
Crit Rev Oncol Hematol. 2024;194:104236.
Abstract

AN L, Dong K, Chi S, Wei S, et al
lncRNA UCA1 promotes tumor progression by targeting SMARCD3 in cervical cancer.
Mol Carcinog. 2023 Dec 20. doi: 10.1002/mc.23659.
Abstract

URSO L, Bauckneht M, Albano D, Chondrogiannis S, et al
The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential.
Expert Rev Med Devices. 2024;21.
Abstract

ZHAO J, Guo CC, Rao P
Contemporary Issues in Urothelial Carcinoma of Upper Urinary Tract.
Adv Anat Pathol. 2024;31:80-87.
Abstract

LARKINS MC, Pasli M, Bhatt A, Burke A, et al
Squamous cell carcinoma of the bladder: Demographics and outcomes associated with surgery and radiotherapy.
J Surg Oncol. 2024;129:649-658.
Abstract

MATSUE T, Kato M, Kosugi Y, Ishizaki K, et al
Investigation of eligibility for adjuvant therapy from real-world data of patients with urothelial carcinoma undergoing radical cystectomy and radical nephroureterectomy.
Jpn J Clin Oncol. 2024;54:182-191.
Abstract

ARSHIA A, Hassan FA, Hensley PJ, Allison DB, et al
Urinary tract cytology showing variant morphology and divergent differentiation.
Cytopathology. 2024;35:199-212.
Abstract

KHAJIR G, Sun T, Wang H, Sprenkle PC, et al
Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow-up.
Cytopathology. 2024;35:235-241.
Abstract

YAMAMOTO S, Kato M, Matsue T, Yukimatsu N, et al
Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma.
Jpn J Clin Oncol. 2024;54:221-224.
Abstract

MA G, Jia H, Zhang G, Liang Y, et al
Presence, Subtypes, and Prognostic Significance of Tertiary Lymphoid Structures in Urothelial Carcinoma of the Bladder.
Oncologist. 2024;29:e248-e258.
Abstract

HORIKIRIZONO H, Nakaichi M, Itoh H, Itamoto K, et al
Intraoperative hypertensive crisis in a dog with functional paraganglioma of the gall bladder.
J Small Anim Pract. 2024;65:144-148.
Abstract

YE J, Liao X, Qiu Y, Wei Q, et al
A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients.
Tumori. 2024;110:25-33.
Abstract

PIETZAK EJ, Herr HW
An Interleukin-15 Superagonist with BCG - A Major Therapeutic Advancement or Just a Small Step in the Right Direction?
NEJM Evid. 2023;2:EVIDe2200264.
Abstract

CHAMIE K, Chang SS, Kramolowsky E, Gonzalgo ML, et al
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
NEJM Evid. 2023;2:EVIDoa2200167.
Abstract

DJUG H, Hasukic S, Jagodic S, Ivanic D, et al
Adjuvant Intravesical Chemotherapy Versus Immunotherapy for All Risk Groups of Patients With Non-muscle Invasive Bladder Cancer.
Med Arch. 2023;77:460-464.
Abstract

RAHMAN ZA, Hidayatullah F, Lim J, Hakim L, et al
A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer: Promising alternative therapy in high tuberculosis burden countries.
Arch Ital Urol Androl. 2024 Feb 16. doi: 10.4081/aiua.2024.12154.
Abstract

PRONTERA PP, Prusciano FR, Lattarulo M, Utano E, et al
Quality of bladder cancer treatment information on YouTube: May the user's profile affect the quality of results?
Arch Ital Urol Androl. 2024 Feb 16. doi: 10.4081/aiua.2024.12179.
Abstract

BRETON-PATIENT C, Billotte S, Duchambon P, Fontaine G, et al
Light-Activatable Photocaged UNC2025 for Triggering TAM Kinase Inhibition in Bladder Cancer.
Chembiochem. 2024 Feb 16:e202300855. doi: 10.1002/cbic.202300855.
Abstract

MAIMON Y, Amiel G, Cohen Z, Hoffman A, et al
Prevention of Bladder Cancer Recurrence With the Botanical Formula LCS103: A Case Series Study.
Integr Cancer Ther. 2024;23:15347354241233233.
Abstract

CAO B, Li Q, Xu P, Zhang Y, et al
Vesical Imaging-Reporting and Data System (VI-RADS) as a grouping imaging biomarker combined with a decision-tree mode to preoperatively predict the pathological grade of bladder cancer.
Clin Radiol. 2024 Feb 9:S0009-9260(24)00082-5. doi: 10.1016/j.crad.2024.
Abstract

KATIMS AB, Tallman J, Vertosick E, Porwal S, et al
Response to 2 Induction Courses of Bacillus Calmette-Guerin Therapy Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial.
JAMA Oncol. 2024 Feb 15. doi: 10.1001/jamaoncol.2023.6804.
Abstract

CHENNIAPPAN A, Stephen NS, Srinivas BH, Sreenivasan SK, et al
Plasmacytoid urothelial carcinoma with duodenal metastasis-A rare tumor with unusual site of metastasis with grim outcome.
Indian J Pathol Microbiol. 2024;67:175-177.
Abstract

GUPTA RK, Wasnik P, Sharma AR
Papillary urothelial neoplasm of low malignant potential with osseous metaplasia in a 19-year-old chronic smoker: A case report with review of literature.
Indian J Pathol Microbiol. 2024;67:159-161.
Abstract

SU Y, Chen L, Yang J
Hesperetin Inhibits Bladder Cancer Cell Proliferation and Promotes Apoptosis and Cycle Arrest by PI3K/AKT/FoxO3a and ER Stress-mitochondria Pathways.
Curr Med Chem. 2024 Feb 13. doi: 10.2174/0109298673283888231217174702.
Abstract

PAN G, Xie H, Xia Y
Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Heliyon. 2024;10:e25573.
Abstract

RIJNDERS M, Nakauma-Gonzalez JA, Robbrecht DGJ, Gil-Jimenez A, et al
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
Nat Commun. 2024;15:1349.
Abstract

AMARA CS, Kami Reddy KR, Yuntao Y, Chan YS, et al
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.
Nat Commun. 2024;15:1373.
Abstract

ALI M, Koo K, Chang D, Chan P, et al
Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
Radiat Oncol. 2024;19:23.
Abstract

SUZUKI A, Ito H, Uemura K, Muraoka K, et al
Surgical proficiency in laparoscopic radical cystectomy with extracorporeal urinary diversion and its adequacy for the execution of robot-assisted radical cystectomy with intracorporeal urinary diversion.
Asian J Endosc Surg. 2024;17:e13289.
Abstract

LI C, Qin W, Hu J, Lin J, et al
A Machine Learning Computational Framework Develops a Multiple Programmed Cell Death Index for Improving Clinical Outcomes in Bladder Cancer.
Biochem Genet. 2024 Feb 14. doi: 10.1007/s10528-024-10683.
Abstract

ORTNER G, Guven S, Somani BK, Nicklas A, et al
Experts' recommendations in laser use for the treatment of bladder cancer: a comprehensive guide by the European Section of Uro-Technology (ESUT) and Training and Research in Urological Surgery and Technology (TRUST)-Group.
World J Urol. 2024;42:79.
Abstract

LUO S, Huang X, Li S, Chen Y, et al
Homogeneous Polyporus polysaccharide exerts anti-bladder cancer effects via autophagy induction.
Pharm Biol. 2024;62:214-221.
Abstract

SHISHKOV DD, Shishkov DG, Todorov S, Mihaylov N, et al
Laparoscopic vs. open surgical access radical cystectomy with subsequent orthotopic reconstruction in the treatment of invasive urothelial carcinoma of the bladder.
Folia Med (Plovdiv). 2023;65:894-901.
Abstract

SILVA IMD, Vacario BGL, Okuyama NCM, Barcelos GRM, et al
Polymorphisms in drug-metabolizing genes and urinary bladder cancer susceptibility and prognosis: Possible impacts and future management.
Gene. 2024;907:148252.
Abstract

WEI Z, Xv Y, Liu H, Li Y, et al
A CT-based deep learning model predicts overall survival in patients with muscle invasive bladder cancer after radical cystectomy: a multicenter retrospective cohort study.
Int J Surg. 2024 Feb 13. doi: 10.1097/JS9.0000000000001194.
Abstract

LEE CU, Lee JH, Lee HW, Chung JH, et al
Analysis of progression after elective distal ureterectomy and effects of salvage radical nephroureterectomy in patients with distal ureteral urothelial carcinoma.
Sci Rep. 2024;14:3497.
Abstract

XU Y, Sun G, Yang T, Li H, et al
Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights from a bladder cancer organoid model.
Int J Hyperthermia. 2024;41:2316085.
Abstract

LOPEZ-BELTRAN A, Cookson MS, Guercio BJ, Cheng L, et al
Advances in diagnosis and treatment of bladder cancer.
BMJ. 2024;384:e076743.
Abstract

SU Y, Chen L, Yang J
Network pharmacology and in vitro experiments reveal sophoridine-induced apoptosis and G(1) phase arrest via ROS-dependent PI3K/Akt/FoxO3a pathway activation in human bladder cancer cells.
Chem Biol Drug Des. 2024;103:e14476.
Abstract

LIEDBERG F, Hagberg O, Aljabery F, Falini V, et al
[Radical cystectomy for bladder cancer is a complex procedure].
Lakartidningen. 2024;121:23132.
Abstract

CETIN T, Bolat D, Cesur G, Erdemoglu O, et al
Comparison of Monopolar Versus Bipolar Repeat Transurethral Resection of Bladder Tumours.
J Coll Physicians Surg Pak. 2024;34:230-234.
Abstract

XIE T, Peng S, Liu S, Zheng M, et al
Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer.
Mol Cancer. 2024;23:30.
Abstract

MATHEW THOMAS V, Grivas P, Agarwal N
Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?
Med. 2024;5:109-111.
Abstract

LU Q, Wang J, Tao Y, Zhong J, et al
Small Cajal Body-Specific RNA12 Promotes Carcinogenesis through Modulating Extracellular Matrix Signaling in Bladder Cancer.
Cancers (Basel). 2024;16:483.
Abstract

LI AH, Park SY, Li P, Zhou C, et al
Transcriptome Analysis Reveals Anti-Cancer Effects of Isorhapontigenin (ISO) on Highly Invasive Human T24 Bladder Cancer Cells.
Int J Mol Sci. 2024;25:1783.
Abstract

KUSTRIMOVIC N, Bilato G, Mortara L, Baci D, et al
The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer.
Int J Mol Sci. 2024;25:1732.
Abstract

GILL E, Perks CM
Mini-Review: Current Bladder Cancer Treatment-The Need for Improvement.
Int J Mol Sci. 2024;25:1557.
Abstract

FAN LW, Li YR, Wu CM, Chuang KT, et al
Inpatient Outcomes of Patients Undergoing Robot-Assisted versus Laparoscopic Radical Cystectomy for Bladder Cancer: A National Inpatient Sample Database Study.
J Clin Med. 2024;13:772.
Abstract

TANG R, Wang H, Liu J, Song L, et al
TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Eur J Med Res. 2024;29:112.
Abstract

IBRAHIM M, Rabinowitz J, Hilbert R, Ghose A, et al
The role of URO17(R) in diagnosis and follow up of bladder cancer patients.
BMC Urol. 2024;24:34.
Abstract

KAWADA T, Yanagisawa T, Rajwa P, Motlagh RS, et al
The Prognostic Value of Tumor Infiltrating Lymphocytes After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2024 Jan 17:S1558-7673(24)00009.
Abstract

HUANG SY, Su PJ, Lin CT, Kuo MC, et al
The impact of body mass index on survival endpoints among patients with metastatic urothelial carcinoma undergoing treatment with immune checkpoint inhibitors: A real-world multicenter analysis.
Cancer Med. 2024;13:e7008.
Abstract

[Not Available].
Aktuelle Urol. 2024;55:24-25.
Abstract

[Not Available].
Aktuelle Urol. 2024;55:22-23.
Abstract

[Not Available].
Aktuelle Urol. 2024;55:18-20.
Abstract

NGUYEN NJ, Sherman C, van der Kwast TH, Downes MR, et al
Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Pathol Res Pract. 2024;254:155105.
Abstract

KARAHAN I, Bilgin B
Is my patient with urothelial cancer (in)eligible for platinum?
Urol Oncol. 2024;42:27.
Abstract

ZHU X, Koshkin VS
Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
Med. 2024;5:106-108.
Abstract

TAUZIEDE-ESPARIAT A, Masliah-Planchon J, Tran S, Filser M, et al
Brain metastasis of a urothelial neuroendocrine carcinoma: A double pitfall for neuropathologists and DNA-methylation profiling.
Neuropathol Appl Neurobiol. 2024;50:e12951.
Abstract

TAMURA D, Abe M, Hiraki H, Sasaki N, et al
Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
Cancer Sci. 2024;115:529-539.
Abstract

GWAK CH, Suh J, Lim B, Song C, et al
Preoperative C-reactive protein to albumin ratio as a novel prognostic biomarker for the oncological outcomes of radical nephroureterectomy.
Urol Oncol. 2024;42:30.
Abstract

CARMONA O, Kleinmann N, Zilberman DE, Dotan ZA, et al
Do Urine Cytology and FISH Analysis Have a Role in the Follow-Up Protocol of Upper Tract Urothelial Carcinoma?
Clin Genitourin Cancer. 2024;22:98-105.
Abstract

FILIPPI L, Schillaci O
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
Expert Rev Anticancer Ther. 2024;24.
Abstract

SONPAVDE GP, Subbiah V
Unlocking precision oncology with FGFR inhibition in urothelial carcinoma.
Ann Oncol. 2024;35:150-153.
Abstract

NECCHI A, Pouessel D, Leibowitz R, Gupta S, et al
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
Ann Oncol. 2024;35:200-210.
Abstract

LI M, Yan X, Liu H, Miao W, et al
Novel MSH2 and TSC2 variants in a Chinese family with Lynch syndrome and their synergistic impact in urothelial carcinoma.
Transl Res. 2024;265:26-35.
Abstract

WEI Y, Zhao M, He T, Chen N, et al
Quantitatively Lighting up the Spatial Organization of CD47/SIRPalpha Immune Checkpoints on the Cellular Membrane with Single-Molecule Localization Microscopy.
ACS Nano. 2023;17:21626-21638.
Abstract

VOS N, Minner J, Bohm J
[Paraganglioma of the urinary bladder-a rare, but relevant differential diagnosis].
Urologie. 2024;63:168-170.
Abstract

LUO S, Wu Y, Yang R, Huang G, et al
Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC.
Urol Oncol. 2024;42:30.
Abstract

YILMAZ H, Teke K, Suer E, Izol V, et al
Does neo-adjuvant chemotherapy improve the negative effect of lymphovascular invasion in survival after radical cystectomy?
Urol Oncol. 2024;42:30.
Abstract

MATHAVAN A, Mathavan A, Murillo-Alvarez R, Gera K, et al
Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies.
Clin Genitourin Cancer. 2024;22:67-75.
Abstract

RAC G, Patel HD, James C, Desai S, et al
Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy.
Mol Oncol. 2024;18:291-304.
Abstract

GURNEY H, Clay TD, Oliveira N, Wong S, et al
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia.
Asia Pac J Clin Oncol. 2023;19:585-595.
Abstract

NECCHI A, Faltas BM, Slovin SF, Meeks JJ, et al
Immunotherapy in the Treatment of Localized Genitourinary Cancers.
JAMA Oncol. 2023;9:1447-1454.
Abstract

SOTELO M, Munoz-Unceta N, Matorras A, Jara P, et al
Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution.
Clin Transl Oncol. 2024;26:682-688.
Abstract

JOYCE DD, Shan Y, Stewart CA, Chamie K, et al
A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma.
Clin Genitourin Cancer. 2024;22:14-22.
Abstract

PARK K, Lee HJ, Kim TU, Ryu H, et al
Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
Asia Pac J Clin Oncol. 2023;19:739-746.
Abstract

TAN KL, Viswambaram P, McCombie S, Moe A, et al
Fremantle protocol: Multicenter clinical outcomes for a pragmatic protocol for intravesical bacillus Calmette-Guerin.
Asia Pac J Clin Oncol. 2023;19:697-705.
Abstract

ABOU CHAKRA M, Duquesne I, Peyromaure M, Mott SL, et al
Impact of bladder cancer family history on the prognosis of patients with Non-Muscle Invasive bladder cancer Treated with Bacillus Calmette-Guerin (BCG).
Expert Opin Pharmacother. 2024 Feb 23. doi: 10.1080/14656566.2024.2323609.
Abstract

PROIETTI F, Flammia RS, Licari LC, Bologna E, et al
Impacts of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients with Bladder Cancer Treated with Radical Cystectomy: A Single High-Volume Center Experience.
J Pers Med. 2024;14:212.
Abstract

LIDAGOSTER S, Ben-David R, De Leon B, Sfakianos JP, et al
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer.
Curr Oncol. 2024;31:1063-1078.
Abstract

TUFANO A, Rosati D, Moriconi M, Santarelli V, et al
Diagnostic Accuracy of Contrast-Enhanced Ultrasound (CEUS) in the Detection of Muscle-Invasive Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis.
Curr Oncol. 2024;31:818-827.
Abstract

XU H, Sun D, Zhou D, Sun S, et al
Immune Cell Infiltration Types as Biomarkers for the Recurrence Diagnosis and Prognosis of Bladder Cancer.
Cancer Invest. 2024 Feb 23:1-13. doi: 10.1080/07357907.2024.2308161.
Abstract

ATES SG, Demirel BB, Basar H, Ucmak G, et al
The Added-value of Staging (18)F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.
Mol Imaging Radionucl Ther. 2024;33:11-18.
Abstract

YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
Reply to Shun-Fa Hung's Letter to the editor regarding the article "Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer".
Urol Oncol. 2024 Feb 21:S1078-1439(24)00021.
Abstract

BEATRICI E, Labban M, Filipas DK, Stone BV, et al
Smoking characteristics and years since quitting smoking of US adults diagnosed with lung and bladder cancer: A national health and nutrition examination survey analysis.
Int Braz J Urol. 2024;50:199-208.
Abstract

WANG X, Song D, Zhu B, Jin Y, et al
Urinary exosomal mRNA as a biomarker for the diagnosis of bladder cancer.
Anticancer Drugs. 2024 Feb 23. doi: 10.1097/CAD.0000000000001571.
Abstract

YU H, Zhuang J, Zhou Z, Song Q, et al
METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway.
Int J Biol Sci. 2024;20:1471-1491.
Abstract

DU W, Tu S, Zhang W, Zhang Y, et al
UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT.
Int J Biol Sci. 2024;20:1389-1409.
Abstract

FALABELLA R, La Falce S, Ponti FC, Di Fino G, et al
A rare case of muscle invasive bladder cancer in a Vescical inguinal hernia.
Urol Case Rep. 2024;53:102673.
Abstract

SAAD R, Ghaddar A, Zeenny RM
Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
J Med Case Rep. 2024;18:107.
Abstract

YUAN H, Wang T, Peng P, Xu Z, et al
Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment.
Clin Genitourin Cancer. 2024 Jan 22:S1558-7673(24)00012.
Abstract

WANG X, Wang L
Research progress of ICIS in the treatment of bladder cancer.
Panminerva Med. 2024 Feb 21. doi: 10.23736/S0031-0808.24.05102.
Abstract

QI D, Lu Y, Qu H, Dong Y, et al
Independent prognostic value of CLDN6 in bladder cancer based on M2 macrophages related signature.
iScience. 2024;27:109138.
Abstract

KANG NW, Feng YH, Lin KL, Chen YC, et al
Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
Cancer Med. 2024;13:e6972.
Abstract

OMURA M, Kosaka T, Kobayashi H, Shigeta K, et al
Vasohibin-1 Expression Can Predict Pathological Complete Remission of Advanced Bladder Cancer with Neoadjuvant Chemotherapy.
Ann Surg Oncol. 2024 Feb 20. doi: 10.1245/s10434-024-15009.
Abstract

ISALI I, Helstrom EK, Uzzo N, Lakshmanan A, et al
Current Trends and Challenges of Microbiome Research in Bladder Cancer.
Curr Oncol Rep. 2024 Feb 20. doi: 10.1007/s11912-024-01508.
Abstract

RAJA D, Singh A, Kurra S, Nayak B, et al
Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target.
Med Oncol. 2024;41:74.
Abstract

FAN N, Zhang L, Wang Z, Ding H, et al
Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage.
Anticancer Agents Med Chem. 2024;24:348-357.
Abstract

HAN X, Gao K, Shang L, Wei L, et al
Caregiver experiences of caring for family members with urostomy: a qualitative study.
Support Care Cancer. 2024;32:167.
Abstract

ZHANG S, Lin T, Xiong X, Chen C, et al
Targeting histone modifiers in bladder cancer therapy - preclinical and clinical evidence.
Nat Rev Urol. 2024 Feb 19. doi: 10.1038/s41585-024-00857.
Abstract

YAO Q, Jiang H, Niu H, Hu G, et al
Prospective learning curve analysis of en bloc resection of bladder tumor using an ex vivo porcine model.
BMC Surg. 2024;24:65.
Abstract

LI Q, Su X, Qing L, Xu W, et al
HER2 Affects the Biological Behaviours of Bladder Cancer Cells and is Closely Associated with the Progression and Prognosis of Bladder Cancer.
Arch Esp Urol. 2024;77:79-91.
Abstract

LIN R, Fu X, Huang J
Relationship between Changes of Serum Vascular Endothelial Growth Factor and Folate Receptor-alpha Levels and Clinical Efficacy of Toripalimab in Patients with Bladder Cancer.
Arch Esp Urol. 2024;77:31-37.
Abstract

HARSANYI S, Kianickova K, Katrlik J, Danisovic L, et al
Current look at the most promising proteomic and glycomic biomarkers of bladder cancer.
J Cancer Res Clin Oncol. 2024;150:96.
Abstract

RT R, Sharma A, Biswal D, Goel S, et al
Comparison of narrow band imaging versus white light imaging in detecting non muscle invasive bladder cancer.
Urologia. 2024 Feb 19:3915603241232115. doi: 10.1177/03915603241232115.
Abstract

ABUHASANEIN S, Jahnson S, Kjolhede H
Shortened time to diagnosis for patients suspected of urinary bladder cancer managed in a standardized care pathway was associated with an improvement in tumour characteristics.
BJUI Compass. 2023;5:261-268.
Abstract

MIYAKE M, Kitamura H, Nishimura N, Miyamoto T, et al
Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
BJUI Compass. 2023;5:269-280.
Abstract

ZHOU Q, Fang L, Tang Y, Wang Q, et al
Exosome-mediated delivery of artificial circular RNAs for gene therapy of bladder cancer.
J Cancer. 2024;15:1770-1778.
Abstract

YU L, Lin N, Ye Y, Zhou S, et al
Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance.
J Cancer. 2024;15:1734-1749.
Abstract

TAN Z, Chen X, Li H, Huang Y, et al
HES4 is a potential biomarker for bladder cancer: a Mendelian randomization study.
J Cancer. 2024;15:1624-1641.
Abstract

LV H, Zhou X, Liu Y, Liu Y, et al
Feasibility analysis of arterial CT radiomics model to predict the risk of local and metastatic recurrence after radical cystectomy for bladder cancer.
Discov Oncol. 2024;15:40.
Abstract

LIU S, Wang X, Sun X, Wei B, et al
Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1.
Phytomedicine. 2024;126:155426.
Abstract

XIE S, Friesen MC, Baris D, Schwenn M, et al
Occupational exposure to organic solvents and risk of bladder cancer.
J Expo Sci Environ Epidemiol. 2024 Feb 16. doi: 10.1038/s41370-024-00651.
Abstract

LI T, Huang M, Sun N, Hua X, et al
Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation.
J Exp Clin Cancer Res. 2024;43:50.
Abstract

SHAO B, Wu K, Wan S, Sun P, et al
Prediction of future research trends in bladder urothelial carcinoma: Bibliometric analysis.
Medicine (Baltimore). 2024;103:e37176.
Abstract

BODDU VK, Zamzow P, Kramer MW, Merseburger AS, et al
Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells.
Cell Commun Signal. 2024;22:129.
Abstract

YIP W, Assel MJ, Wong NC, Tracey AT, et al
Changes in the Perioperative Management and Outcomes of Patients With Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy at Memorial Sloan Kettering Cancer Center: Over 20 Years of Experience.
Urol Pract. 2024;11:356-366.
Abstract

BERG SA, McGregor BA
One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.
Curr Treat Options Oncol. 2024;25:206-219.
Abstract

DONG Y, Wu X, Xu C, Hameed Y, et al
Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
Aging (Albany NY). 2024;16:2591-2616.
Abstract

GALSKY MD, Guan X, Rishipathak D, Rapaport AS, et al
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Cell Rep Med. 2024;5:101393.
Abstract

PALIOGIANNIS P, Lobrano R, Bella MA, Fara A, et al
PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
Ann Diagn Pathol. 2024;69:152267.
Abstract

NIZIOL J, Ossolinski K, Plaza-Altamer A, Kolodziej A, et al
Untargeted metabolomics of bladder tissue using liquid chromatography and quadrupole time-of-flight mass spectrometry for cancer biomarker detection.
J Pharm Biomed Anal. 2024;240:115966.
Abstract

ZHANG T, Li H, Lin C, An R, et al
Effects of an intraoperative intravenous Bolus Dose of Dexmedetomidine on postoperative catheter-related bladder discomfort in male patients undergoing transurethral resection of bladder tumors: a randomized, double-blind, controlled trial.
Eur J Clin Pharmacol. 2024;80:465-474.
Abstract

CAN O, Danis E, Kutluturk EG, Polat EC, et al
Hybrid technique has lower stricture rates than Wallace and Bricker.
Surg Oncol. 2024;52:102036.
Abstract

RAGI N, Walmsley SJ, Jacobs FC, Rosenquist TA, et al
Screening DNA Damage in the Rat Kidney and Liver by Untargeted DNA Adductomics.
Chem Res Toxicol. 2024;37:340-360.
Abstract

TOSI G, Barnes JR
Early-Onset Asymptomatic Polypoid Cystitis in Two Adolescent Male Beagle Dogs.
Toxicol Pathol. 2023;51:357-360.
Abstract

STORMOEN DR, Joensen UN, Daugaard G, Oturai P, et al
Glomerular filtration rate measurement during platinum treatment for urothelial carcinoma: optimal methods for clinical practice.
Int J Clin Oncol. 2024;29:309-317.
Abstract

NAMUGOSA M, Matthew AN, Fogg R, Klausner AP, et al
Characterization of Cystoscopy Performance and Reporting Practices at Academic Urology Centers.
Urol Pract. 2024;11:249-253.
Abstract

BURALLI R, Ribeiro A, Cremonese C, Vineis P, et al
Cancer mortality and premature deaths among hairdressers in Brazil.
Environ Res. 2024;244:117942.
Abstract

CHEN Y, Liao Y, Yang Y, Zheng X, et al
Letter to the editor: Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis.
Int J Surg. 2024;110:1289-1290.
Abstract

HUANG J, Chen G, Liu H, Jiang W, et al
MRI-based automated machine learning model for preoperative identification of variant histology in muscle-invasive bladder carcinoma.
Eur Radiol. 2024;34:1804-1815.
Abstract

BOTROUS S, Elmaghraby A, El-Achy S, Mustafa Y, et al
Inhibition of TNF-alpha Oncogene Expression by Artemisia Annua L. Extract Against Pioglitazone Side Effects in Male Albino Mice.
Mol Biotechnol. 2024;66:432-441.
Abstract

SUTO H, Inui Y, Nishikawa S, Okamura A, et al
Delayed diagnosis of bladder cancer in a patient with autosomal dominant polycystic kidney disease.
J Cancer Res Ther. 2023;19.
Abstract

DURUR S, Uzun H, Bedir R, Nalkiran I, et al
Prognostic importance of PD-L1 expression in bladder cancer patients.
J Cancer Res Ther. 2023;19.
Abstract

LI C, Wang Z, Feng N, Dong J, et al
[Retracted] Human HLA?F adjacent transcript 10 promotes the formation of cancer initiating cells and cisplatin resistance in bladder cancer.
Mol Med Rep. 2024;29:63.
Abstract

WU Y, Gu X, Chen X, Cui Y, et al
Hydrogel: a new material for intravesical drug delivery after bladder cancer surgery.
J Mater Chem B. 2024 Mar 1. doi: 10.1039/d3tb02837.
Abstract

HOU DY, Zhang NY, Wang L, Lv MY, et al
Inducing mitochondriopathy-like damages by transformable nucleopeptide nanoparticles for targeted therapy of bladder cancer.
Natl Sci Rev. 2024;11:nwae028.
Abstract

ZHONG L, Wang F
Comparative analysis of wound healing techniques in postoperative bladder cancer patients.
Int Wound J. 2024;21:e14820.
Abstract

QIN F, Wu J
Impact of sarcopenia on outcomes of bladder cancer undergoing radical cystectomy: A systematic review and meta-analysis.
Scott Med J. 2024 Feb 29:369330241234690. doi: 10.1177/00369330241234690.
Abstract

CHIEN TM, Yang CW, Yen CH, Yeh BW, et al
Excavatolide C/cisplatin combination induces antiproliferation and drives apoptosis and DNA damage in bladder cancer cells.
Arch Toxicol. 2024 Feb 29. doi: 10.1007/s00204-024-03699.
Abstract

ZHANG R, Jiang W, Wang G, Zhang Y, et al
Parkin inhibits proliferation and migration of bladder cancer via ubiquitinating Catalase.
Commun Biol. 2024;7:245.
Abstract

MUHUITIJIANG B, Zhou J, Zhou R, Zhang Z, et al
Development and experimental validation of an M2 macrophage and platelet-associated gene signature to predict prognosis and immunotherapy sensitivity in bladder cancer.
Cancer Sci. 2024 Feb 29. doi: 10.1111/cas.16113.
Abstract

SONG Y, Xu T
Neoadjuvant combination therapy (immunotherapy and chemotherapy) and treatment-related biomarkers in upper tract urothelial carcinoma.
World J Urol. 2024;42:110.
Abstract

BAHLBURG H, Tully KH, Bach P, Butea-Bocu MC, et al
Improvements in urinary symptoms, health-related quality of life, and psychosocial distress in the early recovery period after radical cystectomy and urinary diversion in 842 German bladder cancer patients: data from uro-oncological rehabilitation.
World J Urol. 2024;42:111.
Abstract

QIU X, Jiang Z, Luo Y, Tian D, et al
PPP3CB Inhibits Cell Proliferation and the Warburg Effect in Bladder Cancer by Blocking PDHK1.
Front Biosci (Landmark Ed). 2024;29:48.
Abstract

WESOLOW JT
Ogilvie's Syndrome in a Male With Bladder Cancer.
Cureus. 2024;16:e55097.
Abstract

HUANG Y, Chen Z, Shen G, Fang S, et al
Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis.
Hum Vaccin Immunother. 2024;20:2318815.
Abstract

AKAGI N, Kanematsu A, Shigesaka K, Shimatani K, et al
Prostate Biopsy May Not Be Indicated Early after Bacillus Calmette Guerin Treatment.
Acta Med Okayama. 2024;78:9-13.
Abstract

ZHOU Z, Zou L, Guan Y, Jiang L, et al
Survivin as a potential biomarker in the diagnosis of bladder cancer: A systematic review and meta-analysis.
Urol Oncol. 2024 Feb 27:S1078-1439(24)00019.
Abstract

MINATO A, Murooka K, Okumura Y, Takaba T, et al
Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.
In Vivo. 2024;38:873-880.
Abstract

FAN J, Chen B, Luo Q, Li J, et al
Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer.
Biomed Pharmacother. 2024;173:116312.
Abstract

BUONERBA C, Ingenito C, Di Trolio R, Cappuccio F, et al
Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond.
Oncol Ther. 2024 Feb 28. doi: 10.1007/s40487-024-00266.
Abstract

ELSAYED AM, Mahmoud EI, Salem MM, Khairy RA, et al
Immunohistochemical Expression of Claudin-1 and Claudin-4 in Urothelial Carcinoma of the Urinary Bladder.
Asian Pac J Cancer Prev. 2024;25:637-646.
Abstract

LncRNA HCP5 Promotes Cell Invasion and Migration by Sponging miR-29b-3p in Human Bladder Cancer [Retraction].
Onco Targets Ther. 2024;17:159-160.
Abstract

MCNICHOLAS DP, El-Taji O, Siddiqui Z, Hanchanale V, et al
Systematic review comparing uretero-enteric stricture rates between open cystectomy with ileal conduit, robotic cystectomy with extra-corporeal ileal conduit and robotic cystectomy with intra corporeal ileal conduit formation.
J Robot Surg. 2024;18:100.
Abstract

HU P, Dai HI, Bourdage J, Zhou D, et al
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
Clin Transl Sci. 2024;17:e13730.
Abstract

ZHOU X, Xue F, Li T, Xue J, et al
Exploration of potential biomarkers for early bladder cancer based on urine proteomics.
Front Oncol. 2024;14:1309842.
Abstract

SHEN D, Kang S
Comprehensive analysis of mitochondria-related genes indicates that PPP2R2B is a novel biomarker and promotes the progression of bladder cancer via Wnt signaling pathway.
Biol Direct. 2024;19:17.
Abstract

CHEN Q, Tan S, Long S, Wang K, et al
Vagococcus fluvialis isolation from the urine of a bladder cancer patient: a case report.
BMC Infect Dis. 2024;24:261.
Abstract

YEARY KHK, Yu H, Kuliszewski MG, Li Q, et al
Outcomes of a Dietary Intervention to Reduce Bladder Cancer Recurrence and Progression in Survivors of Non-Muscle-Invasive Bladder Cancer.
J Natl Compr Canc Netw. 2024 Feb 26:1-9. doi: 10.6004/jnccn.2023.7086.
Abstract

URABE F
Letter to the editor for the article "Prognostic factors of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma".
World J Urol. 2024;42:101.
Abstract

KORNER SK, Dreyer T, Carus A, Dohn LH, et al
DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer.
Scand J Urol. 2024;59:39-46.
Abstract

BENDERSKA-SODER N, Ecke T, Kleinlein L, Roghmann F, et al
Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.
Urol Oncol. 2024 Feb 24:S1078-1439(24)00041.
Abstract

LIU G, Jin K, Liu Z, Su X, et al
Integration of CD4(+) T cells and molecular subtype predicts benefit from PD-L1 blockade in muscle-invasive bladder cancer.
Cancer Sci. 2024 Feb 25. doi: 10.1111/cas.16119.
Abstract

PANG ZQ, Wang JS, Wang JF, Wang YX, et al
JAM3 is a potential risk biomarker for predicting prognosis and immune cell infiltration by regulating epithelial-mesenchymal transition in bladder cancer.
Biomol Biomed. 2024 Feb 23. doi: 10.17305/bb.2024.9979.
Abstract

FAN Z, Deng J, Wang Y, Fan X, et al
Bladder Cancer: Immunotherapy and Pelvic Lymph Node Dissection.
Vaccines (Basel). 2024;12:150.
Abstract

CORVINO A, Basile L, Cocco G, Delli Pizzi A, et al
Complications Subsequent to Urinary Tract Stent Placement: An Overview Focusing on the Imaging of Cancer Patients.
Medicina (Kaunas). 2024;60:338.
Abstract

ALBERCA-DEL ARCO F, Prieto-Cuadra D, Santos-Perez de la Blanca R, Saez-Barranquero F, et al
New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine.
Cancers (Basel). 2024;16:803.
Abstract

KRAVCHUK AP, Wolff I, Gilfrich C, Wirtz RM, et al
Urine-Based Biomarker Test Uromonitor((R)) in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer-A Systematic Review and Meta-Analysis of Diagnostic Test Performance.
Cancers (Basel). 2024;16:753.
Abstract

VUKOVIC M, Chamlati JM, Hennenlotter J, Todenhofer T, et al
Interleukin-1beta/Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) Axis in Invasive Bladder Cancer-An Exploratory Analysis of Clinical and Tumor Biological Significance.
Int J Mol Sci. 2024;25:2447.
Abstract

TORRES-BUSTAMANTE MI, Vazquez-Urrutia JR, Solorzano-Ibarra F, Ortiz-Lazareno PC, et al
The Role of miRNAs to Detect Progression, Stratify, and Predict Relevant Clinical Outcomes in Bladder Cancer.
Int J Mol Sci. 2024;25:2178.
Abstract

HE K, Meng X, Wang Y, Feng C, et al
Progress of Multiparameter Magnetic Resonance Imaging in Bladder Cancer: A Comprehensive Literature Review.
Diagnostics (Basel). 2024;14:442.
Abstract

XU C, Zhou J, Zhang X, Kang X, et al
N(6)-methyladenosine-modified circ_104797 sustains cisplatin resistance in bladder cancer through acting as RNA sponges.
Cell Mol Biol Lett. 2024;29:28.
Abstract

LUO H, Wang Z
Pan-cancer analysis reveals potential immunological and prognostic roles of COA6 in human cancers and preliminary exploration of COA6 in bladder cancer.
Cell Signal. 2024;117:111111.
Abstract

MINATO A, Furubayashi N, Nagata Y, Tomoda T, et al
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Curr Oncol. 2024;31:862-871.
Abstract

ENDO Y, Akatsuka J, Takeda H, Hasegawa H, et al
Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions.
Curr Oncol. 2024;31:759-768.
Abstract

MORIA FA, Park CL, Eigl BJ, Macfarlane R, et al
A Real-World Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada.
Curr Oncol. 2024;31:704-722.
Abstract

CARDILLO TM, Zalath MB, Arrojo R, Sharkey RM, et al
Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
Oncotarget. 2024;15:144-158.
Abstract

PULIATTI S, Ferretti S, Penaranda NR, Eissa A, et al
Applicability and feasibility of robot-assisted cystectomy and intracorporeal urinary diversion in a patient with right renal pelvic ectopia.
Int Braz J Urol. 2024;50:227-228.
Abstract

BITTING RL, Tooze JA, Goodman M, Vile DC, et al
Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.
Cancer Res Commun. 2024;4:530-539.
Abstract

STOLL AK, Koll FJ, Eckstein M, Reis H, et al
[Histomolecular classification of urothelial carcinoma of the urinary bladder : From histological phenotype to genotype and back].
Pathologie (Heidelb). 2024;45:106-114.
Abstract

OLDAN JD, Schroeder JA, Hoffman-Censits J, Rathmell WK, et al
PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers.
PET Clin. 2024;19:197-206.
Abstract

HOFFMAN-CENSITS J, Grivas P, Powles T, Hawley J, et al
The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
Future Oncol. 2024;20:179-190.
Abstract

LIU G, Jin K, Liu Z, Su X, et al
POLQ identifies a better response subset to immunotherapy in muscle-invasive bladder cancer with high PD-L1.
Cancer Med. 2024;13:e6962.
Abstract

NAGATA Y, Goto T, Teramoto Y, Matsukawa T, et al
Mineralocorticoid receptor signaling inhibits bladder cancer progression.
Am J Cancer Res. 2024;14:696-708.
Abstract

WEI L, Wang SS, Huang ZG, He RQ, et al
TM9SF1 promotes bladder cancer cell growth and infiltration.
World J Clin Oncol. 2024;15:302-316.
Abstract

ZHOU SQ, Luo LX
TM9SF1 is implicated in promoting the proliferation and invasion of bladder cancer cells.
World J Clin Oncol. 2024;15:175-177.
Abstract

PENG Z, Zhuang J, Shen B
The role of microbiota in tumorigenesis, progression and treatment of bladder cancer.
Microbiome Res Rep. 2023;3:5.
Abstract

DJATISOESANTO W, Azmi YA, Yatindra IBGTY
The relationship between income, health insurance, and employment status as prognostic indicators of bladder cancer: a survival analysis.
Arch Ital Urol Androl. 2024 Mar 7:12305. doi: 10.4081/aiua.2024.12305.
Abstract

NOLTING J, Nitzsche R, Kiss B, Hakenberg OW, et al
Prospective evaluation of sexual health following radical cystectomy due to bladder cancer.
Sex Med. 2024;12:qfae005.
Abstract

OSHIRO H, Shimizu Y, Nakayasu R, Yamaguchi R, et al
[Bladder Cancer Detected Incidentally by Cystoscopy before Radical Prostatectomy].
Hinyokika Kiyo. 2024;70:39-43.
Abstract

NIEGISCH G
Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.
N Engl J Med. 2024;390:944-946.
Abstract

POWLES T, Valderrama BP, Gupta S, Bedke J, et al
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
N Engl J Med. 2024;390:875-888.
Abstract

MAIORANO BA, Di Maio M, Cerbone L, Maiello E, et al
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
JAMA Netw Open. 2024;7:e241215.
Abstract

KONG YL, Wang HD, Gao M, Rong SZ, et al
LncRNA XIST promotes bladder cancer progression by modulating miR-129-5p/TNFSF10 axis.
Discov Oncol. 2024;15:65.
Abstract

HUANG Y, Liao C, Shen Z, Zou Y, et al
A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues.
Front Immunol. 2024;15:1297542.
Abstract

HUANG XL, Sun Y, Wen P, Pan JC, et al
The potential mechanism of ursolic acid in the treatment of bladder cancer based on network pharmacology and molecular docking.
J Int Med Res. 2024;52:3000605241234006.
Abstract

WANG Q, Zhang R, He Y, Mao G, et al
Taraxasterol enhanced bladder cancer cells radiosensitivity via inhibiting the COX-2/PGE2/JAK2/STAT3/MMP pathway.
Int J Radiat Biol. 2024 Mar 5:1-11. doi: 10.1080/09553002.2024.2324475.
Abstract

ZHANG Q, Wang L, Yu L, Yu Q, et al
Tectoridin inhibits the growth of bladder cancer by regulating PI3K/MAPK pathway through RAB27B.
Mol Carcinog. 2024 Mar 5. doi: 10.1002/mc.23712.
Abstract

MITANI K, Tsuboi I, Tanaka G, Yosioka S, et al
Metastatic small cell bladder cancer treated with sequential systemic therapy including pembrolizumab and amrubicin: A case report.
IJU Case Rep. 2023;7:127-130.
Abstract

CHEN YT, Tang QY, Zhang YX, Wang SZ, et al
An Atlas of Dietary Intakes and Medication Uses on Risk of Bladder Cancer: A Wide-Angle Mendelian Randomization Analysis.
Nutr Cancer. 2024 Mar 5:1-10. doi: 10.1080/01635581.2024.2324504.
Abstract

ABOU CHAKRA M, Moussa M, O'Donnell MA
Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability.
J Chemother. 2024 Mar 4:1-4. doi: 10.1080/1120009X.2024.2325765.
Abstract

LIU Y, Zou SH, Gao X
Bioinformatics analysis and experimental validation reveal that CDC20 overexpression promotes bladder cancer progression and potential underlying mechanisms.
Genes Genomics. 2024 Mar 4. doi: 10.1007/s13258-024-01505.
Abstract

LI M, Nandurkar R, Toniolo J, Davis ID, et al
A phase 2 pilot study of water irrigation after transurethral resection of bladder tumor (WATIP) demonstrating safety, feasibility and activity.
World J Urol. 2024;42:115.
Abstract

XIONG Q, Liu T, Ying Y, Yu X, et al
Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response.
Bioeng Transl Med. 2023;9:e10624.
Abstract

WEI H, Cheng X, Wang G, Li Z, et al
Causal association of smoking, blood lipids, and bladder cancer: Insights from a multivariable and mediation mendelian randomization investigation.
J Cancer. 2024;15:1929-1939.
Abstract

CHEN J, Fan S, Guo J, Yang J, et al
Discovery of anticancer function of Febrifugine: Inhibition of cell proliferation, induction of apoptosis and suppression steroid synthesis in bladder cancer cells.
Toxicol Appl Pharmacol. 2024;484:116878.
Abstract

SZCZESNIEWSKI JJ, Marquez-Sanchez MT, Padilla-Fernandez B, Llanes-Gonzalez L, et al
Recurrent Bacteriuria as a Prognosis Marker in the Adjuvant Treatment of Non-Muscle Invasive Bladder Cancer.
Clin Genitourin Cancer. 2024;22:102048.
Abstract

HAO S, Shen L, Liu P, Yong Q, et al
Development of a prognostic model for muscle-invasive bladder cancer using glutamine metabolism.
Comput Biol Med. 2024;171:108223.
Abstract

LI B, Jin K, Liu Z, Su X, et al
Integrating molecular subtype and CD8(+) T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer.
Cancer Immunol Immunother. 2024;73:66.
Abstract

FU Y, Sun S, Shi D, Bi J, et al
Construction of endothelial cell signatures for predicting the diagnosis, prognosis and immunotherapy response of bladder cancer via machine learning.
J Cell Mol Med. 2024;28:e18155.
Abstract

ODURO MS
A Bayesian Bernoulli-Exponential joint model for binary longitudinal outcomes and informative time with applications to bladder cancer recurrence data.
BMC Med Res Methodol. 2024;24:54.
Abstract

COOKE I, Abou Heidar N, Mahmood AW, Ahmad A, et al
The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: Data from the International Robotic Cystectomy Consortium.
Urol Oncol. 2024 Feb 29:S1078-1439(24)00002.
Abstract

CHEN KC, Dhar T, Chen CR, Chen CY, et al
Nicotinamide phosphoribosyltransferase modulates PD-L1 in bladder cancer and enhances immunotherapeutic sensitivity.
Biochim Biophys Acta Mol Basis Dis. 2024 Feb 28:167106.
Abstract

QI F, Bao Q, Hu P, Guo Y, et al
Mild magnetic hyperthermia-activated immuno-responses for primary bladder cancer therapy.
Biomaterials. 2024;307:122514.
Abstract

BASILE G, Gallioli A, Martini A, Verri P, et al
Oncologic surveillance intensity after endoscopic treatment of upper tract urothelial carcinoma.
Minerva Urol Nephrol. 2024;76:88-96.
Abstract

OKUDA Y, Kato T, Fujita K, Fushimi H, et al
Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma.
Cancer Genomics Proteomics. 2024;21:137-143.
Abstract

FAVERO PRIETTO DOS SANTOS J, Ghezzi CLA, Pedrollo IM, Cruz IR, et al
Practical Guide to VI-RADS: MRI Protocols, Lesion Characterization, and Pitfalls.
Radiographics. 2024;44:e230149.
Abstract

HOEGGER MJ
Invited Commentary: VI-RADS and Routing Patient Care at the Muscularis Propria.
Radiographics. 2024;44:e230234.
Abstract

KAPAGANTI VK, Purkait S, Nayak P, Biswas D, et al
Diminution of Primary Cilia in the Stromal Cells at the Tumor-stromal Interface Correlates With an Aggressive Tumor Biology in the Urothelial Carcinoma of the Urinary Bladder.
Appl Immunohistochem Mol Morphol. 2024;32:130-136.
Abstract

BARCENA PGQ, Aprikian AG, Dragomir A
Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.
Cancer Med. 2024;13:e6922.
Abstract

ZHANG H, Lee S, Muthakana RR, Lu B, et al
Intragenic Rearrangement Burden Associates with Immune Cell Infiltration and Response to Immune Checkpoint Blockade in Cancer.
Cancer Immunol Res. 2024;12:287-295.
Abstract

LI JJX, Ng JKM, Tang CY, Chan BCH, et al
Urine cytology in the detection of renal cell carcinomas - a territory-wide multi-institutional retrospective review of more than 2 decades.
Cancer Cytopathol. 2024;132:186-192.
Abstract

DASON S, Lee CT
Paradigm Shifting Research: Key Studies in Urologic Oncology.
Ann Surg Oncol. 2024;31:2529-2537.
Abstract

MUQUITH M, Hsiehchen D
Landscape and Saturation Analysis of Mutations Associated With Race in Cancer Genomes by Clinical Sequencing.
Oncologist. 2024;29:219-226.
Abstract

MILOJEVIC B, Janicic A, Grozdic Milojevic I, Grubor N, et al
Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma.
Ann Surg Oncol. 2024;31:2538-2544.
Abstract

KANNAN N, Gochhait D, Ramanitharan M, Siddaraju N, et al
A comparison between conventional and the Paris systems of reporting urinary cytopathology with a literature update.
Diagn Cytopathol. 2024;52:187-199.
Abstract

XU Q, Li T, Lin J, Wu X, et al
Label-free screening of common urinary system tumors from blood plasma based on surface-enhanced Raman spectroscopy.
Photodiagnosis Photodyn Ther. 2024;45:103900.
Abstract

ALHAMAR M, Al-Ahmadie HA, Feratovic R, Lin O, et al
Sensitivity of urine cytology in detecting high-grade urothelial carcinoma in patients with neoplastic urinary bladder diverticula: A major cancer center experience.
Cancer Cytopathol. 2024;132:144-151.
Abstract

LORIOT Y, O'Hagan A, Siefker-Radtke AO
Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
Future Oncol. 2024;20:231-243.
Abstract

GUPTA S, Costantino H, Ike C, Gupta S, et al
Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study.
Oncologist. 2024;29:244-253.
Abstract

RAICES FRANCISCO N, Suarez Gil R, Ayuso Garcia B, Romay Lema E, et al
BCGitis with aortoiliac aneurysm involvement: Report of two cases and review of the literature.
Enferm Infecc Microbiol Clin (Engl Ed). 2024;42:152-157.
Abstract

A prognostic risk prediction model based on ferroptosis-related long non-coding RNAs in bladder cancer: A bulk RNA-seq research and scRNA-seq validation: Erratum.
Medicine (Baltimore). 2024;103:e37547.
Abstract

WANG W, Chen Y, Gu J
Effectiveness of integrated nursing interventions in enhancing patient outcomes during postoperative intravesical instillation for non-muscle invasive bladder cancer: A comparative study.
Medicine (Baltimore). 2024;103:e36871.
Abstract

LI S, Wang J, Zhang Z, Wu Y, et al
Establishment and validation of nomograms to predict the overall survival and cancer-specific survival for non-metastatic bladder cancer patients: A large population-based cohort study and external validation.
Medicine (Baltimore). 2024;103:e37492.
Abstract

XIE L, Liang S, Jiwa H, Zhang L, et al
Securinine inhibits the tumor growth of human bladder cancer cells by suppressing Wnt/beta-catenin signaling pathway and activating p38 and JNK signaling pathways.
Biochem Pharmacol. 2024 Mar 12:116125. doi: 10.1016/j.bcp.2024.116125.
Abstract

BRUNELLI M, Gobbo S, Malpeli G, Sirgiovanni G, et al
TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma.
Pathologica. 2024;116:55-61.
Abstract

LI H, Bao X, Xiao Y, Yin H, et al
Identification and verification of anoikis-related gene markers to predict the prognosis of patients with bladder cancer and assist in the diagnosis and treatment of bladder cancer.
Transl Cancer Res. 2024;13:579-593.
Abstract

YIN JJ, Song YL, Guo YF, Dai YH, et al
Transcriptome-wide 1-methyladenosine functional profiling of messenger RNA and long non-coding RNA in bladder cancer.
Front Genet. 2024;15:1333931.
Abstract

FENG S, Zhou D, Li Y, Yuan R, et al
Prediction of Ki-67 expression in bladder cancer based on CT radiomics nomogram.
Front Oncol. 2024;14:1276526.
Abstract

MENG W, Li N, Chen B, Zhang H, et al
Reliable prognostic definition and immunotherapy response prediction in bladder cancer, based on a novel aging-associated 5-gene signature model.
Transl Androl Urol. 2024;13:193-208.
Abstract

JALALIZADEH M, Reis LO
Understanding bladder cancer by genome-wide association studies.
Transl Androl Urol. 2024;13:363-365.
Abstract

LAN T, Ran S, Gao M, Li W, et al
A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined treatment be the new trend?
Transl Androl Urol. 2024;13:293-307.
Abstract

SHAH S, Ince J, Kockelbergh R
Patient experience of bladder cancer: A data linkage study.
BJUI Compass. 2024;5:382-388.
Abstract

WANG R, Xu F, Yang Z, Cao J, et al
The mechanism of PFK-1 in the occurrence and development of bladder cancer by regulating ZEB1 lactylation.
BMC Urol. 2024;24:59.
Abstract

REIKE MJ, de Jong JJ, Bismar TA, Boorjian SA, et al
Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
Urol Oncol. 2024 Mar 12:S1078-1439(24)00043.
Abstract

XU VE, Antar RM, Bertozzi L, Drouaud A, et al
Efficacy of cytoreductive radical cystectomy in metastatic urothelial bladder cancer based on site and number of metastases.
Urol Oncol. 2024 Mar 12:S1078-1439(24)00337.
Abstract

WANG P, Wei X, Shen L, Xu K, et al
Amplification-Free Analysis of Bladder Cancer MicroRNAs on Wrinkled Silica Nanoparticles with DNA-Functionalized Quantum Dots.
Anal Chem. 2024 Mar 13. doi: 10.1021/acs.analchem.3c05204.
Abstract

PFISTER C, Harter V, Allory Y, Culine S, et al
Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?
World J Urol. 2024;42:140.
Abstract

YANAGISAWA T, Sato S, Hayashida Y, Okada Y, et al
Prognostic value of micrometric substaging in pT1 bladder cancer patients treated with en-bloc transurethral resection.
Histopathology. 2024 Mar 13. doi: 10.1111/his.15177.
Abstract

LI F, Wang P, Ye J, Xie G, et al
Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis.
Front Oncol. 2024;14:1303918.
Abstract

XIE H, Rutz J, Maxeiner S, Grein T, et al
Sulforaphane Inhibits Adhesion and Migration of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro.
Nutrients. 2024;16:623.
Abstract

DU C, Waltzer WC, Wilusz JE, Spaliviero M, et al
Circular STAG2 RNA Modulates Bladder Cancer Progression via miR-145-5p/TAGLN2 and Is Considered as a Biomarker for Recurrence.
Cancers (Basel). 2024;16:978.
Abstract

STANKOWSKA W, Sarkisyan D, Bruhn-Olszewska B, Duzowska K, et al
Tumor Predisposing Post-Zygotic Chromosomal Alterations in Bladder Cancer-Insights from Histologically Normal Urothelium.
Cancers (Basel). 2024;16:961.
Abstract

CHANG PH, Chen HY, Chang YS, Su PJ, et al
Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy.
Cancers (Basel). 2024;16:894.
Abstract

JIANG YH, Liu YS, Wei YC, Jhang JF, et al
Hypermethylation Loci of ZNF671, IRF8, and OTX1 as Potential Urine-Based Predictive Biomarkers for Bladder Cancer.
Diagnostics (Basel). 2024;14:468.
Abstract

LUO C, Luo S, Wusimanjiang W, Wang Z, et al
Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study.
Clin Transl Oncol. 2024 Mar 12. doi: 10.1007/s12094-024-03400.
Abstract

FAN L, Wang J, Zhang Z, Zuo Z, et al
Identification of RNA methylation-related lncRNAs for prognostic assessment and immunotherapy in bladder cancer-based on single cell/Bulk RNA sequencing data.
Funct Integr Genomics. 2024;24:56.
Abstract

SEGATTO NV, Simoes LD, Bender CB, Sousa FS, et al
Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro.
Front Oncol. 2024;14:1323422.
Abstract

TONG Z, Zhao Y, Bai S, Ebner B, et al
The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer.
Cancer Commun (Lond). 2024 Mar 11. doi: 10.1002/cac2.12532.
Abstract

SUN H, Gao F, Liu Y, Shao J, et al
Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis.
BMC Urol. 2024;24:57.
Abstract

ZHANG L, Shi X, Zhang L, Mi Y, et al
A first-in-class TIMM44 blocker inhibits bladder cancer cell growth.
Cell Death Dis. 2024;15:204.
Abstract

FLURY-SUTTER S, Heuzeroth F, Arbelaez E, Bubendorf L, et al
Efficacy and tolerability of bacillus Calmette-Guerin strain Russia for the treatment of non-muscle-invasive bladder cancer: Analysis of a prospective registry.
Can Urol Assoc J. 2024 Mar 1. doi: 10.5489/cuaj.8552.
Abstract

ENLUND M, Hallberg H, Berglund A, Sherif A, et al
Long-term survival after volatile or propofol general anesthesia for bladder cancer surgery: a retrospective national registry cohort study.
Anesthesiology. 2024 Mar 11. doi: 10.1097/ALN.0000000000004969.
Abstract

ZHANG Y, Jia R, Wang X, Zhang Y, et al
Targeted Delivery of Catalase and Photosensitizer Ce6 by a Tumor-Specific Aptamer Is Effective against Bladder Cancer In Vivo.
Mol Pharm. 2024 Mar 11. doi: 10.1021/acs.molpharmaceut.3c01047.
Abstract

WANG P, Ning J, Chen W, Zou F, et al
Comprehensive analysis indicated that NDE1 is a potential biomarker for pan-cancer and promotes bladder cancer progression.
Cancer Med. 2024;13:e6931.
Abstract

WONG JYY, Fischer AH, Baris D, Beane Freeman LE, et al
Urinary mutagenicity and bladder cancer risk in northern New England.
Environ Mol Mutagen. 2024 Mar 11. doi: 10.1002/em.22588.
Abstract

YANG K, Qi ZX, Sun MX, Xie LP, et al
Hyperoside induces cell cycle arrest and suppresses tumorigenesis in bladder cancer through the interaction of EGFR-Ras and Fas signaling pathways.
Int J Med Sci. 2024;21:690-702.
Abstract

ZHUANG J, Zhang L, Zhang S, Zhang Z, et al
Membrane-associated RING-CH 7 inhibits stem-like capacities of bladder cancer cells by interacting with nucleotide-binding oligomerization domain containing 1.
Cell Biosci. 2024;14:32.
Abstract

LIN H, Fu L, Zhou X, Yu A, et al
LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.
Cancer Lett. 2024 Mar 8:216807. doi: 10.1016/j.canlet.2024.216807.
Abstract

OTVAGIN VF, Krylova LV, Peskova NN, Kuzmina NS, et al
A first-in-class beta-glucuronidase responsive conjugate for selective dual targeted and photodynamic therapy of bladder cancer.
Eur J Med Chem. 2024;269:116283.
Abstract

SHI X, Pang S, Zhou J, Yan G, et al
Bladder-cancer-derived exosomal circRNA_0013936 promotes suppressive immunity by up-regulating fatty acid transporter protein 2 and down-regulating receptor-interacting protein kinase 3 in PMN-MDSCs.
Mol Cancer. 2024;23:52.
Abstract

MITTAL K, Joshi M
FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape.
Med. 2024;5:176-178.
Abstract

HAGA N, Hashimoto S, Morimoto M
[Multiple Pulmonary Metastases Seven Years After Transurethral Bladder Tumor Resection for Non-muscle Invasion Bladder Cancer:Report of a Case].
Kyobu Geka. 2024;77:155-159.
Abstract

MEAGHER M, Morgan KM, Deshler L, Puri D, et al
The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study.
Clin Genitourin Cancer. 2024 Feb 15:102055. doi: 10.1016/j.clgc.2024.
Abstract

GUO L, Liu L, Liu Y, Yang T, et al
Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
BMJ Open. 2024;14:e080092.
Abstract

LI L, Fu S, Wang J, Lu J, et al
SRT1720 inhibits bladder cancer cell progression by impairing autophagic flux.
Biochem Pharmacol. 2024;222:116111.
Abstract

WOLF B, Jain RK
Unraveling a hidden player in lymphovascular invasion in bladder cancer.
Cancer Cell. 2024 Mar 6:S1535-6108(24)00051-5. doi: 10.1016/j.ccell.2024.
Abstract

SUSKI M
Reconstruction of a large scalp defect secondary to a rare cutaneous metastasis from urothelial bladder carcinoma using intact fish skin xenografts.
J Wound Care. 2024;33.
Abstract

CHENG S, Li C, Liu L, Liu X, et al
Dysregulation and antimetastatic function of circLRIG1 modulated by miR-214-3p/LRIG1 axis in bladder carcinoma.
Biol Direct. 2024;19:20.
Abstract

LI Q, Zhuo L, Zhang T
Shame in patients undergoing ureterostomy: A cross-sectional survey.
Int Wound J. 2024;21:e14793.
Abstract

WANG J, Xiao B, Ren S, Zeng D, et al
A systematic review and meta-analysis of the anti-tumor effects of Paeoniae Radix Rubra in animal models.
J Ethnopharmacol. 2024;326:117987.
Abstract

YANG W, Liu Z, Liu T
Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Cell Signal. 2024;117:111107.
Abstract

ALEXANDER BH, Ryan A, Church TR, Kim H, et al
Mortality and cancer incidence in perfluorooctanesulfonyl fluoride production workers.
Am J Ind Med. 2024;67:321-333.
Abstract

JIA L, Rood T, Kirkpatrick J, Sarode V, et al
Utility of The Paris System (TPS) for upper urinary tract cytopathology: correlation with histology follow-up and UroVysion fluorescence in situ hybridization (FISH) analysis.
J Am Soc Cytopathol. 2024;13:149-155.
Abstract

WOLDU S, Lotan Y
Reply to Khurshid R. Ghani's letter to editor regarding the article "Early experience with UGN-101 for the treatment of upper tract urothelial cancer: a multicenter evaluation of practice patterns and outcomes".
Urol Oncol. 2024;42:36.
Abstract

MCKENNA C, Poirier VJ, Oblak ML, Nykamp S, et al
Reason for euthanasia in dogs with urothelial carcinoma treated with chemotherapy or radiation therapy or both: A retrospective observational study.
J Vet Intern Med. 2024;38:1127-1134.
Abstract

NIZAM A, Rader RK, Tzeng A, Wei W, et al
Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
Clin Genitourin Cancer. 2024;22:368-379.
Abstract

JAGANMURUGAN R, Arora A, Chandankhede U, Prakash G, et al
Prognostic Significance of Lymph Node Density in Pathological Node Positive Urothelial Carcinoma of the Bladder -Upfront Surgery and Post Neoadjuvant Chemotherapy Cohorts.
Clin Genitourin Cancer. 2024;22:385-393.
Abstract

LYNCH C, Sweis RF, Modi P, Agarwal PK, et al
Bladder-Preserving Trimodality Therapy With Capecitabine.
Clin Genitourin Cancer. 2024;22:476-482.
Abstract

SOARES A, Bourlon MT, Wong A, Joshi A, et al
Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion.
Clin Genitourin Cancer. 2024;22:467-475.
Abstract

VON DEIMLING M, Rink M, Klemm J, Koelker M, et al
Comprehensive Evaluation of the Ability of Comorbidity and Health Status Indices to Improve the Prediction of Perioperative Morbidity and Long-Term Survival Outcomes After Radical Cystectomy.
Clin Genitourin Cancer. 2024;22:336-346.
Abstract

TREPANIER G, Nykopp T, Rosebush-Mercier R, Gris T, et al
Circulating Basophils as a Prognostic Marker for Response to Bacillus Calmette-Guerin.
Clin Genitourin Cancer. 2024;22:354-359.
Abstract

LIANG PI, Wei YC, Chen HD, Ma YC, et al
TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma.
Kaohsiung J Med Sci. 2024;40:269-279.
Abstract

FENOR DE LA MAZA MD, Villacampa G, Minana B, Barbas Bernardos G, et al
First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies.
Clin Genitourin Cancer. 2024;22:330-335.
Abstract

NAGAYAMA J, Yamamoto A, Naito Y, Kamikawa H, et al
Efficacy of the Addition of Robot-assisted Radical Cystectomy with Extracorporeal Urinary Diversion after an Enhanced Recovery Protocol.
Urol J. 2024;21:40-46.
Abstract

YE J, Wang X, Liao X, Chen Z, et al
Survival impact of variant histology in patients with upper tract urothelial carcinoma after radical nephroureterectomy.
Urol Oncol. 2024;42:69.
Abstract

KITAHAMA K, Shigematsu Y, Amori G, Sugawara E, et al
RAS Family Gene Mutations, Clinicopathological Features, and Spread Patterns of Inverted Urothelial Papilloma of the Bladder.
Am J Surg Pathol. 2024;48:458-464.
Abstract

KATAYAMA S, Iwata T, Kawada T, Okamoto Y, et al
Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Urol Oncol. 2024;42:70.
Abstract

SHIPP C, Jindal T, Chou J, Friedlander TW, et al
Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series.
Clin Genitourin Cancer. 2024;22:315-321.
Abstract

TAGUCHI S, Kawai T, Nakagawa T, Kume H, et al
Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review.
Jpn J Clin Oncol. 2024;54:254-264.
Abstract

KOHADA Y, Goto K, Tasaka R, Nishida K, et al
Prognostic Impact of the Modified 5-Item Frailty Index After Radical Nephroureterectomy in Patients With Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Study.
Clin Genitourin Cancer. 2024;22:322-329.
Abstract

KOU Z, Wang P, Jia D, Zhu H, et al
Clinical analysis of small-cell carcinoma of the urinary bladder: A case report and review of literature.
Asian J Surg. 2024;47:1602-1603.
Abstract

MIYAKE M, Nishimura N, Oda Y, Miyamoto T, et al
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Jpn J Clin Oncol. 2024;54:329-338.
Abstract

STANGL FP, Buehler OD, Wuethrich PY, Furrer MA, et al
Sex Does Not Affect Survival: A Propensity Score-Matched Comparison in a Homogenous Contemporary Radical Cystectomy Cohort.
Clin Genitourin Cancer. 2024;22:171-180.
Abstract

CAMPBELL RA, Khanna A, Boorjian SA, Knorr J, et al
Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy.
Clin Genitourin Cancer. 2024;22:157-163.
Abstract

HOIMES CJ, Flaig TW, Milowsky MI, Friedlander TW, et al
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Future Oncol. 2024;20:351-360.
Abstract

GUO Q, Jin L, Zhang T, Gao R, et al
Literature analysis of cutaneous adverse reactions induced by tislelizumab.
Cutan Ocul Toxicol. 2024;43:52-57.
Abstract

FERRO M, Chiujdea S, Vartolomei MD, Bove P, et al
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
Clin Genitourin Cancer. 2024;22:27-37.
Abstract

ARITA Y, Kwee TC, Woo S, Shigeta K, et al
Biparametric versus Multiparametric Magnetic Resonance Imaging for Assessing Muscle Invasion in Bladder Urothelial Carcinoma with Variant Histology Using the Vesical Imaging-Reporting and Data System.
Eur Urol Focus. 2024;10:131-138.
Abstract

CAI L, Yu R, Liu P, Zhuang J, et al
A Nomogram of MRI Features to Assess Muscle Invasion in VI-RADS 2 Tumors With Stalk.
J Magn Reson Imaging. 2023 Aug 21. doi: 10.1002/jmri.28924.
Abstract

TAKEUCHI M
Editorial for "A Nomogram of MRI Features to Assess Muscle Invasion in VI-RADS 2 Tumors With Stalk".
J Magn Reson Imaging. 2023 Aug 9. doi: 10.1002/jmri.28922.
Abstract

SARI MOTLAGH R, Ghoreifi A, Yanagisawa T, Kawada T, et al
Survival of Patients with Chronic Kidney Disease Treated with Radical Cystectomy and Risk Factors of Glomerular Filtration Rate Loss Following Radical Cystectomy: Two Systematic Reviews and Meta-analyses of Interplay Between Radical Cystectomy and Ren
Eur Urol Focus. 2024;10:169-181.
Abstract

HASHEM M, Mohandesi Khosroshahi E, Aliahmady M, Ghanei M, et al
Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism.
Noncoding RNA Res. 2024;9:560-582.
Abstract

BERGMAN DR, Wang Y, Trujillo E, Fernald AA, et al
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
Front Immunol. 2024;15:1358019.
Abstract

DU G, Jiang Z, Qu W, Zhang J, et al
Downstaging guided neoadjuvant strategy shift and bladder preservation in locally advanced bladder cancer: A case report.
Heliyon. 2024;10:e27685.
Abstract

TAO T, Chen Y, Shang Y, He J, et al
SMMF: a self-attention-based multi-parametric MRI feature fusion framework for the diagnosis of bladder cancer grading.
Front Oncol. 2024;14:1337186.
Abstract

LI L, Jiang P, Hu W, Zou F, et al
AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
J Transl Med. 2024;22:295.
Abstract

MOADAB A, Valizadeh MR, Nazari A, Khorramdelazad H, et al
Association of interleukin-17A and chemokine/vascular endothelial growth factor-induced angiogenesis in newly diagnosed patients with bladder cancer.
BMC Immunol. 2024;25:20.
Abstract

MURAKAMI T, Minami K, Harabayashi T, Maruyama S, et al
Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients.
Sci Rep. 2024;14:6801.
Abstract

BENBASSAT J
Estimates of the lead time in screening for bladder cancer.
Urol Oncol. 2024;42:110-114.
Abstract

NISHIMURA N, Miyake M, Iida K, Miyamoto T, et al
Treatment patterns and prognosis in patients with Bacillus Calmette-Guerin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
World J Urol. 2024;42:185.
Abstract

YE J, Zheng L, Chen Z, Wang Q, et al
Serum alpha-hydroxybutyrate dehydrogenase as a biomarker for predicting survival outcomes in patients with UTUC after radical nephroureterectomy.
BMC Urol. 2024;24:62.
Abstract

IKUMA S, Akatsuka J, Takeda H, Endo Y, et al
Determining the clinicopathological significance of the VI-RADS >==4 group: a retrospective study.
BMC Urol. 2024;24:63.
Abstract

CZECH AK, Gronostaj K, Frydrych J, Polok K, et al
The assessment of bladder cancer resectability with bimanual palpation: A prospective study in laparoscopy and open cystectomy patients.
Urol Oncol. 2024 Mar 19:S1078-1439(24)00335.
Abstract

BAARD J, Cormio L, Dasgupta R, Maruzzi D, et al
Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study.
World J Urol. 2024;42:177.
Abstract

KLEIN C, Brunelle S, Illy M, De Luca V, et al
Multiparametric Magnetic Resonance Imaging in the follow-up of non-muscle-invasive bladder tumors after intravesical instillations: a promising tool.
World J Urol. 2024;42:178.
Abstract

ALHAJAHJEH A, Abdulelah AA, Hmeidan M, Kakish D, et al
Gender inequality in genitourinary malignancies clinical trials leadership.
World J Urol. 2024;42:174.
Abstract

SKOWRONSKI M, Halicki P, Halicka A
Disseminated BCGitis after intravesical Bacillus Calmette-Guerin therapy in a patient with bladder cancer.
Pol Arch Intern Med. 2024 Mar 20:16710. doi: 10.20452/pamw.16710.
Abstract

WANG Y, Wang J, Zhang L, He J, et al
Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target.
J Cell Mol Med. 2024;28:1-20.
Abstract

DONG C, Hui P, Wu Z, Li J, et al
CircRNA LOC729852 promotes bladder cancer progression by regulating macrophage polarization and recruitment via the miR-769-5p/IL-10 axis.
J Cell Mol Med. 2024;28:e18225.
Abstract

YANG J, Xiang H, Cheng M, Jiang X, et al
microRNA-15a-5p suppresses hypoxia-induced tumor growth and chemoresistance in bladder cancer by binding to eIF5A2.
Neoplasma. 2024;71:60-69.
Abstract

TOUALA-CHAILA Z, Abderrahmane RK, Kerroumi S, Yousfi MJ, et al
Association study of the polymorphisms rs2228611 of the DNMT1 gene and rs1569686 of the DNMT3B gene with bladder cancer development in a sample of the Algerian population.
Mol Biol Res Commun. 2024;13:65-72.
Abstract

LIU F, Li J, Zhou B, Shen Y, et al
The Role of Emodin in the Treatment of Bladder Cancer based on Network Pharmacology and Experimental Verification.
Comb Chem High Throughput Screen. 2024.
Abstract

ANGELONI M, van Doeveren T, Lindner S, Volland P, et al
A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.
J Pathol Clin Res. 2024;10:e12369.
Abstract

WU J, Lin Y, Yang K, Liu X, et al
Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial.
Mol Cancer. 2024;23:57.
Abstract

LV L, Wei Q, Zhang J, Dong Y, et al
IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development.
Cell Mol Biol Lett. 2024;29:39.
Abstract

CHAI JL, Roller LA, Liu X, Lan Z, et al
Performance of VI-RADS in predicting muscle-invasive bladder cancer after transurethral resection: a single center retrospective analysis.
Abdom Radiol (NY). 2024 Mar 19. doi: 10.1007/s00261-024-04245.
Abstract

LIANG JP, Yin L, Gao LK, Yin L, et al
Contrast-enhanced CT in the differential diagnosis of bladder cancer and paraganglioma.
Abdom Radiol (NY). 2024 Mar 19. doi: 10.1007/s00261-024-04217.
Abstract

MOUSSA M, Abou Chakra M, Shore ND, Papatsoris A, et al
Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists.
Arch Ital Urol Androl. 2024 Mar 19:12244. doi: 10.4081/aiua.2024.12244.
Abstract

LEONARDI R, Ambrosini F, Cafarelli A, Calarco A, et al
Office-based management of non-muscle invasive bladder cancer (NMIBC): a position paper on current state of the art and future perspectives.
Arch Ital Urol Androl. 2024 Mar 19:12404. doi: 10.4081/aiua.2024.12404.
Abstract

CHEN S, Zhang S, Fan W, Sun W, et al
[Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice bearing ectopic bladder cancer xenograft].
Nan Fang Yi Ke Da Xue Xue Bao. 2024;44:210-216.
Abstract

WANG B, Fan X, Wang L, Wei X, et al
The RNA-binding protein sorbin and SH3 domain-containing 2 are transcriptionally regulated by specificity protein 1 and function as tumor suppressors in bladder cancer by stabilizing tissue factor pathway inhibitor.
Mol Carcinog. 2024 Mar 19. doi: 10.1002/mc.23717.
Abstract

KIMURA T, Okita Y, Nagumo Y, Chin JM, et al
Glycoprotein nonmetastatic melanoma protein B impacts the malignant potential of bladder cancer cells through its hem-immunoreceptor tyrosine-based activation motif.
Pathol Int. 2024 Mar 19. doi: 10.1111/pin.13419.
Abstract

WANG KY, Wang KJ, Shen LL, Wang XH, et al
The down-regulation of GADD45B leads to a conversion of cellular oxidative phosphorylation to glycolysis and promotes the progression of bladder cancer.
Heliyon. 2024;10:e27427.
Abstract

CHEN Y, Shi K, Fu X, Guo H, et al
Diagnostic and prognostic potential of exosome non-coding RNAs in bladder cancer: a systematic review and meta-analysis.
Front Oncol. 2024;14:1336375.
Abstract

OHARA K, Rendeiro AF, Bhinder B, Eng KW, et al
The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.
Nat Commun. 2024;15:2009.
Abstract

QIN X, Wang H, Xu W, Zheng B, et al
A Selective-Tumor-Penetrating Strategy via Unidirectional Direct Transfer for Intravesical Therapy of Bladder Cancer.
J Med Chem. 2024 Mar 18. doi: 10.1021/acs.jmedchem.4c00060.
Abstract

SUN X, Liu C, Zhang C, Zhang Z, et al
Nomogram for predicting postoperative ileus after radical cystectomy and urinary diversion: a retrospective single-center study.
Ann Med. 2024;56:2329125.
Abstract

WANG JF, Gong YQ, He YH, Ying WW, et al
Author Correction: High expression of MMP14 is associated with progression and poor short-term prognosis in muscle-invasive bladder cancer.
Eur Rev Med Pharmacol Sci. 2024;28:1640.
Abstract

WU H, Jin H, Cai Y
Unveiling therapeutic prospects: targeting MDM-2 in non-muscle invasive bladder cancer.
J Biomol Struct Dyn. 2024 Mar 18:1-10. doi: 10.1080/07391102.2024.2329799.
Abstract

WANG Y, Wang J, Liu Y, Wang X, et al
Multidimensional pan-cancer analysis of HSPA5 and its validation in the prognostic value of bladder cancer.
Heliyon. 2024;10:e27184.
Abstract

HAN H, Oh TJ, Heo JE, Lee J, et al
Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non-muscle-invasive Bladder Cancer.
Eur Urol Open Sci. 2024;62:99-106.
Abstract

DE JONG FC, Ifle IG, van der Made AC, Kooper D, et al
A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.
Eur Urol Open Sci. 2024;62:131-139.
Abstract

PAVAN N, Scaggiante B
Editorial: Liquid biopsy in the detection and prediction of outcomes in bladder cancer.
Front Oncol. 2024;14:1391466.
Abstract

YAO R, Ai B, Wang Z, Shen B, et al
Uncovering Microbial Composition of the Tissue Microenvironment in Bladder Cancer using RNA Sequencing Data.
J Cancer. 2024;15:2431-2441.
Abstract

KOMORI K, Koyama K, Shimizu K, Kanemoto R, et al
[A Case of Colon Metastasis after Surgery for Left Renal Pelvis Cancer].
Gan To Kagaku Ryoho. 2024;51:340-342.
Abstract

ARABYAN G, Hambartzhumian R, Lim A, Quizon M, et al
Unusual Urothelial Tumors and Refractory Uremia Due to Balkan Endemic Nephropathy: A Case Report.
J Investig Med High Impact Case Rep. 2024;12:23247096241238529.
Abstract

WEI T, Yuan P
[Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression].
Zhonghua Zhong Liu Za Zhi. 2024;46:211-220.
Abstract

LIU Y, Zhang K, Yang X
CircMCTP2 enhances the progression of bladder cancer by regulating the miR-99a-5p/FZD8 axis.
J Egypt Natl Canc Inst. 2024;36:8.
Abstract

WU J, Gao F, Meng R, Li H, et al
Single-cell and multi-omics analyses highlight cancer-associated fibroblasts-induced immune evasion and epithelial mesenchymal transition for smoking bladder cancer.
Toxicology. 2024;504:153782.
Abstract

PAZIR Y, Esmeray A, Gelmis M, Caglar U, et al
Performance of the EORTC and CUETO Models to Predict Recurrence and Progression in High-risk Non-muscle-invasive Bladder Cancer Patients.
Urol J. 2024 Mar 17. doi: 10.22037/uj.v20i.7854.
Abstract

ROSENBAUM CM, Filmar S, Gross AJ, Jobst N, et al
The influence of socioeconomic status and gender on incidence and survival in bladder cancer: a longitudinal study based on the Hamburg Cancer Registry.
World J Urol. 2024;42:166.
Abstract

VAN DEN BRANDT PA
Diabetes and the risk of bladder cancer subtypes in men and women: results from the Netherlands Cohort Study.
Eur J Epidemiol. 2024 Mar 16. doi: 10.1007/s10654-024-01100.
Abstract

CEASAR RC, Ladi-Seyedian SS, Escobar D, Han J, et al
"I think my vagina is still there?": Women's perspectives on sexual function and dysfunction following radical cystectomy for bladder cancer, a qualitative study.
J Sex Med. 2024 Mar 15:qdae025. doi: 10.1093.
Abstract

WANG C, Yang X
CircRAPGEF5 sponges miR-582-3p and targets KIF3A to regulate bladder cancer cell proliferation, migration and invasion.
Int Immunopharmacol. 2024;131:111613.
Abstract

PYRGIDIS N, Schulz GB, Volz Y, Ebner B, et al
The impact of perioperative risk factors on long-term survival after radical cystectomy: a prospective, high-volume cohort study.
World J Urol. 2024;42:164.
Abstract

EMINAGA O, Lee TJ, La V, Breil B, et al
Electronic Documentation of Intraoperative Observation of Cystoscopic Procedures Using the cMDX Information System.
JCO Clin Cancer Inform. 2024;8:e2300114.
Abstract

KEHL KL, Lavery JA, Brown S, Fuchs H, et al
Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set.
JCO Precis Oncol. 2024;8:e2300489.
Abstract

SUARTZ CV, Cordeiro MD, Botelho LAA, Gallucci FP, et al
Predicting individual outcomes after radical cystectomy in urothelial variants with Cancer of the Bladder Risk Assessment (COBRA) score.
World J Urol. 2024;42:155.
Abstract

DE CARLO A, Tosca EM, Fantozzi M, Magni P, et al
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma.
Clin Pharmacol Ther. 2024;115:825-838.
Abstract

YU TW, Yamamoto H, Morita S, Fukushima R, et al
Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration.
J Vet Med Sci. 2024;86:317-321.
Abstract

WU KY, Cheong IS, Lai JN, Hu CY, et al
Risk of secondary primary malignancies in survivors of upper tract urothelial carcinoma: A nationwide population-based analysis.
Cancer Epidemiol. 2024;89:102536.
Abstract

CRITCHLOW S, Bullement A, Crabb S, Jones R, et al
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
Future Oncol. 2024;20:459-470.
Abstract

INTERNATIONAL BR
Retracted: lncRNA MIR4435-2HG Accelerates the Development of Bladder Cancer through Enhancing IQGAP3 and CDCA5 Expression.
Biomed Res Int. 2024;2024:9783095.
Abstract

WU S, Li G, Ouyang W, Tian Y, et al
Ferrous Selenide Stabilized Black Phosphorus Heterojunction Sonosensitizer for MR Imaging-Guided Sonodynamic Therapy of Bladder Cancer.
Biomater Res. 2024;28:0014.
Abstract

LI G, Wu S, Liu J, Wang K, et al
Narrow Bandgap Schottky Heterojunction Sonosensitizer with High Electron-Hole Separation Boosted Sonodynamic Therapy in Bladder Cancer.
Adv Mater. 2024 Mar 28:e2401252. doi: 10.1002/adma.202401252.
Abstract

LIM Y, Park J, Lim JE, Park M, et al
Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy.
Sci Rep. 2024;14:7390.
Abstract

ZHANG X, Guo J, Yun Y, Shan D, et al
Differentiation of Muscular Invasion in Bladder Cancer: Additional Value of Synthetic Magnetic Resonance Imaging.
Acad Radiol. 2024 Mar 27:S1076-6332(24)00153-3. doi: 10.1016/j.acra.2024.
Abstract

JIANG C, Li X, Chen R, Yang Y, et al
Enzyme-labeled liquid-based cytology (ELLBC): a new noninvasive diagnostic method for bladder cancers.
J Cancer Res Clin Oncol. 2024;150:169.
Abstract

Retraction: 'ASPM predicts poor prognosis and regulates cell proliferation in bladder cancer'. Zhen-Ya Gao, Fang Yu, Huan-Xia Jia, Zhuo Ye, Shi-Jie Yao, Kaohsiung J Med Sci. 2020; 36: 1021-1029 (https://doi.org/10.1002/kjm2.12284).
Kaohsiung J Med Sci. 2024 Mar 28. doi: 10.1002/kjm2.12825.
Abstract

NANDANA PI, Rasyid H, Prihantono P, Yustisia I, et al
Cytotoxicity and Apoptosis Studies of Brucein D against T24 Bladder Cancer Cells.
Asian Pac J Cancer Prev. 2024;25:921-930.
Abstract

KDIMATI S, Christoph C, Glass A, Engel N, et al
Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
Int J Mol Sci. 2024;25:3492.
Abstract

VIKERFORS A, Davidsson S, Carlsson J, Jerlstrom T, et al
Plasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients.
Int J Mol Sci. 2024;25:3473.
Abstract

FERREIRA E, Ferreira D, Relvas-Santos M, Freitas R, et al
Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer.
Int J Mol Sci. 2024;25:3462.
Abstract

PEREIRA F, Domingues MR, Vitorino R, Guerra IMS, et al
Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.
Int J Mol Sci. 2024;25:3347.
Abstract

SHIN J, Park JW, Kim SY, Lee JH, et al
Strategies for Overcoming Immune Evasion in Bladder Cancer.
Int J Mol Sci. 2024;25:3105.
Abstract

OTOSHI T, Yamasaki T, Matsue T, Yukimatsu N, et al
Comparison of Oncological Outcomes between Transperitoneal and Retroperitoneal Approaches in Laparoscopic Nephroureterectomies for Upper Tract Urothelial Carcinoma.
Medicina (Kaunas). 2024;60:421.
Abstract

DA PRAT V, Aretano L, Moschini M, Bettiga A, et al
Effectiveness of Preoperative Immunonutrition in Improving Surgical Outcomes after Radical Cystectomy for Bladder Cancer: Study Protocol for a Multicentre, Open-Label, Randomised Trial (INu-RC).
Healthcare (Basel). 2024;12:696.
Abstract

PEREIRA M, Vale N
Exploring Darunavir, Rilpivirine and Etravirine as Potential Therapies for Bladder Cancer: Efficacy and Synergistic Effects.
Biomedicines. 2024;12:647.
Abstract

DUGBARTEY GJ, Relouw S, McFarlane L, Sener A, et al
Redox System and Oxidative Stress-Targeted Therapeutic Approaches in Bladder Cancer.
Antioxidants (Basel). 2024;13:287.
Abstract

DUEX J, Theodorescu D
CD44 in Bladder Cancer.
Cancers (Basel). 2024;16:1195.
Abstract

AL-MARSOUMMI S, Mehus AA, Garrett SH, Sens DA, et al
The Effect of Retinoic Acid on Arsenite-Transformed Malignant UROtsa Bladder Cancer Cells: In Vitro Model of Basal Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:1178.
Abstract

[Not Available].
Aktuelle Urol. 2024;55:100-102.
Abstract

LV Z, Hou J, Wang Y, Wang X, et al
Reply to "Knowledge-map analysis and bladder cancer immunotherapy: Comment".
Hum Vaccin Immunother. 2024;20:2325756.
Abstract

URABE F, Tsuzuki S, Kimura T
Letter to the editor for the article "Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma".
World J Urol. 2024;42:198.
Abstract

JOHN H
[BCG instillation sepsis in bladder carcinoma].
Praxis (Bern 1994). 2024;113:44.
Abstract

BARBOS V, Feciche B, Latcu S, Croitor A, et al
The Assessment of SF-36 Survey for Quality-of-Life Measurement after Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Systematic Review.
Diseases. 2024;12:56.
Abstract

SANGUEDOLCE F, Falagario UG, Zanelli M, Palicelli A, et al
Prognostic Value of P63 Expression in Muscle-Invasive Bladder Cancer and Association with Molecular Subtypes-Preliminary Report.
Curr Issues Mol Biol. 2024;46:2456-2467.
Abstract

RAHMAN KMM, Kumbham S, Bist G, Woo S, et al
Comparison of red and green light for treating non-muscle invasive bladder cancer in rats using singlet oxygen-cleavable prodrugs with PPIX-PDT.
Photochem Photobiol. 2024 Mar 27. doi: 10.1111/php.13933.
Abstract

DU L, Wang B, Wen J, Zhang N, et al
Examining the causal association between psoriasis and bladder cancer: A two-sample Mendelian randomization analysis.
Skin Res Technol. 2024;30:e13663.
Abstract

GERCEK O, Senkol M, Yazar VM, Topal K, et al
The Effect of Lymphovascular Invasion on Short-Term Tumor Recurrence and Progression in Stage T1 Bladder Cancer.
Cureus. 2024;16:e54844.
Abstract

KONG T, Qu Y, Zhao T, Niu Z, et al
Identification of novel protein biomarkers from the blood and urine for the early diagnosis of bladder cancer via proximity extension analysis.
J Transl Med. 2024;22:314.
Abstract

TANG C, Fan Y, Zhu S
Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.
BMC Urol. 2024;24:69.
Abstract

JIN P, Yang L, Liu Y, Huang J, et al
Quantitative differentiation of non-invasive bladder urothelial carcinoma and inverted papilloma based on CT urography.
BMC Urol. 2024;24:73.
Abstract

LIU FL, Zhang ZC, Zhou SL, Liu XL, et al
Unlocking the Therapeutic Potential of LncRNA BLACAT1 in Hypopharynx Squamous Cell Carcinoma.
Discov Med. 2024;36:546-558.
Abstract

YANG F, Nie J, Xiao F, Liu J, et al
Impacts of enhanced recovery after surgery nursing interventions on wound infection and complications following bladder cancer surgery: A meta-analysis.
Int Wound J. 2024;21:e14781.
Abstract

SHOJO K, Takeda T, Akita H, Suzuki T, et al
Prediction of pathological up-staging after radical nephroureterectomy in patients with upper tract urothelial carcinoma.
World J Urol. 2024;42:192.
Abstract

HE Y, Pan C, Zhang Y, Lv M, et al
Nomogram for customized recurrence prediction in primary non-muscle-invasive bladder cancer based on routine blood and urine parameters.
BMC Urol. 2024;24:67.
Abstract

ADELMANN TG, Ceausu AR, Gaje NP, Raica M, et al
Endothelial cell proliferation and vascular patterns in urothelial carcinoma.
Rom J Morphol Embryol. 2024;65:61-67.
Abstract

CHE X, Huang H, Wang W, Zhong L, et al
Parastomal Hernia Following Ileal Conduit: Incidence, Risk Factors, and Health-Related Quality of Life.
J Wound Ostomy Continence Nurs. 2024;51:126-131.
Abstract

WANG J, Yin Y, Ren X, Wang S, et al
Electrospun nanofibrous mats loaded with gemcitabine and cisplatin suppress bladder tumor growth by improving the tumor immune microenvironment.
J Mater Sci Mater Med. 2024;35:21.
Abstract

YANG G, Bai J, Hao M, Zhang L, et al
Enhancing recurrence risk prediction for bladder cancer using multi-sequence MRI radiomics.
Insights Imaging. 2024;15:88.
Abstract

XIE M, Zhou L, Li T, Lin Y, et al
Targeting the KAT8/YEATS4 Axis Represses Tumor Growth and Increases Cisplatin Sensitivity in Bladder Cancer.
Adv Sci (Weinh). 2024 Mar 25:e2310146. doi: 10.1002/advs.202310146.
Abstract

AUBERT C, Culty T, Zidane M, Bigot P, et al
Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment.
Front Oncol. 2024;13:1240378.
Abstract

YANG XX, Wang C
CircITGA7 regulates malignant phenotypes in bladder cancer cells via targeting miR-330-3p/KLF10 axis.
Kaohsiung J Med Sci. 2024 Mar 25. doi: 10.1002/kjm2.12821.
Abstract

LIN L, Ning K, Xiang L, Peng L, et al
SGLT2 inhibition and three urological cancers: Up-to-date results.
Diabetes Metab Res Rev. 2024;40:e3797.
Abstract

REJEB SB, Elfekih S, Kouki N, Boulma R, et al
Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancer.
J Egypt Natl Canc Inst. 2024;36:9.
Abstract

SHI Y, Xia W, Liu H, Liu J, et al
Trihalomethanes in global drinking water: Distributions, risk assessments, and attributable disease burden of bladder cancer.
J Hazard Mater. 2024;469:133760.
Abstract

SCHUBACH K, Niyonsenga T, Turner M, Paterson C, et al
Identifying the supportive care needs of people affected by non-muscle invasive bladder cancer: An integrative systematic review.
J Cancer Surviv. 2024 Mar 23. doi: 10.1007/s11764-024-01558.
Abstract

ZARZYCKA M, Kotula-Balak M, Gil D
The mechanism of the contribution of ICAM-1 to epithelial-mesenchymal transition (EMT) in bladder cancer.
Hum Cell. 2024 Mar 22. doi: 10.1007/s13577-024-01053.
Abstract

LI D, Wu R, Wang J, Ye J, et al
A Prognostic Index Derived From LASSO-Selected Preoperative Inflammation and Nutritional Markers for Non-Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2024 Feb 29:102061. doi: 10.1016/j.clgc.2024.
Abstract

CAO M, Cao Y, Xue S, Zhang Q, et al
Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Altern Ther Health Med. 2024 Mar 22:AT10582.
Abstract

TAN H, Li Y, Li J, Wang K, et al
The Mechanism of miR-29 in Bladder Cancer Released by Exosomes into Brain Microglia to Promote M2 Polarization and Angiogenesis in Brain Metastasis of Bladder Cancer.
Altern Ther Health Med. 2024 Mar 22:AT10593.
Abstract

SALEH M, Raffoul P, Akil A, Bassil P, et al
Arab world's impact on bladder cancer research and opportunities for growth: A bibliometric review study.
Medicine (Baltimore). 2024;103:e37554.
Abstract

DENG Y, Huang M, Deng R, Wang J, et al
Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature.
Medicine (Baltimore). 2024;103:e37562.
Abstract

LIU Y, Pang Z, Wang J, Wang J, et al
Multi-omics comprehensive analysis reveals the predictive value of N6-methyladenosine- related genes in prognosis and immune escape of bladder cancer.
Cancer Biomark. 2024 Jan 25. doi: 10.3233/CBM-230286.
Abstract

Bladder cancer: An Update.
Nursing. 2024;54:39-40.
Abstract

PULLEN RL JR
Bladder cancer: An Update.
Nursing. 2024;54:27-39.
Abstract

YOGEETA F, Malik Z, Rauf SA, Devi M, et al
Recurrent bladder leiomyoma: a case report.
J Med Case Rep. 2024;18:173.
Abstract

ROSS J, Lavallee LT, Hickling D, van Walraven C, et al
Development of the multivariate administrative data cystectomy model and its impact on misclassification bias.
BMC Med Res Methodol. 2024;24:73.
Abstract

GIL-JIMENEZ A, van Dijk N, Vos JL, Lubeck Y, et al
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.
Nat Commun. 2024;15:2538.
Abstract

SMITH B, Khanna K, Pierce DP, Patel T, et al
Chronic pelvic pain and dysmenorrhea disguising a rare submucosal leiomyoma of the urinary bladder.
BMJ Case Rep. 2024;17:e258971.
Abstract

LI D, Wang J, Tuo Z, Yoo KH, et al
Natural products and derivatives in renal, urothelial and testicular cancers: Targeting signaling pathways and therapeutic potential.
Phytomedicine. 2024;127:155503.
Abstract

JHUANG JR, Lee CH, Chiang CJ, Chen CJ, et al
Reduced burden of Arsenic-Related cancers after water mitigation in Taiwan.
Environ Int. 2024;185:108542.
Abstract

KATOH M, Loriot Y, Brandi G, Tavolari S, et al
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
Nat Rev Clin Oncol. 2024;21:312-329.
Abstract

DI GIACOMO AM, Schenker M, Medioni J, Mandziuk S, et al
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
ESMO Open. 2024;9:102387.
Abstract

TEITSSON S, Brodtkorb TH, Kurt M, Patel MY, et al
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo.
J Med Econ. 2024;27:473-481.
Abstract

GHOREIFI A, Shishido SN, Sayeed S, Courcoubetis G, et al
Blood-based liquid biopsy: A promising noninvasive test in diagnosis, surveillance, and prognosis of patients with upper tract urothelial carcinoma.
Urol Oncol. 2024;42:118.
Abstract

STROTHER M, Barlotta R, Uzzo R, Bloom E, et al
Symptomatic and functional recovery after transurethral resection of bladder tumor: Data from ecological momentary symptom assessment.
Urol Oncol. 2024;42:117.
Abstract

ALIMOHAMED N, Sridhar SS
Combination strategies for advanced-stage urothelial carcinoma: a paradigm shift.
Nat Rev Clin Oncol. 2024;21:255-256.
Abstract

EGEN L, Wessels F, Quan A, Westhoff N, et al
Maximizing efficiency and ensuring safety: Exploring the outcomes of 2 consecutive open radical cystectomies by the same team within a single surgical day.
Urol Oncol. 2024;42:118.
Abstract

NUIJENS ST, van Osch FHM, van Hoogstraten LMC, Witjes JA, et al
Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes.
Urol Oncol. 2024;42:117.
Abstract

POSADA JM, Yakirevich E, Kamat AM, Sood A, et al
Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
Mod Pathol. 2024;37:100424.
Abstract

TSUJI K, Kaneko M, Harada Y, Fujihara A, et al
A Fully Automated Artificial Intelligence System to Assist Pathologists' Diagnosis to Predict Histologically High-grade Urothelial Carcinoma from Digitized Urine Cytology Slides Using Deep Learning.
Eur Urol Oncol. 2024;7:258-265.
Abstract

TANDON M, Chakraborty S, Barkondaj B, Choudhury S, et al
Role of multiparametric MRI in predicting muscle invasiveness in urinary bladder neoplasms with pathological correlations.
Urologia. 2024;91:55-60.
Abstract

SINGH V, Sarangi SS, Bhirud DP, Sharma K, et al
Assessing pentafecta outcomes post radical cystectomy: A tertiary care center study.
Urologia. 2024;91:49-54.
Abstract

CHEVARRIA J, Ebad CA, Hamill M, Constandache C, et al
Long-term renal function following radical cystectomy and ileal conduit creation.
Ir J Med Sci. 2024;193:639-644.
Abstract

KEALEY J, Ip C, Davis ID, Sengupta S, et al
The impact of multidisciplinary cancer meetings in guiding treatment intent in patients with upper tract urothelial carcinoma.
Asia Pac J Clin Oncol. 2024;20:41-45.
Abstract

KLEBE M, Olbert PJ, Hofmann R, Barth PJ, et al
[CpG-ODN instillation boosts ICAM-1 expression in an orthotopic murine UCC model: immunohistochemical evaluation of the local response to immunostimulatory DNA].
Aktuelle Urol. 2024;55:154-160.
Abstract

AVUDAIAPPAN AP, Prabhakar P, Eldefrawy A, Caso J, et al
CLO24-074: Impact of Neoadjuvant Chemotherapy on Survival and Pathological Response Among Octogenarians Who Underwent Radical Cystectomy for Muscle-Invasive Bladder Cancer.
J Natl Compr Canc Netw. 2024;22.
Abstract

AVUDAIAPPAN AP, Prabhakar P, Chundru S, Renshaw A, et al
CLO24-064: Evaluation of the Reliability of mpMRI in Diagnosing Prostate Cancer Following Intravesical Bacillus Calmette Guerin Therapy for Bladder Cancer.
J Natl Compr Canc Netw. 2024;22.
Abstract

LIYANAGE T, Liyanage AH
QIM24-194: A Cost Effective, Noninvasive Mutiomics Assay (BCDx) for Diagnostic Accuracy of Bladder Cancer Compares to the Gold Standard of Cytoscopy and Cytology.
J Natl Compr Canc Netw. 2024;22.
Abstract

PILALA KM, Kotronopoulos G, Levis P, Giagkos GC, et al
MIR145 Core Promoter Methylation in Pretreatment Cell-Free DNA: A Liquid Biopsy Tool for Muscle-Invasive Bladder Cancer Treatment Outcome.
JCO Precis Oncol. 2024;8:e2300414.
Abstract

PAN W, Liu X, Liu S
ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment.
Medicine (Baltimore). 2024;103:e37590.
Abstract

LOPEZ VALCARCEL M, Barrado Los Arcos M, Ferri Molina M, Cienfuegos Belmonte I, et al
Is trimodal therapy the current standard for muscle-invasive bladder cancer?
Actas Urol Esp (Engl Ed). 2024 Apr 2:S2173-5786(24)00028.
Abstract

ZHANG W, Wang Y, Tang Q, Li Z, et al
PAX2 mediated upregulation of ESPL1 contributes to cisplatin resistance in bladder cancer through activating the JAK2/STAT3 pathway.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr 4. doi: 10.1007/s00210-024-03061.
Abstract

SWINTON M, Devi A, Song YP, Hoskin P, et al
Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer.
World J Urol. 2024;42:210.
Abstract

NIGLIO SA, Purswani JM, Schiff PB, Lischalk JW, et al
Organ preservation in muscle-invasive urothelial bladder cancer.
Curr Opin Oncol. 2024;36:155-163.
Abstract

COLAK R, Erdem GU, Kapar C, Gulturk I, et al
Change in the neutrophil-lymphocyte ratio may predict early recurrence in operated bladder cancer.
Asia Pac J Clin Oncol. 2024 Apr 4. doi: 10.1111/ajco.14065.
Abstract

LUO HM, Xiong YJ
Comparing surgical site wound infection after laparoscopic and open radical cystectomies in patients with bladder cancer.
Int Wound J. 2024;21:e14718.
Abstract

CAI T, Feng T, Li G, Wang J, et al
Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75.
Cancer Cell Int. 2024;24:125.
Abstract

LEARY JB, Enright T, Bakaloudi DR, Basnet A, et al
Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Target Oncol. 2024 Apr 3. doi: 10.1007/s11523-024-01056.
Abstract

SLUSARCZYK A, Ismail H, Zapala L, Piecha T, et al
Changes in the Urinary Microbiome After Transurethral Resection of Non-muscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study.
Ann Surg Oncol. 2024 Apr 3. doi: 10.1245/s10434-024-15198.
Abstract

TEKIN B, Erickson LA, Gupta S
Secondary Involvement of the Urinary Bladder by Endometrial Carcinoma.
Mayo Clin Proc. 2024;99:680-682.
Abstract

LEE S, Yoon Y, Suh J, You D, et al
Association of preoperative sarcopenia with the long-term prognosis of patients with bladder cancer undergoing radical cystectomy.
J Cancer Res Clin Oncol. 2024;150:173.
Abstract

JIANG SC, Liao YG, Luo J, Hu D, et al
Comparison of intravesical chemotherapy regimens after radical nephroureterectomy for upper tract urothelial carcinoma and analysis of risk factors for postoperative recurrence.
Eur Rev Med Pharmacol Sci. 2024;28:2387-2395.
Abstract

ROSSER CJ
Assessing the Causal Relationship between Waterpipe Smoking and Bladder Cancer.
Cancer Epidemiol Biomarkers Prev. 2024;33:461-462.
Abstract

ZHOU J, Zhou R, Zhu Y, Deng S, et al
Investigating the impact of regulatory B cells and regulatory B cell-related genes on bladder cancer progression and immunotherapeutic sensitivity.
J Exp Clin Cancer Res. 2024;43:101.
Abstract

STANIORSKI CJ, Yu M, Sharbaugh D, Stencel MG, et al
Predictors of persistent opioid use in bladder cancer patients undergoing radical cystectomy: A SEER-Medicare analysis.
Urol Oncol. 2024 Apr 1:S1078-1439(24)00362-4. doi: 10.1016/j.urolonc.2024.
Abstract

JI Q, Ma F, Zhang X, Liu Y, et al
Hsa_circ_0005320 affects cell proliferation and the cell cycle via the IGF2BP3/CDK2 axis in bladder cancer.
Cell Signal. 2024 Mar 31:111154. doi: 10.1016/j.cellsig.2024.111154.
Abstract

OMURA M, Kosaka T, Kobayashi H, Shigeta K, et al
ASO Author Reflections: Vasohibin-1 as a Biomarker for Chemotherapeutic Response in Patients with Advanced Bladder Cancer.
Ann Surg Oncol. 2024 Apr 2. doi: 10.1245/s10434-024-15122.
Abstract

BEN REJEB S, Kouki N, Ben Ghachem D, Khouni H, et al
Prognostic significance of E-Cadherin and B-Catenin in non-muscle invasive bladder cancer.
J Immunoassay Immunochem. 2024 Apr 1:1-10. doi: 10.1080/15321819.2024.2335154.
Abstract

LIN M, Xu X, Zhou X, Feng H, et al
Sialylation on vesicular integrin beta1 determined endocytic entry of small extracellular vesicles into recipient cells.
Cell Mol Biol Lett. 2024;29:46.
Abstract

KADORIKU F, Sasaki Y, Fukuta K, Nishiyama M, et al
Robot-assisted intracorporeal ileal conduit urinary diversion: A two-center comparative study of Bricker versus Wallace ureteroileal anastomosis.
Asian J Endosc Surg. 2024;17:e13307.
Abstract

CHENG M, Chen S, Li K, Wang G, et al
CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer.
Nat Commun. 2024;15:2818.
Abstract

YADOLLAHVANDMIANDOAB R, Jalalizadeh M, Dionato FAV, Buosi K, et al
Clinical implications of single cell sequencing for bladder cancer.
Oncol Res. 2024;32:597-605.
Abstract

HUANG Y, Lv Y, Yang B, Zhang S, et al
Enhancing m(6)A modification of lncRNA through METTL3 and RBM15 to promote malignant progression in bladder cancer.
Heliyon. 2024;10:e28165.
Abstract

SCHROECK FR, Grubb R, MacKenzie TA, Ould Ismail AA, et al
Clinical Trial Protocol for "Replace Cysto": Replacing Invasive Cystoscopy with Urine Testing for Non-muscle-invasive Bladder Cancer Surveillance-A Multicenter, Randomized, Phase 2 Healthcare Delivery Trial Comparing Quality of Life During Cancer Surv
Eur Urol Open Sci. 2024;63:19-30.
Abstract

MEAGHER M, Krause H, Elliott A, Farrell A, et al
Characterization and impact of non-canonical WNT signaling on outcomes of urothelial carcinoma.
Cancer Med. 2024;13:e7148.
Abstract

NAHAR R, Jinnah MSA, Karim SS, Alam MM, et al
Expression of Cyclin D1 in Urothelial Carcinoma of Urinary Bladder and its Association with Tumour Grade.
Mymensingh Med J. 2024;33:461-465.
Abstract

CAO Y, Zhu H, Li Z, Liu C, et al
CT Image-Based Radiomic Analysis for Detecting PD-L1 Expression Status in Bladder Cancer Patients.
Acad Radiol. 2024 Mar 30:S1076-6332(24)00138-7. doi: 10.1016/j.acra.2024.
Abstract

ACHARD V, Fournier B, D'Haese D, Krzystyniak J, et al
Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Tri
Eur Urol Oncol. 2024 Mar 30:S2588-9311(24)00084.
Abstract

LI L, Zhang J, Zhe X, Tang M, et al
Prediction of histopathologic grades of bladder cancer with radiomics based on MRI: Comparison with traditional MRI.
Urol Oncol. 2024 Mar 30:S1078-1439(24)00338.
Abstract

FENG X, Chen Z
Case report and literature review of penile metastasis of bladder cancer.
Asian J Surg. 2024 Mar 29:S1015-9584(24)00529.
Abstract

CHEN Y, Jiao W, Wang Y, Liang Z, et al
MITD1 deficiency leads to poor survival via tissue factor-mediated coagulation in bladder cancer.
J Thromb Haemost. 2024 Mar 28:S1538-7836(24)00173.
Abstract

MONTGOMERY J, Lybbert D, Sana S, El-Zawahry A, et al
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guerin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previo
Clin Genitourin Cancer. 2024;22:102059.
Abstract

JAIN NK, Tailang M, Thangavel N, Makeen HA, et al
A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
Acta Pharm. 2024;74:1-36.
Abstract

VERMEULEN R, Bodinier B, Dagnino S, Wada R, et al
A prospective study of smoking-related white blood cell DNA methylation markers and risk of bladder cancer.
Eur J Epidemiol. 2024 Mar 30. doi: 10.1007/s10654-024-01110.
Abstract

SASAKI Y, Izumi K, Fukuta K, Kadoriku F, et al
Impact of lymph node dissection on surgical and oncological outcomes in patients undergoing robot-assisted radical cystectomy for bladder cancer: a multicenter retrospective study.
J Robot Surg. 2024;18:141.
Abstract

HOHAGEN M, Sanchez L, Herbst AJ, Kahlig H, et al
MANNosylation of Mesoporous Silica Nanoparticles Modifies TLR4 Localization and NF-kappaB Translocation in T24 Bladder Cancer Cells.
Adv Healthc Mater. 2024 Mar 30:e2304150. doi: 10.1002/adhm.202304150.
Abstract

WASHINGTON SL 3RD, Lonergan PE, Odisho AY, Meng MV, et al
Association of household net worth with healthcare costs after radical cystectomy using real-world data.
Cancer Med. 2024;13:e7116.
Abstract

AHMADI S, Ambite I, Brisuda A, Hacek J, et al
Similar immune responses to alpha1-oleate and Bacillus Calmette-Guerin treatment in patients with bladder cancer.
Cancer Med. 2024;13:e7091.
Abstract

PORTEN SP, Wang EY, Vohra P, Carroll PR, et al
Evaluation of URO17(R) to improve non-invasive detection of bladder cancer.
Urol Oncol. 2024 Mar 28:S1078-1439(24)00345.
Abstract

LABIDI S, Meti N, Barua R, Li M, et al
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.
BMJ Open. 2024;14:e081480.
Abstract

DING X, Jin Y, Shi X, Wang Y, et al
TDO2 promotes bladder cancer progression via AhR-mediated SPARC/FILIP1L signaling.
Biochem Pharmacol. 2024 Mar 27:116172. doi: 10.1016/j.bcp.2024.116172.
Abstract

LIN YH, Tsai HY, Wu CT
From TURP to enucleation: navigating the complex relationship between BPH treatments and bladder cancer.
World J Urol. 2024;42:203.
Abstract

BIZZARRI FP, Scarciglia E, Russo P, Marino F, et al
Elderly and bladder cancer: The role of radical cystectomy and orthotopic urinary diversion.
Urologia. 2024 Mar 29:3915603241240644. doi: 10.1177/03915603241240644.
Abstract

BRODTKORB TH, Knight C, Kamgar F, Teitsson S, et al
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.
J Med Econ. 2024;27:543-553.
Abstract

SIMHAL RK, Simon DP, Wang KR, Shah YB, et al
Perioperative and Complication Related Outcomes for Robotic-Assisted vs Open Radical Cystectomy: A Comparative National Surgical Quality Improvement Project Analysis.
J Endourol. 2024;38:331-339.
Abstract

ZHANG KY, Hu JS, Liu XH
Efficacy and safety of robot-assisted total cystectomy: A systematic review and meta-analysis.
Asian J Surg. 2024;47:2028-2032.
Abstract

CHEN BH, Hsieh SJ, Chiu B
Non-functional bladder paraganglioma with urinary frequency: A case report.
Asian J Surg. 2024;47:1990-1991.
Abstract

XIN JH, Jiang B, Yuan YH, Zou XF, et al
Primary diffuse large B-cell lymphoma of the urinary bladder: A case report.
Asian J Surg. 2024;47:1930-1931.
Abstract

HUANG P, Xin JH, Zou XF, Wu GQ, et al
Isolated myeloid sarcoma in the urinary bladder: A cases report.
Asian J Surg. 2024;47:1928-1929.
Abstract

SU BY, Tan H, Bao JS, He QQ, et al
Obstructive ureteral calculi and upper-tract urothelial carcinoma: A tale of two cases.
Asian J Surg. 2024;47:1825-1826.
Abstract

NISHIYAMA H, Yonese J, Kawahara T, Matsumoto R, et al
TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naive Locally Advanced or Metastatic Urothelial Carcinoma.
Mol Cancer Ther. 2024;23:532-540.
Abstract

TANAKA S, Tokuhara Y, Ariyasu S, Morinishi T, et al
Diagnostic Immunocytostaining with Peroxisome Proliferator-Activated Receptor-Gamma in Urine Cytology Samples.
Acta Cytol. 2024;68:60-65.
Abstract

MONTOSA RODENAS P, Gomez Huertas M, Perez Rosillo MA, Lainez Ramos-Bossini AJ, et al
Intravesical fat-fluid level as a warning sign of contained bladder perforation: Correlation between cystoscopy and computed tomography findings.
Actas Urol Esp (Engl Ed). 2024;48:254-256.
Abstract

TORIBIO-VAZQUEZ C, Gomez Rivas J, Amigo F, Carrion DM, et al
Prevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study.
Actas Urol Esp (Engl Ed). 2024;48:228-237.
Abstract

ZHANG M, Guo S, Gan S, Xu Q, et al
"Internet Plus" continuous nursing for patients with advanced bladder cancer: A retrospective observational study.
Medicine (Baltimore). 2024;103:e37822.
Abstract

ALHOZEEL B, Pandey SK, Shteinfer-Kuzmine A, Santhanam M, et al
Silencing the Mitochondrial Gatekeeper VDAC1 as a Potential Treatment for Bladder Cancer.
Cells. 2024;13:627.
Abstract

HE S, Xu J, Chen M, Li J, et al
A meta-analysis of UCA1 accuracy in the detection of bladder cancer.
Expert Rev Anticancer Ther. 2024 Apr 12. doi: 10.1080/14737140.2024.2342528.
Abstract

DU Y, Zhang X, Zhang H, Chen Y, et al
[Retracted] Propofol modulates the proliferation, invasion and migration of bladder cancer cells through the miR?145?5p/TOP2A axis.
Mol Med Rep. 2024;29:94.
Abstract

SLUSARCZYK A
ASO Author Reflections: Changes in the Urinary Microbiome After Transurethral Resection of Nonmuscle-Invasive Bladder Cancer: Insights from a Prospective Observational Study.
Ann Surg Oncol. 2024 Apr 11. doi: 10.1245/s10434-024-15248.
Abstract

TANG L, Xu H, Wu T, Wu W, et al
Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review.
Discov Oncol. 2024;15:111.
Abstract

AVILEZ ND, Capibaribe DM, Reis LO
Experimental and New Approaches for Bladder Preservation in Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).
Res Rep Urol. 2024;16:89-113.
Abstract

MAROOF H, Paramore L, Ali A
Theories behind Bacillus Calmette-Guerin failure in high-risk non-muscle-invasive bladder cancer and update on current management.
Cancer Pathog Ther. 2023;2:74-80.
Abstract

TOSI A, Parisatto B, Gaffo E, Bortoluzzi S, et al
A paclitaxel-hyaluronan conjugate (ONCOFID-P-B) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment.
J Exp Clin Cancer Res. 2024;43:109.
Abstract

HONG S, Lee JH, Heo JY, Suh KJ, et al
Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
J Cancer Res Clin Oncol. 2024;150:186.
Abstract

KIM JS, Lee J, Nguyen TT, Choi SY, et al
Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer.
Sci Rep. 2024;14:8440.
Abstract

IGLESIAS DE USSEL GALARRETA I, Queipo Gutierrez FJ
Stromal osseous metaplasia in urothelial carcinoma of the bladder: An unusual and challenging feature. A case report.
Rev Esp Patol. 2024;57:116-119.
Abstract

LI C, Lu B, Zhao Q, Lu Q, et al
Development and validation of a clinical and ultrasound features-based nomogram for preoperative differentiation of renal urothelial carcinoma and central renal cell carcinoma.
World J Urol. 2024;42:227.
Abstract

SU SW, Chen X, Wang G, Li P, et al
A study on the significance of serine hydroxymethyl transferase expression and its role in bladder cancer.
Sci Rep. 2024;14:8324.
Abstract

KURAL S, Jain G, Agarwal S, Das P, et al
Urinary extracellular vesicles-encapsulated miRNA signatures: A new paradigm for urinary bladder cancer diagnosis and classification.
Urol Oncol. 2024 Apr 8:S1078-1439(24)00361-2. doi: 10.1016/j.urolonc.2024.
Abstract

LIU K, Chen H, Li Y, Wang B, et al
Autophagy flux in bladder cancer: Cell death crosstalk, drug and nanotherapetuics.
Cancer Lett. 2024 Apr 7:216867. doi: 10.1016/j.canlet.2024.216867.
Abstract

HIRASAWA Y, Adachi T, Hashimoto T, Fukuokaya W, et al
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
J Cancer Res Clin Oncol. 2024;150:182.
Abstract

SONG B, Kim JK, Lee H, Lee S, et al
Evaluation of histological variants of upper tract urothelial carcinoma as prognostic factor after radical nephroureterectomy.
World J Urol. 2024;42:225.
Abstract

ELSHEWY NE, Ramadan AA, Sameh WM, Eid ME, et al
Does volumetric measurement of ADC values achieve higher diagnostic performance in bladder cancer MRI?
Acta Radiol. 2024 Apr 9:2841851241241055. doi: 10.1177/02841851241241055.
Abstract

HASSAN M, Quereshi AH
Paraganglioma of the urinary bladder: A case report.
J Pak Med Assoc. 2024;74:570-572.
Abstract

NUSRAT NB, Rehman AU, Zafar N, Muhammad S, et al
Challenges and technical aspects in the management of muscle invasive bladder cancer as retrograde radical cystectomy with ileal conduit.
J Pak Med Assoc. 2024;74:513-518.
Abstract

PIJPERS OM, Boormans JL
Disease progression in Bacillus Calmette Guerin unresponsive non-muscle invasive bladder cancer patients with carcinoma in situ, participating in clinical trials on bladder-sparing treatment.
Transl Androl Urol. 2024;13:479-482.
Abstract

KIM S, St-Laurent MP, Black P
Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314.
Transl Androl Urol. 2024;13:458-462.
Abstract

AGRAWAL S, Gupta A, Kapoor V, Rahul R, et al
Predictors of Toxicity in a Randomized Study of Consolidation Chemoradiation Versus Observation After First Line Chemotherapy in Advanced Gall Bladder Cancers.
Adv Radiat Oncol. 2024;9:101468.
Abstract

WEN X, Hou J, Chu Y, Liao G, et al
Immunotherapeutic value of NUSAP1 associated with bladder cancer through a comprehensive analysis of 33 human cancer cases.
Am J Cancer Res. 2024;14:959-978.
Abstract

WANG B, Zhou B, Chen J, Sun X, et al
Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses.
J Immunother Cancer. 2024;12:e007808.
Abstract

HANNA P, Zabell J, Konety B, Warlick C, et al
Perioperative complications and oncological outcomes of open versus robotic-assisted radical cystectomy: a propensity score-matched study.
World J Urol. 2024;42:220.
Abstract

WANG J, Guo F, Zhang J, Chao J, et al
Potential-resolved electrochemiluminescence for simultaneous determination of multiplex bladder cancer markers.
Chem Commun (Camb). 2024 Apr 8. doi: 10.1039/d4cc00996.
Abstract

HAN Z, Ai J
Editorial: Biomarkers and immunotherapy for genitourinary tumors.
Front Immunol. 2024;15:1394170.
Abstract

P VAN VALENBERG FJ, van der Heijden AG, Cutie CJ, Bhanvadia S, et al
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study.
Eur Urol Open Sci. 2024;62:8-15.
Abstract

ZHANG X, Wang Y, Wang Y, Zhang J, et al
MRI evaluation of vesical imaging reporting and data system for bladder cancer after neoadjuvant chemotherapy.
Cancer Imaging. 2024;24:49.
Abstract

SANG J, Liu CK, Liu J, Luo GC, et al
Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells.
Biochem Pharmacol. 2024;223:116194.
Abstract

LYU F, Huang S, Yan Z, He Q, et al
CircUGGT2 facilitates progression and cisplatin resistance of bladder cancer through nonhomologous end-joining pathway.
Cell Signal. 2024 Apr 5:111164. doi: 10.1016/j.cellsig.2024.111164.
Abstract

PULLEN L, Costa PF, Darr C, Hess J, et al
Near-infrared fluorescence lymph node template region dissection plus backup lymphadenectomy in open radical cystectomy for bladder cancer using an innovative handheld device: A single center experience.
J Surg Oncol. 2024 Apr 7. doi: 10.1002/jso.27618.
Abstract

ZHANG X, Liu Q, Yi K, Liu S, et al
The Prognostic Value of the Combination of the Prognostic Nutritional Index and the Lymphocyte:Monocyte Ratio for the Prediction of Patients with Muscle-Invasive Bladder Cancer.
Arch Esp Urol. 2024;77:164-172.
Abstract

REN H, Wang K, Liu C
Analysis of the Clinicopathological Characteristics and Prognosis of Patients with Nonurothelial Bladder Cancer.
Arch Esp Urol. 2024;77:148-157.
Abstract

ARIAFAR A, Kohansal E, Mousania A, Faghih Z, et al
Natural Killer Cell Subsets in Tumor Draining Lymph Nodes of Patients with Bladder Cancer and Their Clinical Implications.
Iran J Immunol. 2024;21.
Abstract

VOGL UM, Testi I, De Santis M
Front-line Platinum Continues To Have a Role in Advanced Bladder Cancer.
Eur Urol Focus. 2024 Apr 5:S2405-4569(24)00049-X. doi: 10.1016/j.euf.2024.
Abstract

WANG Z, Kwan ML, Haque R, Singh PK, et al
Modifying Effects of Genetic Variations on the Association Between Dietary Isothiocyanate Exposure and Non-muscle Invasive Bladder Cancer Prognosis in the Be-Well Study.
Mol Nutr Food Res. 2024 Apr 6:e2400087. doi: 10.1002/mnfr.202400087.
Abstract

ZENG X, Su H, Liu Z, Wang Y, et al
Integrative analysis of the bladder cancer from a cell cycle NCAM1 perspective at both single cell and bulk resolution.
Environ Toxicol. 2024 Apr 6. doi: 10.1002/tox.24260.
Abstract

CARROLL RA, Rice ES, Murphy WJ, Lyons LA, et al
A chromosome-scale fishing cat reference genome for the evaluation of potential germline risk variants.
Sci Rep. 2024;14:8073.
Abstract

ZHANG C, Xu X, Wang T, Lu Y, et al
Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder.
Sci Rep. 2024;14:7941.
Abstract

AKBULUT D, Al-Ahmadie H
Updates on Urinary Bladder Tumors With Neuroendocrine Features.
Adv Anat Pathol. 2024;31:169-177.
Abstract

DENG H, Cheng F, Cheng S
Comprehensive analysis of scRNA-seq and bulk RNA-seq reveal the characteristics of disulfidptosis and a prognostic signature in BLCA.
Aging (Albany NY). 2024;16:5751-5771.
Abstract

MILOJEVIC B
Reply to: Letter to the Editor for the Article "Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma," by Urabe, Fumihik et al.
Ann Surg Oncol. 2024;31:3565-3566.
Abstract

URABE F, Tsuzuki S, Kimura T
Letter to the Editor for the Article "Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma".
Ann Surg Oncol. 2024;31:3563-3564.
Abstract

MONTEIRO FSM, Soares A, Mollica V, Leite CA, et al
Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis.
Crit Rev Oncol Hematol. 2024;196:104321.
Abstract

OTIS SU, Banna GL, Maniam A
The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma - A review of the literature.
Crit Rev Oncol Hematol. 2024;196:104314.
Abstract

MIYAI K, Nakayama M, Minabe S, Ogata S, et al
Implementation of The Paris System for Reporting Urine Cytology improves diagnostic accuracy of selective upper urinary tract cytology.
Cancer Cytopathol. 2024;132:242-249.
Abstract

LORIOT Y, Petrylak DP, Rezazadeh Kalebasty A, Flechon A, et al
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
Ann Oncol. 2024;35:392-401.
Abstract

CHO WC, Saade R, Nagarajan P, Aung PP, et al
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.
J Cutan Pathol. 2024 Jan 10. doi: 10.1111/cup.14579.
Abstract

TANG F, Wang X, Liu T, Wang H, et al
Multiple Fluorescences in Situ Hybridization Status in Excreted Urine Improve Diagnostic Efficacy for Upper Urinary Tract Urothelial Carcinomas.
Urol J. 2024;21:107-113.
Abstract

CEYHAN E, Mammadov E, Onder SC, Dogan HS, et al
Fish: A Promising Screening Tool for Malignancy After Augmentation Cystoplasty?
J Pediatr Surg. 2024;59:725-730.
Abstract

PANEBIANCO V, Briganti A, Boellaard TN, Catto J, et al
Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System.
Nat Rev Urol. 2024;21:243-251.
Abstract

GUPTA S, Andreev-Drakhlin A, Fajardo O, Fasso M, et al
Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment.
J Natl Cancer Inst. 2024;116:547-554.
Abstract

XU C, Xiong B
Prognostic Nomograms for Patients with Primary Sarcomatoid Carcinoma of The Urinary Bladder: Based on The SEER Database.
Urol J. 2024;21:87-97.
Abstract

SZYMANSKA B, Debowski J, Malkiewicz B, Piwowar A, et al
Assessment of interleukin 17A and 23 in the course of bladder cancer and selected benign urological diseases.
J Physiol Pharmacol. 2024;75.
Abstract

RANA Z, Kamran SC, Shetty AC, Sutera P, et al
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712.
Eur Urol Oncol. 2024 Apr 18:S2588-9311(24)00095.
Abstract

HERZBERG H, Ventura Y, Lifshitz K, Savin Z, et al
Natural history and health care burden of non-curative treatment for muscle-invasive bladder cancer.
Urol Oncol. 2024 Apr 18:S1078-1439(24)00365.
Abstract

JIANG Q, Wei ZF, Xiong Y, Jiang B, et al
[Identification of lncrnas associated with aniline toxicity in male bladder cancer and construction of tumor risk prediction models].
Zhonghua Nan Ke Xue. 2023;29:790-798.
Abstract

SHEN D, Kang S
Correction: Comprehensive analysis of mitochondria-related genes indicates that PPP2R2B is a novel biomarker and promotes the progression of bladder cancer via Wnt signaling pathway.
Biol Direct. 2024;19:27.
Abstract

KWONG JCC, Wu J, Malik S, Khondker A, et al
Predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: a systematic review using APPRAISE-AI.
NPJ Digit Med. 2024;7:98.
Abstract

WANG A, Chen M, Li D, Shi J, et al
Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study.
Clin Genitourin Cancer. 2024;22:102085.
Abstract

MASSARI F, Santoni M, Takeshita H, Okada Y, et al
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother. 2024;73:106.
Abstract

QING L, Li Q, Yang Y, Xu W, et al
Hypoxia-mediated attenuation of EGLN2 inhibition of the NF-kappaB signaling pathway leads to the formation of a loop between HIF-1alpha and MUC1-C promoting chemoresistance in bladder cancer.
Mol Carcinog. 2024 Apr 18. doi: 10.1002/mc.23725.
Abstract

AL-ZUBAIDI M, Ong K, Viswambaram P, Bangash H, et al
Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer.
BJUI Compass. 2024;5:473-479.
Abstract

CHEN H, Wen J, Zhang W, Ma W, et al
circKDM1A suppresses bladder cancer progression by sponging miR-889-3p/CPEB3 and stabilizing p53 mRNA.
iScience. 2024;27:109624.
Abstract

ZHENG K, Hai Y, Chen H, Zhang Y, et al
Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
J Transl Med. 2024;22:365.
Abstract

MEGHANI K, Frydenlund N, Yu Y, Choy B, et al
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer.
J Immunother Cancer. 2024;12:e008571.
Abstract

YANG Y, Li J, Yao W, Zou G, et al
Diagnostic value of urine cyclic RNA-0071196 for bladder urothelial carcinoma.
BMC Urol. 2024;24:88.
Abstract

WEBER A, Vignat J, Shah R, Morgan E, et al
Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates.
World J Urol. 2024;42:237.
Abstract

VARCHULOVA NOVAKOVA Z, Harsanyi S, Bevizova K, Kuniakova M, et al
Expression of BCL2, TP53, FOXA1, and GATA3 in pTa bladder cancer recurrence.
Bratisl Lek Listy. 2024;125:311-317.
Abstract

HARTERT M, Deppe C, Fink L, Kappes J, et al
Chest wall tumor following intravesical BCG instillation for non-muscle invasive bladder cancer.
J Clin Tuberc Other Mycobact Dis. 2024;35:100438.
Abstract

MASONE MC
A CAF subpopulation promotes LVI in early-stage bladder cancer.
Nat Rev Urol. 2024 Apr 15. doi: 10.1038/s41585-024-00881.
Abstract

FERNANDEZ MI
Implementation of new treatments for BCG-unresponsive non-muscle-invasive bladder cancer. Considerations in Latin America.
Actas Urol Esp (Engl Ed). 2024 Apr 12:S2173-5786(24)00058.
Abstract

ABD ELHAMEED ZA, Tag El Din LM, Sherif T, Abdel Aal AM, et al
Plasma metadherin mRNA expression in bladder cancer.
Egypt J Immunol. 2024;31:28-43.
Abstract

KLEMM J, Shariat SF, Laukhtina E, Rajwa P, et al
Impact of Preoperative Plasma Potassium Levels on Oncological Outcomes, Major Complications, and 30-Day Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy.
Clin Genitourin Cancer. 2024 Mar 21:102079. doi: 10.1016/j.clgc.2024.102079.
Abstract

LI J, Song Y, Peng Y, Lin J, et al
The role of histological subtype and chemotherapy on prognosis of ureteral cancer.
J Cancer Res Clin Oncol. 2024;150:192.
Abstract

BAEK SW, Leem SH
A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guerin and Immune Checkpoint Inhibitors.
Int J Mol Sci. 2024;25:3800.
Abstract

PADULLES B, Carrasco R, Ingelmo-Torres M, Roldan FL, et al
Prognostic Value of Liquid-Biopsy-Based Biomarkers in Upper Tract Urothelial Carcinoma.
Int J Mol Sci. 2024;25:3695.
Abstract

AFONSO J, Barbosa-Matos C, Silvestre R, Pereira-Vieira J, et al
Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect.
Cancers (Basel). 2024;16:1418.
Abstract

JAROMIN M, Konecki T, Kutwin P
Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:1366.
Abstract

MAAS M, Hilsendecker A, Pertoll A, Stuhler V, et al
PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette-Guerin (BCG) Therapy.
Cancers (Basel). 2024;16:1356.
Abstract

PERRI D, Rocco B, Sighinolfi MC, Bove P, et al
Open versus Robot-Assisted Radical Cystectomy for the Treatment of pT4a Bladder Cancer: Comparison of Perioperative Outcomes.
Cancers (Basel). 2024;16:1329.
Abstract

LADI-SEYEDIAN SS, Ghoreifi A, Konety B, Pohar K, et al
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.
Cancers (Basel). 2024;16:1268.
Abstract

YOO YC, Kim NY, Shin S, Yang Y, et al
Anti-Proliferative Effects of Lidocaine as an Autophagy Inducer in Bladder Cancer via Intravesical Instillation: In Vitro and Xenograft Mouse Model Experiments.
Cancers (Basel). 2024;16:1267.
Abstract

PICHLER R, Stablein J, Mari A, Afferi L, et al
Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder Cancer.
J Clin Med. 2024;13:2031.
Abstract

XIE T, Guo J, Wang W
The Long Noncoding RNA Gall Bladder Cancer-Associated Suppressor of Pyruvate Carboxylase Inhibits the Proliferation, Migration, and Invasion of Colorectal Cancer Cells and Induces Their Apoptosis.
Biochem Genet. 2024 Apr 12. doi: 10.1007/s10528-024-10786.
Abstract

VOVK V, Duda I, Vovk A
THE EFFECT OF A MULTIMODAL APPROACH ON THE RESULTS OF TREATMENT IN SURGERY: INTEGRATION OF CHEMOTHERAPY, SURGERY, AND RADIOTHERAPY.
Georgian Med News. 2024;:41-46.
Abstract

PEZESHKI A, Cheville JC, Florio AB, Leibovich BC, et al
Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model.
Front Immunol. 2024;15:1356144.
Abstract

GONG J, Mita AC, Wei Z, Cheng HH, et al
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
JCO Precis Oncol. 2024;8:e2300406.
Abstract

GONG J, Mita AC, Wei Z, Cheng HH, et al
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
JCO Precis Oncol. 2024;8:e2300407.
Abstract

NAKAUMA-GONZALEZ JA, Rijnders M, Noordsij MTW, Martens JWM, et al
Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.
Cell Genom. 2024;4:100528.
Abstract

DALL CP, Mason JB, Goldman CC, Fabrizio G, et al
Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy: A systematic review and meta-analysis.
Urol Oncol. 2024;42:121-132.
Abstract

MORRA S, Scheipner L, Baudo A, Jannello LMI, et al
Regional differences in upper tract urothelial carcinoma patients across the United States.
Urol Oncol. 2024;42:162.
Abstract

ZHAO X, Lai L, Li Y, Zhou X, et al
A lightweight bladder tumor segmentation method based on attention mechanism.
Med Biol Eng Comput. 2024;62:1519-1534.
Abstract

GREENBERG DR, Rhodes S, Bhambhvani HP, Gago LC, et al
The association between frailty, hypogonadism, and postoperative outcomes among men undergoing radical cystectomy.
Urol Oncol. 2024;42:161.
Abstract

FEBRIYANTO T, Muhammad F, Wijaya W, Oey O, et al
Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: A systematic review and meta-analysis.
Urol Oncol. 2024;42:160.
Abstract

YANG R, He J, Luo W, Xiang R, et al
Comprehensive analysis and prognostic assessment of senescence-associated genes in bladder cancer.
Discov Oncol. 2024;15:130.
Abstract

PARRAO D, Lizana N, Saavedra C, Larranaga M, et al
Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review.
Curr Oncol. 2024;31:2201-2220.
Abstract

BARBAUD A, Lascombe I, Pechery A, Arslan S, et al
GW501516-Mediated Targeting of Tetraspanin 15 Regulates ADAM10-Dependent N-Cadherin Cleavage in Invasive Bladder Cancer Cells.
Cells. 2024;13:708.
Abstract

IBRAHIM OM, Kalinski P
Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette-Guerin Immunotherapy of Bladder Cancer.
Cells. 2024;13:699.
Abstract

BILSKI K, Zeber-Lubecka N, Kulecka M, Dabrowska M, et al
Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer.
Curr Issues Mol Biol. 2024;46:3595-3609.
Abstract

DUDAIE M, Dotan E, Barnea I, Haifler M, et al
Detection of bladder cancer cells using quantitative interferometric label-free imaging flow cytometry.
Cytometry A. 2024 Apr 26. doi: 10.1002/cyto.a.24846.
Abstract

WANG Y, Nan Y, Ma C, Lu X, et al
A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE.
Cell Death Dis. 2024;15:293.
Abstract

KNORR J, Lone Z, Werneburg G, Adler A, et al
An exploratory study investigating the impact of the bladder tumor microbiome on Bacillus Calmette Guerin (BCG) response in non-muscle invasive bladder cancer.
Urol Oncol. 2024 Apr 24:S1078-1439(24)00430.
Abstract

GOMEZ DEL CANIZO C, Gonzalez Ginel I, Martin-Arriscado Arroba C, de la Calle Moreno A, et al
Voided urine cytology is a useful tool predicting non-muscle-invasive bladder cancer risk before surgery.
Urol Oncol. 2024 Apr 24:S1078-1439(24)00401.
Abstract

YU XI, He ZIQI, Wang QINGHUA, Ke SHUAI, et al
Brusatol hinders the progression of bladder cancer by Chac1/Nrf2/SLC7A11 pathway.
Exp Cell Res. 2024 Apr 23:114053. doi: 10.1016/j.yexcr.2024.114053.
Abstract

ZHANG B, Chen P, Zhu J, Lu Y, et al
The quantity, function and anti-tumor effect of Mucosal associated invariant T cells in patients with bladder cancer.
Int Immunopharmacol. 2024;133:111892.
Abstract

MA Q, Wu F, Liu X, Zhao C, et al
20-hydroxyecdysone suppresses bladder cancer progression via inhibiting USP21: A mechanism associated with deubiquitination and degradation of p65.
Transl Oncol. 2024;45:101958.
Abstract

CHENG WC, Heng HG, Cheng HY, Lin KY, et al
Findings of an Extraluminal Leiomyosarcoma of the Urinary Bladder in a Dog.
J Am Anim Hosp Assoc. 2024;60:109-113.
Abstract

XIAO Y, Shen Y, Song H, Gao F, et al
AKR1C2 genetic variants mediate tobacco carcinogens metabolism involving bladder cancer susceptibility.
Arch Toxicol. 2024 Apr 25. doi: 10.1007/s00204-024-03737.
Abstract

KOSOVA I, Barsegian V, Gundorova L, Kolbasov D, et al
PD-L1 Expression in Nonbacterial Chronic Cystitis and Bladder Cancer.
Int Urogynecol J. 2024 Apr 25. doi: 10.1007/s00192-024-05782.
Abstract

LI DX, Wu RC, Wang J, Yu QX, et al
An endothelial-related prognostic index for bladder cancer patients.
Discov Oncol. 2024;15:128.
Abstract

WANG ZQ, Qu TR, Zhang ZS, Zeng FS, et al
A Transformable Specific-Responsive Peptide for One-Step Synergistic Therapy of Bladder Cancer.
Small. 2024 Apr 25:e2310416. doi: 10.1002/smll.202310416.
Abstract

CZERNIAK B, Lee S, Jung SY, Kus P, et al
Inferring Bladder Cancer Evolution from Mucosal Field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping.
Res Sq [Preprint]. 2024 Apr 10:rs.3.rs-3994376. doi: 10.21203/rs.3.rs-3994376.
Abstract

QIAN J, Zhang Q, Cao Y, Chu X, et al
Perfusion drugs for non?muscle invasive bladder cancer (Review).
Oncol Lett. 2024;27:267.
Abstract

PLAGE H, Furlano K, Hofbauer S, Weinberger S, et al
PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors.
BMC Urol. 2024;24:96.
Abstract

ZHANG H, Zhang X, Zhang Y, Han D, et al
Pan-Cancer Analysis Shows that KIFC2 is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Bladder Cancer.
Mol Biotechnol. 2024 Apr 24. doi: 10.1007/s12033-024-01149.
Abstract

YOUNG M
The Future of Front-line Metastatic Bladder Cancer is Platinum-free.
Eur Urol Focus. 2024 Apr 23:S2405-4569(24)00057.
Abstract

LI Y, Jiang C, Liu Q, Zhou P, et al
USP15 facilitates the progression of bladder cancer by amplifying the activation of the NF-kappaB signaling pathway.
Aging (Albany NY). 2024;16.
Abstract

WU P, Zhao L, Kong G, Song B, et al
Study on the Role and Mechanism of SLC3A2 in Tumor-Associated Macrophage Polarization and Bladder Cancer Cells Growth.
Technol Cancer Res Treat. 2024;23:15330338241246649.
Abstract

OHENE-AGYEI J, Madhira M, Smith H, Sardiu ME, et al
Open or robotic? Radical cystectomies for patients with non-metastatic bladder cancer: A systematic review and meta-analysis.
J Clin Transl Sci. 2024;8:e57.
Abstract

OKAWA S, Gatellier L
Projection of the number of new cases of bladder cancer in the world.
Jpn J Clin Oncol. 2024 Apr 23:hyae050. doi: 10.1093.
Abstract

LI J, Wang Z, Wang T
Machine-learning prediction of a novel diagnostic model using mitochondria-related genes for patients with bladder cancer.
Sci Rep. 2024;14:9282.
Abstract

PSUTKA SP, Veleber S, Siman J, Holt SK, et al
Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guerin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2024 Apr 22:S2588-9311(24)00091.
Abstract

KASTNER L, Rieger C, Pfister D, Schmautz M, et al
HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center.
Urol Oncol. 2024 Apr 22:S1078-1439(24)00340.
Abstract

BEN-DAVID R, Pellegrino F, Alerasool P, Tillu N, et al
Robotic-assisted radical cystectomy with cutaneous ureterostomies: a contemporary multicenter analysis.
World J Urol. 2024;42:251.
Abstract

GAO P, Li X, He Z, Zhang H, et al
Lethal Immune Myocarditis and Myasthenia Gravis Due to Anti-PD-1 Treatment for a Bladder Cancer Patient: A Case Report and Possible Treatment Inspiration.
Int Med Case Rep J. 2024;17:359-365.
Abstract

LOU K, Chi J, Wu J, Ma J, et al
Research progress on the microbiota in bladder cancer tumors.
Front Cell Infect Microbiol. 2024;14:1374944.
Abstract

ZLOBINA NV, Budylin GS, Tseregorodtseva PS, Andreeva VA, et al
In vivo assessment of bladder cancer with diffuse reflectance and fluorescence spectroscopy: A comparative study.
Lasers Surg Med. 2024 Apr 22. doi: 10.1002/lsm.23788.
Abstract

CZERNIAK B
Bladder cancer variants - one disease with many faces.
Nat Rev Urol. 2024 Apr 22. doi: 10.1038/s41585-024-00886.
Abstract

ZHANG X, Lian H, Song X, Li J, et al
Bacillus Calmette-Guerin-induced kidney granulomas.
Kidney Int. 2024;105:1131.
Abstract

ZHANG T, Hu B, Xu S, Wang Y, et al
Association Between CYP24A1 Polymorphisms and Bladder Cancer Risk in the Chinese Han Population.
Biochem Genet. 2024 Apr 20. doi: 10.1007/s10528-024-10771.
Abstract

OH CH, Cho SB, Lee HJ, Kwon H, et al
Migration of double-J ureteral stent in patients with ureteroileal anastomosis stricture undergoing radical cystectomy and orthotopic neobladder: Analysis risk factors of stent migration.
Medicine (Baltimore). 2024;103:e37765.
Abstract

NIEGISCH G, Grimm MO, Hardtstock F, Krieger J, et al
Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data.
J Med Econ. 2024;27:531-542.
Abstract

SCHWARZ L, Sobania D, Rothlauf F
On relevant features for the recurrence prediction of urothelial carcinoma of the bladder.
Int J Med Inform. 2024;186:105414.
Abstract

GAO Z, Pang Y, Qin X, Li G, et al
Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy.
Int J Clin Oncol. 2024;29:592-601.
Abstract

SIDAWAY P
A new standard of care for advanced-stage urothelial carcinoma.
Nat Rev Clin Oncol. 2024;21:336.
Abstract

HASHIMOTO M, Fukuokaya W, Yanagisawa T, Yamamoto S, et al
Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Int J Clin Oncol. 2024;29:612-619.
Abstract

TAOKA R, Kamada M, Izumi K, Tanimoto R, et al
Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
Int J Clin Oncol. 2024;29:602-611.
Abstract

SIVAKUMAAR K, Griffin J, Schofield E, Catto JWF, et al
Gene of the month: the uroplakins.
J Clin Pathol. 2024;77:291-296.
Abstract

MOHAMED AS, Salama AF, Sabaa MA, Toraih E, et al
GEMIN4 Variants: Risk Profiling, Bioinformatics, and Dynamic Simulations Uncover Susceptibility to Bladder Carcinoma.
Arch Med Res. 2024;55:102970.
Abstract

FU S, Shi H, Fan Z, Li J, et al
Robot-assisted radical cystectomy with intracorporeal urinary diversion: an updated systematic review and meta-analysis of its differential effect on effectiveness and safety.
Int J Surg. 2024;110:2366-2380.
Abstract

UNTERRAINER LM, Eismann L, Lindner S, Gildehaus FJ, et al
[(68 )Ga]Ga-FAPI-46 PET/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis.
Eur J Nucl Med Mol Imaging. 2024;51:1786-1789.
Abstract

SATO S, Yanagisawa T, Miki J, Hayashida Y, et al
pT1 Subclassification Predicts Progression-Free Survival in En Bloc Resection of Bladder Tumor Specimens.
Arch Pathol Lab Med. 2024;148:573-580.
Abstract

PRAHARAJ M, Shen F, Lee AJ, Zhao L, et al
Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancer tumors.
Cancer Immunol Res. 2024 May 3. doi: 10.1158/2326-6066.CIR-23-1105.
Abstract

YE Z, Liu C, Wu S, Jin X, et al
Identification of cuproptosis-related long non-coding RNA and construction of a novel prognostic signature for bladder cancer: An observational study.
Medicine (Baltimore). 2024;103:e38005.
Abstract

LIN FX, Wang L, Xu ZP
A balanced perspective on bladder preservation and systemic treatment in muscle-invasive bladder cancer.
World J Urol. 2024;42:288.
Abstract

ABUHASANEIN S, Edenbrandt L, Enqvist O, Jahnson S, et al
A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria.
Scand J Urol. 2024;59:90-97.
Abstract

XIA L, Dadabhoy A, Wood EL, Mehta SV, et al
Pathologic and survival outcomes following radical cystectomy for "progressive" and "de novo" muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status.
Urol Oncol. 2024 May 1:S1078-1439(24)00438-1. doi: 10.1016/j.urolonc.2024.
Abstract

Erdafitinib (Balversa) for urothelial carcinoma.
Med Lett Drugs Ther. 2024;66:e83-e84.
Abstract

KOSHKIN VS
Therapy Attrition and Lessons for Future Approaches to Treatment of Advanced Urothelial Cancer.
JAMA Netw Open. 2024;7:e249426.
Abstract

MATHEW THOMAS V, Jo Y, Tripathi N, Roy S, et al
Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
JAMA Netw Open. 2024;7:e249417.
Abstract

ZHAO F, Jia Z, Xie H
Identification of a pyroptosis-immune-related lncRNA signature for prognostic and immune landscape prediction in bladder cancer patients.
Discov Oncol. 2024;15:140.
Abstract

MENECEUR S, De Vos CE, Petzsch P, Kohrer K, et al
New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
J Cell Mol Med. 2024;28:e18342.
Abstract

BEN-DAVID R, Galsky MD, Sfakianos JP
Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer.
Trends Mol Med. 2024 Apr 30:S1471-4914(24)00092.
Abstract

LI J, Cheng C, Zhang J
Autoimmune diseases and the risk of bladder cancer: A Mendelian randomization analysis.
J Autoimmun. 2024;146:103231.
Abstract

LENIS AT, Whiting K, Ravichandran V, Tallman JE, et al
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
JCO Precis Oncol. 2024;8:e2300274.
Abstract

LI T, You Q, Zhang S, Li R, et al
Performance of (18)F-FDG PET/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer.
iScience. 2024;27:109657.
Abstract

GADE VKV, Yadav BS
Understanding the role of transmembrane 9 superfamily member 1 in bladder cancer pathogenesis.
World J Clin Oncol. 2024;15:468-471.
Abstract

ZHANG W, Chen XS, Wei Y, Wang XM, et al
Overexpressed KCNK1 regulates potassium channels affecting molecular mechanisms and biological pathways in bladder cancer.
Eur J Med Res. 2024;29:257.
Abstract

SCIMECA M, Bischof J, Bonfiglio R, Nale E, et al
Molecular profiling of a bladder cancer with very high tumour mutational burden.
Cell Death Discov. 2024;10:202.
Abstract

INGRAM JW, Chung R, Laplaca C, McKiernan JM, et al
Incidence and management of prostatic urethra recurrence in a cohort of 21 patients who received BCG induction for non-muscle invasive bladder cancer.
Urol Oncol. 2024 Apr 29:S1078-1439(24)00436.
Abstract

SUARTZ CV, Martinez LM, Cordeiro MD, Botelho LAA, et al
Honing the Hunt: A Comprehensive Review of Cell-free Tumor DNA to Predict Neoadjuvant Therapy Efficacy in Bladder Cancer.
Clin Genitourin Cancer. 2024;22:102087.
Abstract

REDDY AC, Gu JZ, Koo BH, Fruh V, et al
Urothelial Carcinoma: Epidemiology and Imaging-Based Review.
R I Med J (2013). 2024;107:26-32.
Abstract

LIEDBERG F, Hagberg O, Aljabery F, Andren O, et al
Cystectomy for bladder cancer in Sweden - short-term outcomes after centralization.
Scand J Urol. 2024;59:84-89.
Abstract

LI J
Correlation between Ki-67 or Profilin-1 Expression Levels, Clinicopathological Characteristics and Postoperative Prognosis in Patients with Bladder Cancer.
Ann Ital Chir. 2024;95:246-252.
Abstract

YOUSSEF M, Sewell J, Grills R
Unrecognised paraganglioma of the urinary bladder precipitating hypertensive crisis.
BMJ Case Rep. 2024;17:e259283.
Abstract

LIN P, Yang X, Wang L, Zou X, et al
Novel artesunate-metformin conjugate inhibits bladder cancer cell growth associated with Clusterin/SREBP1/FASN signaling pathway.
Korean J Physiol Pharmacol. 2024;28:219-227.
Abstract

LIU S, Wang Y, Duan L, Cui D, et al
Whole transcriptome sequencing identifies a competitive endogenous RNA network that regulates the immunity of bladder cancer.
Heliyon. 2024;10:e29344.
Abstract

YIN C, Liufu C, Zhu T, Ye S, et al
Bladder Cancer in Exosomal Perspective: Unraveling New Regulatory Mechanisms.
Int J Nanomedicine. 2024;19:3677-3695.
Abstract

GARCIA-PERDOMO HA, Davila-Raigoza AM, Korkes F
Metabolomics for the diagnosis of bladder cancer: A systematic review.
Asian J Urol. 2024;11:221-241.
Abstract

WANG LS, Hubbard RA, Mamtani R
Comparing survival in trial- versus routine-care advanced urothelial cancer patients on immune checkpoint blockade.
Pharmacoepidemiol Drug Saf. 2024;33:e5798.
Abstract

PELLEGRINO F, Leni R, Basile G, Rosiello G, et al
Peri- and post-operative outcomes of robot-assisted radical cystectomy after the implementation of the EAU guidelines recommendations for collecting and reporting complications at a high-volume referral center.
World J Urol. 2024;42:270.
Abstract

CHEN L, Liu LT, Sun MJ, He SR, et al
[Practical application of the Paris system for reporting urinary cytology].
Zhonghua Bing Li Xue Za Zhi. 2024;53:470-476.
Abstract

ZHANG R, Jia S, Zhai L, Wu F, et al
Predicting preoperative muscle invasion status for bladder cancer using computed tomography-based radiomics nomogram.
BMC Med Imaging. 2024;24:98.
Abstract

BANG BR, Zhong J, Oh TJ, Lee JY, et al
A Streamlined PENK Methylation Test in Urine DNA, EarlyTect BCD, Effectively Detects Bladder Cancer in Patients with Hematuria.
J Mol Diagn. 2024 Apr 25:S1525-1578(24)00084.
Abstract

LU C, Gao H, Li H, Luo N, et al
A novel LINC02321 promotes cell proliferation and decreases cisplatin sensitivity in bladder cancer by regulating RUVBL2.
Transl Oncol. 2024;45:101962.
Abstract

ETURI A, Bhasin A, Zarrabi KK, Tester WJ, et al
Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
Molecules. 2024;29:1896.
Abstract

PEZZICOLI G, Ciciriello F, Musci V, Minei S, et al
Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
Medicina (Kaunas). 2024;60:585.
Abstract

MONYOK A, Mansour B, Vadnay I, Makra N, et al
Change in Tissue Microbiome and Related Human Beta Defensin Levels Induced by Antibiotic Use in Bladder Carcinoma.
Int J Mol Sci. 2024;25:4562.
Abstract

SANGUEDOLCE F, Falagario UG, Zanelli M, Palicelli A, et al
Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.
J Clin Med. 2024;13:2182.
Abstract

SARRIO-SANZ P, Martinez-Cayuelas L, Beltran-Perez A, Munoz-Montoya M, et al
A Novel Decision Tree Model for Predicting the Cancer-Specific Survival of Patients with Bladder Cancer Treated with Radical Cystectomy.
J Clin Med. 2024;13:2177.
Abstract

STROMME O, Heck KA, Brede G, Lindholm HT, et al
tRNA-Derived Fragments as Biomarkers in Bladder Cancer.
Cancers (Basel). 2024;16:1588.
Abstract

TOTONJI S, Ramos-Triguero A, Willmann D, Sum M, et al
Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:1532.
Abstract

KAPRINIOTIS K, Tzelves L, Lazarou L, Mitsogianni M, et al
Circulating Tumour DNA and Its Prognostic Role in Management of Muscle Invasive Bladder Cancer: A Narrative Review of the Literature.
Biomedicines. 2024;12:921.
Abstract

SLUSARCZYK A, Ismail H, Zapala L, Piecha T, et al
ASO Visual Abstract: Changes in the Urinary Microbiome following Transurethral Resection of Non-muscle-invasive Bladder Cancer-Insights from a Prospective Observational Study.
Ann Surg Oncol. 2024 Apr 26. doi: 10.1245/s10434-024-15340.
Abstract

MULLARD A
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer.
Nat Rev Drug Discov. 2024 Apr 26. doi: 10.1038/d41573-024-00073.
Abstract

LIN YH, Tsai HY, Tsao SH
Re: Steven Monda, Manolis Pratsinis, Hansen Lui, et al. Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and Surgery. Eur Urol Focus. In press. http://doi.org/10.1016/j.euf.2023.09.002.
Eur Urol Focus. 2024 Apr 25:S2405-4569(24)00061.
Abstract

MELGAREJO SEGURA MT, Yanez Castillo Y, Lozano Lorca M, Morales Martinez A, et al
Efficacy of conduction hyperthermia in the treatment of non-muscle invasive bladder cancer: A systematic review.
Urol Oncol. 2024 Apr 25:S1078-1439(24)00399.
Abstract

REWARI H, Wadhwa P, Talwar H, Taneja D, et al
Anastomosing haemangioma of adrenal gland: an unusual vascular tumour.
BMJ Case Rep. 2024;17:e259092.
Abstract

FUJIWARA Y, Karol AB, Joshi H, Reford E, et al
C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis.
Crit Rev Oncol Hematol. 2024;197:104352.
Abstract

LIU MA, Li JW, Runcie K
Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma.
Curr Oncol Rep. 2024;26:496-503.
Abstract

RUSCHOFF J, Kumar G, Badve S, Jasani B, et al
Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
Virchows Arch. 2024;484:597-608.
Abstract

MAMTANI R, Tsingas K, Parikh RB, Elsouda D, et al
Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.
Urol Oncol. 2024;42:177.
Abstract

PARK JY, Yu J, Kim CS, Kim YK, et al
Reply for Comment on: Vitamin C and catheter-related bladder discomfort after transurethral resection of bladder tumor.
J Clin Anesth. 2024;95:111445.
Abstract

BHARTI AM, Rakesh Kumar RK, Chuang CH, Shaikh MO, et al
Universal nanocomposite coating with antifouling and redox capabilities for electrochemical affinity biosensing in complex biological fluids.
Nanoscale Horiz. 2024;9:843-852.
Abstract

FANG AM, Hayek O, Kaylor JM, Peyton CC, et al
Postoperative Outcomes and Analgesic Requirements of Single-Port vs Multiport Robotic-Assisted Radical Cystectomy.
J Endourol. 2024;38:438-443.
Abstract

BERTUCCI F, de Nonneville A, Finetti P, Cohendet A, et al
The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
Ann Oncol. 2024;35:477-478.
Abstract

AI J, Zhang S, Qian Y, Kang L, et al
Radiotherapy and Anrotinib in Malignant Glomus Tumor of the Bladder: A Case Report and Literature Review.
Cancer Biother Radiopharm. 2024;39:318-321.
Abstract

SAUNDERS KE, Gerken N, Khani F, Williamson SR, et al
Current gross examination and reporting patterns of post-neoadjuvant chemotherapy cystectomy specimens: Is it time for a standardized approach?
Am J Clin Pathol. 2024;161:483-489.
Abstract

PARIS A, Bodaghi B, Touhami S
Pan fibroblast growth factor receptor inhibitor associated retinopathy.
Eur J Ophthalmol. 2023 Dec 12:11206721231220334. doi: 10.1177/11206721231220334.
Abstract

MARVASO G, Vitullo A, Corrao G, Vincini MG, et al
Muscle-invasive bladder cancer in elderly and frail people: Is hypofractionated radiotherapy a feasible approach when no other local options are available?
Tumori. 2024 May 10:3008916241252326. doi: 10.1177/03008916241252326.
Abstract

SHARMA AP, Singh PP, Chauhan R, Panda I, et al
Clinical study of steroid receptors in nonmuscle invasive bladder cancer: A domain worth revisiting.
Indian J Urol. 2024;40:127-132.
Abstract

ZHAN T, Li X, Liu J, Ye C, et al
CRISPR-based gene expression platform for precise regulation of bladder cancer.
Cell Mol Biol Lett. 2024;29:66.
Abstract

SHINDO T, Hashimoto K, Fujino K, Takahashi A, et al
Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.
World J Urol. 2024;42:307.
Abstract

MACDONALD A, Bao L, Mehrnoush V, Ismail A, et al
Does intravesical BCG for bladder cancer protect from COVID-19?
Arch Ital Urol Androl. 2024 May 9:12449. doi: 10.4081/aiua.2024.12449.
Abstract

LI J, Li H, Yang Y, Sen Y, et al
miRNA-143 as a potential biomarker in the detection of bladder cancer: a meta-analysis.
Future Oncol. 2024 May 9. doi: 10.2217/fon-2023-0922.
Abstract

PLOUVIER SD, Marcq G, Vankemmel O, Colin P, et al
Practice patterns and survival outcomes for Muscle-Invasive Bladder Cancer: real-life experience in a general population setting.
Int J Qual Health Care. 2024 May 6:mzae040. doi: 10.1093.
Abstract

LICHTBROUN B, Ghodoussipour S, Packiam VT
Ablative therapy with UGN-102 for low-grade intermediate risk non-muscle-invasive bladder cancer: ready for primetime?
Transl Androl Urol. 2024;13:647-649.
Abstract

GONZALEZ-PADILLA DA, Subiela JD, Villacampa-Auba F
Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?
Transl Androl Urol. 2024;13:639-642.
Abstract

VEDELD HM, Pharo H, Sorbo AK, Brandt-Winge S, et al
Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer.
Mol Oncol. 2024 May 8. doi: 10.1002/1878-0261.13639.
Abstract

YIN T, Mou S, Zhang H, Dong Y, et al
CXCL10 could be a prognostic and immunological biomarker in bladder cancer.
Discov Oncol. 2024;15:148.
Abstract

CHOI J, Lee J, Hwang YB, Jeong BC, et al
Preoperative smoking and robot-assisted radical cystectomy outcomes & complications in multicenter KORARC database.
Sci Rep. 2024;14:10550.
Abstract

CHENG K, Wan S, Chen SY, Yang JW, et al
Nuclear matrix protein 22 in bladder cancer.
Clin Chim Acta. 2024 May 6:119718. doi: 10.1016/j.cca.2024.119718.
Abstract

SUGUMAR K, De Mond J, Vijay A, Paramesh AS, et al
Bile Spillage as a Prognostic Factor for Gall Bladder Cancer: A Systematic Review and Meta-analysis.
J Surg Res. 2024;299:94-102.
Abstract

KHWAJA SA, Caglic I, Shaida N, Colquhoun AJ, et al
Evaluation of magnetic resonance imaging for bladder cancer detection following transurethral resection of bladder tumour (TURBT).
Abdom Radiol (NY). 2024 May 8. doi: 10.1007/s00261-024-04235.
Abstract

CHEN W, Wang Y, Hu H, Zhu Y, et al
NIR-II light powered hydrogel nanomotor for intravesical instillation with enhanced bladder cancer therapy.
Nanoscale. 2024 May 8. doi: 10.1039/d4nr01128.
Abstract

GHORBANI H, AfzalAghai M, Soltani S, Mottaghi M, et al
Translation, Linguistic Validation, and Cultural Adaptation of the Bladder Cancer Index (BCI) Questionnaire Into the Persian (Farsi) Language and Comparing it With WHO Quality of Life Questionnaire: An Observational Study.
J Family Reprod Health. 2023;17:128-135.
Abstract

FENG L, Huang G, Peng L, Liang R, et al
Comparison of bladder carcinogenesis biomarkers in the urine of traditional cigarette users and e-cigarette users.
Front Public Health. 2024;12:1385628.
Abstract

ZHOU Y, Zheng X, Sun Z, Wang B, et al
Analysis of Bladder Cancer Staging Prediction Using Deep Residual Neural Network, Radiomics, and RNA-Seq from High-Definition CT Images.
Genet Res (Camb). 2024;2024:4285171.
Abstract

HU H
Effectiveness and Safety of Extended Lymph Node Dissection during Radical Surgery in Patients with Bladder Cancer: A Meta-Analysis.
Arch Esp Urol. 2024;77:303-314.
Abstract

CHENG G, Zhou Z, Li S, Yang S, et al
Predicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes.
Sci Rep. 2024;14:10482.
Abstract

KIM DH, Choi MS, Choi JH, Lee C, et al
Correlation between urine cytology results on the day after overnight continuous saline irrigation following transurethral resection of bladder tumor and bladder tumor recurrence.
Investig Clin Urol. 2024;65:279-285.
Abstract

QIN R, Ma X, Pu S, Shen C, et al
Identification and validation of a signature based on myofibroblastic cancer-associated fibroblast marker genes for predicting prognosis, immune infiltration, and therapeutic response in bladder cancer.
Investig Clin Urol. 2024;65:263-278.
Abstract

KANG H, Suh J, You D, Jeong IG, et al
Risk factors for failing to complete gemcitabine-cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients.
Investig Clin Urol. 2024;65:256-262.
Abstract

CHOI J, Kim KH, Kim HS, Yoon HS, et al
Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guerin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective m
Investig Clin Urol. 2024;65:248-255.
Abstract

PAK S, Park SG, Park J, Cho ST, et al
Applications of artificial intelligence in urologic oncology.
Investig Clin Urol. 2024;65:202-216.
Abstract

VALIZADEH S, Taghiyar S, Vahidi S, Abazari O, et al
Application of PLK1 and HOXA13 Gene Expression Levels in Urine in the Diagnosis of Non-muscle Invasive Bladder Cancer.
Biochem Genet. 2024 May 7. doi: 10.1007/s10528-024-10735.
Abstract

LIN YZ, Liu WH, Wu YP, Cai H, et al
Revealing the potential of solute carrier family 31 (copper transporters), member 1: Insights into its role in bladder cancer progression and therapeutic implications.
Int J Immunopathol Pharmacol. 2024;38:3946320241240706.
Abstract

ECKE TH, Wirtz RM, Heidenreich A, Fussel S, et al
[Multicenter networks, innovative concepts, and basic research-the mixture is important: report from the 14th symposium of the German Research Group on Bladder Cancer (DFBK) in Cologne].
Urologie. 2024 May 6. doi: 10.1007/s00120-024-02353.
Abstract

YAO Z, Yang L, Yang X, Liu F, et al
Stimulator of interferon genes mediated immune senescence reveals the immune microenvironment and prognostic characteristics of bladder cancer.
Heliyon. 2024;10:e28803.
Abstract

YANG J, Liu X, Dai G, Qu L, et al
Erratum: CircNT5E promotes the proliferation and migration of bladder cancer via sponging miR-502-5p: Erratum.
J Cancer. 2024;15:3152-3153.
Abstract

ZHENG Y, Shi H, Hai B, Zhang J, et al
A commentary on "A CT-based deep learning model predicts overall survival in patients with muscle invasive bladder cancer after radical cystectomy: a multicenter retrospective cohort study".
Int J Surg. 2024 May 3. doi: 10.1097/JS9.0000000000001510.
Abstract

LIU Y, Zhang X, Shang P
Comment on 'HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study'.
Int J Surg. 2024 May 3. doi: 10.1097/JS9.0000000000001527.
Abstract

BUKAVINA L, Helstrom E, Wallis CJD, Fulmes A, et al
Association Between GLP1R Agonists and Prostate, Kidney, and Bladder Cancers.
Eur Urol Oncol. 2024 May 2:S2588-9311(24)00098-1. doi: 10.1016/j.euo.2024.
Abstract

MELCHIODE Z, Hu S, Xu J, Riveros C, et al
Contemporary morbidity and mortality of open versus robotic cystectomy for bladder cancer: An analysis of the National Surgical Quality Improvement Program (NSQIP) procedure targeted cystectomy database.
Urol Oncol. 2024 May 2:S1078-1439(24)00404-6. doi: 10.1016/j.urolonc.2024.
Abstract

ISAACS LL, Gonzalez NJ
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer.
Altern Ther Health Med. 2024 May 3:AT9333.
Abstract

AESCHLIMANN L, Kehl A, Guscetti F, Posthaus C, et al
Effective detection of BRAF(V595E) mutation in canine urothelial and prostate carcinomas using immunohistochemistry.
Vet Comp Oncol. 2024;22:295-302.
Abstract

BAJEOT AS, Roumiguie M
[Not Available].
Ann Pathol. 2024;44:183-187.
Abstract

CANAKCI C, Ozkaptan O, Dincer E, Ipek OM, et al
Perioperative Outcomes of Open Extra-peritoneal Versus Laparoscopic Radical Cystoprostatectomy: A single Center Comparative Study.
Urol J. 2024;21:175-181.
Abstract

CAI Z, Cheng X, Liao S, Zou W, et al
POU2F3-positive small cell carcinoma of the bladder: A clinicopathologic analysis of 4 cases and literature review.
Pathol Res Pract. 2024;257:155296.
Abstract

LACOSTE-COLLIN L
[What contribution can make artificial intelligence to urinary cytology?].
Ann Pathol. 2024;44:195-203.
Abstract

IRWIN T, Donlan AW, Owens L, Alvarez R, et al
Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
Hum Pathol. 2024;146:43-48.
Abstract

GUERRERO-RAMOS F, Alvarez-Maestro M, Pinto Marin A, Dominguez Escrig JL, et al
Multidisciplinary consensus document on the current treatment of bacille Calmette-Guerin-unresponsive non-muscle invasive bladder tumor.
Actas Urol Esp (Engl Ed). 2024;48:262-272.
Abstract

SONG W, Yu J, Jeong BC
ASO Author Reflections: Advancing Early Outcome Assessment in Robot-Assisted Radical Cystectomy: RARC Tetrafecta.
Ann Surg Oncol. 2024;31:3908-3909.
Abstract

BRAMAN SL, Peterson H, Elbe A, Mani E, et al
Urinary and household chemical exposures in pet dogs with urothelial cell carcinoma.
Vet Comp Oncol. 2024;22:217-229.
Abstract

JIN K, Xu J, Su X, Xu Z, et al
TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
J Pathol. 2024;263:139-149.
Abstract

WANG XJ, Qiu X
A case of primary small-cell neuroendocrine carcinoma of the bladder.
Asian J Surg. 2024;47:2421-2422.
Abstract

WANG Z, Bi H, Wang YD, Liu Q, et al
Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study.
Actas Urol Esp (Engl Ed). 2024;48:295-303.
Abstract

LI Z, Xu Z, Wang J, Wang M, et al
Nomograms for predicting the overall and cancer-specific survival in patients with non-urothelial carcinoma of the bladder: A population-based study.
Biomol Biomed. 2024;24:633-646.
Abstract

LI J, Kong Z, Qi Y, Wang W, et al
Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8+ T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine-learning bioinformatics retrospective study.
Int J Surg. 2024 May 17. doi: 10.1097/JS9.0000000000001516.
Abstract

QIU Y, Jiang Z, Zhang J
Causal effects of BMI, waist circumference, and body fat percentage on the risk of bladder cancer: A Mendelian randomization study.
Medicine (Baltimore). 2024;103:e38231.
Abstract

EKICI M, Demir E, Aydin C, Caglayan MS, et al
Can the use of antithrombotic drugs be a predictive factor in the early diagnosis of bladder cancer?: A single-center analysis.
Medicine (Baltimore). 2024;103:e38228.
Abstract

ZAWKY M, Elsayed A, Awadallah A, Abdelhalim A, et al
The impact of purified protein derivative prior to intravesical bacillus Calmette-Guerin for the treatment of patients with non-muscle invasive bladder cancer.
Minerva Urol Nephrol. 2024 May 17. doi: 10.23736/S2724-6051.23.05515.
Abstract

SERRETTA V
BCG and bladder cancer. Forty-eight years after Morales report.
Urologia. 2024 May 17:3915603241252909. doi: 10.1177/03915603241252909.
Abstract

QIAO X, Xue R, Li S, Li J, et al
Expression of LASS2 Can be Regulated by Dihydroartemisinin to Regulate Cisplatin Chemosensitivity in Bladder Cancer Cells.
Curr Pharm Biotechnol. 2024 May 16. doi: 10.2174/0113892010305651240514100129.
Abstract

LIAO G, Chen F, Zhong J, Jiang X, et al
[Retracted] MicroRNA?539 inhibits the proliferation and invasion of bladder cancer cells by regulating IGF?1R.
Mol Med Rep. 2024;30:116.
Abstract

LI R, Ning Y, Yuan Y, Yang X, et al
Molecular mechanisms of ferroptosis and its effects on bladder cancer.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024;49:286-295.
Abstract

GUTMANN M, Ertl IE, Herek P, Vician P, et al
Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models.
Eur Urol Oncol. 2024 May 15:S2588-9311(24)00115.
Abstract

FLAIG TW, Spiess PE, Abern M, Agarwal N, et al
Bladder Cancer, Version 3.2024.
J Natl Compr Canc Netw. 2024;22:216-225.
Abstract

GUO L, Cid A, Cucci J, Kunkel B, et al
Acu-URO17 is a highly sensitive and specific bladder cancer biomarker.
BJUI Compass. 2024;5:497-501.
Abstract

PAN YC, Chu PY, Lin CC, Hsieh CY, et al
Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles are involved in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer.
Mol Oncol. 2024 May 15. doi: 10.1002/1878-0261.13659.
Abstract

Retraction: Wang C, Chen Z, Ge Q, Hu J, Li F, Hu J, Xu H, Ye Z, Li LC (2014) Up-regulation of p21(WAF1/CIP1) by miRNAs and its implications in bladder cancer cells. FEBS Letters 588, 4654-4664. https://doi.org/10.1016/j.febslet.2014.10.037.
FEBS Lett. 2024 May 15. doi: 10.1002/1873-3468.14892.
Abstract

QIAN L, Zhang Y, Chen H, Pang Y, et al
The clinical effect of gratitude extension-construction theory nursing program on bladder cancer patients with fear of cancer recurrence.
Front Oncol. 2024;14:1364702.
Abstract

FARKAS AM, Tran MA, Youssef D, Balan S, et al
Natural Killer Cell Dysfunction In Human Bladder Cancer Is Caused By Tissue-Specific Suppression of SLAMF6 Signaling.
bioRxiv [Preprint]. 2024 May 3:2024.04.30.591366. doi: 10.1101/2024.04.30.591366
Abstract

THEN CK, Paillas S, Moomin A, Misheva MD, et al
Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity.
Microbiome. 2024;12:89.
Abstract

WANG Z, Zhang J, Luo L, Zhang C, et al
Nucleoporin 93 Regulates Cancer Cell Growth and Stemness in Bladder Cancer via Wnt/beta-Catenin Signaling.
Mol Biotechnol. 2024 May 14. doi: 10.1007/s12033-024-01184.
Abstract

ZHENG W, Zhang P, Yao C, Tao Y, et al
The clinical significance of PD-1 expression in patients with bladder cancer without lymph node metastasis: a comparative study with drained lymph nodes and tumor tissues.
Int J Neurosci. 2024 May 14:1-17. doi: 10.1080/00207454.2024.2356152.
Abstract

GINIL KUMAR P, Gideon M, Ravi Chandran K, Pullara SK, et al
Our Experience of OSAKA Regimen (Bladder Preservation) in Patients with Advanced Bladder Cancer.
Indian J Surg Oncol. 2024;15:264-267.
Abstract

NECCHI A, Roumiguie M, Kamat AM, Shore ND, et al
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
Lancet Oncol. 2024 May 10:S1470-2045(24)00178.
Abstract

SCILIPOTI P, Liedberg F, Garmo H, Wilberg Orrason A, et al
Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based study.
Scand J Urol. 2024;59:98-103.
Abstract

GRIFFIN RL, Shuman L, Yamashita H, Wu Q, et al
The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.
Am J Clin Exp Urol. 2024;12:88-99.
Abstract

LI DX, Yu QX, Wu RC, Wang J, et al
Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review.
Ther Adv Med Oncol. 2024;16:17588359241249068.
Abstract

TUO Z, Lin Y, Zhang Y, Gao L, et al
Prognostic significance and immune landscape of a cell cycle progression-related risk model in bladder cancer.
Discov Oncol. 2024;15:160.
Abstract

TEMIRCAN Z
Investigation of Knowledge, Attitudes, and Healthy Lifestyle Behaviors on Bladder Cancer in Turkey.
J Med Invest. 2024;71.
Abstract

CANO VELASCO J, Artero Fullana S, Polanco Pujol L, Lafuente Puentedura A, et al
Use of Bladder Epicheck(R) in the follow-up of high-risk non-muscle-invasive Bladder cancer: A systematic literature review.
Actas Urol Esp (Engl Ed). 2024 May 10:S2173-5786(24)00064.
Abstract

BEN-DAVID R, Tillu N, Alerasool P, Bieber C, et al
Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.
World J Urol. 2024;42:315.
Abstract

NAKAYAMA S, Yoda E, Yamashita S, Takamatsu Y, et al
Knockdown of iPLA(2)gamma enhances cisplatin-induced apoptosis by increasing ROS-dependent peroxidation of mitochondrial phospholipids in bladder cancer cells.
Free Radic Biol Med. 2024;220:301-311.
Abstract

OTERO-MURIEL IJ, Jimenez Giraldo S, Garcia-Perdomo HA
The association between the human papillomavirus (HPV) and the diagnosis of bladder cancer: systematic review and meta-analysis.
Actas Urol Esp (Engl Ed). 2024 May 9:S2173-5786(24)00062.
Abstract

TANG Z, Can L, Xuan S, Chen L, et al
Unveiling the Etiology of Urological Tumors: A Systematic Review of Mendelian Randomization Applications in Renal Cell Carcinoma, Bladder Cancer, and Prostate Cancer.
Urol J. 2024 May 11. doi: 10.22037/uj.v21i.7970.
Abstract

TYAGI P, Hafron J, Kaufman J, Chancellor M, et al
Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration.
Int J Mol Sci. 2024;25:4945.
Abstract

STURM S, Niegisch G, Windolf J, Suschek CV, et al
Exposure of Bladder Cancer Cells to Blue Light (lambda = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine.
Int J Mol Sci. 2024;25:4868.
Abstract

DRACHNERIS J, Morkunas M, Fabijonavicius M, Cekauskas A, et al
Spatial Distribution of Macrophage and Lymphocyte Subtypes within Tumor Microenvironment to Predict Recurrence of Non-Muscle-Invasive Papillary Urothelial Carcinoma after BCG Immunotherapy.
Int J Mol Sci. 2024;25:4776.
Abstract

CONTIERI R, Pichler R, Del Giudice F, Marcq G, et al
Variation in Follow-Up after Radical Cystectomy for Bladder Cancer-An Inventory Roundtable and Literature Review.
J Clin Med. 2024;13:2637.
Abstract

SLUSARCZYK A, Garbas K, Pustula P, Zapala L, et al
Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guerin Therapy in Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:1684.
Abstract

CHI J, Jiang X, Liu Q, Cui Y, et al
Elevated expression of SRRM3 in bladder cancer predicts poor prognosis and is associated with immune infiltration.
Asian J Surg. 2024 May 9:S1015-9584(24)00869.
Abstract

WANG Y, Song Y, Peng Y, Han S, et al
Effects of androgen suppression therapy on the incidence and prognosis of bladder cancer: An updated systematic review and meta-analysis.
Urol Oncol. 2024 May 9:S1078-1439(24)00431-9. doi: 10.1016/j.urolonc.2024.
Abstract

LIU L, Xu L, Wu D, Zhu Y, et al
Impact of tumour stroma-immune interactions on survival prognosis and response to neoadjuvant chemotherapy in bladder cancer.
EBioMedicine. 2024;104:105152.
Abstract

XIN L, Xiao X, Xiao W, Peng R, et al
Screening for urothelial carcinoma cells in urine based on digital holographic flow cytometry through machine learning and deep learning methods.
Lab Chip. 2024;24:2736-2746.
Abstract

OLAH C, Kubik A, Matrai P, Engh MA, et al
Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies.
Urol Oncol. 2024;42:221.
Abstract

PALERMO M, D'Elia C, Trenti E, Comploj E, et al
Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck(R) as a diagnostic tool in upper urinary tract tumor.
Minerva Urol Nephrol. 2024;76:195-202.
Abstract

BENJAMIN DJ, Rezazadeh Kalebasty A, Prasad V
The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Eur Urol Oncol. 2024;7:313-315.
Abstract

WOO HK, Park J, Kim KH, Ku JY, et al
Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables precision monitoring of urothelial cancer.
Cancer Sci. 2024;115:1602-1610.
Abstract

LI X, Huang J, Ji P
Comment on 'Robot-assisted radical cystectomy with intracorporeal urinary diversion: an updated systematic review and meta-analysis of its differential effect on effectiveness and safety'.
Int J Surg. 2024;110:3114-3115.
Abstract

MAHLOW J, Gupta S
Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance.
Urol Oncol. 2024;42:193-202.
Abstract

SAAL J, Grunwald V, Bald T, Ritter M, et al
On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy.
Eur Urol Oncol. 2024;7:328-331.
Abstract

MONTORSI F, Rosiello G, Gandaglia G, Salonia A, et al
Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/1
Eur Urol Oncol. 2024;7:636.
Abstract

ZHANG C, Wang Y, Guo X, Wang Z, et al
SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer.
Cancer Cell Int. 2024;24:182.
Abstract

BECKABIR W, Zhou M, Lee JS, Vensko SP, et al
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
Nat Commun. 2024;15:4448.
Abstract

LIU L, Li K, Wang SG, Wang J, et al
The prognostic impact of tumor location in non-muscle-invasive bladder cancer patients undergoing transurethral resection: insights from a cohort study utilizing chinese multicenter and SEER registries.
Int J Surg. 2024 May 24. doi: 10.1097/JS9.0000000000001675.
Abstract

CHANG Q, Chen Y, Yin J, Wang T, et al
Comprehensive Urinary Proteome Profiling Analysis Identifies Diagnosis and Relapse Surveillance Biomarkers for Bladder Cancer.
J Proteome Res. 2024 May 24. doi: 10.1021/acs.jproteome.4c00199.
Abstract

ANTAR RM, Xu VE, Adesanya O, Drouaud A, et al
Income Disparities in Survival and Receipt of Neoadjuvant Chemotherapy and Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer.
Curr Oncol. 2024;31:2566-2581.
Abstract

RAMAMURTHY C, Wheeler KM, Trecarten S, Hassouneh Z, et al
Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.
J Cancer Immunol (Wilmington). 2024;6:29-39.
Abstract

GLAVINOV MS, Krsteska B, Stojmenova V, Petrovska T, et al
Adenoid cystic/basal-cell carcinoma of the prostate following high-grade urothelial bladder cancer: a case report.
Oxf Med Case Reports. 2024;2024:omae050.
Abstract

WANG XL, Wang YX, Chen JZ, Liu XY, et al
Clinical characteristics and molecular mechanisms underlying bladder cancer in individuals with spinal cord injury: a systematic review.
BMC Urol. 2024;24:111.
Abstract

LIU Z, Teng C, Wan W, Wu F, et al
A panel of four plasma amino acids is a promising biomarker for newly diagnosed bladder cancer.
Clin Nutr. 2024;43:1599-1608.
Abstract

MURTA CB, Hayek KKRE, Dias BC, Yorioka MAW, et al
Increased risk of bladder cancer recurrence due to bacillus Calmette-Guerin shortage in Brazil.
Rev Assoc Med Bras (1992). 2024;70:e20231116.
Abstract

SOUZA AWS, Dantas JG, Montandon ACOES, Calich AL, et al
Position statement of the Brazilian society of Rheumatology on mesna use as a preventive therapy for bladder disease in patients with systemic autoimmune diseases and systemic vasculitis under cyclophosphamide treatment.
Adv Rheumatol. 2024;64:41.
Abstract

HEMENWAY G, Anker JF, Riviere P, Rose BS, et al
Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient.
Am Soc Clin Oncol Educ Book. 2024;44:e432054.
Abstract

MATYE D, Leak J, Woolbright BL, Taylor JA 3rd, et al
Preclinical models of bladder cancer: BBN and beyond.
Nat Rev Urol. 2024 May 20. doi: 10.1038/s41585-024-00885.
Abstract

CHEN Z, Ou Y, Ye F, Li W, et al
Machine learning identifies the role of SMAD6 in the prognosis and drug susceptibility in bladder cancer.
J Cancer Res Clin Oncol. 2024;150:264.
Abstract

LU C, Lin S, Wen Z, Sun C, et al
Testing the accuracy of a four serum microRNA panel for the detection of primary bladder cancer: a discovery and validation study.
Biomarkers. 2024 May 20:1-21. doi: 10.1080/1354750X.2024.2358312.
Abstract

KOEHNE EL, Bakaloudi DR, Ghali F, Nyame Y, et al
Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer.
Clin Genitourin Cancer. 2024 Apr 25:102100. doi: 10.1016/j.clgc.2024.102100.
Abstract

ZHAO J, Luo X, Yang C, Yang X, et al
Chemokine receptor 7 contributes to T- and B-cell filtering in ageing bladder, cystitis and bladder cancer.
Immun Ageing. 2024;21:33.
Abstract

ALFARIZI ZY, Subekti E, Danarto, Yuri P, et al
A rare case of spontaneous bladder wall abscess mimicking bladder tumour in young women.
BMC Urol. 2024;24:109.
Abstract

LOU K, Chi J, Zheng X, Cui Y, et al
PPP1R14A as a potential biomarker for predicting the progression and prognosis of bladder cancer.
Asian J Surg. 2024 May 18:S1015-9584(24)00966.
Abstract

WU Z, Zhao G, Zhang Z, Shen C, et al
Phase 2 Study of Preoperative Tislelizumab in Combination with Low-dose Nab-Paclitaxel in Patients with Muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2024 May 17:S2588-9311(24)00110.
Abstract

YU Y, Liang Y, Xie F, Zhang Z, et al
Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation.
Cancer Lett. 2024 May 16:216964. doi: 10.1016/j.canlet.2024.216964.
Abstract

ZENG XX, Wu Y
Strategies of Bladder Reconstruction after Partial or Radical Cystectomy for Bladder Cancer.
Mol Biotechnol. 2024 May 18. doi: 10.1007/s12033-024-01163.
Abstract

WANG Y, Zhu H, Zhang L, He J, et al
Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as potential immunotherapeutic target.
J Cell Mol Med. 2024;28:e18384.
Abstract

FARIA EF, Maciel CVM, Melo PA, Tobias-Machado M, et al
Mesentery-Sparing Technique: a New Intracorporeal Approach for Urinary Diversion in Robot-Assisted Radical Cystectomy.
Int Braz J Urol. 2024;50:489-499.
Abstract

MAO X, Chen X, Xu Z, Ding L, et al
The identification of a N(6)-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma.
Aging (Albany NY). 2024;16:7774-7798.
Abstract

ZHANG X, Wang Y, Xu X, Zhang J, et al
Bladder MRI with deep learning-based reconstruction: a prospective evaluation of muscle invasiveness using VI-RADS.
Abdom Radiol (NY). 2024;49:1615-1625.
Abstract

SIECH C, Baudo A, de Angelis M, Jannello LMI, et al
Perioperative complications and in-hospital mortality in radical cystectomy patients with heart-valve replacement.
Eur J Surg Oncol. 2024;50:108297.
Abstract

WOHLFAHRT J, Verma N, Alsaleh R, Kersch C, et al
A pilot study exploring time- and dose-dependent DNA damage and chromosomal instability caused by benzo[a]pyrene in two urothelial cell types.
Mutat Res. 2024;828:111855.
Abstract

LOUIS EK, Abdelkawi IF, Refaiy A, Ahmed AM, et al
N-myc downstream-regulated gene 1 can promote vasculogenic mimicry and angiogenesis in urothelial carcinoma.
Virchows Arch. 2024;484:827-836.
Abstract

UCHIMOTO T, Tsuchida S, Komura K, Fukuokaya W, et al
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Target Oncol. 2024;19:401-410.
Abstract

MA R, Sheybaee Moghaddam F, Ghoreifi A, Ladi-Seyedian S, et al
The effect of enhanced recovery after surgery on oncologic outcome following radical cystectomy for urothelial bladder carcinoma.
Surg Oncol. 2024;54:102061.
Abstract

STROPE AM, Phillips C, Khadgi S, Jenkinson SA, et al
Differential expression of WNT5A long and short isoforms in non-muscle-invasive bladder urothelial carcinoma.
Histol Histopathol. 2024;39:715-727.
Abstract

CLIMENT MA, Alvarez C, Morales R, Maroto P, et al
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.
Clin Transl Oncol. 2024;26:1532-1538.
Abstract

LI DX, Yu QX, Wu RC, Wang J, et al
Efficiency of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer: An umbrella review.
Cancer Med. 2024;13:e7323.
Abstract

CALOUDAS AB, Haltom TM, Goltz HH, Badr HJ, et al
Patient-centered development of a bladder cancer survivorship care plan.
Support Care Cancer. 2024;32:397.
Abstract

LIAO YX, Zeng JM, Zhou JJ, Yang GH, et al
[Retracted] Silencing of RTKN2 by siRNA suppresses proliferation, and induces G1 arrest and apoptosis in human bladder cancer cells.
Mol Med Rep. 2024;30:134.
Abstract

QIAO Y, Jia Y, Luo L, Li B, et al
Development and validation of a nomogram to predict lymph node metastasis in patients with progressive muscle-invasive bladder cancer.
Front Oncol. 2024;14:1342244.
Abstract

YU X, Li S, Ke S, Ye C, et al
CSF2 Impairs Nrf2 Signaling through the Akt/Mtor Pathway in the Development of Bladder Cancer.
J Cancer. 2024;15:3242-3253.
Abstract

WANG T, Wang G, Shan D, Fang Y, et al
ACAT1 promotes proliferation and metastasis of bladder cancer via AKT/GSK3beta/c-Myc signaling pathway.
J Cancer. 2024;15:3297-3312.
Abstract

LINDEMANN-DOCTER K, Gaisa NT
[Mimickers and diagnostic pitfalls of urinary bladder cancer].
Pathologie (Heidelb). 2024 May 30. doi: 10.1007/s00292-024-01335.
Abstract

ONDER T, Karacin C, Kekilli E, Goksel F, et al
Predicting survival after brain metastases in patients with bladder cancer.
J Clin Neurosci. 2024;125:146-151.
Abstract

SEREMAK JR, Gupta KB, Bonigala S, Liu E, et al
Targeting Chemoresistance in Advanced Bladder Cancers with a Novel Adjuvant Strategy.
Mol Cancer Ther. 2024 May 30. doi: 10.1158/1535-7163.MCT-23-0806.
Abstract

MUSLUM O, Ahmet K, Ebru O, Ahmet T, et al
Impacts of Chlorine 1-3 ion channels on localized bladder neoplasms.
Cell Mol Biol (Noisy-le-grand). 2024;70:76-81.
Abstract

YU X, Liao B, Du Z, Zhu P, et al
EGFR/TKIs induce excessive apoptosis of bladder carcinoma cells by arresting cell cycle and promoting mitochondrial peroxidation damage.
Cell Mol Biol (Noisy-le-grand). 2024;70:258-262.
Abstract

GHANADIAN M, Aghaei M, Akhavan Roofigar A, Ayatollahi SA, et al
Discovery of new 13(17)-epoxymyrsinane diterpenes from aerial flowering parts of euphorbia spinidens Bornm. ex Prokh. with proapoptotic activities against human bladder cancer EJ138 cells.
Nat Prod Res. 2024 May 30:1-8. doi: 10.1080/14786419.2024.2358389.
Abstract

AVCI MA, Arslan B, Arslan O, Ozdemir E, et al
The Role of Thrombocyte/Lymphocyte Ratio and Aspartate Transaminase/Alanine Transaminase (De Ritis) Ratio in Prediction of Recurrence and Progression in Non-muscle Invasive Bladder Cancer.
Cureus. 2024;16:e59299.
Abstract

ZHANG W, Liang ZQ, He RQ, Huang ZG, et al
The upregulation and transcriptional regulatory mechanisms of Extra spindle pole bodies like 1 in bladder cancer: An immunohistochemistry and high-throughput screening Evaluation.
Heliyon. 2024;10:e31192.
Abstract

GHALI F, Holt SK, Koehne EL, Chen JJ, et al
Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older.
Front Oncol. 2024;14:1341655.
Abstract

YOON AR, Jiao A, Hong J, Kim B, et al
Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3beta inhibitor enhances antitumor immune response against bladder cancer.
Front Immunol. 2024;15:1360436.
Abstract

XIAO S, Chen J, Wei Y, Song W, et al
BHLHE41 inhibits bladder cancer progression via regulation of PYCR1 stability and thus inactivating PI3K/AKT signaling pathway.
Eur J Med Res. 2024;29:302.
Abstract

MIYAZAKI T, Taguchi S, Obata N, Mizobuchi S, et al
Severe hypotension and postoperative cardiac arrest caused by 5-aminolevulinic acid: a case report.
J Med Case Rep. 2024;18:264.
Abstract

YANG Z, Guo R, Bi Y, Xu W, et al
Peimenine unleashes therapeutic promise in urothelial bladder cancer: inhibition of proliferation, induction of cell death and modulation of key pathways.
Chem Biol Drug Des. 2024;103:e14528.
Abstract

WANG X, Jin L, Zhang X, Li M, et al
Transcriptomic profiling and risk assessment in bladder cancer: Insights from copper death-related genes.
Cell Signal. 2024 May 27:111237. doi: 10.1016/j.cellsig.2024.111237.
Abstract

WONG JKM, McCulloch TR, Alim L, Omer N, et al
TGF-beta signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer.
EBioMedicine. 2024;104:105176.
Abstract

KANMALAR M, Kamal R, Abdul Sani SF, Pathmanathan D, et al
Spectroscopic diagnosis and metabolite characterization of cisplatin resistance regulated by FDFT1 in bladder cancer tissue.
Appl Radiat Isot. 2024;210:111372.
Abstract

LI CC, Tsai BC, Annseles Rajula S, Hsu CH, et al
Tannic Acid Impedes the Proliferation of Bladder Cancer Cells by Elevating Mitochondrial Pathways of Apoptosis.
Cell Biochem Biophys. 2024 May 29. doi: 10.1007/s12013-024-01286.
Abstract

LI Z, Yang J, Chen L, Chen P, et al
Moscatilin Reverses EMT Progression and its Resulting Enhanced Invasion and Migration by Affecting the TGF-beta Signaling Pathway in Bladder Cancer.
Anticancer Agents Med Chem. 2024.
Abstract

WANG P, Wei X, Qu X, Zhu Y, et al
Potential clinical application of microRNAs in bladder cancer.
J Biomed Res. 2024 Jan 25:1-18. doi: 10.7555/JBR.37.20230245.
Abstract

SAVCHENKO E, Bunimovich-Mendrazitsky S
Investigation toward the economic feasibility of personalized medicine for healthcare service providers: the case of bladder cancer.
Front Med (Lausanne). 2024;11:1388685.
Abstract

NISHIMURA N, Miyake M, Miyamoto T, Shimizu T, et al
Routine Surveillance of Upper Urinary Tract Imaging for Diagnosing Upper Urinary Tract Urothelial Cancer Recurrence in Patients with Nonmuscle Invasive Bladder Cancer.
Adv Urol. 2024;2024:5894288.
Abstract

DAVIS K, Orf J, Ballon-Landa E, Hamilton Z, et al
Neoadjuvant chemotherapy prior to radical cystectomy for non-muscle invasive bladder cancer: national trends and pathologic outcomes.
Front Oncol. 2024;14:1392062.
Abstract

SHI W, Dong J, Zhong B, Hu X, et al
Predicting the Prognosis of Bladder Cancer Patients Through Integrated Multi-omics Exploration of Chemotherapy-Related Hypoxia Genes.
Mol Biotechnol. 2024 May 28. doi: 10.1007/s12033-024-01203.
Abstract

PICARD LC, Rich FJ, Kenwright DN, Stevens AJ, et al
Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer.
Biochim Biophys Acta Rev Cancer. 2024 May 26:189123.
Abstract

[Not Available].
Aktuelle Urol. 2024;55:202-204.
Abstract

[Not Available].
Aktuelle Urol. 2024;55:194.
Abstract

[Not Available].
Aktuelle Urol. 2024;55:192-194.
Abstract

CHANG CF, Chang PC, Lee YC, Pan CY, et al
The Antimicrobial Peptide Tilapia Piscidin 4 Induced the Apoptosis of Bladder Cancer Through ERK/SIRT1/PGC-1alpha Signaling Pathway.
Probiotics Antimicrob Proteins. 2024 May 28. doi: 10.1007/s12602-024-10296.
Abstract

ROBISON M, Bush NJ
Clamp for Safety: Improving Intravesical Chemotherapy Practices.
AORN J. 2024;119:412-420.
Abstract

QIU D, Zhao B, Wang W, Zheng G, et al
The predictive value of PFKFB3 in bladder cancer prognosis.
Heliyon. 2024;10:e31347.
Abstract

CHATTERJEE D, Heeamoni SA, Sultana T, Mou SI, et al
Delineating the mechanistic relevance of the TP53 gene and its mutational impact on gene expression and patients' survival in bladder cancer.
Heliyon. 2024;10:e31286.
Abstract

BALCIK OY, Demir B, Ilhan Y, Akagunduz B, et al
Geriatric nutritional risk index and controller nutritional status score before metastatic first-line chemotherapy predict survival in patients over 70 years of age with metastatic bladder cancer.
Front Med (Lausanne). 2024;11:1376607.
Abstract

FAHOUM I, Naamneh R, Silberberg K, Hagege R, et al
Detection of Muscularis propria Invasion in Urothelial Carcinoma Using Artificial Intelligence.
Technol Cancer Res Treat. 2024;23:15330338241257479.
Abstract

LIU C, Zou Z, Lu S, Jin K, et al
CircPKN2 promotes ferroptosis in bladder cancer by promoting the ubiquitination of Stearoyl-CoA Desaturase 1.
Cancer Gene Ther. 2024 May 27. doi: 10.1038/s41417-024-00784.
Abstract

DRESSLER FF, Diedrichs F, Sabtan D, Hinrichs S, et al
Proteomic analysis of the urothelial cancer landscape.
Nat Commun. 2024;15:4513.
Abstract

MASSARI M, O'Malley P, Benidir T, Su LM, et al
Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.
Urol Oncol. 2024 May 26:S1078-1439(24)00465.
Abstract

WU J, Zhao X, He Y, Pan B, et al
IDMIR: identification of dysregulated miRNAs associated with disease based on a miRNA-miRNA interaction network constructed through gene expression data.
Brief Bioinform. 2024;25:bbae258.
Abstract

YANG FK, Tian C, Zhou LX, Guan TY, et al
The value of urinary exosomal microRNA-21 in the early diagnosis and prognosis of bladder cancer.
Kaohsiung J Med Sci. 2024 May 27. doi: 10.1002/kjm2.12845.
Abstract

LI B, Jin K, Liu Z, Su X, et al
RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.
J Immunother. 2024 May 27. doi: 10.1097/CJI.0000000000000525.
Abstract

BANSAL K, Chaudhary N, Bhati H, Vanshita, et al
Unveiling FDA-Approved Drugs and Formulations in the Management of Bladder Cancer: A Review.
Curr Pharm Biotechnol. 2024 May 23. doi: 10.2174/0113892010314650240514053735.
Abstract

ABOU CHAKRA M, McElree IM, Packiam VT, Mott SL, et al
Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer.
Urol Oncol. 2024 May 24:S1078-1439(24)00464.
Abstract

HEERS H, Gut JM, Hofmann R, Flegar L, et al
Pilot study for bladder cancer detection with volatile organic compounds using ion mobility spectrometry: a novel urine-based approach.
World J Urol. 2024;42:353.
Abstract

BLICHERT-REFSGAARD L, Graugaard-Jensen C, Norgaard M, Jensen JB, et al
Use of Bladder-Related Medication in Non-Muscle Invasive Bladder Cancer Patients.
Cancers (Basel). 2024;16:1936.
Abstract

MCNALL S, Hooper K, Sullivan T, Rieger-Christ K, et al
Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review.
Cancers (Basel). 2024;16:1843.
Abstract

LIN YH, Chen TM, Tsai YL, Tsai WC, et al
The Reduction of PSMB4 in T24 and J82 Bladder Cancer Cells Inhibits the Angiogenesis and Migration of Endothelial Cells.
Int J Mol Sci. 2024;25:5559.
Abstract

STOJNEV S, Conic I, Ristic Petrovic A, Petkovic I, et al
The Association of Death Receptors and TGF-beta1 Expression in Urothelial Bladder Cancer and Their Prognostic Significance.
Biomedicines. 2024;12:1123.
Abstract

YUE X, Huang X, Xu Z, Chen Y, et al
Involving logical clinical knowledge into deep neural networks to improve bladder tumor segmentation.
Med Image Anal. 2024;95:103189.
Abstract

LEE S, Bondaruk J, Wang Y, Chen H, et al
Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis.
Cell Rep. 2024;43:114146.
Abstract

HERRMANN J, Hartung FO, Kriegmair MC, Becker B, et al
[Should we all switch to en-bloc resection of bladder tumours?].
Aktuelle Urol. 2024;55:250-254.
Abstract

NECCHI A, Ramlau R, Falcon Gonzalez A, Chaudhry A, et al
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
JNCI Cancer Spectr. 2024;8:pkae030.
Abstract

SUZUKI S, Nagumo Y, Ikeda A, Kojo K, et al
Patient characteristics correlate with diagnostic performance of photodynamic diagnostic assisted transurethral resection of bladder tumors: A retrospective, single-center study.
Photodiagnosis Photodyn Ther. 2024;46:104052.
Abstract

NAKAGAWA R, Nohara T, Kano H, Makino T, et al
Does the quality of endoscopic equipment influence the recurrence rate after photodynamic diagnosis-assisted transurethral resection of bladder tumor?
Photodiagnosis Photodyn Ther. 2024;46:104023.
Abstract

SINHA S, Choudhury S, Mishra J, Kundu G, et al
A study on immunohistochemical expression of HER2/Neu and p63 and its association with grade and invasiveness in case of bladder carcinoma.
Urologia. 2024;91:284-288.
Abstract

ABDULFATAH E, Kunju LP
Diagnostic Approach to and Differential Diagnosis of Clear Cell and Glandular Lesions of the Lower Urinary Tract.
Arch Pathol Lab Med. 2024;148:642-648.
Abstract

RUSSELL DH, Epstein JI, Kryvenko ON, Schlumbrecht M, et al
Adenocarcinomas of the Gynecologic Tract Involving the Urinary Bladder: A Series of 16 Cases Potentially Mimicking Urothelial Malignancy.
Arch Pathol Lab Med. 2024;148:705-714.
Abstract

RONAN K, Jordan E, Leonard C, McDermott R, et al
Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.
Ir J Med Sci. 2024;193:1155-1161.
Abstract

BASIRI A, Zahir M, Soleimani M, Khoshdel AR, et al
Comparison of different urinary diversions after radical cystectomy in Iran: Assessment of health-related quality of life and financial burden in a Middle Eastern country.
Urologia. 2024;91:276-283.
Abstract

TRAN MA, Youssef D, Shroff S, Chowhan D, et al
Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment.
J Exp Med. 2024;221:e20240045.
Abstract

LI H, Ma H, Ma J, Qin F, et al
Unveiling the role of RAC3 in the growth and invasion of cisplatin-resistant bladder cancer cells.
J Cell Mol Med. 2024;28:e18473.
Abstract

GALBIATI S, Bettiga A, Colciago G, Senti C, et al
The long noncoding RNA SUMO1P3 as urinary biomarker for monitoring bladder cancer progression.
Front Oncol. 2024;14:1325157.
Abstract

BABADI F, Ahmadi A, Sarkarian M, Cheraghi M, et al
Relationship between oral health literacy and oral health-related quality of life in patients with bladder cancer.
Front Public Health. 2024;12:1385443.
Abstract

WU N, Wong KY, Yu X, Zhao JW, et al
Multispectral 3D DNA Machine Combined with Multimodal Machine Learning for Noninvasive Precise Diagnosis of Bladder Cancer.
Anal Chem. 2024 Jun 6. doi: 10.1021/acs.analchem.4c01749.
Abstract

LI R, Shah PH, Stewart TF, Nam JK, et al
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Nat Med. 2024 Jun 6. doi: 10.1038/s41591-024-03025.
Abstract

ZHOU W, Yang Y, Wang W, Yang C, et al
Pseudogene OCT4-pg5 upregulates OCT4B expression to promote bladder cancer progression by competing with miR-145-5p.
Cell Cycle. 2024 Jun 6:1-17. doi: 10.1080/15384101.2024.2353554.
Abstract

CICIONE A, Lombardo R, Nacchia A, Franco A, et al
No clinical benefit from sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomiz
Minerva Urol Nephrol. 2024 Jun 5. doi: 10.23736/S2724-6051.24.05777.
Abstract

HUANG Y, Chen L, Zou Y, Yu H, et al
Bibliometric insights into drug resistance in bladder cancer: Two decades of progress (1999-2022).
Heliyon. 2024;10:e31587.
Abstract

ZHANG Y, Guo X, Zhang Y, Wei J, et al
A preliminary investigation of precise visualization, localization, and resection of pelvic lymph nodes in bladder cancer by using indocyanine green fluorescence-guided approach through intracutaneous dye injection into the lower limbs and perineum.
Front Oncol. 2024;14:1384268.
Abstract

WANG Z, Zhang G, Liu X, Tan G, et al
A commentary on "Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8+ T cell - Fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine-learning" (Int J Surg. 2024 May 17.).
Int J Surg. 2024 Jun 4. doi: 10.1097/JS9.0000000000001769.
Abstract

TIAN F, Wei Y, Wang T, Yuan X, et al
Letter to the Editor Re: Treatment Progress of Compound Kushen Injection and Gemcitabine in Postoperative Patients with Bladder Cancer and Selection of Drug Delivery Mode.
Arch Esp Urol. 2024;77:453-454.
Abstract

BOOT IWA, Wesselius A, Jochems SHJ, Yu EYW, et al
Fruits and vegetables intake and bladder cancer risk: a pooled analysis from 11 case-control studies in the BLadder cancer Epidemiology and Nutritional Determinants (BLEND) consortium.
Eur J Nutr. 2024 Jun 5. doi: 10.1007/s00394-024-03436.
Abstract

ZUCCA LER, Laus AC, Sorroche BP, Paro E, et al
Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer.
Transl Oncol. 2024;46:102003.
Abstract

LINSCOTT JA, Miyagi H, Murthy PB, Yao S, et al
From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.
Curr Oncol Rep. 2024 Jun 5. doi: 10.1007/s11912-024-01555.
Abstract

ZHANG X, Ma L
Predictive Value of the Total Bilirubin and CA50 Screened Based on Machine Learning for Recurrence of Bladder Cancer Patients.
Cancer Manag Res. 2024;16:537-546.
Abstract

YE L, Lu L, Feng D, Ke M, et al
DMRT1 could serve as a prognostic biomarker for bladder cancer patients.
Asian J Surg. 2024 Jun 3:S1015-9584(24)01111.
Abstract

VARRIOR AR, Thakkar H, Kale S
Radiological features of multifocal embryonal rhabdomyosarcoma affecting the vagina and the urinary bladder in a pediatric patient.
BMJ Case Rep. 2024;17:e259549.
Abstract

JIN F, Thaiparambil J, Donepudi SR, Vantaku V, et al
Retraction: Tobacco-specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer.
Cancer Prev Res (Phila). 2024;17:281.
Abstract

ZHANG T, Zhu J, Li Z, Zhao Y, et al
The UF-5000 Atyp.C parameter is an independent risk factor for bladder cancer.
Sci Rep. 2024;14:12659.
Abstract

KIM SH, Ryu E, Jeong BC
Role performance and factors affecting quality of life in bladder cancer survivors with ileal orthotopic neobladder.
Asia Pac J Oncol Nurs. 2024;11:100490.
Abstract

BALLI S, Bolek H, Urun Y
Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments.
Clin Med Insights Oncol. 2024;18:11795549241257238.
Abstract

KIM H, Cho U, Hong SH, Park HS, et al
New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B.
Oncol Res. 2024;32:1021-1030.
Abstract

ZHANG J, Huang Y, Tan X, Wang Z, et al
Integrated analysis of multiple transcriptomic approaches and machine learning integration algorithms reveals high endothelial venules as a prognostic immune-related biomarker in bladder cancer.
Int Immunopharmacol. 2024;136:112184.
Abstract

JUAN RAMON A, Parmar C, Carrasco-Zevallos OM, Csiszer C, et al
Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial.
Nat Commun. 2024;15:4690.
Abstract

SHEN C, Liu J, Xie F, Yu Y, et al
N6-Methyladenosine enhances the translation of ENO1 to promote the progression of bladder cancer by inhibiting PCNA ubiquitination.
Cancer Lett. 2024;595:217002.
Abstract

LI J, Feng S, Wang X, Zhang B, et al
Exploring the Targets and Molecular Mechanisms of Curcumin for the Treatment of Bladder Cancer Based on Network Pharmacology, Molecular Docking and Molecular Dynamics.
Mol Biotechnol. 2024 Jun 1. doi: 10.1007/s12033-024-01190.
Abstract

KONG L, Li H, Cai Q, Cao W, et al
Amide Proton Transfer-Weighted Imaging in Assessing the Aggressive and Proliferative Potential of Bladder Cancer.
J Magn Reson Imaging. 2024 Jun 1. doi: 10.1002/jmri.29464.
Abstract

AL-AHMADIE H, Netto GJ
Molecular Pathology of Urothelial Carcinoma.
Clin Lab Med. 2024;44:181-198.
Abstract

WU L, Hu Z, Song XF, Liao YJ, et al
Targeting Nrf2 signaling pathways in the role of bladder cancer: From signal network to targeted therapy.
Biomed Pharmacother. 2024;176:116829.
Abstract

YAN B, Luo P, Qiu H, Wang J, et al
PC4 promotes bladder cancer progression and stemness by directly interacting with Sp1 to transcriptionally activate the Wnt5a/beta-catenin pathway.
Pathol Res Pract. 2024;259:155369.
Abstract

CHEN J, Wang M, Qi X, Long H, et al
RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China.
Clin Genitourin Cancer. 2024;22:102093.
Abstract

VLACHOU E, Mamtani R, Hahn NM, Iii BJ, et al
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin.
Clin Genitourin Cancer. 2024;22:102090.
Abstract

NARITA C, Urabe F, Fukuokaya W, Iwatani K, et al
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study.
Clin Genitourin Cancer. 2024;22:102082.
Abstract

POWLES T, Bellmunt J, Comperat E, De Santis M, et al
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Ann Oncol. 2024;35:485-490.
Abstract

CARBONE L, Webber V, Rothenberger R, Lenger SM, et al
Robotic Vaginal Hernia Repair for Recurrent Vaginal Prolapse Status Post-Radical Cystectomy with an Indiana Pouch.
Int Urogynecol J. 2024;35:1097-1099.
Abstract

BLACHIER M, Ye H, Long JA, Descotes JL, et al
Interest of the POSPOM score in estimating postoperative complication risk after radical cystectomy.
Fr J Urol. 2024;34:102610.
Abstract

FLEMING S, Gifkins D, Resnick HE, Shalaby W, et al
Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma.
Clin Genitourin Cancer. 2024;22:102054.
Abstract

TAPIA JC, Bosma F, Gavira J, Sanchez S, et al
Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021.
Clin Genitourin Cancer. 2024;22:102047.
Abstract

MUNIZ SUAREZ L, Subira Rios J, Gayarre Abril P, Montero Martoran A, et al
Influence of laparoscopic surgery on the outcomes of radical cystectomy within a multimodal rehabilitation protocol.
Actas Urol Esp (Engl Ed). 2024;48:364-370.
Abstract

KAWAHARA I, Yoshino H, Fukumoto W, Arima J, et al
Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models.
Mol Oncol. 2024 Jun 14. doi: 10.1002/1878-0261.13684.
Abstract

PENG X, Liu C, Zhang L, Chen Y, et al
IL4I1: a novel molecular biomarker represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Front Pharmacol. 2024;15:1365683.
Abstract

LAHOUD J, Patel MI, Naher S, Mercieca-Bebber R, et al
A systematic review of the patient reported outcomes that affect patients with muscle invasive bladder cancer after radical cystectomy and urinary diversion.
BJUI Compass. 2024;5:524-540.
Abstract

BORNA MR, Sepehri MM, Shadpour P, Khaleghi Mehr F, et al
Enhancing bladder cancer diagnosis through transitional cell carcinoma polyp detection and segmentation: an artificial intelligence powered deep learning solution.
Front Artif Intell. 2024;7:1406806.
Abstract

FENG K
Effectiveness of Comprehensive Nursing Intervention Based on the Roy Adaptation Model in the Perioperative Period of Bladder Cancer.
Altern Ther Health Med. 2024 Jun 14:AT10139.
Abstract

VLACHOU E, Johnson BA 3rd, Baraban E, Nadal R, et al
Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer.
Am Soc Clin Oncol Educ Book. 2024;44:e438640.
Abstract

CHI Q, Wang Z, Xu H, Li H, et al
Circ_0000758 Facilitates Bladder Cancer Cell Growth, Migration and Angiogenesis Via Severing as miR-1236-3p Sponge.
Biochem Genet. 2024 Jun 13. doi: 10.1007/s10528-024-10855.
Abstract

ZHAI Z, Fu J, Ye ML, Wang JY, et al
The changes of intestinal microbiota and metabolomics during the inhibition of bladder cancer by liquiritigenin.
J Asian Nat Prod Res. 2024 Jun 13:1-10. doi: 10.1080/10286020.2024.2366010.
Abstract

DUCHENE L, Davenne E, Lifrange F, Detrembleur N, et al
[Urinary cytology for the detection of urothelial lesions].
Rev Med Liege. 2024;79.
Abstract

LI J
Editorial for "Amide Proton Transfer-Weighted Imaging in Assessing the Aggressive and Proliferative Potential of Bladder Cancer".
J Magn Reson Imaging. 2024 Jun 13. doi: 10.1002/jmri.29468.
Abstract

UYSAL D, Thaqi B, Fierek A, Jurgowski D, et al
Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancer.
Front Oncol. 2024;14:1370303.
Abstract

YANG Z, Li X, Zhou L, Luo Y, et al
Ferroptosis-related lncRNAs: Distinguishing heterogeneity of the tumour microenvironment and predicting immunotherapy response in bladder cancer.
Heliyon. 2024;10:e32018.
Abstract

PAKMANESH H, Khajehsalimi A, Hesamarefi M, Ebadzadeh MR, et al
Comparison of the overall survival of different treatment methods in patients with Muscle-invasive bladder cancer: A retrospective study.
Urologia. 2024 Jun 12:3915603241256009. doi: 10.1177/03915603241256009.
Abstract

ZAREINEJAD M, Faghih Z, Ramezani A, Safaei A, et al
Exploring heterogeneous expression of beta-actin (ACTB) in bladder cancer by producing a monoclonal antibody 6D6.
BMC Urol. 2024;24:124.
Abstract

KONG L, Ling J, Cao W, Wen Z, et al
Multiparametric MR characterization for human epithelial growth factor receptor 2 expression in bladder cancer: an exploratory study.
Abdom Radiol (NY). 2024 Jun 13. doi: 10.1007/s00261-024-04378.
Abstract

ZHANG P, Song D, Fang Z, Sun D, et al
Cardamomin Inhibits the Proliferation and Tumorigenesis of Bladder Cancer by ESR1 in PI3K/AKT Pathway.
Biochem Genet. 2024 Jun 12. doi: 10.1007/s10528-024-10854.
Abstract

SATYAL U, Valentine H, Liu D, Slifker M, et al
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.
JCO Precis Oncol. 2024;8:e2300362.
Abstract

POON DMC, Ho LY, Kwong YM
Avelumab maintenance therapy for node-positive muscle invasive bladder cancer: a report of two cases.
Front Oncol. 2024;14:1397738.
Abstract

KHENE ZE, Lotan Y
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer.
Expert Opin Biol Ther. 2024 Jun 13:1-9. doi: 10.1080/14712598.2024.2365802.
Abstract

HUANG J, Michaud E, Shinde-Jadhav S, Fehric S, et al
Effects of combined radiotherapy with immune checkpoint blockade on immunological memory in luminal-like subtype murine bladder cancer model.
Cancer Biol Ther. 2024;25:2365452.
Abstract

JIANG J, Xu J, Ou L, Yin C, et al
ITM2A inhibits the progression of bladder cancer by downregulating the phosphorylation of STAT3.
Am J Cancer Res. 2024;14:2202-2215.
Abstract

WANG X, Zhang S, Sun Y, Cai L, et al
The prognostic significance of preoperative platelet-to-lymphocyte ratio and interleukin-6 level in non-muscle invasive bladder cancer.
Int J Biol Markers. 2024 Jun 11:3936155241261719. doi: 10.1177/03936155241261719
Abstract

REZAEE ME, Mahon KM, Trock BJ, Nguyen TE, et al
ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol.
BMJ Open. 2024;14:e076763.
Abstract

ZHANG G, Wei W, Li S, Yang J, et al
Transcription Factor yin-Yang 1 augments nucleoporin 93 oncogene activity and modulates bladder Cancer malignancy.
Toxicol In Vitro. 2024 Jun 8:105875. doi: 10.1016/j.tiv.2024.105875.
Abstract

ZHU X, He J, Chen J
A commentary on "Genetically proxied intestinal microbiota and risk of bladder cancer".
Int J Surg. 2024 Jun 10. doi: 10.1097/JS9.0000000000001780.
Abstract

LI Q, Zhan S, Yang X, Zhang Z, et al
Choline Phosphate-Grafted Nanozymes as Universal Extracellular Vesicle Probes for Bladder Cancer Detection.
ACS Nano. 2024 Jun 10. doi: 10.1021/acsnano.4c00280.
Abstract

FANG K, Fang DL, Yu H, Chen YA, et al
Exploring the microRNA-mRNA regulatory network associated with solasonine in bladder cancer.
Transl Androl Urol. 2024;13:812-827.
Abstract

FAN Z, Guo J, Zhang X, Chen Z, et al
Non-Gaussian diffusion metrics with whole-tumor histogram analysis for bladder cancer diagnosis: muscle invasion and histological grade.
Insights Imaging. 2024;15:138.
Abstract

MCINERNEY S, Jones RJ
Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer.
Eur Urol Focus. 2024 Jun 7:S2405-4569(24)00075-0. doi: 10.1016/j.euf.2024.
Abstract

FAHOUM I, Tsuriel S, Rattner D, Greenberg A, et al
Automatic analysis of nuclear features reveals a non-tumoral predictor of tumor grade in bladder cancer.
Diagn Pathol. 2024;19:75.
Abstract

ALBADAWY A, Alqudaimi M, Cui H, Yan X, et al
Identification of Hydroxysteroid Dehydrogenase Type 1 As a Potential Bladder Tumor Marker.
Iran Biomed J. 2024;28.
Abstract

DU L, Wang B, Wen J, Zhang N, et al
No causal association between insomnia and bladder cancer: a bidirectional two-sample Mendelian randomization study.
Eur J Med Res. 2024;29:316.
Abstract

WANG JN, Zhang Y, Huang CY, Li K, et al
Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
BMC Ophthalmol. 2024;24:240.
Abstract

LUO J, Luo F, Li Q, Liu Q, et al
An immunogenic cell death-related lncRNA signature correlates with prognosis and tumor immune microenvironment in bladder cancer.
Sci Rep. 2024;14:13106.
Abstract

GUERRERO-RAMOS F, Boormans JL, Daneshmand S, Gontero P, et al
Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2024 Jun 6:S2588-9311(24)00143-3. doi: 10.1016/j.euo.2024.
Abstract

DAY E, Gavira J, Tapia JC, Anguera G, et al
What About Variant Histologies in Bladder Cancer?
Eur Urol Focus. 2024 Jun 6:S2405-4569(24)00078-6. doi: 10.1016/j.euf.2024.
Abstract

ZHOU R, Zhou J, Deng S, Zhu Y, et al
Developing and experimental validating a B cell exhaustion-related gene signature to assess prognosis and immunotherapeutic response in bladder cancer.
Gene. 2024;927:148634.
Abstract

SCHRODER C, Ploger R, Knupfer S, Tascon Padron L, et al
Anterior enterocele after cystectomy: case report and review of the literature.
Arch Gynecol Obstet. 2024;310:11-21.
Abstract

ZHENG L, Chen H, Zhao J, Roy-Chowdhuri S, et al
Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.
Hum Pathol. 2024;148:1-6.
Abstract

SONG W, Yu J, Chung JH, Kang M, et al
A Proposal for Standardization of Early Outcomes Following Robot-Assisted Radical Cystectomy (RARC): RARC Tetrafecta.
Ann Surg Oncol. 2024;31:4752-4761.
Abstract

KHOSLA H, Bhatt S, Wang MJ, Gignac G, et al
Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
J Oncol Pharm Pract. 2024;30:941-944.
Abstract

LAMMERT FC, Pannhausen J, Noetzel E, Friedland F, et al
Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes.
Mol Oncol. 2024;18:1397-1416.
Abstract

COELHO JQ, Ramos MJ, Ranchor R, Pichel R, et al
What's new about the tumor microenvironment of urothelial carcinoma?
Clin Transl Oncol. 2024;26:1549-1560.
Abstract

YOO C, Lamarca A, Choi HJ, Vogel A, et al
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
Future Oncol. 2024;20:1069-1077.
Abstract

VANGURI RS, Smithy JW, Li Y, Zhuang M, et al
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
J Pathol. 2023;261:349-360.
Abstract

In brief: Anktiva for bladder cancer.
Med Lett Drugs Ther. 2024;66:e105-e106.
Abstract

LI Y, Shan S, Zhang R, Sun C, et al
Imaging and Downstaging Bladder Cancer with the (177)Lu-Labeled Bioorthogonal Nanoprobe.
ACS Nano. 2024 Jun 21. doi: 10.1021/acsnano.4c04303.
Abstract

SEREMAK JR, Gupta KB, Bonigala S, Liu E, et al
Targeting Chemoresistance in Advanced Bladder Cancers with a Novel Adjuvant Strategy.
Mol Cancer Ther. 2024 Jun 21:OF1-OF15. doi: 10.1158/1535-7163.MCT-23-0806.
Abstract

HUANG Z, Wang Z, Xu C, Yan Y, et al
FGL2 as a predictive biomarker for prognosis and immunotherapy in bladder cancer.
Int J Med Sci. 2024;21:1447-1460.
Abstract

ZHANG Q, Wang C, Qin M, Ye Y, et al
Investigating cellular similarities and differences between upper tract urothelial carcinoma and bladder urothelial carcinoma using single-cell sequencing.
Front Immunol. 2024;15:1298087.
Abstract

ZHANG W, Chen XS, Wei Y, Wang XM, et al
Correction: Overexpressed KCNK1 regulates potassium channels affecting molecular mechanisms and biological pathways in bladder cancer.
Eur J Med Res. 2024;29:342.
Abstract

SCILIPOTI P, Slusarczyk A, de Angelis M, Soria F, et al
The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Eur Urol Oncol. 2024 Jun 19:S2588-9311(24)00152.
Abstract

WU SX, Chen X, Hong GB, Xu SZ, et al
[Exploration of the clinical transformation application of the artificial intelligence diagnosis system for bladder cancer based on cystoscopy].
Zhonghua Yi Xue Za Zhi. 2024;104:2260-2262.
Abstract

TAKEUCHI M, Tamada T, Higaki A, Kojima Y, et al
Pictorial review of the diagnosis of muscle-invasive bladder cancer using vesical imaging-reporting and data system (VI-RADS).
Abdom Radiol (NY). 2024 Jun 20. doi: 10.1007/s00261-024-04424.
Abstract

ABOU CHAKRA M, Shore ND, Brown ES, Du GJ, et al
Establishing an Intravesical Doublet Chemotherapy Clinic for Nonmuscle-Invasive Bladder Cancer Patients.
Urol Pract. 2024;11:613-623.
Abstract

MAHMOOD AW, Ahmad A, Howlader M, Plecas Z, et al
Is Stent-Free Ureteroenteric Anastomosis Associated With Lower Ureteroenteric Strictures After Robot-Assisted Radical Cystectomy and Ileal Conduit?
Urol Pract. 2024;11:753-759.
Abstract

SILVA-FERREIRA M, Carvalho JA, Salta S, Henriques TS, et al
Diagnostic Test Accuracy of Urinary DNA Methylation-based Biomarkers for the Detection of Primary and Recurrent Bladder Cancer: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2024 Jun 19:S2405-4569(24)00088.
Abstract

WANG YS, Zheng AH, Zhao JW, Gu HY, et al
Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery.
Int Immunopharmacol. 2024;137:112417.
Abstract

RUTTEN VC, Al CM, Festen S, Zuiverloon TCM, et al
Selecting the right treatment: Health outcome priorities in older patients with bladder cancer.
J Geriatr Oncol. 2024;15:101811.
Abstract

YING X, Hu W, Huang Y, Lv Y, et al
A Novel tsRNA, m(7)G-3' tiRNA Lys(TTT), Promotes Bladder Cancer Malignancy Via Regulating ANXA2 Phosphorylation.
Adv Sci (Weinh). 2024 Jun 18:e2400115. doi: 10.1002/advs.202400115.
Abstract

TENG C, Lu W, Che J, Wu Y, et al
Association of Pro-Inflammatory Diet, Smoking, and Alcohol Consumption with Bladder Cancer: Evidence from Case-Control and NHANES Studies from 1999 to 2020.
Nutrients. 2024;16:1793.
Abstract

ARIMA J, Yoshino H, Fukumoto W, Kawahara I, et al
LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer.
Int J Mol Sci. 2024;25:5955.
Abstract

KOUKOURIKIS P, Papaioannou M, Pervana S, Apostolidis A, et al
Exploring the DNA Methylation Profile of Genes Associated with Bladder Cancer in Bladder Tissue of Patients with Neurogenic Lower Urinary Tract Dysfunction.
Int J Mol Sci. 2024;25:5660.
Abstract

SINCIC V, Arlenhold KF, Richtmann S, Lilljebjorn H, et al
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes.
Cells. 2024;13:926.
Abstract

LI R, Shah PH, Stewart TF, Nam JK, et al
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Nat Med. 2024 Jun 18. doi: 10.1038/s41591-024-03137.
Abstract

EYERS M, Irlam J, Marshall G, Smith V, et al
Digital spatial profiling of the microenvironment of muscle invasive bladder cancer.
Commun Biol. 2024;7:737.
Abstract

ZENG Y, Cai C, Pan N
Prognostic Effects of Sarcopenia on Patients with Bladder Cancer: A Systematic Review and Meta-Analysis.
Cancer Invest. 2024 Jun 18:1-15. doi: 10.1080/07357907.2024.2363879.
Abstract

LEE DH, Yoo JK, Um KH, Ha W, et al
Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment.
J Exp Clin Cancer Res. 2024;43:170.
Abstract

LI S, Fan Z, Guo J, Li D, et al
Compressed sensing 3D T2WI radiomics model: improving diagnostic performance in muscle invasion of bladder cancer.
BMC Med Imaging. 2024;24:148.
Abstract

SZABADOS B, Powles T
On the Road Towards Curing Advanced Bladder Cancer.
Eur Urol Focus. 2024 Jun 16:S2405-4569(24)00056.
Abstract

LOUDA M, Navratil P, Sachova S, Holub L, et al
Prophylactic surgical mesh placement as a prevention of parastomal hernia in open radical cystectomy with ileal conduit diversion - pilot study.
Rozhl Chir. 2024;103:91-95.
Abstract

HELSTROM E, Lakshmanan A, Fulmes A, Sindhani M, et al
Examining the Concordance of Patient Age Distribution between Genitourinary (GU) Clinical Trials and Real-World Disease Populations: Kidney, Prostate and Bladder Cancer Analysis.
Ann Surg Oncol. 2024 Jun 17. doi: 10.1245/s10434-024-15559.
Abstract

JHA P, Pengal R, Shah M, Kulkarni PM, et al
Identification of Rare EIF3E::RSPO2 Fusion in Recurrent and Aggressive Urachal Adenocarcinoma.
Genes Chromosomes Cancer. 2024;63:e23250.
Abstract

YOSEF M, Bunimovich-Mendrazitsky S
Mathematical model of MMC chemotherapy for non-invasive bladder cancer treatment.
Front Oncol. 2024;14:1352065.
Abstract

CHEN B, Chen L, Yang J, Hou M, et al
Cepharanthine inhibits migration, invasion, and EMT of bladder cancer cells by activating the Rap1 signaling pathway in vitro.
Am J Transl Res. 2024;16:1602-1619.
Abstract

ISHIDA K, Ogose A, Kawaguchi G, Hasegawa G, et al
Bladder Cancer Invading the Prostate and Penis and Multiple Bone Metastases Showing Significant Improvement after a Short-Term Pembrolizumab Therapy following Radiation and Gemcitabine and Cisplatin Therapy Leading to a Pathologically Complete Remissi
Case Rep Urol. 2024;2024:7525757.
Abstract

VENEGONI C, Pederzoli F, Locatelli I, Alchera E, et al
Topographic modification of the extracellular matrix precedes the onset of bladder cancer.
Matrix Biol Plus. 2024;23:100154.
Abstract

LI P, Zhao Z, Chen Q, Liu Y, et al
CircACTR2 promotes bladder cancer progression through IKBKB-mediated NF-kappaB signaling pathway activation.
Heliyon. 2024;10:e30778.
Abstract

WANG H, Luo W, Ji J, Qu M, et al
Integrated bioinformatics investigation of adenylyl cyclase family co-expression network in bladder cancer followed by preliminary validation of member 2 (ADCY2) in tumorigenesis and prognosis.
Transl Cancer Res. 2024;13:2222-2237.
Abstract

SVEDMAN FC, Holmsten K, Jawdat F, Hailom W, et al
Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience.
Radiat Oncol. 2024;19:74.
Abstract

AHRENDT H, Sun H, Mishra K, Gupta S, et al
Multidisciplinary management of sexual and gender minorities with bladder cancer.
Urol Oncol. 2024 Jun 15:S1078-1439(24)00496.
Abstract

CAMPBELL RA, Wood A, Michael PD, Shin D, et al
Impact of pathologic re-review on grade, clinical stage, and risk stratification for patients with nonmuscle invasive bladder cancer.
Urol Oncol. 2024 Jun 15:S1078-1439(24)00494.
Abstract

FU Q, Zheng H, Wang X, Tang F, et al
GINS1 promotes the initiation and progression of bladder cancer by activating the AKT/mTOR/c-Myc signaling pathway.
Exp Cell Res. 2024;440:114125.
Abstract

LI J, Deng Z, Soerensen SJC, Kachuri L, et al
Ambient air pollution and urological cancer risk: A systematic review and meta-analysis of epidemiological evidence.
Nat Commun. 2024;15:5116.
Abstract

BATHA O, Aldolly A, Alsaffaf Y, Hamsho S, et al
Carcinoma in situ within the bladder trigone with an isolated metastasis to the prostate without involvement of prostatic urethra: a unique case report.
BMC Urol. 2024;24:127.
Abstract

KOIKE A, Colado Simao AN, Ahrens TM, Cardoso KM, et al
CTLA4 genetic variants associated with urothelial bladder cancer susceptibility.
Urol Oncol. 2024 Jun 14:S1078-1439(24)00490.
Abstract

ZAGHLOUL MS, Alnagmy AK, Kasem HA, AbdelHakim MM, et al
The value and safety of adjuvant radiotherapy (ART) after radical cystectomy in locally advanced urothelial bladder cancer: A controlled randomized study.
Int J Radiat Oncol Biol Phys. 2024 Jun 13:S0360-3016(24)00670.
Abstract

BELLMUNT J, Nadal R
Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
Med. 2024;5:490-492.
Abstract

LI K, Lv J, Wang J, Wei Y, et al
CircZNF609 inhibited bladder cancer immunotherapy sensitivity via enhancing fatty acid uptake through IGF2BP2/CD36 pathway.
Int Immunopharmacol. 2024;137:112485.
Abstract

OBIEDAT S, Murshed K, Szabados L, Al Rumaihi K, et al
Urachal mixed adenocarcinoma and small cell neuroendocrine carcinoma with widespread metastasis and resistance to chemotherapy: a case report.
Diagn Pathol. 2024;19:81.
Abstract

DE ANGELIS M, Scheipner L, Siech C, Jannello LMI, et al
Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy.
Clin Genitourin Cancer. 2024;22:102119.
Abstract

KASEB H, Leslie SW, Soon-Sutton TL, Aeddula NR, et al
Hydronephrosis as a Prognostic Factor in Primary Bladder Adenocarcinoma: Insights from a 15-Year Tertiary Center Experience.
Clin Genitourin Cancer. 2024;22:102120.
Abstract

KIM YJ, Lee M, Kim EH, Lee S, et al
Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
Cancer Lett. 2024;596:216998.
Abstract

TSUMURA K, Fujimoto M, Tian Y, Kawahara T, et al
Aberrant cell adhesiveness due to DNA hypermethylation of KLF11 in papillary urothelial carcinomas.
Exp Mol Pathol. 2024;137:104908.
Abstract

ALHARIRY NS, El Saftawy EA, Aboulhoda BE, Abozamel AH, et al
Comparison of tissue biomarkers between non-schistosoma and schistosoma-associated urothelial carcinoma.
Tissue Cell. 2024;88:102416.
Abstract

BUKAVINA L, Ginwala R, Eltoukhi M, Sindhani M, et al
Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation.
Cancer Res Commun. 2024;4:1505-1516.
Abstract

TATEO V, Cigliola A, Mercinelli C, Agarwal N, et al
Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel.
Clin Genitourin Cancer. 2024;22:102091.
Abstract

GRIMM MO, Schostak M, Grun CB, Loidl W, et al
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.
JAMA Oncol. 2024;10:755-764.
Abstract

GHABOUSIAN A, Shafigh A, Tayebi S, Salehi-Pourmehr H, et al
The Potential Role of Urinary Microbiota in Bladder Carcinogenesis: A Systematic Review.
Urol J. 2024;21:208-220.
Abstract

ALLAMEH F, Eslami AH
Extra-peritoneal vs. Trans-peritoneal Radical Cystectomy pros and cons.
Urol J. 2024;21:271.
Abstract

COLLINS K, Yocum BP, Idrees MT, Saeed O, et al
Carcinoma arising in ileal conduit or orthotopic ileal neobladder reconstruction: A 20-year single institute experience.
Histopathology. 2024;85:182-189.
Abstract

LEE KS, Choi E, Cho SI, Park S, et al
An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
Histopathology. 2024;85:81-91.
Abstract

SPISAROVA M, Losse S, Jakubec P, Hartmann I, et al
Bacillus Calmette-Guerin pneumonitis after intravesical instillation: Report of two cases and a review of the literature.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024;168:181-186.
Abstract

KONG J, Zou Y, Zhou H, Huang Y, et al
Assessing the predictive value of smoking history for immunotherapy outcomes in bladder cancer patients.
Front Immunol. 2024;15:1404812.
Abstract

SU W, Xu C, Hu J, Chen Q, et al
Non-invasive screening of bladder cancer using digital microfluidics and FLIM technology combined with deep learning.
J Biophotonics. 2024 Jun 28:e202400192. doi: 10.1002/jbio.202400192.
Abstract

XU PH, Li T, Qu F, Tian M, et al
Comprehensive Collection of Whole-Slide Images and Genomic Profiles for Patients with Bladder Cancer.
Sci Data. 2024;11:699.
Abstract

HU M, Wei W, Zhang J, Wang S, et al
Impact of virtual monochromatic images of different low-energy levels in dual-energy CT on radiomics models for predicting muscle invasion in bladder cancer.
Abdom Radiol (NY). 2024 Jun 27. doi: 10.1007/s00261-024-04459.
Abstract

PEPE P, Salemi M, Marchese G, Salluzzo MG, et al
Transcriptome Analysis in Patients With Muscle-invasive Bladder Cancer.
In Vivo. 2024;38:1660-1664.
Abstract

MINATO A, Ohno D, Murooka K, Okumura Y, et al
Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
In Vivo. 2024;38:1927-1934.
Abstract

WEI PJ, Guo Z, Gao Z, Ding Z, et al
Inference of gene regulatory networks based on directed graph convolutional networks.
Brief Bioinform. 2024;25:bbae309.
Abstract

YAN P, Wang G, Huang M, Liu Z, et al
Combinatorial Biosynthesis Creates a Novel Aglycone Polyether with High Potency and Low Side Effects Against Bladder Cancer.
Adv Sci (Weinh). 2024 Jun 27:e2404668. doi: 10.1002/advs.202404668.
Abstract

SU L, Wang Y, Ma J
Analysis of the short-term efficacy and impact on the quality of life of patients with bladder cancer after surgery treated with Shenhu soup empirical formula combined with bladder perfusion.
Panminerva Med. 2024 Jun 27. doi: 10.23736/S0031-0808.24.05136.
Abstract

FARCI R, Tolu S, Trombetta M, Murgia A, et al
An unusual "linitis plastica" like breast cancer bladder metastasis.
Arch Ital Urol Androl. 2024;96:12483.
Abstract

KANG M, Wilkens LR, Wirth MD, Shivappa N, et al
Diet Quality and Risk of Bladder Cancer in the Multiethnic Cohort Study.
Nutrients. 2024;16:1965.
Abstract

ELEZ-BURNJAKOVIC N, Pojskic L, Haveric A, Lojo-Kadric N, et al
Halogenated Boroxine K(2)[B(3)O(3)F(4)OH] Modulates Metabolic Phenotype and Autophagy in Human Bladder Carcinoma 5637 Cell Line.
Molecules. 2024;29:2919.
Abstract

GERMANA E, Pepe L, Pizzimenti C, Ballato M, et al
Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications.
Int J Mol Sci. 2024;25:6750.
Abstract

SMOLKA C, Eckstein M, Jung R, Lieb V, et al
Prognostic and Predictive Potential of CCL5 Expression in Muscle-Invasive Bladder Cancer Patients.
Int J Mol Sci. 2024;25:6325.
Abstract

DESPONDS E, Kioseoglou K, Zdimerova H, Ongaro M, et al
Development of Traceable Mouse Models of Advanced and Metastatic Bladder Cancer.
Cancers (Basel). 2024;16:2245.
Abstract

FERRARIO N, Marras E, Vivona V, Randisi F, et al
Mechanisms of the Antineoplastic Effects of New Fluoroquinolones in 2D and 3D Human Breast and Bladder Cancer Cell Lines.
Cancers (Basel). 2024;16:2227.
Abstract

MANITZ J, Gerhold-Ay A, Kieslich P, Shah P, et al
Avelumab first-line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial.
Cancer Med. 2024;13:e7411.
Abstract

ESCOTT M, Yi Y, Foret A, Li T, et al
Impact of rural location on receipt of standard of care treatment and survival for locally advanced bladder cancer in Louisiana.
Cancer Med. 2024;13:e7301.
Abstract

ARIHARA Y, Omori G, Kobayashi K, Sugita S, et al
Marked Response to Nivolumab by a Patient With SMARCA4-Deficient Undifferentiated Urothelial Carcinoma Showing High PD-L1 Expression: A Case Report.
Cancer Rep (Hoboken). 2024;7:e2127.
Abstract

ZHOU D, Huang J, Zheng H, Liu Y, et al
Insight into Fructose-to-Sucrose Ratio as the Potential Target of Urinalysis in Bladder Cancer.
Metabolites. 2024;14:345.
Abstract

MOUSSA MJ, Khandelwal J, Wilson NR, Naik SA, et al
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy.
Curr Oncol. 2024;31:3342-3349.
Abstract

DEL GIUDICE F, Tresh A, Li S, Basran S, et al
The impact of venous thromboembolism before open or minimally-invasive radical cystectomy in the USA: insurance claims data on perioperative outcomes and healthcare costs.
Minerva Urol Nephrol. 2024;76:320-330.
Abstract

ELFIEKY MMM, Abd El Rahman M, Fayed AM, Haleem Al-Qaim Z, et al
Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays.
Asian Pac J Cancer Prev. 2024;25:2113-2121.
Abstract

YAN Z, Liu Y, Wang M, Wang L, et al
A novel signature constructed by mitochondrial function and cell death-related gene for the prediction of prognosis in bladder cancer.
Sci Rep. 2024;14:14667.
Abstract

YOLMO P, Rahimi S, Chenard S, Conseil G, et al
Atypical B cells promote cancer progression and poor response to Bacillus Calmette-Guerin in non-muscle invasive bladder cancer.
Cancer Immunol Res. 2024 Jun 25. doi: 10.1158/2326-6066.CIR-23-1114.
Abstract

VLACHOU E, Johnson ? BA, Guancial E, Lombardo KA, et al
Frontline immune checkpoint inhibitors in patients >/= 90 years with advanced urothelial cancer: a single center experience.
Can J Urol. 2024;31:11875-11879.
Abstract

PENG F, Meng Y, Sun L, Dong B, et al
People-Oriented Nursing Mode on the Negative Emotions and Psychological Status of Patients with Bladder Cancer.
Iran J Public Health. 2024;53:1087-1095.
Abstract

CHANDI J, Soundararajan S, Bukowski W, Britt W, et al
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors.
Bladder Cancer. 2024;10:61-69.
Abstract

XIAO H, Huang X, Chen H, Zheng Y, et al
Establishment of a SUMO pathway related gene signature for predicting prognosis, chemotherapy response and investigating the role of EGR2 in bladder cancer.
J Cancer. 2024;15:3841-3856.
Abstract

HU Z, Liu C, Mei Z, Wang X, et al
A-to-I edited miR-154-p13-5p inhibited cell proliferation and migration and induced apoptosis by targeting LIX1L in the bladder cancer.
J Cancer. 2024;15:3708-3723.
Abstract

NGUYEN T, Ordulu Z, Shrestha S, Patel U, et al
Case report: A novel somatic SDHB variant in a patient with bladder paraganglioma.
Front Endocrinol (Lausanne). 2024;15:1386285.
Abstract

RAO P, Li J, Xiong J, Shen S, et al
MicroRNA-150-5p-mediated Inhibition of Cell Proliferation, G1/S Transition, and Migration in Bladder Cancer through Targeting NEDD4-binding Protein 2-like 1 Gene.
J Physiol Investig. 2024;67:118-128.
Abstract

WU J, Zhang F, Zheng X, Chen D, et al
Identification of bladder cancer subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes.
Sci Rep. 2024;14:14431.
Abstract

QIN J, Li Z, Su L, Wen X, et al
Expression of transferrin receptor/TFRC protein in bladder cancer cell T24 and its role in inducing iron death in bladder cancer.
Int J Biol Macromol. 2024;274.
Abstract

DEWULF K, Richter K, Illy M, Branger N, et al
Can Bladder MRI Improve the Follow-Up of Non-Muscle-Invasive Bladder Cancer by Detecting Endoscopic Invisible Recurrence?
Clin Genitourin Cancer. 2024;22:102136.
Abstract

YOSHITANI S, Kaneda K, Nishida M, Komura K, et al
A case of urothelial carcinoma with successful continuation of enfortumab vedotin without dose reduction despite grade 3 diffuse erythema with fever.
Eur J Dermatol. 2024;34:214-216.
Abstract

XIONG H, Lin C, Huang X, Wang H, et al
A novel mitochondrial-related lncRNA signature mediated prediction of overall survival, immune landscape, and the chemotherapeutic outcomes for bladder cancer patients.
Discov Oncol. 2024;15:239.
Abstract

MERTENS LS, Bruins HM, Contieri R, Babjuk M, et al
Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels.
Eur Urol Oncol. 2024 Jun 20:S2588-9311(24)00141.
Abstract

SORIA F, Rosazza M, Livoti S, Moschini M, et al
Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaborati
Eur Urol Oncol. 2024 Jun 20:S2588-9311(24)00151.
Abstract

AALAMI AH, Abdeahad H, Aalami F, Sathyapalan T, et al
Investigating angiogenin/ribonuclease 5 as a diagnostic biomarker for bladder cancer: In-depth analysis from a systematic review and meta-analysis.
Clin Biochem. 2024 Jun 19:110780. doi: 10.1016/j.clinbiochem.2024.110780.
Abstract

KASEB H, Leslie SW, Soon-Sutton TL, Aeddula NR, et al
Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma.
Pharmacol Res. 2024;205:107230.
Abstract

RANGANATHAN S, Riveros C, Xu J, Hu S, et al
Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.
Urol Oncol. 2024;42:291.
Abstract

VLAJNIC T, Chijioke O, Roma L, Savic Prince S, et al
Loss of MTAP Expression by Immunohistochemistry Is a Surrogate Marker for Homozygous 9p21.3 Deletion in Urothelial Carcinoma.
Mod Pathol. 2024;37:100495.
Abstract

AGGEN DH, Rosenberg JE
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma.
Nat Rev Clin Oncol. 2024;21:487-488.
Abstract

XUE J, Zhuang Z, Peng L, Chen X, et al
Prognostic predictive value of urothelial carcinoma of the bladder after TURBT based on multiphase CT radiomics.
Abdom Radiol (NY). 2024;49:1975-1986.
Abstract

XIAO Y, Jin W, Qian K, Ju L, et al
Integrative Single Cell Atlas Revealed Intratumoral Heterogeneity Generation from an Adaptive Epigenetic Cell State in Human Bladder Urothelial Carcinoma.
Adv Sci (Weinh). 2024;11:e2308438.
Abstract

LIU H, Chen J, Huang Y, Zhang Y, et al
Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
Int J Surg. 2024;110:3923-3936.
Abstract

BANNER L, Rohan TZ, Zachian R, Gross T, et al
Increased incidence of thyroid, renal, lung, melanoma, bladder, and prostate cancers after diagnosis of primary cutaneous B-cell lymphoma: A SEER database analysis.
J Am Acad Dermatol. 2024 Mar 19:S0190-9622(24)00505.
Abstract

LEE IW, Wang HJ, Liu HY, Chang YL, et al
Prevalence and oncologic impact of chronic kidney disease for upper tract urothelial carcinoma in endemic area.
J Formos Med Assoc. 2024;123:758-763.
Abstract

YANG X, Zhang Y, Liu J, Feng Y, et al
Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs.
Medicine (Baltimore). 2024;103:e38750.
Abstract

NAGAHAMA K, Ito M, Imai K, Masuda N, et al
[Repair of Vaginal Cuff Dehiscence after Laparoscopic Radical Cystectomy with Gracilis Myocutaneous Flap].
Hinyokika Kiyo. 2024;70:155-159.
Abstract

AKAI T, Ueno S, Takeda A, Tokuyama S, et al
[A Case of Lymphorrhea after Radical Cystectomy Treated by Ultrasound-Guided Inguinal Intranodal Lymphangiography].
Hinyokika Kiyo. 2024;70:123-127.
Abstract

PAPADIMITRIOU MA, Pilala KM, Panoutsopoulou K, Levis P, et al
CDKN2A copy number alteration in bladder cancer: Integrative analysis in patient-derived xenografts and cancer patients.
Mol Ther Oncol. 2024;32:200818.
Abstract

GLAVCIC M, Cudina I, Hrabac P, Glavcic G, et al
UROTHELIAL CARCINOMA BEFORE AND DURING THE COVID-19 PANDEMIC IN CROATIA - A SINGLE-CENTER STUDY.
Acta Clin Croat. 2023;62.
Abstract

VIDOSAVLJEVIC M, Puntaric D, Gvozdic V, Vidosavljevic D, et al
ARSENIC IN DRINKING WATER AND URINE AND ITS RELATIONSHIP WITH MALIGNANT TUMORS OF URINARY TRACT IN OSIJEK-BARANJA COUNTY, CROATIA.
Acta Clin Croat. 2023;62.
Abstract

CIKIC B, Zekulic T, Penezic L, Andelic J, et al
OPEN RADICAL CYSTECTOMY: SINGLE CENTER RESULTS AND OUTCOMES IN THE LAST FIVE YEARS.
Acta Clin Croat. 2023;62.
Abstract

YAMASAKI T, Yoshino T, Kojo K, Kimura T, et al
[Two Cases of Bleeding from the Ileal Conduit Due to Ectopic Varices].
Hinyokika Kiyo. 2024;70:101-106.
Abstract

AIGASE T, Tatenuma T, Uemura K, Makiyama K, et al
[A Case of Successful Treatment of Small Cell Carcinoma of the Bladder with Pembrolizumab].
Hinyokika Kiyo. 2024;70:93-99.
Abstract

KIYAMA Y, Sekii Y, Inoguchi S, Matsumura S, et al
[A Case of Primary Adenocarcinoma Mucinous Subtype of the Bladder].
Hinyokika Kiyo. 2024;70:89-92.
Abstract

NARA T, Numakura K, Furihata K, Kikuchi A, et al
Arterio-ureteral fistula from a pseudoaneurysm of the right common iliac artery after robot-assisted laparoscopic radical cystectomy: A case report.
Asian J Endosc Surg. 2024;17:e13348.
Abstract

SAIZONOU I, Lascombe I, Monnien F, Bedgedjian I, et al
Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients.
Sci Rep. 2024;14:15390.
Abstract

JIANG D, Zhang H, Yin B, He M, et al
The Prognostic Hub Gene POLE2 Promotes BLCA Cell Growth via the PI3K/AKT Signaling Pathway.
Comb Chem High Throughput Screen. 2024;27:1984-1998.
Abstract

TORII S, Narita T, Homma T, Kinoshita T, et al
Successful pre-surgical treatment with carboplatin and gemcitabine chemotherapy for a patient with muscle-invasive bladder cancer and severe renal dysfunction.
Int Cancer Conf J. 2024;13:230-234.
Abstract

MOROOKA D, Nakajima Y, Tabata H, Hotta H, et al
[A Case of Systemic Wild-Type Transthyretin Amyloid (ATTR) Amyloidosis Diagnosed in a Patient with Gross Hematuria].
Hinyokika Kiyo. 2024;70:65-69.
Abstract

WANG B, Qiu Y, Xie M, Huang P, et al
Gut microbiota Parabacteroides distasonis enchances the efficacy of immunotherapy for bladder cancer by activating anti-tumor immune responses.
BMC Microbiol. 2024;24:237.
Abstract

CELLA L, Basile G, Moretto S, Paciotti M, et al
Robotic assisted vs open radical cystectomy: an updated systematic review and meta-analysis.
J Robot Surg. 2024;18:277.
Abstract

PEREIRA SANTOS CARVALHO I, Bueno Silva L, Luis Ferraz do Amaral R, Nader Chrysostomo-Massaro T, et al
Evaluation of in vivo and in vitro efficacy of solasonine/solamargine-loaded lipid-polymer hybrid nanoparticles against bladder cancer.
Int J Pharm. 2024 Jul 1:124411. doi: 10.1016/j.ijpharm.2024.124411.
Abstract

ALWALI A, Schafmayer C, Kamaleddine I
Combined endoscopic management of a postoperative rectocutaneous fistula after cystectomy using modified percutaneous endofistular and transanal endoluminal vacuum therapy.
Endoscopy. 2024;56.
Abstract

JIAN Y, Chen Q, Al-Danakh A, Xu Z, et al
Identification and validation of sialyltransferase ST3Gal5 in bladder cancer through bioinformatics and experimental analysis.
Int Immunopharmacol. 2024;138:112569.
Abstract

LI C, Chu G, Ma G, Chen X, et al
SLC16A3 is a Prognostic Marker and Affects Immune Regulation in Bladder Cancer.
Comb Chem High Throughput Screen. 2024.
Abstract

PICHLER R, Fritz J, Mari A, Cadenar A, et al
Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomy.
Oncologist. 2024 Jul 2:oyae160. doi: 10.1093.
Abstract

SEOK J, Kwak Y, Kim S, Kim EM, et al
Advances in Liquid Biopsy for Diagnosis of Bladder Cancer.
Int Neurourol J. 2024;28:83-95.
Abstract

YANG Z, Chen Q, Dong S, Xu P, et al
Hypermethylated TAGMe as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma.
J Transl Med. 2024;22:608.
Abstract

LIU J, Wang X, Jiang W, Azoitei A, et al
Impairment of alpha-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion.
Cell Mol Biol Lett. 2024;29:94.
Abstract

LI R, Shah PH, Stewart TF, Nam JK, et al
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Nat Med. 2024 Jul 2. doi: 10.1038/s41591-024-03157.
Abstract

FUKATA S, Kawaguchi A, Yoshimura R, Fukuhara H, et al
Investigation of risk factors for vaginal dehiscence and development of small bowel evisceration after robot-assisted radical cystectomy for female bladder cancer and an improved vaginal reconstruction technique to prevent its onset.
J Robot Surg. 2024;18:276.
Abstract

CHAMIE K, Chang SS, Rosser CJ, Kramolowski E, et al
N-803 Plus BCG Treatment for BCG-Naive or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review.
Future Oncol. 2024 Jul 2:1-11. doi: 10.1080/14796694.2024.2363744.
Abstract

HOSSEINI SA
The therapeutic effect of baicalin in the treatment of bladder cancer: a mini-review.
Nat Prod Res. 2024 Jul 2:1-5. doi: 10.1080/14786419.2024.2373955.
Abstract

PARK J, Lee SG, Jeong SM, Nam A, et al
Inflammatory myofibroblastic tumor in the urinary bladder in a dog.
Can Vet J. 2024;65:643-648.
Abstract

SMITH DJ, Lunj S, Adamson AD, Nagarajan S, et al
CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer.
Nat Rev Urol. 2024 Jul 1. doi: 10.1038/s41585-024-00901.
Abstract

LE M, Qing M, Zeng X, Cheng S, et al
m6A-YTHDF1 Mediated Regulation of GRIN2D in Bladder Cancer Progression and Aerobic Glycolysis.
Biochem Genet. 2024 Jun 29. doi: 10.1007/s10528-024-10875.
Abstract

PETRELLA G, Ciufolini G, Lentini S, Montorsi F, et al
The grade of systemic inflammation, immune inhibition, and gut dysbiosis as prognostic factors for bladder cancer recurrence: a metabolomics approach.
Minerva Urol Nephrol. 2024 Jul 1. doi: 10.23736/S2724-6051.24.05747.
Abstract

LI W, Chen C, Zheng H, Lin Y, et al
UBE2C-induced crosstalk between mono- and polyubiquitination of SNAT2 promotes lymphatic metastasis in bladder cancer.
J Clin Invest. 2024;134:e179122.
Abstract

SAEED S, Khan D, Faisal S, Rauf F, et al
A histopathological and epidemiological study of urothelial carcinoma at a tertiary care centre in Peshawar, Pakistan.
J Pak Med Assoc. 2024;74:1160-1162.
Abstract

PENG Y, Song Y, Du Y, Qin C, et al
Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS database.
Expert Opin Drug Saf. 2024 Jul 4:1-8. doi: 10.1080/14740338.2024.2374921.
Abstract

VINICIUS SUARTZ C, Araujo Simoes PA, Doratioto Serrano Faria Braz N, da Silva FR, et al
Surviving the Storm: Challenges of Bladder Cancer Care During the COVID-19 Pandemic.
Clin Genitourin Cancer. 2024;22:102129.
Abstract

SHABBIR R, Telfer BA, Dickie B, Reardon M, et al
Implementation of Oxygen Enhanced Magnetic Resonance Imaging (OE-MRI) and a Pilot Genomic Study of Hypoxia in Bladder Cancer Xenografts.
Cancer Genomics Proteomics. 2024;21:380-387.
Abstract

NAGATA Y, Quynh NT, Aono H, Harada K, et al
Melatonin Inhibits Chemical Carcinogen-mediated Malignant Transformation of Urothelial Cells: In Vitro Evidence.
Cancer Genomics Proteomics. 2024;21:388-394.
Abstract

WATANABE S, Kobayashi H, Hiroe N, Iwasawa T, et al
Robot-assisted radical cystectomy for bladder cancer after low anterior resection: A case report.
Asian J Endosc Surg. 2024;17:e13345.
Abstract

CHEN ST, Chang KS, Lin WY, Hsu SY, et al
Activating transcription factor 3 is an antitumor gene synergizing with growth differentiation factor 15 to modulate cell growth in human bladder cancer.
Biomed J. 2024 Jun 26:100756. doi: 10.1016/j.bj.2024.100756.
Abstract

LLOYD L
The bladder tumour microbiome and BCG response.
Nat Rev Urol. 2024;21:389.
Abstract

CHEN H, Cai Z, Dong X, Chen W, et al
Cigarette smoking-related OLC1 overexpression associated with poor prognosis in bladder urothelial carcinoma.
Life Sci. 2024;351:122821.
Abstract

BOUE-RAFLE A, Briens A, Supiot S, Blanchard P, et al
[Does radiation therapy for prostate cancer increase the risk of second cancers?].
Cancer Radiother. 2024;28:293-307.
Abstract

XU J, Chen R, Yang Y, Xu S, et al
Genetically predicted 91 circulating inflammatory proteins in relation to risk of urological malignancies: a Mendelian randomization study.
Aging (Albany NY). 2024;16:10366-10379.
Abstract

SANTONI M, Takeshita H, Massari F, Bamias A, et al
Pembrolizumab plus enfortumab vedotin in urothelial cancer.
Nat Rev Urol. 2024;21:387-388.
Abstract

NAKAMURA K, Ohno T, Inamoto T, Takai T, et al
Pattern of Expression of MicroRNA in Patients with Radiation-Induced Bladder Injury.
Oncology. 2024;102:585-592.
Abstract

ZHANG M, Wu J, Zhang Y, Shang H, et al
Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer.
Ann Surg Oncol. 2024 Jul 12. doi: 10.1245/s10434-024-15725.
Abstract

RADVANYI F, Real FX, McConkey D
What is a Bladder Cancer Molecular Subtype? - Counterpoint.
Bladder Cancer. 2023;9:299-304.
Abstract

ABDELTWAB RM, Yacoub E, Rashad AH, Shohdy KS, et al
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets.
Bladder Cancer. 2023;9:313-322.
Abstract

MESSING EM
A New Standard of Care for Bladder Cancer.
Bladder Cancer. 2023;9:383-385.
Abstract

VAN ZUTPHEN M, Kiemeney LALM, Oldenhof UTH, Maurits JSF, et al
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort.
Bladder Cancer. 2023;9:355-363.
Abstract

HOGLUND M
What is a Bladder Cancer Molecular Subtype?
Bladder Cancer. 2023;9:293-298.
Abstract

GRAJALES V, Contieri R, Tan WS, Flores M, et al
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile.
Bladder Cancer. 2023;9:327-334.
Abstract

HUANG C, Yang Y, Wang X, Chen S, et al
PTBP1-mediated biogenesis of circATIC promotes progression and cisplatin resistance of bladder cancer.
Int J Biol Sci. 2024;20:3570-3589.
Abstract

MCCONKEY DJ, Baumann BC, Cooper Greenberg S, DeGraff DJ, et al
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer.
Bladder Cancer. 2024;10:1-8.
Abstract

SOLOWAY MS, Abrahams NA
Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer.
Bladder Cancer. 2024;10:93-103.
Abstract

HEARD JR, Mitra AP
Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays.
Bladder Cancer. 2024;10:71-81.
Abstract

DURANT AM, Lee YS, Mi L, Faraj K, et al
Effect of Bacille Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer After Prostate Radiotherapy.
Bladder Cancer. 2024;10:35-45.
Abstract

SCHMITZ-DRAGER C, Goebell PJ, Paxinos E, Bismarck E, et al
Potential of an mRNA-Based Urine Assay (Xpert((R)) Bladder Cancer Detection(1)) in Hematuria Patients - Results from a Cohort Study.
Bladder Cancer. 2024;10:25-33.
Abstract

ALAM SM, Martin A, McLeay MT 2nd, Smith H, et al
Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer.
Bladder Cancer. 2023;9:167-174.
Abstract

PARE JF, Tabasinezhad M, Grossman A, Atallah A, et al
Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy.
Bladder Cancer. 2023;9:175-186.
Abstract

MOORE A, Lobaugh SM, Zhang Z, Rosenberg JE, et al
Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer.
Bladder Cancer. 2023;9:141-150.
Abstract

MELGAREJO SEGURA MT, Morales Martinez A, Yanez Castillo Y, Arrabal Polo MA, et al
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer.
Bladder Cancer. 2023;9:159-166.
Abstract

MESSING EM
Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer.
Bladder Cancer. 2023;9:191-192.
Abstract

ZHANG JH, Starr SL, Chamie K
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer.
Bladder Cancer. 2023;9:109-123.
Abstract

WANG YA, Ranti D, Bieber C, Galsky M, et al
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors.
Bladder Cancer. 2023;9:125-139.
Abstract

MENG XY, Wang QL, Shi MJ, Zhang HY, et al
Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic Difference in Bladder Cancer Susceptibility.
Bladder Cancer. 2023;9:211-216.
Abstract

CHANG E, Hahn NM, Lerner SP, Fallah J, et al
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.
Bladder Cancer. 2023;9:271-286.
Abstract

MESSING EM
Y Chromosome Loss and Bladder Cancer.
Bladder Cancer. 2023;9:287-288.
Abstract

AZURI W, Jaunarena JH, Camean JJ, Chemi J, et al
The Impact of Dose Reduction of Bacillus Calmette-Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Bladder Cancer. 2023;9:227-236.
Abstract

ASIMAKOPOULOS AD, Kochergin M, Colalillo G, Fahmy O, et al
New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer.
Bladder Cancer. 2023;9:237-251.
Abstract

ZENG S, Xing S, Zhang Y, Wang H, et al
Nano-Bacillus Calmette-Guerin immunotherapies for improved bladder cancer treatment.
J Zhejiang Univ Sci B. 2024 Jul 9:1-11. doi: 10.1631/jzus.B2300392.
Abstract

WANG Z, Chen DN, Huang XY, Zhu JM, et al
Machine learning-based autophagy-related prognostic signature for personalized risk stratification and therapeutic approaches in bladder cancer.
Int Immunopharmacol. 2024;138:112623.
Abstract

WANG L, Wang P, Liu B, Zhang H, et al
LncRNA MEG3 Inhibits the Epithelial-mesenchymal Transition of Bladder Cancer Cells through the Snail/E-cadherin Axis.
Curr Med Sci. 2024 Jul 11. doi: 10.1007/s11596-024-2895.
Abstract

CHUNG YL, Lin MH, Liaw YP, Guo HR, et al
Dose-response relationship between arsenic in drinking water and mortality of urinary cancers in Taiwan.
Environ Geochem Health. 2024;46:299.
Abstract

CHEN K, Chen S, Wu S, Sun G, et al
Prognostic value of GARS in bladder cancer and its role in the tumor microenvironment.
Transl Cancer Res. 2024;13:2825-2846.
Abstract

WEI S, Lei C
Noninvasive detection for bladder cancer: Quantitative interferometric imaging flow cytometry.
Cytometry A. 2024 Jul 10. doi: 10.1002/cyto.a.24887.
Abstract

ISHIDA N, Nagata K, Fukuda J, Oguma Y, et al
Stereotactic body radiation therapy for multiple lung cancers in a patient with six primary cancers: a case report.
J Med Case Rep. 2024;18:316.
Abstract

CHEN TF, Chen HY, Jiang WL, Li SN, et al
A rare case of rapid progression from cystitis to bladder cancer.
Asian J Surg. 2024 Jul 9:S1015-9584(24)01403.
Abstract

SANO T, Yoshida T, Nakamoto T, Ohe C, et al
Diagnostic performance of photodynamic diagnosis with oral 5-aminolevulinic acid for upper tract- and bladder urothelial carcinoma: a single-centre, retrospective analysis.
World J Urol. 2024;42:389.
Abstract

SONG Y, Xu T
Gender difference of bladder cancer: insights from hormone, anatomy and tumor microenvironment.
World J Urol. 2024;42:401.
Abstract

LU B, Ding M, Xu HB, Yan CY, et al
Status quo and factors of depression and anxiety in patients with non-muscle invasive bladder cancer after plasma electrocision.
World J Psychiatry. 2024;14:822-828.
Abstract

XU Z, Zhao Y, Zhang Y, Liu X, et al
Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment.
Front Pharmacol. 2024;15:1387647.
Abstract

ZHANG X, Pei Z, Ren J, Shi J, et al
PA-MSHA improves prognosis of patients undergoing radical cystectomy: a retrospective cohort study using inverse probability of treatment weighting.
Front Immunol. 2024;15:1403302.
Abstract

XIANG L, Xie QQ, Xu SS, Ruan WJ, et al
Association between tobacco exposure and bladder cancer recurrence: A systematic review and meta-analysis.
World J Methodol. 2024;14:91889.
Abstract

LINDSKROG SV, Dyrskjot L
Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer.
Transl Androl Urol. 2024;13:1056-1060.
Abstract

AKINSOLA OA, Talwar R, Baskin A, Luckenbaugh AN, et al
Use of atezolizumab in bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer.
Transl Androl Urol. 2024;13:1061-1063.
Abstract

ABAZARI O, Dayati P, Shahidi M, ZavarReza J, et al
Exploring a Desirable Quadr-mRNAs Panel for Non-invasive and Ultrasensitive Bladder Cancer Diagnosis: In-silico and Clinical Studies.
Curr Med Chem. 2024 Jul 8. doi: 10.2174/0109298673302140240627053904.
Abstract

CHENG H, Wang R, Lu L, Gong Y, et al
Bladder Cancer Patients with Elevated SPRR1B Expression Experiencing a Poor Prognosis.
Arch Esp Urol. 2024;77:554-569.
Abstract

YORULMAZ EM, Kose O, Ozcan S, Gorgel SN, et al
Factors Influencing Bladder Perforation during Transurethral Resection of Bladder Cancer: A Comprehensive Analysis.
Arch Esp Urol. 2024;77:471-478.
Abstract

PEREZ GONZALEZ S, Heredia-Soto V, Giron de Francisco M, Perez-Fernandez E, et al
Clinical, Pathological Characteristics and Progression of Urothelial Bladder Cancer in Young Adult Patients. Our Experience and Literature Review.
Arch Esp Urol. 2024;77:463-470.
Abstract

GAO Y, Zhang X, Wang X, Sun R, et al
The clinical value of rapidly detecting urinary exosomal lncRNA RMRP in bladder cancer with an RT-RAA-CRISPR/Cas12a method.
Clin Chim Acta. 2024 Jul 7:119855. doi: 10.1016/j.cca.2024.119855.
Abstract

CHOU WH, Wang A, Bassale S, Latour E, et al
Utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in elderly patients: a retrospective cohort study.
Med Oncol. 2024;41:197.
Abstract

JIANG Y, Yu Z, Zheng H, Zhou X, et al
An immune biomarker associated with EMT serves as a predictor for prognosis and drug response in bladder cancer.
Aging (Albany NY). 2024;16.
Abstract

WANG MS, Zhang SH, Wang JW, Jia BL, et al
[Functional analysis of laparoscopic intracorporeal Xing's neobladder in long-term follow-up].
Zhonghua Yi Xue Za Zhi. 2024;104:2449-2451.
Abstract

CHENG K, Wan S, Yang JW, Chen SY, et al
Applications of Biosensors in Bladder Cancer.
Crit Rev Anal Chem. 2024 Jul 8:1-20. doi: 10.1080/10408347.2024.2373923.
Abstract

HAN D, Xiong B, Zhang X, Chen C, et al
Knockdown of AMIGO2 suppresses proliferation and migration through regulating PPAR-gamma in bladder cancer.
Hereditas. 2024;161:21.
Abstract

XIONG S, Fu Z, Deng Z, Li S, et al
Machine learning-based CT radiomics enhances bladder cancer staging predictions: A comparative study of clinical, radiomics, and combined models.
Med Phys. 2024 Jul 8. doi: 10.1002/mp.17288.
Abstract

HUANG G, Liu J, Yu A, Luo C, et al
Nuclear translocation of ISG15 regulated by PPP2R2B inhibits cisplatin resistance of bladder cancer.
Cell Mol Life Sci. 2024;81:292.
Abstract

STORMOEN DR, Rohrberg KS, Mouw KW, Orum K, et al
Similar genetic profile in early and late stage urothelial tract cancer.
J Cancer Res Clin Oncol. 2024;150:339.
Abstract

LIU J, Zhijin Z, Zhang W, Niraj M, et al
Urinary exosomes: Potential diagnostic markers and application in bladder cancer.
Heliyon. 2024;10:e32621.
Abstract

ABOU CHAKRA M, Duquesne I, Peyromaure M, Mott SL, et al
A Multinational, Multi-Institutional Study Assessing the Impact of Diabetes Mellitus on the Prognosis of Patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin.
Nutr Cancer. 2024 Jul 7:1-9. doi: 10.1080/01635581.2024.2374046.
Abstract

WU C, Wei X, Huang Z, Zheng Z, et al
Urinary microbiome dysbiosis is associated with an inflammatory environment and perturbed fatty acids metabolism in the pathogenesis of bladder cancer.
J Transl Med. 2024;22:628.
Abstract

SAINT F, Pasquier D, Villers A, Massa J, et al
Incidence, initial management and survival of high-risk non-muscle invasive bladder cancer in Northern France.
Fr J Urol. 2024 Jul 3:102675. doi: 10.1016/j.fjurol.2024.102675.
Abstract

GUPTA S, Moon HH, Sridhar SS
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Target Oncol. 2024;19:483-494.
Abstract

ZHUANG S, Jin X, Cen L, Shao Y, et al
Encapsulation of hydroxycamptothecin within porous and hollow poly(L-lactide-co-epsilon-caprolactone) microspheres as a floating delivery system for intravesical instillation.
Biomater Sci. 2024;12:3659-3671.
Abstract

SZARVAS T, Reis H
Beyond driver mutations: exploring the landscape of mutational signatures in adenocarcinomas of the bladder(dagger).
J Pathol. 2024;263.
Abstract

WONG CH, Ko IC, Kang SH, Kitamura K, et al
ASO Visual Abstract: Long-Term Outcomes of Orthotopic Neobladder versus Ileal Conduit Urinary Diversion in Robot-Assisted Radical Cystectomy (RARC): Multicenter Results from the Asian RARC Consortium.
Ann Surg Oncol. 2024;31:5119-5120.
Abstract

UCHIMOTO T, Matsuda T, Komura K, Fukuokaya W, et al
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Target Oncol. 2024;19:635-644.
Abstract

GARIAZZO C, Massari S, Consonni D, Marchetti MR, et al
Cancer-Specific Mortality Odds Ratios in the Food, Accommodation, and Beverage Activities in Italy.
J Occup Environ Med. 2024;66:572-579.
Abstract

YOKOYAMA M, Chen W, Waseda Y, Fujiwara M, et al
Comparisons of in-hospital fee and surgical outcomes between robot-assisted, laparoscopic, and open radical cystectomy: a Japanese nationwide study.
Jpn J Clin Oncol. 2024;54:822-826.
Abstract

YU R, Cai L, Cao Q, Liu P, et al
Development and Validation of an MRI-Based Nomogram for Preoperative Detection of Muscle Invasion in VI-RADS 3.
J Magn Reson Imaging. 2023 Oct 30. doi: 10.1002/jmri.29103.
Abstract

HONDA Y, Sekine T, Kimata R, Motoda N, et al
Early and Post-Treatment Imaging Findings in Perineural Spread: A Pathway to Diffuse Muscle Metastasis in Recurrent Bladder Carcinoma.
J Nippon Med Sch. 2024;91:333-338.
Abstract

SALARI A, Ghahari M, Bitaraf M, Fard ES, et al
Prognostic Value of NLR, PLR, SII, and dNLR in Urothelial Bladder Cancer Following Radical Cystectomy.
Clin Genitourin Cancer. 2024;22:102144.
Abstract

SKELTON WP 4TH, Masur J, Thomas J, Fallah P, et al
Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer.
Clin Genitourin Cancer. 2024;22:102143.
Abstract

BOGALE DE
The roles of FGFR3 and c-MYC in urothelial bladder cancer.
Discov Oncol. 2024;15:295.
Abstract

GUEL DNB, Laverick N, MacLaren L, MacLeod N, et al
Adaptive radiotherapy for muscle invasive bladder cancer: a retrospective audit of two bladder filling protocols.
Radiat Oncol. 2024;19:92.
Abstract

ZHANG S, Han Z, Qi H, Zhang Z, et al
Machine learning assisted microfluidics dual fluorescence flow cytometry for detecting bladder tumor cells based on morphological characteristic parameters.
Anal Chim Acta. 2024;1317:342899.
Abstract

LAI F, He L, Lia T, Yang Z, et al
Identification and validation of basement membrane-related genes predicting prognosis and immune infiltration associated with bladder cancer.
Medicine (Baltimore). 2024;103:e38858.
Abstract

HUANG F, Zhou L, Sun J, Ma X, et al
Prognostic analysis of anoikis-related genes in bladder cancer: An observational study.
Medicine (Baltimore). 2024;103:e38999.
Abstract

TKACZ J, Ireland A, Agatep B, Ellis L, et al
An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study.
J Med Econ. 2024 Jul 19:1-14. doi: 10.1080/13696998.2024.2382639.
Abstract

LANGE F, Geppert CI, Bahlinger V, Bertz S, et al
Digital volumetric assessment of CIS and tumor mass compliments conventional histopathological assessment in muscle-invasive urothelial bladder cancer.
Virchows Arch. 2024 Jul 19. doi: 10.1007/s00428-024-03875.
Abstract

ZHAO Z, Jiang Y, Xu K, Xu X, et al
Response to article by Ruochen Bao et al., "Bibliometric analysis of immunotherapy for bladder cancer: A correspondence".
Hum Vaccin Immunother. 2024;20:2351617.
Abstract

NGUYEN NP, Karlsson UL, Page BR, Chirila ME, et al
Immunotherapy and radiotherapy for older patients with invasive bladder cancer unfit for surgery or chemotherapy: practical proposal by the international geriatric radiotherapy group.
Front Oncol. 2024;14:1371752.
Abstract

TILLU N, Zaytoun O, Kolanukuduru K, Venkatesh A, et al
Analysis of early perioperative outcomes of robot-assisted radical cystectomy and colonic diversion.
J Robot Surg. 2024;18:286.
Abstract

HAGE CHEHADE C, Jo Y, Gebrael G, Tripathi N, et al
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers.
JAMA Netw Open. 2024;7:e2423186.
Abstract

SAYYID RK, Bernardino R, Chavarriaga J, Kumar R, et al
Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis.
World J Urol. 2024;42:418.
Abstract

HU L, Wu N, Wang J, Yao M, et al
Network Pharmacology Combined with Bioinformatics Analysis to Texplore the Potential Mechanism of Phellodendri Chinensis Cortex Against Bladder Cancer.
Cell Biochem Biophys. 2024 Jul 18. doi: 10.1007/s12013-024-01414.
Abstract

SAH A, Triveni GS, Chandrashekhara SH
Case series of urachal adenocarcinoma: Imaging features.
J Cancer Res Ther. 2024;20:1057-1060.
Abstract

WANG W, Shen J, Song D, Fu K, et al
Identification of macrophage-related genes in bladder cancer patients using single-cell sequencing and construction of a prognostic model.
Am J Clin Exp Immunol. 2024;13:88-104.
Abstract

KLEMPFNER H, Anderson P
Comparison of staging MRI to re-resection for localised bladder cancer: Narrative review.
BJUI Compass. 2024;5:651-661.
Abstract

SARWAR KA, Hussain S, Mahmood A, Alvi ZA, et al
Comparative efficacy of palliative radiotherapy dose schedules in advanced bladder cancer-associated gross hematuria.
Ecancermedicalscience. 2024;18:1718.
Abstract

ANDERSSON E, Bradvik G, Nilsson FOL, Arpegard J, et al
Prevalence of diabetes and hospitalization due to poor glycemic control in people with bladder cancer or renal cell carcinoma in Sweden.
BMC Urol. 2024;24:148.
Abstract

ZHANG P, Wang P, Wang Y
ASF1B is an essential prognostic indicator linked to the growth and resistance characteristics of bladder cancer.
Tissue Cell. 2024;89:102477.
Abstract

KAYYAL-TARABEIA I, Zick A, Kloog I, Levy I, et al
Beyond lung cancer: air pollution and bladder, breast and prostate cancer incidence.
Int J Epidemiol. 2024;53:dyae093.
Abstract

CHEN C, Wang C, Huang H, Li H, et al
The role of adjuvant chemotherapy after radical surgery in patients with lymph node-positive bladder cancer or locally advanced (pT3, pT4a) bladder cancer: A meta-analysis and systematic review.
Int J Surg. 2024 Jul 17. doi: 10.1097/JS9.0000000000001954.
Abstract

ICKRATH K, Fleissner J, Egenolf T, Schmieder A, et al
Acrodermatitis continua of Hallopeau upon PD-L1 therapy for metastatic urothelial carcinoma.
Eur J Dermatol. 2024;34:296-298.
Abstract

MIZUTANI Y, Noda E, Kondo M, Hayashi A, et al
Pityriasis Lichenoides et Varioliformis Acuta Developing during Pembrolizumab Treatment for Bladder Cancer.
Case Rep Dermatol. 2024;16:116-122.
Abstract

FU D, Shi X, Yi X, Wu D, et al
m6A reader IGF2BP2 promotes M2 macrophage polarization and malignant biological behavior of bladder cancer by stabilizing NRP1 mRNA expression.
BMC Urol. 2024;24:147.
Abstract

SFAKIANOS JP, Basu A, Laliotis G, Cumarasamy S, et al
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.
Eur Urol Oncol. 2024 Jul 15:S2588-9311(24)00174.
Abstract

ZENG S, Xing S, Zhang Y, Wang H, et al
Nano-Bacillus Calmette-Guerin immunotherapies for improved bladder cancer treatment.
J Zhejiang Univ Sci B. 2024;25:557-567.
Abstract

MUKHLIF RT, Abol-Enein H, Elsaid AM, Abdelkhalek M, et al
Association of interleukin6 rs1800796 gene polymorphism and serum level with bladder cancer in Egyptian population.
Mol Biol Rep. 2024;51:815.
Abstract

DE JONG FC, Zuiverloon TCM, Boormans JL
Reply to Chao Song's Letter to the Editor re: Florus C. de Jong, Iris G. Ifle, Angelique C. van der Made, et al. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy. Eur Urol Open Sci 2024;62:131-9.
Eur Urol Open Sci. 2024;66:9.
Abstract

SONG C, Bao J, Wan Y, Tang J, et al
Re: Florus C. de Jong, Iris G. Ifle, Angelique C. van der Made, et al. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy. Eur Urol Open Sci 2024;62:131-9.
Eur Urol Open Sci. 2024;66:10-11.
Abstract

GAO M, Guo H, Xu H, Jin X, et al
Analysis of cell death-related genes to evaluate the prognostic and immunotherapeutic value in bladder cancer.
Heliyon. 2024;10:e33200.
Abstract

AKMAN B, Bursali A, Gurses M, Suner A, et al
Nucleocytoplasmic beta-catenin expression contributes to neuroendocrine differentiation in muscle invasive bladder cancer.
Cancer Sci. 2024 Jul 14. doi: 10.1111/cas.16275.
Abstract

CHENG C, Zhang Z, Wang J, Wang C, et al
CircPGM5 regulates Foxo3a phosphorylation via MiR-21-5p/MAPK10 axis to inhibit bladder cancer progression.
Cell Signal. 2024 Jul 12:111297. doi: 10.1016/j.cellsig.2024.111297.
Abstract

TUO Z, Zhang Y, Li D, Wang Y, et al
Relationship Between Clonal Evolution and Drug Resistance in Bladder Cancer: A Genomic Research Review.
Pharmacol Res. 2024 Jul 12:107302. doi: 10.1016/j.phrs.2024.107302.
Abstract

LIU TJ, Yang WC, Huang SM, Yang WL, et al
Evaluating artificial intelligence-enhanced digital urine cytology for bladder cancer diagnosis.
Cancer Cytopathol. 2024 Jul 14. doi: 10.1002/cncy.22884.
Abstract

SAM OZDEMIR M, Azamat S, Ozdemir H, Keskin ET, et al
Preoperative Prediction of Muscle Invasiveness in Bladder Cancer: The Role of 3D Volumetric Radiomics Using Diffusion-Weighted MRI, the VI-RADS Score, or a Combination of Both.
Ann Surg Oncol. 2024 Jul 13. doi: 10.1245/s10434-024-15760.
Abstract

LI W, Liu J, Yu T, Lu F, et al
ZDHHC9-mediated Bip/GRP78 S-palmitoylation inhibits unfolded protein response and promotes bladder cancer progression.
Cancer Lett. 2024;598:217118.
Abstract

ANGELIS M, Siech C, Di Bello F, Penaranda NR, et al
Incidence, Characteristics and Survival Rates of Bladder Cancer after Rectosigmoid Cancer Radiation.
Cancers (Basel). 2024;16:2404.
Abstract

SRINIVASALU VK, Robbrecht D
Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions.
Cancers (Basel). 2024;16:2398.
Abstract

DENG Y, Tsai CW, Chang WS, Xu Y, et al
The Significant Associations between Epigenetic Clocks and Bladder Cancer Risks.
Cancers (Basel). 2024;16:2357.
Abstract

GUMUS KZ, Nicolas J, Gopireddy DR, Dolz J, et al
Deep Learning Algorithms for Bladder Cancer Segmentation on Multi-Parametric MRI.
Cancers (Basel). 2024;16:2348.
Abstract

KURABAYASHI A, Fukuhara H, Furihata K, Iwashita W, et al
Photodynamic Diagnosis and Therapy in Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:2299.
Abstract

KNEZOVIC D, Milic Roje B, Vilovic K, Frankovic L, et al
MyD88 Signaling Accompanied by Microbiota Changes Supports Urinary Bladder Carcinogenesis.
Int J Mol Sci. 2024;25:7176.
Abstract

CHIUJDEA S, Ferro M, Vartolomei MD, Lucarelli G, et al
Epirubicin and Non-Muscle Invasive Bladder Cancer Treatment: A Systematic Review.
J Clin Med. 2024;13:3789.
Abstract

JIANG Z, Liu Z
Target recycle initiated entropy driven assembly strategy for sensitive, enzyme-free, and portable miRNA detection.
Anal Biochem. 2024;693:115593.
Abstract

NALLY E, Young M, Wells C, Fairhead R, et al
Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
Eur Urol Focus. 2024;10:219-221.
Abstract

LI Q, Sun Y, Zhai K, Geng B, et al
Microbiota-induced inflammatory responses in bladder tumors promote epithelial-mesenchymal transition and enhanced immune infiltration.
Physiol Genomics. 2024;56:544-554.
Abstract

BROWN JR, Koshkin VS
Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
Eur Urol Focus. 2024;10:231-233.
Abstract

KLUMPER N, Eckstein M
Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.
Eur Urol Focus. 2024;10:224-226.
Abstract

CHO SW, Lim SH, Kwon GY, Kim CK, et al
Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies.
Cancer Res Treat. 2024;56:893-897.
Abstract

LEE JH, Lee CU, Chung JH, Song W, et al
Single Early Intravesical Instillation of Epirubicin for Preventing Bladder Recurrence after Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma.
Cancer Res Treat. 2024;56:877-884.
Abstract

MSAOUEL P, Sweis RF, Bupathi M, Heath E, et al
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Eur Urol Oncol. 2024;7:933-943.
Abstract

LOMBARDO R, Riolo S, De Nunzio C
Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. 2023;6:508-515.
Eur Urol Oncol. 2024;7:965-966.
Abstract

D'ANDREA D, Soria F, Hurle R, Enikeev D, et al
Reply to Riccardo Lombardo, Sara Riolo, and Cosimo De Nunzio's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-lab
Eur Urol Oncol. 2024;7:967-968.
Abstract

KOLLER CR, Greenberg JW, Natale C, Krane LS, et al
Assessing the safety of bladder-preserving therapy as an alternative to surgical intervention in elderly patients with muscle invasive bladder cancer.
Urologia. 2024 Jul 26:3915603241265828. doi: 10.1177/03915603241265828.
Abstract

QIU D, Gao L, Yu X
Knockdown of YAP1 Reduces YTHDF3 to Stabilize SMAD7 and thus Inhibit Bladder Cancer Stem Cell Stemness.
Discov Med. 2024;36:1486-1498.
Abstract

PICCARDO A, Bottoni G, Puppo C, Massollo M, et al
Role of (64)CuCl(2) PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and (18)F-FDG PET/CT.
J Nucl Med. 2024 Jul 25:jnumed.124.267474. doi: 10.2967/jnumed.124.267474.
Abstract

YANG J, Liu B, Wang Q, Yan H, et al
Carboxylated mesoporous silica nanoparticle-nucleic acid chimera conjugate-assisted delivery of siRNA and doxorubicin effectively treat drug-resistant bladder cancer.
Biomed Pharmacother. 2024;178:117185.
Abstract

ZHOU X, Xiao L, Meng F, Zuo F, et al
GAS6-AS1 drives bladder cancer progression by increasing MMP7 expression in a ceRNA- and RBP-dependent manner.
Transl Oncol. 2024;48:102065.
Abstract

RONEY M, Uddin MN, Fasihi Mohd Aluwi MF
Comprehending the pharmacological mechanism of marine phenolic acids in bladder cancer therapy against matrix metalloproteinase 9 protein by integrated network pharmacology and in-silico approaches.
Comput Biol Chem. 2024;112:108149.
Abstract

MAHMOUD O, Krafft U, HEss J, Kesch C, et al
The impact of double-J ureteral stenting before radical cystectomy on the development of upper tract urothelial carcinoma.
Minerva Urol Nephrol. 2024;76:442-451.
Abstract

PETOV V, Timofeeva E, Sukhanov R, Baniel J, et al
Prospective non-randomized comparison of transurethral laser en bloc resection vs. conventional resection of bladder tumors larger than 3 cm.
Minerva Urol Nephrol. 2024;76:436-441.
Abstract

AVUDAIAPPAN AP, Prabhakar P, Sandman MS, Rubens M, et al
Pathological response and survival outcomes after neoadjuvant chemotherapy with radical cystectomy in octogenarians for muscle-invasive bladder cancer: an observational database study.
BMC Urol. 2024;24:150.
Abstract

MEI Y, Xu J, Li W, Chen S, et al
Gambogic Acid Improves Cisplatin Resistance of Bladder Cancer Cells through the Epithelial-Mesenchymal Transition Pathway Mediated by the miR-205-5p/ZEB1 Axis.
Ann Clin Lab Sci. 2024;54:354-362.
Abstract

YE JN, Gan MP, Wu XL, Dong Z, et al
TCGA Database-Based Screening of Tumor Microenvironment Immunomodulators Related to Bladder Cancer Prognosis.
Ann Clin Lab Sci. 2024;54:299-312.
Abstract

[Not Available].
Aktuelle Urol. 2024;55:300-301.
Abstract

[Not Available].
Aktuelle Urol. 2024;55:297-298.
Abstract

KOZIKOWSKI M, Zagrodzka M, Zawadzki M, Zugaj P, et al
The role of VI-RADS scoring criteria for predicting oncological outcomes in bladder cancer.
World J Urol. 2024;42:438.
Abstract

MUILWIJK T, Baekelandt L, Akand M, Daelemans S, et al
Fibroblast Activation Protein-alpha and the Immune Landscape: Unraveling T1 Non-muscle-invasive Bladder Cancer Progression.
Eur Urol Open Sci. 2024;66:67-74.
Abstract

YOSHIDA T, Nakamoto T, Atsumi N, Ohe C, et al
Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma.
J Immunother Cancer. 2024;12:e009358.
Abstract

ZHANG X, Wang Y, Xu X, Hu M, et al
Prospective Comparison of 2D and 3D T2-Weighted Imaging in Multiparametric MRI for Assessing Muscle Invasion Accuracy Using VI-RADS in Bladder Cancer.
Acad Radiol. 2024 Jul 22:S1076-6332(24)00437-9. doi: 10.1016/j.acra.2024.
Abstract

GIUDICE GC, Sonpavde GP
Vaccine approaches to treat urothelial cancer.
Hum Vaccin Immunother. 2024;20:2379086.
Abstract

NEWMAN MT, Bikhchandani M
A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma.
Cancer Rep (Hoboken). 2024;7:e2140.
Abstract

OU J, Ni K, Ma L, Wang G, et al
[Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer].
Beijing Da Xue Xue Bao Yi Xue Ban. 2024;56:582-588.
Abstract

OKHOLM TLH, Kamstrup AB, Nielsen MM, Hollensen AK, et al
circHIPK3 nucleates IGF2BP2 and functions as a competing endogenous RNA.
Elife. 2024;13:RP91783.
Abstract

MILAS I, Kastelan Z, Petrik J, Bingulac-Popovic J, et al
ABO Blood Type and Urinary Bladder Cancer: Phenotype, Genotype, Allelic Association with a Clinical or Histological Stage and Recurrence Rate.
Glob Med Genet. 2024;11:233-240.
Abstract

LIU X, Zhu L, Li D, Chen X, et al
The upregulation of POLR3G correlates with increased malignancy of bladder urothelium.
Eur J Med Res. 2024;29:381.
Abstract

SUN Y, Li G, Zhang H, Xie M, et al
Knockdown of CPSF4 Inhibits Bladder Cancer Cell Growth by Upregulating NRF1.
Biochem Genet. 2024 Jul 22. doi: 10.1007/s10528-024-10891.
Abstract

YE J, Tang C, Wu R, Tang Y, et al
Preoperative blood-based nutritional biomarkers as significant prognostic factors after intravesical BCG therapy in patients with non-muscle-invasive bladder cancer.
World J Urol. 2024;42:428.
Abstract

YAO Q, Niu H, Yang X, Jiang H, et al
A novel laser resection approach: efficacy of rotatable bi-channel en bloc resection of bladder tumor in a pilot in-vivo study.
Lasers Med Sci. 2024;39:188.
Abstract

SONG Y, Xu T
Letter to the editor for the article "Pilot study for bladder cancer detection with volatile organic compounds using ion mobility spectrometry: a novel urine-based approach".
World J Urol. 2024;42:430.
Abstract

LV Y, Yuan Z, Chen D, Chen Z, et al
Circular RNA LMBR1 inhibits bladder cancer progression by enhancing expression of the protein ALDH1A3.
Noncoding RNA Res. 2024;9:1235-1248.
Abstract

DI C, Yu T, Ni L
Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report.
Front Immunol. 2024;15:1423123.
Abstract

ZHAO H, Zhang ZH, Guo HQ, Wei N, et al
[A real-world study of the clinical application of the Paris system for reporting urinary cytology in cancer hospital].
Zhonghua Zhong Liu Za Zhi. 2024;46:703-709.
Abstract

HOLLAND L, Bhanvadia R, Ibeziako N, Taylor J, et al
Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer.
Urol Oncol. 2024 Jul 20:S1078-1439(24)00510.
Abstract

WANG J, Tan Z, Huang Y, Li C, et al
Integrating single-cell RNA-seq to identify fibroblast-based molecular subtypes for predicting prognosis and therapeutic response in bladder cancer.
Aging (Albany NY). 2024;16.
Abstract

FAN Y, Dai T, Zhang D, Guo H, et al
PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer.
Sci Rep. 2024;14:16753.
Abstract

LIU X, Chen C, Li J, Li L, et al
Identification of tumor-specific T cell signature predicting cancer immunotherapy response in bladder cancer by multi-omics analysis and experimental verification.
Cancer Cell Int. 2024;24:255.
Abstract

SASAKI T, Higashi T, Inoue T
Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan.
Int J Clin Oncol. 2024;29:1088-1095.
Abstract

STRUSI A, Pinterpe G, Ciccarese C, Pedone RR, et al
Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer.
Expert Rev Anticancer Ther. 2024;24:661-664.
Abstract

YOSHIZAWA S, Yoshida J, Yoshihara A, Nemoto C, et al
Caution:Patient-specific preoperative preparations combined with procedure-specific 5-aminolevulinic acid may lead to critical events.
Fukushima J Med Sci. 2024;70:169-173.
Abstract

TONG T, Huang M, Yan B, Lin B, et al
Hippo signaling modulation and its biological implications in urological malignancies.
Mol Aspects Med. 2024;98:101280.
Abstract

KAWASHIMA A, Ishizuya Y, Yamamoto Y, Kato T, et al
Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.
Int J Clin Oncol. 2024;29:1096-1104.
Abstract

EL KHOURY MA, Chartier-Kastler E, Parra J, Vaessen C, et al
Continent cutaneous diversion: Unveiling the interplay of neuro-urology and oncological challenges.
Fr J Urol. 2024;34:102665.
Abstract

SIRACUSANO S, Gontero P, Mearini E, Imbimbo C, et al
Short-term effects of bowel function on global health quality of life after radical cystectomy.
Minerva Urol Nephrol. 2024;76:452-457.
Abstract

SPRUIJT LE, Mosch A, Hoffmann CFE, van Nieuwkoop C, et al
Mycobacterium bovis Infection of a Deep Brain Stimulation System Following Intravesical Bacillus Calmette-Guerin (BCG) Instillation.
J Parkinsons Dis. 2024;14:1061-1069.
Abstract

IVAN SJ, Roebuck EH, Sinks AL, Robinson MM, et al
It's complicated: The relationship of non-narcotic medications and postoperative opioid use in radical cystectomy patients.
Urol Oncol. 2024;42:332.
Abstract

BOTHIG R, Schops W, Kowald B, Golka K, et al
[Oncological relevance of neuro-urological diseases].
Aktuelle Urol. 2024;55:326-336.
Abstract

WU K, Liu X, Tang Y, Wang X, et al
Clinicopathologic characteristics and outcomes of prostate cancer incidentally discovered at the time of radical cystoprostatectomy: a population-based cohort study.
Int J Surg. 2024;110:4023-4030.
Abstract

MA YY, Zhang GJ, Liu PF, Liu Y, et al
Comprehensive Genomic Analysis of Puerarin in Inhibiting Bladder Urothelial Carcinoma Cell Proliferation and Migration.
Recent Pat Anticancer Drug Discov. 2024;19:516-529.
Abstract

DJATISOESANTO W, Azmi YA, Yatindra IBGTY
Psychological Impact of Bladder Cancer: Insights from 219 Patients and Caregivers in Indonesia Using DASS-21 (2019-2023).
Med Sci Monit. 2024;30:e945272.
Abstract

ZHUO J, Han J, Yang L, Wang Y, et al
CT and MRI features of sarcomatoid urothelial carcinoma of the bladder and its differential diagnosis with conventional urothelial carcinoma.
Cancer Imaging. 2024;24:102.
Abstract

ZHANG J, Chen J, Xu M, Zhu T, et al
Exploring prognostic DNA methylation genes in bladder cancer: a comprehensive analysis.
Discov Oncol. 2024;15:331.
Abstract

OLISLAGERS M, de Jong FC, Rutten VC, Boormans JL, et al
Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification.
Nat Rev Urol. 2024 Aug 2. doi: 10.1038/s41585-024-00914.
Abstract

KARTTUNEN J, Kalmar L, Grant A, Ying J, et al
miR-182, miR-221 and miR-222 are potential urinary extracellular vesicle biomarkers for canine urothelial carcinoma.
Sci Rep. 2024;14:17967.
Abstract

PLUMBER SA, Tate T, Al-Ahmadie H, Chen X, et al
Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer.
Nat Commun. 2024;15:6538.
Abstract

RYU KH, Lee SH, Shim JG, Park J, et al
Comparative study on the impact of remimazolam and sevoflurane on quality of recovery after transurethral resection of bladder tumor: A randomized controlled noninferiority study.
Medicine (Baltimore). 2024;103:e38962.
Abstract

WONG CH, Lim JY, Ko IC, Leung DK, et al
Monopolar versus bipolar transurethral resection of bladder Tumour: post-hoc analysis of a prospective trial.
World J Urol. 2024;42:466.
Abstract

YUAN J, Chen L, Zhou J, Zang X, et al
Global burden of bladder cancer attributable to smoking in 204 countries and territories, 1990-2019.
Heliyon. 2024;10:e34114.
Abstract

MAO R, Zhou F, Hong Y, Li Y, et al
CRH upregulates supervillin through ERK and AKT pathways to promote bladder cancer cell migration.
Cell Biol Int. 2024 Aug 1. doi: 10.1002/cbin.12227.
Abstract

HE C, Xu H, Yuan E, Ye L, et al
The accuracy and quality of image-based artificial intelligence for muscle-invasive bladder cancer prediction.
Insights Imaging. 2024;15:185.
Abstract

JAIME-CASAS S, Yip W, Jeter JM
Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma: Is It Time for Universal Screening?
JCO Precis Oncol. 2024;8:e2400324.
Abstract

UENO Y, Sofue K, Tamada T, Takeuchi M, et al
Comparison of golden-angle radial sparse parallel (GRASP) and conventional cartesian sampling in 3D dynamic contrast-enhanced mri for bladder cancer: a preliminary study.
Jpn J Radiol. 2024 Aug 1. doi: 10.1007/s11604-024-01637.
Abstract

MUKHOPADHYAY D, Booth S, Sbitli T, Shiley KT, et al
Invasive Mycobacterium bovis Infection Outside the Genitourinary Tract Following Bacille Calmette-Guerin Therapy for Non-muscle Invasive Bladder Cancer.
Cureus. 2024;16:e63613.
Abstract

YOUSF K, Daoud N, Habib A, Salloum R, et al
Bladder cancer with bone marrow metastases and thrombotic microangiopathy: a case report.
Oxf Med Case Reports. 2024;2024:omae081.
Abstract

LIANG J, Li Y, Wan P, Zhang W, et al
CYP19A1 polymorphisms and bladder cancer risk in the Chinese Han population.
Expert Rev Mol Diagn. 2024 Jul 31. doi: 10.1080/14737159.2024.2387652.
Abstract

LI S, Wang J, Zhang Z, Wu Y, et al
Development and validation of competing risk nomograms for predicting cancer?specific mortality in non-metastatic patients with non?muscle invasive urothelial bladder cancer.
Sci Rep. 2024;14:17641.
Abstract

KONG C, Sun J, Hu X, Li G, et al
A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer.
Sci Rep. 2024;14:17704.
Abstract

HUANG L, Wang J, Wang X, Zheng S, et al
Sulforaphane suppresses bladder cancer metastasis via blocking actin nucleation-mediated pseudopodia formation.
Cancer Lett. 2024 Jul 29:217145. doi: 10.1016/j.canlet.2024.217145.
Abstract

SARIKAYA EA, Korhan P, Incir C, Yildiz AH, et al
Evaluation of androgen receptor and androgen receptor splice-variant 7 in bladder cancer; a novel approach into an ancient topic.
World J Urol. 2024;42:459.
Abstract

Long Noncoding RNA UCA1 Targets miR-582-5p and Contributes to the Progression and Drug Resistance of Bladder Cancer Cells Through ATG7-Mediated Autophagy Inhibition [Retraction].
Onco Targets Ther. 2024;17:603-604.
Abstract

LIN G, Wang X, Ma J, Sun W, et al
Fast-track surgery with three-port versus conventional perioperative management of bladder cancer associated laparoscopic radical cystectomy and Ileal conduit diversion: Chinese experience.
World J Surg Oncol. 2024;22:204.
Abstract

WEI H, Luo X, Lan R, Xiong Y, et al
Integrated analysis of patients with bladder cancer from prospective transcription factor activity: Implications for personalized treatment approaches.
Methods. 2024 Jul 28:S1046-2023(24)00168-3. doi: 10.1016/j.ymeth.2024.
Abstract

EROGLU T, Koseoglu H, Yucetas U, Ari E, et al
Quantitative CT Morphometrics: A Novel Approach for Predicting the Bladder Cancer Grade.
Cureus. 2024;16:e63427.
Abstract

ZHENG F, Wang Z, Li S, Xiong S, et al
Development of a propionate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis in bladder cancer.
Eur J Med Res. 2024;29:393.
Abstract

STAMATAKOS PV, Fragkoulis C, Zoidakis I, Ntoumas K, et al
A review of urinary bladder microbiome in patients with bladder cancer and its implications in bladder pathogenesis.
World J Urol. 2024;42:457.
Abstract

PENG R, Ma X, Jiang Z, Duan Y, et al
Integrative analysis of Anoikis-related genes reveals that FASN is a novel prognostic biomarker and promotes the malignancy of bladder cancer via Wnt/beta-catenin pathway.
Heliyon. 2024;10:e34029.
Abstract

GIUDICI N, Seiler R
Histologic subtypes of non-muscle invasive bladder cancer.
World J Clin Oncol. 2024;15:835-839.
Abstract

XU R, Xu C, Li Z, Zheng T, et al
Boundary guidance network for medical image segmentation.
Sci Rep. 2024;14:17345.
Abstract

DAYATI P, Shakhssalim N, Allameh A
Over-expression of KRT17 and MDK genes at mRNA levels in urine-exfoliated cells is associated with early non-invasive diagnosis of non-muscle-invasive bladder cancer.
Clin Biochem. 2024;131-132:110808.
Abstract

WEBSTER A, Francis M, Gribble H, Griffin C, et al
Impact of on-trial IGRT quality assurance in an international adaptive radiotherapy trial for participants with bladder cancer.
Radiother Oncol. 2024 Jul 26:110460. doi: 10.1016/j.radonc.2024.110460.
Abstract

WEI F, Li T, Zhang Y, Ding J, et al
A propensity-score-matched comparison of standard and extended pelvic lymph node dissection in robot-assisted laparoscopic radical cystectomy.
J Robot Surg. 2024;18:295.
Abstract

PENG W, Zhang H, Yin M, Kong D, et al
Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth.
Oncogenesis. 2024;13:29.
Abstract

YANG M, Wang B, Hou W, Zeng H, et al
NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer.
J Immunother Cancer. 2024;12:e009281.
Abstract

DE RUITER BM, Freund JE, Savci-Heijnink CD, van Hattum JW, et al
Grading urothelial carcinoma with probe-based confocal laser endomicroscopy during flexible cystoscopy.
World J Urol. 2024;42:450.
Abstract

KIM C, Oh S, Im H, Gim J, et al
Unveiling Bladder Cancer Prognostic Insights by Integrating Patient-Matched Sample and CpG Methylation Analysis.
Medicina (Kaunas). 2024;60:1175.
Abstract

DI GIANFRANCESCO L, Montagner IM, Tormen D, Crestani A, et al
The Feasibility and Diagnostic Adequacy of PD-L1 Expression Analysis Using the Cytoinclusion Technique in Bladder Cancer: A Prospective Single-Center Study.
J Clin Med. 2024;13:4072.
Abstract

SANTARELLI V, Rosati D, Canale V, Salciccia S, et al
The Current Role of Contrast-Enhanced Ultrasound (CEUS) in the Diagnosis and Staging of Bladder Cancer: A Review of the Available Literature.
Life (Basel). 2024;14:857.
Abstract

BAKULA M, Hudolin T, Knezevic N, Zimak Z, et al
Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naive Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer.
Life (Basel). 2024;14:789.
Abstract

ALOUINI S
Risk Factors Associated with Urothelial Bladder Cancer.
Int J Environ Res Public Health. 2024;21:954.
Abstract

JIAO P, Zheng Q, Yang R, Ni X, et al
Prediction of HER2 Status Based on Deep Learning in H&E-Stained Histopathology Images of Bladder Cancer.
Biomedicines. 2024;12:1583.
Abstract

SLUSARCZYK A, Wolanski R, Milow J, Piekarczyk H, et al
Can We Go beyond Pathology? The Prognostic Role of Risk Scoring Tools for Cancer-Specific Survival of Patients with Bladder Cancer Undergoing Radical Cystectomy.
Biomedicines. 2024;12:1541.
Abstract

PURPUROWICZ P, Kaminski TW, Kordan W, Korzekwa AJ, et al
The Role of Semaphorin 6D (Sema6D) in Non-Muscle-Invasive Bladder Cancer-A Preliminary Study on Human Plasma and Urine.
Biomedicines. 2024;12:1426.
Abstract

GUO P, Qi A, Shang W, Cai Z, et al
Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer.
Eur J Nucl Med Mol Imaging. 2024 Jul 26. doi: 10.1007/s00259-024-06848.
Abstract

SCILIPOTI P, Longoni M, de Angelis M, Re C, et al
Mitomycin C vs. Bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center.
Urol Oncol. 2024 Jul 25:S1078-1439(24)00538.
Abstract

BOUTALEB I, Mjaess G, Roumeguere T
Perioperative chemotherapy and immunotherapy to optimize cystectomy outcomes in the curative intent of non-metastatic muscle-invasive bladder cancer: A systematic review and meta-analysis.
Fr J Urol. 2024;34:102704.
Abstract

OZSOY C, Demir Y, Yilmaz K, Olcucu MT, et al
Prospective evaluation of surgical margins in non-muscle invasive bladder cancer following primary transurethral resection.
Fr J Urol. 2024;34:102705.
Abstract

LI Y, Zheng M, Na L, Wang M, et al
Association between bladder cancer treatment and female sexual function.
Sex Med Rev. 2024 Jul 26:qeae051. doi: 10.1093.
Abstract

OSWALD D, Herrmann TRW, Netsch C, Becker B, et al
[Urinary diversion in old patients (80+ years)].
Urologie. 2024;63:795-803.
Abstract

FU Z, Deng M, Zhou Q, Li S, et al
Arsenic activated GLUT1-mTORC1/HIF-1alpha-PKM2 positive feedback networks promote proliferation and migration of bladder epithelial cells.
Sci Total Environ. 2024;947:174538.
Abstract

KEAM SJ
Nogapendekin alfa Inbakicept: First Approval.
Drugs. 2024 Jul 5. doi: 10.1007/s40265-024-02060.
Abstract

PEDERSEN JE, Petersen KU, Andersen MG, Saber AT, et al
Cancer incidence in a cohort of Danish firefighters: An extended long-term follow-up 1968-2021.
Am J Ind Med. 2024;67:857-864.
Abstract

CHEN SJ, Luo H, Han JC, Huang JH, et al
Multi-modality imaging of the urinary bladder paraganglioma: A rare case report.
Asian J Surg. 2024;47:3791-3793.
Abstract

JIA K, Luo B, Zhong S, Di W, et al
Reconsideration of the surgical treatment plan for a patient with pelvic lipomatosis and urothelial carcinoma of the urinary bladder.
Asian J Surg. 2024;47:3695-3696.
Abstract

OGREDEN E, Oguz U, Demirelli E, Tok DS, et al
The role of multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis mimicking prostate cancer.
Abdom Radiol (NY). 2024;49:2305-2310.
Abstract

HUANG Y, Xu C, Li X, Li X, et al
Urothelial carcinoma recurrence in the ileal conduit and unilateral upper urinary tract: A case report.
Asian J Surg. 2024;47:3659-3660.
Abstract

HO L, Elsheikh TM
Atypical squamous cells in urine cytology are associated with a significant risk of high-grade malignancy.
Cancer Cytopathol. 2024;132:499-509.
Abstract

ZHANG M, Yang Y, He J
Ultrasonic diagnosis of inflammatory myofibroblastic tumor of the urinary bladder: A case report and review of the literature.
Asian J Surg. 2024;47:3569-3570.
Abstract

LI JL, Xu Y, Xiang YS, Wu P, et al
The Value of Amide Proton Transfer MRI in the Diagnosis of Malignant and Benign Urinary Bladder Lesions: Comparison With Diffusion-Weighted Imaging.
J Magn Reson Imaging. 2024 Jan 4. doi: 10.1002/jmri.29199.
Abstract

LI Y, Xia C, Yang B, Yang D, et al
Signet-ring cell carcinoma of the bladder.
Asian J Surg. 2024;47:3507-3508.
Abstract

WU S, Wang X, Zuo Y, Wang K, et al
Clinical evolution of bladder carcinosarcoma: A case report and literature review.
Medicine (Baltimore). 2024;103:e39225.
Abstract

LI L, Liu K, Ma X, Wu Y, et al
Primary exophytic urothelial carcinoma of the bladder: A case report.
Medicine (Baltimore). 2024;103:e39187.
Abstract

MENDOZA-VALDERREY A, Choe J, Kessler DM, Jimenez G, et al
Impact of intra-tumoral immunity on predicting response and survival after neoadjuvant cisplatin-based chemotherapy in patients with muscle invasive bladder cancer.
Cancer Med. 2024;13:e70088.
Abstract

GOLSHANI M, Taylor JA 3rd, Woolbright BL
Understanding the microbiome as a mediator of bladder cancer progression and therapeutic response.
Urol Oncol. 2024 Aug 7:S1078-1439(24)00541-6. doi: 10.1016/j.urolonc.2024.
Abstract

LI C, Lv C, Chen J, Shang K, et al
Complex causal association between immune cell phenotypes and bladder cancer: A mendelian randomization and mediation study.
Int J Surg. 2024 Aug 8. doi: 10.1097/JS9.0000000000002009.
Abstract

LEVY S, Pericart S, Bajeot AS, Fakhfakh S, et al
Do we need a re-TUR after en bloc resection of T1 stage bladder cancer?
World J Urol. 2024;42:475.
Abstract

EGEN L, Keller K, Menold HS, Quan A, et al
Tranexamic acid reduces perioperative blood transfusions following open radical cystectomy - a propensity-score matched analysis.
World J Urol. 2024;42:477.
Abstract

MARTINEZ-LOPEZ MF, de Almeida CR, Fontes M, Mendes RV, et al
Macrophages directly kill bladder cancer cells through TNF signaling as an early response to BCG therapy.
Dis Model Mech. 2024;17:dmm050693.
Abstract

ZOU F, Zhang G, Mei G, Zhang H, et al
CTEN-induced TGF-beta1 expression facilitates EMT and enhances paclitaxel resistance in bladder cancer cells.
Am J Transl Res. 2024;16:3248-3258.
Abstract

MIKOLASKOVA I, Zvarik M, Hesko P, Kopcova M, et al
Increased stress burden and electrodermal reactivity in bladder cancer patients in comparison to healthy controls.
Heliyon. 2024;10:e34453.
Abstract

WU J, Huang M, Dong W, Chen Y, et al
SUMO E3 ligase MUL1 inhibits lymph node metastasis of bladder cancer by mediating mitochondrial HSPA9 translocation.
Int J Biol Sci. 2024;20:3986-4006.
Abstract

WIJETUNGA NA, Gessner KH, Kanchi K, Moore JA, et al
Poor prognosis among radiation associated bladder cancer is defined by clinicogenomic features.
Cancer Res Commun. 2024 Aug 8. doi: 10.1158/2767-9764.CRC-24-0352.
Abstract

WANG R, Li Z, Shen J
Predicting prognosis and drug sensitivity in bladder cancer: an insight into Pan-programmed cell death patterns regulated by M6A modifications.
Sci Rep. 2024;14:18321.
Abstract

WEI H, Li Z, Qian K, Du W, et al
Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: a comprehensive analysis using Mendelian randomization, animal models, and transcriptomics.
Pharmacogenomics J. 2024;24:24.
Abstract

DAI C, Li Q, Wang L, Zhang J, et al
Long Noncoding LINC00115 Facilitates Cell Growth and Inhibits Apoptosis by Regulating the MiR-4701-5p/P4HB Axis in Bladder Cancer.
Tohoku J Exp Med. 2024 Aug 8. doi: 10.1620/tjem.2024.
Abstract

AHN H
Current Status of Magnetic Resonance Imaging Use in Bladder Cancer.
Invest Radiol. 2024 Aug 8. doi: 10.1097/RLI.0000000000001099.
Abstract

VOLLMER P, Amend B, Harland N, Stenzl A, et al
Patient-derived bladder cancer organoids show stable transcript expression along cultivation.
World J Urol. 2024;42:468.
Abstract

ZHANG H, Li A, Wang W, Xu S, et al
Efficacy and safety of radical cystectomy with ileal conduit for muscle-invasive bladder cancer in the elderly: a multicenter retrospective study.
Front Oncol. 2024;14:1402360.
Abstract

LI C, Ren Z, Yang G, Lei J, et al
Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy.
Bull Math Biol. 2024;86:116.
Abstract

HEMAL S, Sobhani S, Hakimi K, Rosenberg S, et al
Single-Port Robot assisted partial cystectomy for urachal adenocarcinoma.
Int Braz J Urol. 2024;50:659-660.
Abstract

JOSHI A, Ghosh A, Rai P, Tilwani S, et al
Cabazitaxel as a promising therapy for cisplatin-resistant bladder cancer: a preliminary study.
Med Oncol. 2024;41:219.
Abstract

GUO T, Yuan Z, Chen J, Wang X, et al
Establishment and identification of bladder cancer cell sheet.
Comput Struct Biotechnol J. 2024;23:2934-2937.
Abstract

HUANG X, Du G, Yang Y, Su P, et al
Advancing bladder cancer management: development of a prognostic model and personalized therapy.
Front Immunol. 2024;15:1430792.
Abstract

DUTTO D, Livoti S, Soria F, Gontero P, et al
Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer.
Expert Opin Pharmacother. 2024 Aug 5:1-14. doi: 10.1080/14656566.2024.2380469.
Abstract

YE L, Zhao M
[Solitary fibrous tumor of urinary bladder with extensive epithelial inclusions: report of a case].
Zhonghua Bing Li Xue Za Zhi. 2024;53:864-866.
Abstract

ZHAO M, Teng XD, He HY, Cheng L, et al
[Several key and difficult issues related to the grading of urothelial carcinoma of urinary bladder].
Zhonghua Bing Li Xue Za Zhi. 2024;53:773-776.
Abstract

UDUBA P, Soares L, Babalola T, Slotnick M, et al
Uranium in Drinking Water and Bladder Cancer: A Case-Control Study in Michigan.
Health Phys. 2024 Aug 5. doi: 10.1097/HP.0000000000001880.
Abstract

MAO XW, Xiao JQ, Xu G, Li ZY, et al
Retraction: CUL4B promotes bladder cancer metastasis and induces epithelial-to-mesenchymal transition by activating the Wnt/beta-catenin signaling pathway.
Oncotarget. 2024;15:542.
Abstract

LI R, Huang G, Li Y, Huang M, et al
Assessing the role of statin therapy in bladder cancer: evidence from a Mendelian Randomization study.
Front Pharmacol. 2024;15:1427318.
Abstract

CHEN C, Zhang J, Liu X, Zhuang Q, et al
Machine learning developed an intratumor heterogeneity signature for predicting clinical outcome and immunotherapy benefit in bladder cancer.
Transl Androl Urol. 2024;13:1104-1117.
Abstract

JAHREISS MC, Heemsbergen WD, Aben KKH, Incrocci L, et al
Risk factors for secondary bladder cancer following prostate cancer radiotherapy.
Transl Androl Urol. 2024;13:1288-1296.
Abstract

SHRIVASTAVA N, Chaudhary GR, Bhargava P, Jena R, et al
Re: Sharma AP, Singh PP, Chauhan R, Panda I, Devana SK, Bora GS, et al. Clinical study of steroid receptors in nonmuscle invasive bladder cancer: A domain worth revisiting. Indian J Urol 2024;40:127-32.
Indian J Urol. 2024;40:209-210.
Abstract

SHARMA AP, Singh PP, Chauhan R
Authors reply Re: Sharma AP, Singh PP, Chauhan R, Panda I, Devana SK, Bora GS, et al. Clinical study of steroid receptors in nonmuscle invasive bladder cancer: A domain worth revisiting. Indian J Urol 2024;40:127-32.
Indian J Urol. 2024;40:210-211.
Abstract

WU N, Sun Y, Xue D, He X, et al
FTO promotes the progression of bladder cancer via demethylating m(6)A modifications in PTPN6 mRNA.
Heliyon. 2024;10:e34031.
Abstract

ZHANG H, Ly A, Chou E, Wang L, et al
Role of Forkhead Box P3 in Interferon gamma-mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition.
Cancer Res Commun. 2024 Aug 5. doi: 10.1158/2767-9764.CRC-23-0493.
Abstract

SALIMIAN J, Baradaran B, Jamalkandi SA, Moridikia A, et al
Corrigendum to 'MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and down-regulation of metastatic genes. Urol Oncol 2020:38:738.e9-738.e21'.
Urol Oncol. 2024 Aug 3:S1078-1439(24)00543-X. doi: 10.1016/j.urolonc.2024.
Abstract

SIECH C, Jannello LMI, de Angelis M, Di Bello F, et al
Critical care therapy use after radical cystectomy in patients with non-metastatic bladder cancer.
Curr Probl Surg. 2024;61:101526.
Abstract

DE FALCO F, Cutarelli A, Fedele FL, Catoi C, et al
Molecular findings and virological assessment of bladder papillomavirus infection in cattle.
Vet Q. 2024;44:1-7.
Abstract

XIONG D, Xu Y, Wang H, Ye Y, et al
Amino-truncated NOV expression and its correlation with clinicopathologic features, prognosis, metastasis, and chemoresistance in bladder cancer.
Cancer Biol Ther. 2024;25:2386753.
Abstract

WINOCK A, Mourey L, Gerard S, Lusque A, et al
Management of older patients with muscle invasive bladder cancer: A retrospective observational study.
J Geriatr Oncol. 2024 Aug 2:101834. doi: 10.1016/j.jgo.2024.101834.
Abstract

LI J, Zhang L, Xie H, Ge Y, et al
[Association of CTLA-4 gene polymorphisms with the genetic susceptibility and prognosis of patients with Bladder urothelial carcinoma].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2024;41:988-993.
Abstract

BARBOUR JA, Ou T, Yang H, Fang H, et al
ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer.
Cell Genom. 2024 Jul 29:100627. doi: 10.1016/j.xgen.2024.100627.
Abstract

ZHANG B, Chen L, Zhao M, Zhang P, et al
Clinicopathological and molecular characterization of extra-appendix goblet cell adenocarcinomas.
Pathol Res Pract. 2024;260:155461.
Abstract

ZHU X, Chan E, Turski ML, Mendez CE, et al
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
Oncologist. 2024;29:e1094-e1097.
Abstract

CHIACCHIO G, Mastroianni R, Simone G
Continent or Incontinent Urinary Diversion: That is the Question.
Ann Surg Oncol. 2024;31:5497-5498.
Abstract

ARITA Y, Woo S, Kwee TC, Shigeta K, et al
Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls.
Abdom Radiol (NY). 2024;49:2797-2811.
Abstract

WONG CH, Ko IC, Kang SH, Kitamura K, et al
Long-Term Outcomes of Orthotopic Neobladder Versus Ileal Conduit Urinary Diversion in Robot-Assisted Radical Cystectomy (RARC): Multicenter Results from the Asian RARC Consortium.
Ann Surg Oncol. 2024;31:5785-5793.
Abstract

LAMBERTINI L, Di Maida F, Cadenar A, Grosso AA, et al
Step by step technique of Stentless Florence Robotic Intracorporeal Neobladder (FloRIN), does the ureteral management influence functional outcomes?
Urologia. 2024;91:563-567.
Abstract

TILALA YM, Panda S, Tripathi A, Sharma S, et al
Long term outcomes and impact on renal function following radical cystectomy.
Urologia. 2024;91:505-511.
Abstract

LI X, Wang J, Wei H, Cong J, et al
MH2AFormer: An Efficient Multiscale Hierarchical Hybrid Attention With a Transformer for Bladder Wall and Tumor Segmentation.
IEEE J Biomed Health Inform. 2024;28:4772-4784.
Abstract

PANG Y, Zhang J, Jiang J, Pamporaki C, et al
Diagnosis and management of urinary bladder paragangliomas: A Sino-American-European retrospective observational study.
Clin Endocrinol (Oxf). 2024;101:234-242.
Abstract

KAWAGUCHI M, Kato H, Koie T, Noda Y, et al
CT and MRI findings of small cell neuroendocrine carcinoma of the urinary bladder: comparison with urothelial carcinoma.
Abdom Radiol (NY). 2024;49:2672-2682.
Abstract

IKEDA A, Izumi K, Katori K, Nosato H, et al
Objective Evaluation of Gaze Location Patterns Using Eye Tracking During Cystoscopy and Artificial Intelligence-Assisted Lesion Detection.
J Endourol. 2024;38:865-870.
Abstract

WANG H, Gao L, Chen Y, Zhang L, et al
Identification of hub genes in bladder transitional cell carcinoma through ceRNA network construction integrated with gene network analysis.
J Cell Mol Med. 2024;28:e17979.
Abstract

DIMOND D, Tehrani N, Ambikkumar A, Madill J, et al
Dermatomyositis Immunosuppression in Bacillus Calmette-Guerin-Treated Urothelial Cancer.
Can J Neurol Sci. 2024;51:441-443.
Abstract

CIGLIOLA A, Basnet A, Jacob JM, Mercinelli C, et al
Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study.
JCO Precis Oncol. 2024;8:e2400200.
Abstract

SAFDER I, Valentine H, Uzzo N, Sfakianos J, et al
Identification and Validation of Prognostic Model for Tumor Microenvironment-Associated Genes in Bladder Cancer Based on Single-Cell RNA Sequencing Data Sets.
JCO Precis Oncol. 2024;8:e2300661.
Abstract

SHI Z, Mi Y, Zhang L, Zhang W, et al
Mechanistic study of NUPR1 in bladder cancer development through transcriptional regulation of CCR2.
J Cell Physiol. 2024 Aug 16:e31412. doi: 10.1002/jcp.31412.
Abstract

WANG GY, Zhu JF, Wang QC, Qin JX, et al
Prediction of non-muscle invasive bladder cancer recurrence using deep learning of pathology image.
Sci Rep. 2024;14:18931.
Abstract

EL AZZOUZI M, El Ahanidi H, Hassan I, Tetou M, et al
Comprehensive behavioural assessment of TERT in bladder cancer.
Urol Oncol. 2024 Aug 14:S1078-1439(24)00536.
Abstract

WANG J, Ren J, Tu X, Yuan H, et al
ARNTL2 facilitates bladder cancer progression through potentiating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner.
Life Sci. 2024 Aug 13:122974. doi: 10.1016/j.lfs.2024.122974.
Abstract

TSEITLINE D, Cohen Y, Adar S
Genomic patterns of somatic mutations provide new prognostic, therapeutic, and biological insights in cancer.
Cell Genom. 2024;4:100635.
Abstract

XU F, Yao X, Zhou N, Hu Z, et al
Tumor hypoxia in immune infiltration and prognosis of bladder cancer.
Transl Cancer Res. 2024;13:3273-3284.
Abstract

TANG C, Guo X, Li Y, Yi Y, et al
Cryptotanshinone Inhibits Bladder Cancer Cell Malignant Progression in a Lipopolysaccharide-Induced Inflammatory Microenvironment through NLRP3 Inhibition.
Mediators Inflamm. 2024;2024:8828367.
Abstract

KAZEEM AO, Hasken W, Sims T, Culp SH, et al
Patient Satisfaction with a Novel Tele-Cystoscopy Model: Expanding Access to Bladder Cancer Surveillance for Rural Patients.
Telemed Rep. 2024;5:229-236.
Abstract

HAUSMANN J, Grunewald CM
[Can muscle invasive bladder cancer be treated without cystectomy in the future? : New data on trimodal therapy and bladder preservation after systemic therapy alone].
Urologie. 2024 Aug 14. doi: 10.1007/s00120-024-02420.
Abstract

MASTROIANNI R, Iannuzzi A, Ragusa A, Flammia RS, et al
Long survivors after radical cystectomy versus healthy population: propensity score matched analysis of health-related quality of life.
World J Urol. 2024;42:484.
Abstract

LIEDBERG F, Gardmark T, Hagberg O, Aljabery F, et al
Treatment Related to Urinary Tract Infections Is Associated with Delayed Diagnosis of Urinary Bladder Cancer: A Nationwide Population-based Study.
Eur Urol Oncol. 2024 Aug 13:S2588-9311(24)00181.
Abstract

KOVACS A, Sukosd F, Kuthi L, Boros IM, et al
Novel method for detecting frequent TERT promoter hot spot mutations in bladder cancer samples.
Clin Exp Med. 2024;24:192.
Abstract

JIN L, Chen T, Sun H, Dai G, et al
The clinical significance and anti-tumor role of PRKG1 in bladder cancer.
Front Immunol. 2024;15:1442555.
Abstract

ABBAS NF, Aoude MR, Kourie HR, Al-Shamsi HO, et al
Uncovering the epidemiology of bladder cancer in the Arab world: A review of risk factors, molecular mechanisms, and clinical features.
Asian J Urol. 2024;11:406-422.
Abstract

WU Z, Li B, Qie Y, Wu S, et al
Targeted Inhibition of Lymphovascular Invasion Formation with CREKA Peptide-Modified Silicasomes to Boost Chemotherapy in Bladder Cancer.
Nano Lett. 2024 Aug 13. doi: 10.1021/acs.nanolett.4c02485.
Abstract

XI Y, Yang Y, Wang Z, Wang J, et al
Higher genetically predicted triglyceride level increases the bladder cancer risk independent of LDL and HDL levels.
Sci Rep. 2024;14:18652.
Abstract

MASONE MC
Field effect and forerunner genes drive bladder cancer initiation.
Nat Rev Urol. 2024 Aug 12. doi: 10.1038/s41585-024-00929.
Abstract

MA YY, Gao W, Wang H, Xu H, et al
Integrated ceRNAs regulating relationship and bioinformatics analysis to study the molecular mechanisms of the inhibition of puerarin on bladder cancer cell.
J Asian Nat Prod Res. 2024 Aug 12:1-21. doi: 10.1080/10286020.2024.2390508.
Abstract

GUIGUI A, Basile G, Zattoni F, Gallioli A, et al
Prognostic significance of residual tumor at restaging transurethral bladder resection in high-risk non-muscle-invasive bladder cancer.
World J Urol. 2024;42:480.
Abstract

TUDERTI G, Chiacchio G, Mastroianni R, Anceschi U, et al
Impact of diabetes mellitus on oncologic outcomes in patients receiving robot-assisted radical cystectomy for bladder cancer.
World J Urol. 2024;42:479.
Abstract

HAQUE TF, Ghoreifi A, Sheybaee Moghaddam F, Kaneko M, et al
Perioperative and extended outcomes of patients undergoing parastomal hernia repair following cystectomy and ileal conduit.
World J Urol. 2024;42:482.
Abstract

LI L, Jin T, Hu L, Ding J, et al
Alternative splicing regulation and its therapeutic potential in bladder cancer.
Front Oncol. 2024;14:1402350.
Abstract

VAN GENNEP EJ, Claps F, Bostrom PJ, Shariat SF, et al
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy.
Bladder Cancer. 2024;10:119-132.
Abstract

DESAI A, Bouknight L, Reed T, Mueller D, et al
Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer.
Bladder Cancer. 2024;10:145-155.
Abstract

MCGONAGLE K, Dematt EJ, Mi Z, Biswas K, et al
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It.
Bladder Cancer. 2024;10:113-117.
Abstract

JOHNSON III BA, Teply BA, Kagemann C, McGuire B, et al
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis.
Bladder Cancer. 2024;10:133-143.
Abstract

ZHANG T, Qi X
Caregiver Burden in Bladder Cancer Patients with Urinary Diversion Post-Radical Cystectomy and the Need for Comprehensive Nursing Education: A Narrative Literature.
J Multidiscip Healthc. 2024;17:3825-3834.
Abstract

LI L, Li C, Miao F, Chen W, et al
Cyclanoline Reverses Cisplatin Resistance in Bladder Cancer Cells by Inhibiting the JAK2/STAT3 Pathway.
Anticancer Agents Med Chem. 2024.
Abstract

LIANG M, Wang Y, Liu L, Deng D, et al
Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy.
J Exp Clin Cancer Res. 2024;43:223.
Abstract

KOCAK O, Kankaya S, Kalender G, Citgez S, et al
Determination of global DNA methylation level by methylation-sensitive comet assay in patients with urinary bladder cancer.
Mutagenesis. 2024 Aug 10:geae018. doi: 10.1093.
Abstract

JIANG Y, Wu J, Guan F, Liang L, et al
O-GlcNAcylation determines the function of the key O-GalNAc glycosyltransferase C1GalT1 in bladder cancer.
Acta Biochim Biophys Sin (Shanghai). 2024 Aug 9. doi: 10.3724/abbs.2024129.
Abstract

CLAPS F, Biasatti A, Di Gianfrancesco L, Ongaro L, et al
The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature.
J Clin Med. 2024;13:4349.
Abstract

EWELL DJ, Vue N, Moinuddin SM, Sarkar T, et al
Development of a Bladder Cancer-on-a-Chip Model to Assess Bladder Cancer Cell Invasiveness.
Cancers (Basel). 2024;16:2657.
Abstract

YANG J, Zhang L, Zhu B, Wu H, et al
Immunogenomic profiles and therapeutic options of the pan-programmed cell death-related lncRNA signature for patients with bladder cancer.
Sci Rep. 2024;14:18500.
Abstract

VITUCCI K, Siech C, Baudo A, Jannello LMI, et al
Rates of Systemic Therapy for Metastatic Bladder Cancer Are Lower in Unmarried Males and Females.
Clin Genitourin Cancer. 2024;22:102166.
Abstract

ZHAO G, Li P, Suo Y, Li C, et al
An integrated pan-cancer assessment of prognosis, immune infiltration, and immunotherapy response for B7 family using multi-omics data.
Life Sci. 2024;353:122919.
Abstract

GUO J, Ma X, Liu D, Wang F, et al
A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis.
Drug Resist Updat. 2024;76:101116.
Abstract

MIRTO BF, Barone B, Balsamo R, Abate M, et al
Early and late post-procedural complications in different orthotopic neobladder surgical approaches: A systematic review.
Surg Oncol. 2024;55:102090.
Abstract

CIAPARRONE C, Maffei E, L'Imperio V, Pisapia P, et al
Computer-assisted urine cytology: Faster, cheaper, better?
Cytopathology. 2024;35:634-641.
Abstract

YANG ML, Hu CY, Lee YC, Chang CC, et al
Syngeneic mesenchymal stem cells loaded with telomerase-dependent oncolytic adenoviruses enhance anti-metastatic efficacy.
Stem Cells Transl Med. 2024;13:738-749.
Abstract

SAKUMO K, Tamura J, Nakamura A, Nukaya T, et al
Nuclear long diameter as a new criterion to distinguish high-grade urothelial carcinoma cells from benign reactive cells.
Cytopathology. 2024;35:642-647.
Abstract

NIEGISCH G, Grimm MO, Hardtstock F, Krieger J, et al
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis.
Future Oncol. 2024;20:1351-1366.
Abstract

BAHLBURG H, Reike M, Tully K, Bach P, et al
Return to work improves quality of life and reduces psychosocial distress after radical cystectomy: data from a contemporary series of 230 German patients.
J Cancer Surviv. 2024;18:1426-1433.
Abstract

ECKE TH, Gakis G
[New therapeutic approaches for non-muscle invasive bladder cancer-is organ preservation also possible after BCG (Bacillus Calmette Guerin)?].
Urologie. 2024 Aug 23. doi: 10.1007/s00120-024-02417.
Abstract

SCHWARZ L, Rothlauf F
On Entity Embeddings for Ordinal Features as Representation Learning in Recurrence Prediction of Urothelial Bladder Cancer.
Stud Health Technol Inform. 2024;316:690-694.
Abstract

NIU Z, Kozminsky M, Day KC, Broses LJ, et al
Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics.
Neoplasia. 2024;57:101036.
Abstract

YANG Z, Dou X, Zhou W, Liu Q, et al
Robot-assisted, laparoscopic and open radical cystectomy for bladder cancer: A sys-tematic review and network meta-analysis.
Int Braz J Urol. 2024;50.
Abstract

ZHANG T, Chen S, Qu S, Wang L, et al
Anoikis-Related Genes Impact Prognosis and Tumor Microenvironment in Bladder Cancer.
Mol Biotechnol. 2024 Aug 22. doi: 10.1007/s12033-024-01255.
Abstract

HUANG J, Deng H, Xiao S, Lin Y, et al
CAB39 modulates epithelial-mesenchymal transition through NF-kappaB signaling activation, enhancing invasion, and metastasis in bladder cancer.
Environ Toxicol. 2024 Aug 22. doi: 10.1002/tox.24333.
Abstract

HA X, Li Y, Gao Z, Cui J, et al
IL1RL2 is related to the expression and prognosis of bladder cancer.
Mol Clin Oncol. 2024;21:75.
Abstract

AHMED MY, Cakir MO, Salman NA, Sandhu S, et al
Concurrent high risk HPV35, HPV45, and HPV59 infections in prostate and bladder cancer tissues of a single patient: A case report.
Heliyon. 2024;10:e35074.
Abstract

WEN Y, Ming Z, Li H, Zhu S, et al
Potential utility of ADNP in circulating tumor cells as biomarker for prognostics in non-muscle-invasive bladder cancer.
Sci Rep. 2024;14:19352.
Abstract

CHIANG CH, Chang YC, Peng CY, Wang SS, et al
Clinical performance of Bladder EpiCheck versus voided urine cytology for detecting recurrence of nonmuscle invasive bladder cancer: Systematic review and meta-analysis.
Urol Oncol. 2024 Aug 20:S1078-1439(24)00548.
Abstract

HU M, Zhang J, Cheng Q, Wei W, et al
Multi-DECT image-based intratumoral and peritumoral radiomics for preoperative prediction of muscle invasion in bladder cancer.
Acad Radiol. 2024 Aug 20:S1076-6332(24)00573-7. doi: 10.1016/j.acra.2024.
Abstract

KUBENDIRAN L
Letter to the Editor: Comment on "Predicting survival after brain metastases in patients with bladder cancer".
J Clin Neurosci. 2024;128:110806.
Abstract

HUANG H, Huang Y, Kaggie JD, Cai Q, et al
Multiparametric MRI-Based Deep Learning Radiomics Model for Assessing 5-Year Recurrence Risk in Non-Muscle Invasive Bladder Cancer.
J Magn Reson Imaging. 2024 Aug 21. doi: 10.1002/jmri.29574.
Abstract

NIKOLAIDIS CG, Gyriki D, Anitsakis C, Stavropoulou E, et al
Tailoring treatment for elderly bladder cancer: a case report of personalized management of high-grade urothelial carcinoma with papillary features.
Front Oncol. 2024;14:1434795.
Abstract

ZHANG Z, Wang Y, Luo F, Li J, et al
Short-term Outcome of RPVBT Combined with Chemotherapy for Patients with Single, < 3 cm, T2 Stage Bladder cancer.
Biol Proced Online. 2024;26:26.
Abstract

TSUBOI I, Matsukawa A, Kardoust Parizi M, Klemm J, et al
Differential effect of surgical technique on intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial cancer: a systematic review and Meta-analysis.
World J Urol. 2024;42:488.
Abstract

NOERAPARAST M, Krajina K, Pichler R, Niedersuss-Beke D, et al
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.
Cancer Commun (Lond). 2024 Aug 19. doi: 10.1002/cac2.12602.
Abstract

JIN M, He K, Zhen S, Wang Y, et al
Asiaticoside enhances the effect of propofol on the invasion, ferroptosis and immune escape of bladder cancer.
Drug Dev Res. 2024;85:e22242.
Abstract

XIE Y, Zhang Y, Du Z, Liu D, et al
Treatment Options for Signet Ring Cell Carcinoma of the Urinary Bladder: A Population-Based Study.
Cancer Control. 2024;31:10732748241278485.
Abstract

LIU X, Wang Z, Peng C, Zhou J, et al
Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system.
Expert Opin Drug Saf. 2024 Aug 22:1-8. doi: 10.1080/14740338.2024.2393283.
Abstract

ZHAO F, Zhang K, Ma L, Huang Y, et al
Identification of epithelial-related artificial neural network prognostic models for the prediction of bladder cancer prognosis through comprehensive analysis of single-cell and bulk RNA sequencing.
Heliyon. 2024;10:e34632.
Abstract

AJAMI T, Han S, Blachman-Braun R, Hougen HY, et al
Optimal Management for Primary High Grade Ta Bladder Cancer: Role of re-staging TURBT and Intravesical Adjuvant Therapy.
BJUI Compass. 2024;5:799-805.
Abstract

CHENG L, Yang C, Lu J, Huang M, et al
Oncogenic SLC2A11-MIF fusion protein interacts with polypyrimidine tract binding protein 1 to facilitate bladder cancer proliferation and metastasis by regulating mRNA stability.
MedComm (2020). 2024;5:e685.
Abstract

CLARK O, Sarmento T, Eccleston A, Brinkmann J, et al
Economic Impact of Bladder Cancer in the USA.
Pharmacoecon Open. 2024 Aug 18. doi: 10.1007/s41669-024-00512.
Abstract

LIU W, Wei C, He Q, Chen Z, et al
Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer.
Sci Rep. 2024;14:19025.
Abstract

LI X, Li R
Exploration of biomarkers for nursing physical examination early screening of multiple tumors.
Medicine (Baltimore). 2024;103:e39231.
Abstract

LESLIE SW, Soon-Sutton TL, Aeddula NR, Fuentes S, et al
An unusual intravesical tumor: nephrogenic adenoma.
An Pediatr (Engl Ed). 2024;101:149-150.
Abstract

HERR H
De-Escalation of Therapy for Low-Grade Papillary Bladder Tumors With Preserved Long-Term Oncologic Outcomes.
Urol Pract. 2024;11:777-780.
Abstract

MIYAKAWA J, Yamada Y, Hakozaki Y, Makino K, et al
Comparison of PDD-TURBT alone versus white light TURBT plus intravesical BCG therapy: A propensity-score matching study.
Photodiagnosis Photodyn Ther. 2024;48:104254.
Abstract

VALIM AC, Costa AMD, Quitzan JG, Borges AS, et al
Urothelial carcinoma in a mule.
J Equine Vet Sci. 2024;139:105127.
Abstract

SUH JW, Kim DW, Lee J, Yang IJ, et al
Comparison of partial and total cystectomy for colorectal cancer with histologically confirmed bladder invasion.
Surgery. 2024;176:652-659.
Abstract

ZHUO Z, Wang Y, Xu Y
Advancements in research on lactate dehydrogenase A in urinary system tumors.
BMC Urol. 2024;24:187.
Abstract

WANG C, An T, Ma X
Urachal adenocarcinoma in an adolescent boy: a case report.
BMC Pediatr. 2024;24:554.
Abstract

HOUSSEIN EH, Emam MM, Alomoush W, Samee NA, et al
An efficient improved parrot optimizer for bladder cancer classification.
Comput Biol Med. 2024;181:109080.
Abstract

RONGJIE B, Lingkai C, Chenghao W, Xiao Y, et al
Letter to the editor: Multiparametric MRI-based VI-RADS: Can it predict 1- to 5-year recurrence of bladder cancer?
Eur Radiol. 2024 Aug 30. doi: 10.1007/s00330-024-10923.
Abstract

WANG W, Wu J, Shen Q, Li W, et al
Assessment of pathological grade and variants of bladder cancer with a continuous-time random-walk diffusion model.
Front Oncol. 2024;14:1431536.
Abstract

SHOU MY, Zheng N, Liu YX, Wu XY, et al
[Changes in the disease burden of male urinary and reproductive system tumors in China from 1990 to 2019: Analysis with a prediction of the future trend].
Zhonghua Nan Ke Xue. 2024;30:397-403.
Abstract

YOLDAS M, Arikan Y, Kuvvet Yoldas T
The Effect of the HALP Score on the Development of Bladder Cancer Recurrence in Patients Undergoing Radical Nephroureterectomy for Upper Urinary Tract Tumours.
Aktuelle Urol. 2024;55:452-457.
Abstract

[Not Available].
Aktuelle Urol. 2024;55:412-413.
Abstract

BOLEK H, Arslan C, Basaran M, Cicin I, et al
Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer.
JCO Glob Oncol. 2024;10:e2400201.
Abstract

AYDOGDU C, Brinkmann I, Casuscelli J
[Novel systemic treatment options for advanced bladder cancer].
Urologie. 2024 Aug 29. doi: 10.1007/s00120-024-02413.
Abstract

CAMPBELL MT, Shah AY, Msaouel P, Tannir NM, et al
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer.
Cancer Res Commun. 2024 Aug 29. doi: 10.1158/2767-9764.CRC-24-0237.
Abstract

ABOU CHAKRA M, Luo Y, Duquesne I, A O'Donnell M, et al
Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer.
Front Biosci (Landmark Ed). 2024;29:295.
Abstract

LV M, Shang S, Liu K, Wang Y, et al
Revitalizing Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches.
Pharmaceutics. 2024;16:1067.
Abstract

RAHMAT JN, Tham SM, Ong TL, Lim YK, et al
Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Response to Bacillus Calmette-Guerin Immunotherapy in Bladder Cancer Patients.
Int J Mol Sci. 2024;25:8947.
Abstract

WANG L, Qiu N, Tong S, Yu Y, et al
Matrine Suppresses Arsenic-Induced Malignant Transformation of SV-HUC-1 Cells via NOX2.
Int J Mol Sci. 2024;25:8878.
Abstract

PALLARES-MENDEZ R, Brassetti A, Bove AM, Simone G, et al
Insights into the Interplay between the Urinary Microbiome and Bladder Cancer: A Comprehensive Review.
J Clin Med. 2024;13:4927.
Abstract

KORNER SK, Tolbod LP, Pedersen BG, Boellaard T, et al
[(15)O]H(2)O PET/MRI for Assessment of Complete Response to Neoadjuvant or Induction Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Pilot Study.
J Clin Med. 2024;13:4652.
Abstract

XU F, Xu X, Deng H, Yu Z, et al
The role of deubiquitinase USP2 in driving bladder cancer progression by stabilizing EZH2 to epigenetically silence SOX1 expression.
Transl Oncol. 2024;49:102104.
Abstract

DI CIVITA MA, Torchia A, Santini D, Marinelli D, et al
Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis.
Curr Oncol. 2024;31:4713-4727.
Abstract

WU Z, Li W, Tan M, How FYX, et al
IL-12 minicircle delivery via extracellular vesicles as immunotherapy for bladder cancer.
Cell Prolif. 2024 Aug 28:e13739. doi: 10.1111/cpr.13739.
Abstract

ZHANG S, Guan Z, Xia Q, Shen C, et al
Bioinformatics analysis of ERCC family in pan-cancer and ERCC2 in bladder cancer.
Front Immunol. 2024;15:1402548.
Abstract

WATANABE R, Kamei J, Yamazaki M, Sugihara T, et al
Robot-Assisted Radical Cystectomy for Invasive Bladder Cancer With Vesicovaginal Fistula: A Case Report.
Cureus. 2024;16:e65234.
Abstract

UENO T, Kiwaki T, Betsunoh H, Ito K, et al
Metastasis of malignant melanoma to urinary tract: a case report.
J Med Case Rep. 2024;18:396.
Abstract

YOSHIHARA Y, Kagiya T, Sakamoto Y, Morohashi H, et al
[A Case of Appendiceal Mucinous Carcinoma with Bladder Invasion Developed from Abscess-Forming Appendicitis, Which Was Curatively Resected after Chemotherapy].
Gan To Kagaku Ryoho. 2024;51:849-851.
Abstract

IKARASHI D, Obara W
[Antibody-Drug Conjugates against Urothelial Carcinoma-Current Issues and Future Development].
Gan To Kagaku Ryoho. 2024;51:691-694.
Abstract

SUARTZ CV, Martinez LM, Cordeiro MD, Flores HA, et al
Artificial intelligence for predicting response to neoadjuvant chemotherapy for bladder cancer: A comprehensive systematic review and meta-analysis.
Can Urol Assoc J. 2024 May 21. doi: 10.5489/cuaj.8681.
Abstract

WEI X, Zhang D, Zhu Y
Exosomes: Toward a potential application in bladder cancer diagnosis and treatment.
Smart Med. 2023;3:e20230027.
Abstract

DOWNS TM, Bailey HH, Lozar T, Schmitz NS, et al
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery.
Cancer Prev Res (Phila). 2024 Aug 27. doi: 10.1158/1940-6207.CAPR-24-0194.
Abstract

RIZZO M, Soares A, Grande E, Bamias A, et al
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
Sci Rep. 2024;14:19802.
Abstract

AVOLIO PP, Kool R, Shayegan B, Marcq G, et al
Effect of complete transurethral resection on oncologic outcomes after radiation therapy for muscle-invasive bladder cancer.: Transurethral resection in radiation therapy.
Int J Radiat Oncol Biol Phys. 2024 Aug 24:S0360-3016(24)03292.
Abstract

NIEGISCH G, Bolenz C, Doehn C, Gakis G, et al
[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].
Urologie. 2024 Aug 26. doi: 10.1007/s00120-024-02416.
Abstract

ZENG X, Lu Z, Dai C, Su H, et al
Establish TIIC signature score based the machine learning fusion in bladder cancer.
Discov Oncol. 2024;15:368.
Abstract

AAYUSH A, Darji S, Estes KM, Yeh E, et al
Development of an Elastin-like Polypeptide-Based Nucleic Acid Delivery System Targeted to EGFR+ Bladder Cancer Cells Using a Layer-by-Layer Approach.
Biomacromolecules. 2024 Aug 26. doi: 10.1021/acs.biomac.4c00165.
Abstract

ARIAFAR A, Mansourabadi Z, Rasekh S, Fakhimi M, et al
Diversity of Memory CD8(+) T Cells in Tumor-Draining Lymph Nodes from Patients with Bladder Cancer.
Int J Mol Cell Med. 2024;13:147-159.
Abstract

DARZI MM, Neamati N, Sadeghi F, Bijani A, et al
An Intricate Relationship Between miR-155-5p Expression and Oxidative Stress in Bladder Cancer Patients Treated with Calmette-Guerin Immunotherapy.
Int J Mol Cell Med. 2024;13:186-197.
Abstract

COELHO KBCA, Wosniaki DK, Marin AM, Fabris L, et al
Urinary mRNA-based biomarkers for non-muscle-invasive bladder cancer: a mini-review.
Front Oncol. 2024;14:1441883.
Abstract

DJATISOESANTO W, Azmi YA, Yatindra IBGTY, Mudjanarko SW, et al
Observational study of in-hospital mortality risk from bladder cancer: Five years of experience at a tertiary referral hospital in Indonesia.
Medicine (Baltimore). 2024;103:e39412.
Abstract

LU B, Zhou Y, Ma Z, Wang Z, et al
CircRNA ATF6 suppresses bladder cancer cell proliferation and migration via miR-146a-5p/FLNA axis.
Mutat Res. 2024;829:111876.
Abstract

WANG C, Zhang X
Pelvic organ-preserving radical cystectomy versus standard radical cystectomy in female patients diagnosed with bladder cancer.
World J Surg Oncol. 2024;22:218.
Abstract

LIN G, Lin J, Wang H, Wang L, et al
Characterization of the stem cell landscape and identification of a stemness-associated prognostic signature in bladder cancer.
Cancer Cell Int. 2024;24:299.
Abstract

JIANG J, Liu Y, Qin J, Chen J, et al
METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics.
Nat Commun. 2024;15:7312.
Abstract

XU X, Wang H
Reply to the Letter to the Editor: Multiparametric MRI-based VI-RADS: can it predict 1- to 5-year recurrence of bladder cancer?
Eur Radiol. 2024 Aug 23. doi: 10.1007/s00330-024-10924.
Abstract

DING M, Lin J, Qin C, Fu Y, et al
Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer.
Adv Sci (Weinh). 2024 Aug 23:e2400156. doi: 10.1002/advs.202400156.
Abstract

KOLAWOLE OM, Khutoryanskiy VV
Potential bladder cancer therapeutic delivery systems: a recent update.
Expert Opin Drug Deliv. 2024 Aug 23. doi: 10.1080/17425247.2024.2396958.
Abstract

LESLIE SW, Soon-Sutton TL, Aeddula NR, Zhou X, et al
The MEF2A/SNHG16/miR-425-5p/NOTCH2 axis induces gemcitabine resistance by inhibiting ferroptosis in the starving bladder tumor microenvironment.
Cell Signal. 2024;122:111337.
Abstract

ROJE B, Zhang B, Mastrorilli E, Kovacic A, et al
Gut microbiota carcinogen metabolism causes distal tissue tumours.
Nature. 2024;632:1137-1144.
Abstract

GONG J, Reimers MA
A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape.
Adv Ther. 2024;41:3441-3451.
Abstract

YOU C, Cheng L, Fang Q, Qing L, et al
Comparative evaluation of reproductive organ-preserving versus standard radical cystectomy in female: a meta-analysis and systematic review of perioperative, oncological, and functional outcomes.
Surg Endosc. 2024;38:5041-5052.
Abstract

MANNAN R, Wang X, Mahapatra S, Wang S, et al
Expression of L1 Cell Adhesion Molecule, a Nephronal Principal Cell Marker, in Nephrogenic Adenoma.
Mod Pathol. 2024;37:100540.
Abstract

TANABE K, Kobayashi S, Maezawa Y, Ishihara K, et al
Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.
Int J Clin Oncol. 2024;29:1302-1310.
Abstract

CHIN ZY, Thian YL, Lim YT
MR Evaluation of an Unusual Intruder of the Bladder: A Bladder Fibroid Case Report.
Curr Med Imaging. 2024;20:e15734056281515.
Abstract

ZHOU X, Lu Z, Zhang R, Zhang R, et al
The Value of Dual Time Point (18)F-FDG PET/CT Imaging in Differentiating Lymph Node Metastasis From Reactive Hyperplasia in Bladder Urothelial Carcinoma.
Acad Radiol. 2024;31:3272-3281.
Abstract

ABULABAN A, Yanchenko N, Briski LM, Punnen S, et al
Stromal and Epithelial Architectural Alterations Mimicking Invasion (Pseudoinvasion) in Noninvasive Papillary Urothelial Carcinoma.
Arch Pathol Lab Med. 2024;148:1007-1013.
Abstract

MAO Z, Gao F, Sun T, Xiao Y, et al
RB1 Mutations Induce Smoking-Related Bladder Cancer by Modulating the Cytochrome P450 Pathway.
Environ Toxicol. 2024 Sep 6. doi: 10.1002/tox.24409.
Abstract

SINGH P, Sachan A, Nayak B, Nayyar R, et al
Comparative Analysis of Clinicopathologic Characteristics and Outcomes of Urothelial Bladder Cancer Between Young and Older Adults-Experience from a Tertiary Care Center.
Indian J Surg Oncol. 2024;15:563-571.
Abstract

CHEN Z, Hu J, Ou Y, Ye F, et al
Integrating single-cell transcriptomics to reveal the ferroptosis regulators in the tumor microenvironment that contribute to bladder urothelial carcinoma progression and immunotherapy.
Front Immunol. 2024;15:1427124.
Abstract

ZHANG W, Liu Q, Zhang J, Wang D, et al
FBXO45 Knockdown Restrains the Progression of Bladder Cancer via the ERK/Cyclin D1/CDK4 Pathway.
Arch Esp Urol. 2024;77:796-804.
Abstract

ZHANG C, Hu J, Liu Z, Deng H, et al
Hsa_circ_0000520 suppresses vasculogenic mimicry formation and metastasis in bladder cancer through Lin28a/PTEN/PI3K signaling.
Cell Mol Biol Lett. 2024;29:118.
Abstract

Retraction: Multicomponent siRNA/miRNA-loaded modified mesoporous silica nanoparticles targeted bladder cancer for a highly effective combination therapy.
Front Bioeng Biotechnol. 2024;12:1478191.
Abstract

SONG DM, Shen T, Feng K, He YB, et al
LIG1 is a novel marker for bladder cancer prognosis: evidence based on experimental studies, machine learning and single-cell sequencing.
Front Immunol. 2024;15:1419126.
Abstract

ZHOU J, Xu J, Cheng L, Li S, et al
Alteration of lncRNA RHPN1-AS1 predicts clinical prognosis and regulates the progression of bladder cancer via modulating miR-485-5p.
Int J Biol Markers. 2024 Sep 5:3936155241281076. doi: 10.1177/03936155241281076.
Abstract

RADIC M, Egger M, Kruithof-de Julio M, Seiler R, et al
Patient-derived Organoids in Bladder Cancer: Opportunities and Challenges.
Eur Urol Focus. 2024 Sep 3:S2405-4569(24)00165-2. doi: 10.1016/j.euf.2024.
Abstract

LUO LS, Luan HH, Zhang P, Jiang JF, et al
The disease burden of bladder cancer and its attributable risk factors in five Eastern Asian countries, 1990-2019: a population-based comparative study.
BMC Public Health. 2024;24:2404.
Abstract

SEYYEDSALEHI MS, Bonetti M, Shah D, DeStefano V, et al
Occupational benzene exposure and risk of kidney and bladder cancers: a systematic review and meta-analysis.
Eur J Cancer Prev. 2024 Aug 20. doi: 10.1097/CEJ.0000000000000911.
Abstract

ZHANG J, Zhang W, Liu J, Liu Y, et al
SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis.
Mol Biomed. 2024;5:36.
Abstract

ZDUN-RYZEWSKA A, Gawlik-Jakubczak T, Trawicka A, Trawicki P, et al
Fatigue and related variables in bladder cancer treatment - Longitudinal pilot study.
Heliyon. 2024;10:e35995.
Abstract

HAAS M, Bahlinger V, Burger M, Bolenz C, et al
[The metastatic and advanced upper tract urothelial carcinoma-a separate entity or bladder cancer's younger sibling?].
Urologie. 2024 Sep 2. doi: 10.1007/s00120-024-02421.
Abstract

MANSOURABADI Z, Ariafar A, Chenari N, Hakimellahi H, et al
Clinical and prognostic significance of follicular helper and regulatory T cells in bladder cancer draining lymph nodes.
Sci Rep. 2024;14:20358.
Abstract

LI W, Ou Y, Ye F, Cheng Z, et al
cirSIRT5 induces ferroptosis in bladder cancer by forming a ternary complex with SYVN1/PHGDH.
Cell Death Discov. 2024;10:391.
Abstract

ACHARYA HH, Thampy A, Karthik R, Rupali P, et al
Disseminated mycobacteriosis secondary to intravenous Bacille Calmette-Guerin (BCG) vaccine.
Natl Med J India. 2024;37:86-88.
Abstract

RUGGERO A, Clark M, Lewkowski A, Hurtado R, et al
Bladder Cancer, a Cytogenomic Update.
J Assoc Genet Technol. 2024;50:114-126.
Abstract

FENG H, Liang L, Deng W, Gao J, et al
Sialyl Lewis X decorated integrin alpha3 on small extracellular vesicles promotes metastasis of bladder cancer via enhancing vascular permeability.
Angiogenesis. 2024 Sep 2. doi: 10.1007/s10456-024-09947.
Abstract

KLAGER J, Koeller MC, Oszwald A, Wasinger G, et al
A single-center retrospective comparison of pT1 substaging methods in bladder cancer.
Virchows Arch. 2024 Sep 2. doi: 10.1007/s00428-024-03907.
Abstract

Retraction: MicroRNA-940 Targets INPP4A or GSK3beta and Activates the Wntbeta-Catenin Pathway to Regulate the Malignant Behavior of Bladder Cancer Cells.
Oncol Res. 2024;32:1537.
Abstract

KUMAR A, Singh VK, Singh V, Singh MK, et al
Evaluation of Fibroblast Growth Factor Receptor 3 (FGFR3) and Tumor Protein P53 (TP53) as Independent Prognostic Biomarkers in High-Grade Non-muscle Invasive Bladder Cancer.
Cureus. 2024;16:e65816.
Abstract

LIU JY, Jiang YY, Li PJ, Yao B, et al
Discovery of a potential bladder cancer inhibitor CHNQD-01281 by regulating EGFR and promoting infiltration of cytotoxic T cells.
Mar Life Sci Technol. 2024;6:502-514.
Abstract

LAURIN O, Baculea S, Cote S, Spigelman S, et al
A population-based registry cohort study on the correlation between bladder-intact event-free survival and overall survival in cystectomy-ineligible/refusal muscle-invasive bladder cancer patients in Sweden.
Scand J Urol. 2024;59:137-140.
Abstract

ZHONG X, Sun L, Liu J, Yang X, et al
Silencing LINC00663 inhibits inflammation and angiogenesis through downregulation of NR2F1 via EBF1 in bladder cancer.
RNA Biol. 2024;21:9-22.
Abstract

CONTIERI R, Soloway MS, Gontero P, Herr H, et al
Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG).
Eur Urol Oncol. 2024 Aug 31:S2588-9311(24)00186.
Abstract

ZHAO J, Ma Y, Zheng X, Sun Z, et al
Bladder cancer: non-coding RNAs and exosomal non-coding RNAs.
Funct Integr Genomics. 2024;24:147.
Abstract

POLI C, Tretarre B, Trouche-Sabatier S, Foucan AS, et al
Sex differences in muscle-invasive bladder cancers: a study of a French regional population.
Fr J Urol. 2024 Aug 29:102723. doi: 10.1016/j.fjurol.2024.102723.
Abstract

LIU Y, Ding M, Liao X, Gao Q, et al
Retraction notice to "High expression of enhancer RNA MARC1 or its activation by DHT is associated with the malignant behavior in bladder cancer" [Exp. Cell Res. Volume 370, Issue 2, 15 September 2018, Pages 303-311].
Exp Cell Res. 2024;442:114223.
Abstract

ZHOU L, He J, Hu Z, Li H, et al
Identification of a circadian-based prognostic signature predicting cancer-associated fibroblasts infiltration and immunotherapy response in bladder cancer.
Aging (Albany NY). 2024;16.
Abstract

NSEYO U, Ginsberg D
Functional Outcomes of Orthotopic Neobladder in Women.
Curr Urol Rep. 2024;25:277-285.
Abstract

YONG C, Slaven JE, Wu Z, Margulis V, et al
The impact of bladder cuff excision on outcomes after nephroureterectomy for upper tract urothelial carcinoma: An analysis of the ROBUUST 2.0 registry.
Urol Oncol. 2024;42:373.
Abstract

HINOJOSA-GONZALEZ DE, Saffati G, Salgado-Garza G, Patel S, et al
Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis.
Urol Oncol. 2024;42:361-369.
Abstract

BARR AR, Burley A, Wilkins A
TP53 mutations in urothelial carcinoma: not all one and the same(dagger).
J Pathol. 2024;264:125-128.
Abstract

KODERA Y, Iguchi T, Kato D, Ikeda N, et al
Anti-tumor effect of proteasome inhibitor on canine urothelial carcinoma.
J Vet Med Sci. 2024;86:961-965.
Abstract

JACKSON-SPENCE F, Ackerman C, Jones R, Toms C, et al
Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel.
Urol Oncol. 2024;42:372.
Abstract

SONG HC, Liu JX, Song J, Li XH, et al
Transurethral enucleation of bladder tumor containing non-functional paraganglioma: A case report.
Asian J Surg. 2024;47:4222-4223.
Abstract

TANG C, Li H, Wei X
Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals heterogeneity in epithelial cells between high- and low-grade bladder urothelial carcinoma.
Asian J Surg. 2024;47:4229-4231.
Abstract

BURMANN SN, Michalowitz AL, Oellig F, Kreuter A, et al
[Plasmacytoid urothelial carcinoma: a rare cause of localized lymphedema].
Dermatologie (Heidelb). 2024;75:729-732.
Abstract

FUNSTON G, Moullet M, Mounce L, Lyratzopoulos G, et al
Pre-diagnostic prescription patterns in bladder and renal cancer: a longitudinal linked data study.
Br J Gen Pract. 2024;74:e149-e155.
Abstract

TRELLES GUZMAN CR, Linares Espinos E, Rios Gonzalez E, Alonso Dorrego JM, et al
Randomized clinical trial on the use of IMAGE1 S LIGHT (SPIES) vs. white light in the prevention of recurrence during transurethral resection of bladder tumors: Analysis after 12-month follow-up.
Actas Urol Esp (Engl Ed). 2024;48:512-520.
Abstract

CHEN C, Fan G, Li P, Yang E, et al
Effect of smoking on the recurrence and progression of non-muscle-invasive bladder cancer.
Clin Transl Oncol. 2024 Sep 12. doi: 10.1007/s12094-024-03694.
Abstract

ZHANG LY, Wang P, Wang YB, He ZQ, et al
Global, regional, and national burden of bladder cancer, 1990-2019: an age-period-cohort analysis based on the Global Burden of Disease 2019 study.
Public Health. 2024;236:193-203.
Abstract

RAN L, Zhao Q, Zhao R, Hu G, et al
Comment on: A panel of four plasma amino acids is a promising biomarker for newly diagnosed bladder cancer.
Clin Nutr. 2024;43:2346-2347.
Abstract

BAKALOUDI DR, Koehne EL, Diamantopoulos LN, Holt SK, et al
Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study.
Clin Genitourin Cancer. 2024;22:102208.
Abstract

PIAO C, Liu D, Liu Z, Shan L, et al
Markers in Identifying Pathological Complete Response Status in Muscle Invasive Bladder Cancer Patients Who Achieved Clinical Complete Response After Neoadjuvant Chemotherapy.
Clin Genitourin Cancer. 2024;22:102211.
Abstract

GATTO F, Bratulic S, Maccari F, Galeotti F, et al
Urinary Free Glycosaminoglycans Identify Adults at High Risk of Developing Early-stage High-grade Bladder Cancer.
Eur Urol Open Sci. 2024;68:40-47.
Abstract

WANG SJ
Trimodality therapy in the modern era for management of bladder cancer.
Transl Cancer Res. 2024;13:3935-3939.
Abstract

WEI L, Wang F, Yang G, Liao N, et al
An ensemble learning model for predicting cancer-specific survival of muscle-invasive bladder cancer patients undergoing bladder preservation therapy.
Transl Cancer Res. 2024;13:4085-4095.
Abstract

FRAIRE JC, Prado-Morales C, Aldaz Sagredo A, Caelles AG, et al
Swarms of Enzymatic Nanobots for Efficient Gene Delivery.
ACS Appl Mater Interfaces. 2024;16:47192-47205.
Abstract

FU X, Li M, Hua R, Yao Q, et al
Laparoscopic Sugarbaker repair of parastomal hernia following radical cystectomy and ileal conduit: a single-center experience.
BMC Surg. 2024;24:258.
Abstract

MOLDOVAN M, Nam P, Satpathy Y, Wang L, et al
Oncological and Survival Outcomes of Pelvic Lymph Node Dissection in Patients with Nonmuscle Invasive Bladder Cancer Undergoing Radical Cystectomy Using the National Cancer Database.
Clin Genitourin Cancer. 2024;22:102197.
Abstract

WANG Y, Wang J, Zeng T, Qi J, et al
Data-mining-based biomarker evaluation and experimental validation of SHTN1 for bladder cancer.
Cancer Genet. 2024;288-289:43-53.
Abstract

GABRIEL PE, Pignot G, Baboudjian M, Lebacle C, et al
Efficacy and tolerance of hyperthermic intravesical chemotherapy (HIVEC) according to the number of instillations administered.
World J Urol. 2024;42:516.
Abstract

YAZDANI NIA I, Ambale-Venkatesh B
Editorial for "Multiparametric MRI-Based Deep Learning Radiomics Model for Assessing 5-Year Recurrence Risk in Non-Muscle Invasive Bladder Cancer".
J Magn Reson Imaging. 2024 Sep 11. doi: 10.1002/jmri.29592.
Abstract

LI K, Zhong W, Fan J, Wang S, et al
Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.
Nat Cancer. 2024 Sep 10. doi: 10.1038/s43018-024-00822.
Abstract

KUMAR A, Singh MK, Singh V, Shrivastava A, et al
The role of autophagy dysregulation in low and high-grade nonmuscle invasive bladder cancer: A survival analysis and clinicopathological association.
Urol Oncol. 2024 Sep 9:S1078-1439(24)00570-2. doi: 10.1016/j.urolonc.2024.
Abstract

ZHOU Y, Zhao K, Li J, Peng C, et al
LINC00461 promotes bladder cancer cells EMT through miR-518b/HNRNPUL1 axis.
Discov Oncol. 2024;15:419.
Abstract

HAN J, Lin M, Lin Q, Guo R, et al
Development and Validation of a Contrast-Enhanced US VI-RADS for Evaluating Muscle Invasion in Bladder Cancer.
Radiology. 2024;312:e232815.
Abstract

HAQ F, Sabari S, Hacek J, Brisuda A, et al
Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer.
Cancer Med. 2024;13:e70149.
Abstract

KAMI REDDY KR, Piyarathna DWB, Park JH, Putluri V, et al
Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer.
JCI Insight. 2024;9:e172336.
Abstract

KURATA Y, Nishio M, Moribata Y, Otani S, et al
Development of deep learning model for diagnosing muscle-invasive bladder cancer on MRI with vision transformer.
Heliyon. 2024;10:e36144.
Abstract

KIM B, Kim K, Yang S, Moon KC, et al
Immunophenotypic and molecular changes during progression of papillary urothelial carcinoma.
Investig Clin Urol. 2024;65:501-510.
Abstract

KIM GK, Jo YH, Lee J, Han HH, et al
Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea.
Investig Clin Urol. 2024;65:435-441.
Abstract

KUO WT, Lee YC, Yang YF, Cheng CF, et al
Sushi Domain Containing 2 Dysfunction Contributes to Cancer Progression in Patients with Bladder Cancer.
J Cancer. 2024;15:5318-5328.
Abstract

ZHANG G, Yang J, Fang J, Yu R, et al
Development of an m6A subtype classifier to guide precision therapy for patients with bladder cancer.
J Cancer. 2024;15:5204-5217.
Abstract

BOYLE J, Ward MH, Koutros S, Karagas MR, et al
Modeling Historic Arsenic Exposures and Spatial Risk for Bladder Cancer.
Stat Biosci. 2024;16:377-394.
Abstract

JAMES N, Pirrie S, Liu W, Catto J, et al
Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT.
Health Technol Assess. 2024;28:1-65.
Abstract

SUN X, Wu H, Tang L, Al-Danakh A, et al
GALNT6 promotes bladder cancer malignancy and immune escape by epithelial-mesenchymal transition and CD8(+) T cells.
Cancer Cell Int. 2024;24:308.
Abstract

FAN G, Luo X, Shi Y, Wang Y, et al
FL118: A potential bladder cancer therapeutic compound targeting H2A.X identified through library screening.
Bioorg Chem. 2024;153:107802.
Abstract

GARG T, Maheshwari C, Frank K, Johns A, et al
"Faith and a sunny day": Association of patient frailty with strain experienced by informal caregivers of older adults with non-muscle-invasive bladder cancer.
J Geriatr Oncol. 2024;15:102060.
Abstract

FINATI M, Stephens A, Chiarelli G, Cirulli GO, et al
Radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer: Analysis of an other-cause mortality matched cohort.
Urol Oncol. 2024 Sep 5:S1078-1439(24)00572-6. doi: 10.1016/j.urolonc.2024.
Abstract

GUNDUZ N, Dogan MB, Kazan HO, Culpan M, et al
Effect of accumulating experience on diagnostic performance of VI-RADS in bladder cancer.
Clin Imaging. 2024;114:110279.
Abstract

RAVEENDRAN S, Al Massih A, Al Hashmi M, Saeed A, et al
Urinary miRNAs: Technical Updates.
Microrna. 2024;13:110-123.
Abstract

LYOUBI Y, Bellal S, Lebdai S, Culty T, et al
[Surgical and pathological consequences of preoperative immunotherapy in onco-urology].
Bull Cancer. 2024;111:822-834.
Abstract

D'ANDREA D, Soria F, Hurle R, Enikeev D, et al
En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial.
Eur Urol Oncol. 2023;6:508-515.
Abstract

ANNAKIB S, Fiteni F, Houede N
Quality of Life with Monoclonal Antibody Therapies for Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review.
Eur Urol Oncol. 2023;6:467-476.
Abstract

KHALAF EM, Taherian M, Almalki SG, Asban P, et al
Relationship between exposure to heavy metals on the increased health risk and carcinogenicity of urinary tract (kidney and bladder).
Rev Environ Health. 2023;39:539-549.
Abstract

GAJARIA PK, Menon S, Bakshi G, Prakash G, et al
Plasmacytoid urothelial carcinoma - A clinicopathological case series of an aggressive variant of urothelial cancer.
Indian J Cancer. 2024;61:312-316.
Abstract

KOLANUKUDURU KP, Ben-David R, Lidagoster S, Almoflihi M, et al
Comparative Effectiveness of Bacillus Calmette-Guerin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naive Intermediate-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Focus. 2024 Sep 20:S2405-4569(24)00173.
Abstract

DE IESO ML, Aldoghachi AF, Tilley WD, Dwyer AR, et al
Are androgen receptor agonists a treatment option in bladder cancer?
J Steroid Biochem Mol Biol. 2024 Sep 19:106623. doi: 10.1016/j.jsbmb.2024.106623
Abstract

LADUKAS A, Patasius A, Kincius M, Drevinskaite M, et al
Risk of bladder cancer in patients with type 2 diabetes mellitus: a retrospective population-based cohort study in Lithuania.
Cancer Causes Control. 2024 Sep 21. doi: 10.1007/s10552-024-01911.
Abstract

YANG E, Jing S, Wang F, Wang H, et al
Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production.
Cell Death Dis. 2024;15:688.
Abstract

CHEN HY, Zhao H, Yang JJ, Zhang Q, et al
Reassessment of pioglitazone and bladder cancer based on FAERS database.
Expert Opin Drug Saf. 2024 Sep 20:1-8. doi: 10.1080/14740338.2024.2390000.
Abstract

WANG Y, Zheng J, Liu Y, Li D, et al
Atypical cells in urine sediment: a novel biomarker for early detection of bladder cancer.
Clin Chem Lab Med. 2024 Sep 23. doi: 10.1515/cclm-2024-0650.
Abstract

DAVIS R, Ladbury C, Tsai K, Maraghechi B, et al
CT-Guided Online Adaptive Hypofractionated Radiotherapy for Primary Bladder Cancer: A Report of Two Cases.
Cureus. 2024;16:e67318.
Abstract

LEE HS, Min KS, Seo WI, Sou SJ, et al
Impact of variant histology in the prognosis of non?muscle invasive bladder cancer with low?tumor burden: A propensity score?matched analysis with conventional urothelial carcinoma.
Mol Clin Oncol. 2024;21:80.
Abstract

KAUFMANN E, Aeppli S, Arnold W, Balermpas P, et al
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.
World J Urol. 2024;42:527.
Abstract

KONG J, Zhao X, Singhal A, Park S, et al
Prediction of immunotherapy response using mutations to cancer protein assemblies.
Sci Adv. 2024;10:eado9746.
Abstract

HUANG R, Peng L
Letter to the editor for the article "Diagnostic performance of photodynamic diagnosis with oral 5-aminolevulinic acid for upper tract- and bladder urothelial carcinoma: a single-centre, retrospective analysis".
World J Urol. 2024;42:529.
Abstract

DUQUESNE I, Vordos D, de la Taille A
Letter to the editor for the article "Pilot study for bladder cancer detection with volatile organic compounds using ion mobility spectrometry: a novel urine-based approach".
World J Urol. 2024;42:531.
Abstract

ALAZWARI S, Alsamri J, Alamgeer M, Alotaibi SS, et al
Automated gall bladder cancer detection using artificial gorilla troops optimizer with transfer learning on ultrasound images.
Sci Rep. 2024;14:21845.
Abstract

HE L, Wang L, Yu X, Tang Y, et al
Full-course NIR-II imaging-navigated fractionated photodynamic therapy of bladder tumours with X-ray-activated nanotransducers.
Nat Commun. 2024;15:8240.
Abstract

VOKO B, Mayer T, Szegedi A, Tenke P, et al
[Uro-oncological robotic procedures performed in our department].
Magy Onkol. 2024;68:263-266.
Abstract

GROENEVELD CS, Pfister C, Culine S, Harter V, et al
Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.
Ann Oncol. 2024 Sep 17:S0923-7534(24)04016-X. doi: 10.1016/j.annonc.2024.
Abstract

GORE JL, Wright P, Shih V, Chang NN, et al
Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data.
JCO Clin Cancer Inform. 2024;8:e2400073.
Abstract

ASTROM LM, Sibolt P, Chamberlin H, Serup-Hansen E, et al
Artificial intelligence-generated targets and inter-observer variation in online adaptive radiotherapy of bladder cancer.
Phys Imaging Radiat Oncol. 2024;31:100640.
Abstract

HUANG FF, Di XF, Bai MH
Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials.
Front Bioeng Biotechnol. 2024;12:1458362.
Abstract

ZI H, Liu MY, Luo LS, Huang Q, et al
Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021.
Mil Med Res. 2024;11:64.
Abstract

DE LA CALLE-FABREGAT C, Calafell-Segura J, Gardet M, Dunsmore G, et al
NF-kappaB and TET2 promote macrophage reprogramming in hypoxia that overrides the immunosuppressive effects of the tumor microenvironment.
Sci Adv. 2024;10:eadq5226.
Abstract

ZHANG X, Hong B, Li H, Sun Z, et al
Disulfidptosis and ferroptosis related genes define the immune microenvironment and NUBPL serves as a potential biomarker for predicting prognosis and immunotherapy response in bladder cancer.
Heliyon. 2024;10:e37638.
Abstract

YAO Z, Wang T, Liu J, Zhou Z, et al
Diagnostic accuracy of cytology and urine methylation test in patients with non-muscle invasive bladder cancer: a systematic review and meta-analysis.
Front Oncol. 2024;14:1412346.
Abstract

ZHANG Y, Li R, Zhang S, Li H, et al
Association between non-neoplastic bladder diseases and bladder cancer risk: insights from Mendelian randomization studies.
Postgrad Med J. 2024 Sep 17:qgae121. doi: 10.1093.
Abstract

HU M, Wei W, Zhang J, Wang S, et al
Assessing muscle invasion in bladder cancer via virtual biopsy: a study on quantitative parameters and classical radiomics features from dual-energy CT imaging.
BMC Med Imaging. 2024;24:245.
Abstract

SAAD-HUSSEIN A, Beshir S, Shaheen W, Saleh IA, et al
Integrated evaluation of workplace exposures and biomarkers of bladder cancer among textile dyeing workers.
J Egypt Public Health Assoc. 2024;99:23.
Abstract

LAI S, Liu J, Hu H, Song Y, et al
Developing a Novel Prognostic Model Based on Muscle-Invasive Bladder Cancer Types: A Multicenter Retrospective Cohort Study of Patients Who Received Radical Cystectomy and Chemotherapy.
Ann Surg Oncol. 2024 Sep 16. doi: 10.1245/s10434-024-16226.
Abstract

KAO WH, Liao LZ, Chen YA, Lo UG, et al
SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade.
Cell Death Dis. 2024;15:678.
Abstract

RUBIN EJ, Yeku OO, Morrissey S
NEJM at ESMO - Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMe2411490.
Abstract

POWLES T, Catto JWF, Galsky MD, Al-Ahmadie H, et al
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2408154.
Abstract

RANTI D, Yu H, Wang YA, Bieber C, et al
HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.
bioRxiv [Preprint]. 2024 Sep 3:2024.09.02.610816. doi: 10.1101/2024.09.02.610816
Abstract

CHEN C, Zhang J, Liu X, Zhuang Q, et al
A platelet-related signature for predicting the prognosis and immunotherapy benefit in bladder cancer based on machine learning combinations.
Transl Androl Urol. 2024;13:1472-1485.
Abstract

ANTAR RM, Xu VE, Farag CM, Lucero J, et al
Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer.
Transl Androl Urol. 2024;13:1349-1363.
Abstract

PON AVUDAIAPPAN A, Prabhakar P, Lusnia C, Ganiyani MA, et al
A comparative study of survival outcomes between partial and radical cystectomy in octogenarians with muscle-invasive bladder cancer.
Transl Androl Urol. 2024;13:1486-1497.
Abstract

LEVIEN P, Pannek J, Janzen J, Wollner J, et al
Squamous cell carcinoma of the urinary bladder in patients with chronic spinal cord injury: A case series.
Spinal Cord Ser Cases. 2024;10:67.
Abstract

CHUANG AE, Tao YK, Dong SW, Nguyen HT, et al
Polypyrrole/iron-glycol chitosan nanozymes mediate M1 macrophages to enhance the X-ray-triggered photodynamic therapy for bladder cancer by promoting antitumor immunity.
Int J Biol Macromol. 2024 Sep 12:135608. doi: 10.1016/j.ijbiomac.2024.135608.
Abstract

MOU Y, Yao C, Liu Z, Zhang P, et al
New clinical insights into the treatment of benign uretero-ileal anastomotic stricture following radical cystectomy and urinary diversion.
Cancer Med. 2024;13:e70229.
Abstract

GURWIN A, Karwacki J, Dorochowicz M, Kowalczyk K, et al
Topography and Lateralization of Nodal Metastases in Muscle-Invasive Bladder Cancer Using Super-Extended Pelvic Lymph Node Dissection with the Sentinel Lymph Node Technique.
J Clin Med. 2024;13:5127.
Abstract

TONNI E, Oltrecolli M, Pirola M, Tchawa C, et al
New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives.
Int J Mol Sci. 2024;25:9696.
Abstract

SINGH SP, Pathuri G, Asch AS, Rao CV, et al
Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models.
Cells. 2024;13:1463.
Abstract

GUPTA KB, Taylor TL, Panda SS, Thangaraju M, et al
Curcumin-Dichloroacetate Hybrid Molecule as an Antitumor Oral Drug against Multidrug-Resistant Advanced Bladder Cancers.
Cancers (Basel). 2024;16:3108.
Abstract

DIMITROV G, Mangaldzhiev R, Slavov C, Popov E, et al
Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review.
Cancers (Basel). 2024;16:3056.
Abstract

DE MELO NETO JS, Miguez SF, Rabelo ALR, Silva AMD, et al
Impact of Age, Period, Cohort, Region, Race, and Health Services on Bladder Cancer Mortality in Brazil: A 23-Year Ecological Study.
Cancers (Basel). 2024;16:3038.
Abstract

ZHENG B, Zhang H, Wang J, Qin X, et al
A mucoadhesive-to-penetrating nanomotors-in-hydrogel system for urothelium-oriented intravesical drug delivery.
J Nanobiotechnology. 2024;22:560.
Abstract

AZHAR NA, Paramanantham Y, B W M Nor WMFS, B M Said NA, et al
MicroRNA-146b-5p/FDFT1 mediates cisplatin sensitivity in bladder cancer by redirecting cholesterol biosynthesis to the non-sterol branch.
Int J Biochem Cell Biol. 2024;176:106652.
Abstract

GOTO T, Teramoto Y, Nagata Y, Miyamoto H, et al
Latrophilin-3 as a downstream effector of the androgen receptor induces bladder cancer progression.
Discov Oncol. 2024;15:440.
Abstract

WU XH, Huang XY, You Q, Zhu JM, et al
Liquid-liquid phase separation-related genes associated with prognosis, tumor microenvironment characteristics, and tumor cell features in bladder cancer.
Clin Transl Oncol. 2024 Sep 13. doi: 10.1007/s12094-024-03719.
Abstract

IKEDA J, Ohe C, Yoshida T, Nakamoto T, et al
Prognostic impact of lymph node invasion levels in patients with bladder cancer undergoing radical cystectomy and pelvic lymphadenectomy.
Oncol Lett. 2024;28:517.
Abstract

LV W, Pan X, Han P, Wu S, et al
Extrachromosomal circular DNA orchestrates genome heterogeneity in urothelial bladder carcinoma.
Theranostics. 2024;14:5102-5122.
Abstract

YAO D, Xin F, He X
RNF26-mediated ubiquitination of TRIM21 promotes bladder cancer progression.
Am J Cancer Res. 2024;14:4082-4095.
Abstract

KUO YC, Huang CY, Ng CCY, Lin CY, et al
Paraneoplastic leukocytosis induces NETosis and thrombosis in bladder cancer PDX model.
Am J Cancer Res. 2024;14:3694-3710.
Abstract

SOUZA VC, Monteiro FSM, Maluf FC, Werutsky G, et al
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.
Clin Genitourin Cancer. 2024;22:102174.
Abstract

DROUAUD A, Xu V, Velasquez A, Antar R, et al
Metastatic Tropism in Urothelial Carcinoma With Variant Histology: A Comprehensive NCDB Analysis.
Clin Genitourin Cancer. 2024;22:102179.
Abstract

TURAL D, Arslan C, Selcukbiricik F, Olmez OF, et al
Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Clin Genitourin Cancer. 2024;22:102163.
Abstract

MAMEDE I, Escalante-Romero L, Celso DSG, Reis PCA, et al
Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Clin Genitourin Cancer. 2024;22:102154.
Abstract

DUWE G, Brandt MP, Haferkamp A
ASO Author Reflections: Temporal Trends in Urinary Diversion in Radical Cystectomies from Europe's Largest Monocentric Cohort with 2224 Cases Over 36 Years.
Ann Surg Oncol. 2024;31:7239-7240.
Abstract

MINATO A, Furubayashi N, Tomoda T, Masaoka H, et al
Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Clin Genitourin Cancer. 2024;22:102148.
Abstract

PORTUGAL-GASPAR F, Lopez-Beltran A, Paner GP, Blanca A, et al
Giant cell carcinoma of the urinary bladder : Clinicopathologic analysis and oncological outcomes.
Virchows Arch. 2024;485:535-546.
Abstract

DI BELLO F, de Angelis M, Siech C, Jannello LMI, et al
Survival of Metastatic Urothelial Carcinoma of Urinary Bladder According to Number and Location of Visceral Metastases.
Clin Genitourin Cancer. 2024;22:102139.
Abstract

DE ANGELIS M, Siech C, Jannello LMI, Bello FD, et al
Neoadjuvant Versus Adjuvant Chemotherapy in Non-Metastatic Locally-Advanced Stage Radical Cystectomy Candidates.
Clin Genitourin Cancer. 2024;22:102132.
Abstract

DUWE G, Kamal MM, Wiesmann C, Banasiewicz KE, et al
Temporal Trends in Urinary Diversion among Patients Undergoing Radical Cystectomy Between 1986 and 2022: Experience at the University Medical Center Mainz with 2224 Cases.
Ann Surg Oncol. 2024;31:7220-7228.
Abstract

MALIK R, Xiang DH, Riew GJ, Sanchez-Melendez S, et al
Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review.
J Am Acad Dermatol. 2024;91:753-755.
Abstract

RODRIGUEZ CABELLO MA, Mendez Rubio S, Vazquez Alba D, Aullo Gonzalez C, et al
Effect of Bacillus Calmette-Guerin Exposure on Prostate Cancer Detection Using Magnetic Resonance Imaging: A Cohort Study.
Clin Genitourin Cancer. 2024;22:102130.
Abstract

BELLMUNT J, Maroto P, Bonfill T, Vazquez F, et al
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.
Clin Genitourin Cancer. 2024;22:102123.
Abstract

POWLES T, Chang YH, Yamamoto Y, Munoz J, et al
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.
Nat Med. 2024;30:2508-2516.
Abstract

SAHAFI P, Soltani S, Aryana K, Aghaee A, et al
(99m)Tc-FAPI uptake in a rare case of metastatic urachal carcinoma.
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2024;43:500019.
Abstract

PADILLA BERMEJO A, Gaton Ramirez J, Pena Pardo FJ, Sicilia Pozo MLN, et al
Incomplete resection in a rare case of bladder paraganglioma revealed by diuretic (123)I-MIBG SPECT/CT scan.
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2024;43:500018.
Abstract

ZHAO J, Xu Q
Comment on 'Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis'.
Int J Surg. 2024;110:5895-5896.
Abstract

NEBIOGLU A, Tanriverdi R, Basaranoglu M, Saylam B, et al
Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value.
BMC Urol. 2024;24:210.
Abstract

RODRIGUEZ FABA O, Fernandez Gomez JM, Guerrero-Ramos F, Alvarez-Maestro M, et al
Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer.
Actas Urol Esp (Engl Ed). 2024 Sep 26:S2173-5786(24)00109.
Abstract

XIAO N, Huang Y, Tang Q, Chen H, et al
Anticancer effects of tanshinone IIA in bladder urothelial carcinoma by down-regulating aurora A, HIF-1alpha and Bcl-2 both in vitro and in vivo.
Pak J Pharm Sci. 2024;37:627-638.
Abstract

QU F, Darji S, Thompson DH
Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024.
Pharmaceutics. 2024;16:1154.
Abstract

RELOUW S, Dugbartey GJ, McLeod P, Knier NN, et al
Pharmacological Inhibition of Endogenous Hydrogen Sulfide Production Slows Bladder Cancer Progression in an Intravesical Murine Model.
Pharmaceuticals (Basel). 2024;17:1212.
Abstract

SAVIN Z, Levin L, Lazarovich A, Rosenzweig B, et al
Evaluating the Survival Benefits of Perioperative Chemotherapy in Frail and Morbid Muscle-Invasive Bladder Cancer Patients.
J Pers Med. 2024;14:954.
Abstract

VENDRELL JA, Cabello-Aguilar S, Senal R, Heckendorn E, et al
Dysbiosis in Human Urinary Microbiota May Differentiate Patients with a Bladder Cancer.
Int J Mol Sci. 2024;25:10159.
Abstract

BEDORE S, van der Eerden J, Boghani F, Patel SJ, et al
Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer-A Systematic Review of the Current Status.
Int J Mol Sci. 2024;25:9899.
Abstract

GOK G, Kucuk T, Cimen S, Gok A, et al
The Effect of Glutathione on Development and Prognosis in Non-Muscle-Invasive Bladder Cancer.
J Clin Med. 2024;13:5483.
Abstract

FLAMMIA RS, Tuderti G, Bologna E, Minore A, et al
Stratifying the Risk of Disease Progression among Surgically Treated Muscle-Invasive Bladder Cancer Eligible for Adjuvant Nivolumab.
J Clin Med. 2024;13:5466.
Abstract

BUZOIANU M, Andras I, Giurgiu L, Militaru CF, et al
Simultaneous Prostate and Bladder Cancer with Collision Lymph Node Metastasis: A Case Report and Literature Review.
Medicina (Kaunas). 2024;60:1482.
Abstract

MEIRELES S, Dias C, Martins D, Marques A, et al
Biomarker Profiling of Upper Tract Urothelial Carcinoma Only and with Synchronous or Metachronous Bladder Cancer.
Biomedicines. 2024;12:2154.
Abstract

HUANG X, Wang Q, Nan Y, Zhang X, et al
Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer.
Biomedicines. 2024;12:2152.
Abstract

NIE Z, Liu B, Liu J, Zu X, et al
Oncogenic ACSM6 impairs CD8(+) T cell-based immune response in bladder cancer.
Biomark Res. 2024;12:112.
Abstract

ZHANG Y, Lin H, Liang L, Jin S, et al
Intratumoral microbiota as a novel prognostic indicator in bladder cancer.
Sci Rep. 2024;14:22198.
Abstract

LIU K, Nicoletti R, Zhao H, Chen X, et al
Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer.
World J Urol. 2024;42:547.
Abstract

MOON HH, Kearney M, Mahmoudpour SH, Ike C, et al
Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States.
Curr Oncol. 2024;31:5662-5676.
Abstract

FUSTER S, Kiraz U, Eftestol T, Janssen EAM, et al
NMGrad: Advancing Histopathological Bladder Cancer Grading with Weakly Supervised Deep Learning.
Bioengineering (Basel). 2024;11:909.
Abstract

LIN Y, Zheng H, Jia L, Luo Y, et al
Integrin alpha6-containing extracellular vesicles promote lymphatic remodelling for pre-metastatic niche formation in lymph nodes via interplay with CD151.
J Extracell Vesicles. 2024;13:e12518.
Abstract

OLKHOV-MITSEL E, Oberc A, Craddock KJ, Sherman C, et al
MTAP protein status is highly concordant with CDKN2A fluorescent in situ hybridization and allows stratification of the luminal subtype in muscle-invasive bladder cancer.
Histopathology. 2024 Sep 26. doi: 10.1111/his.15324.
Abstract

PIJPERS OM, van Hoogstraten LMC, Remmers S, Beijert IJ, et al
Risk of Progression of High-grade Primary T1 Non-muscle-invasive Bladder cancer in a Contemporary Cohort.
Eur Urol Oncol. 2024 Sep 25:S2588-9311(24)00216.
Abstract

FONTEYNE V, Huddart R
Is It Time to Reconsider the Place of Adjuvant Radiation Therapy After Radical Cystectomy?
Int J Radiat Oncol Biol Phys. 2024;120:667-668.
Abstract

CONTIERI R, Uleri A, Hurle R, Lazzeri M, et al
Comment to "Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer".
Eur J Nucl Med Mol Imaging. 2024 Sep 26. doi: 10.1007/s00259-024-06893.
Abstract

SONG Y, Chen J, Peng Y, Jiang S, et al
Comment on "A review of urinary bladder microbiome in patients with bladder cancer and its implications in bladder pathogenesis".
World J Urol. 2024;42:540.
Abstract

KLUTH M, Hitzschke M, Furlano K, Plage H, et al
17p13 (TP53) Deletions Are Associated With an Aggressive Phenotype but Unrelated to Patient Prognosis in Urothelial Bladder Carcinomas.
Genes Chromosomes Cancer. 2024;63:e23271.
Abstract

SHARMA N, Dey S, Singh S, Kumar S, et al
Disulfiram-Copper Potentiates Anticancer Efficacy of Standard Chemo-therapy Drugs in Bladder Cancer Animal Model through ROS-Autophagy-Ferroptosis Signalling Cascade.
Curr Cancer Drug Targets. 2024 Sep 25. doi: 10.2174/0115680096325879240815105227
Abstract

HOSNEY ME, Houssein EH, Saad MR, Samee NA, et al
Efficient bladder cancer diagnosis using an improved RIME algorithm with Orthogonal Learning.
Comput Biol Med. 2024;182:109175.
Abstract

HYLDGAARD JM, Norgaard M, Hjort PE, Jensen JB, et al
Bladder cancer incidence and mortality among men with and without castration therapy for prostate cancer - a nation-wide cohort study.
Acta Oncol. 2024;63:746-754.
Abstract

ZHOU Q, Xu J, Chen X, Ouyang J, et al
CD276 as a promising diagnostic and prognostic biomarker for bladder cancer through bioinformatics and clinical research.
Front Oncol. 2024;14:1445526.
Abstract

MAVADIA A, Choi S, Ismail A, Ghose A, et al
An overview of immune checkpoint inhibitor toxicities in bladder cancer.
Toxicol Rep. 2024;13:101732.
Abstract

HONG X, Wang T, Liu Q, Bi J, et al
Primary signet-ring cell carcinoma of the urinary bladder ? A rare bladder tumor.
Clinics (Sao Paulo). 2024;79:100500.
Abstract

GAO M, Zhu H, Xu H, Jin X, et al
PGK1 can affect the prognosis and development of bladder cancer.
Cancer Med. 2024;13:e70242.
Abstract

ANNANA SK, Ferdoush J, Lamia F, Roy A, et al
Computational Insights into Captopril's Inhibitory Potential Against MMP9 and LCN2 in Bladder Cancer: Implications for Therapeutic Application.
Cancer Inform. 2024;23:11769351241276759.
Abstract

LI A, Wu M, Xie O, Xiang H, et al
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.
Front Immunol. 2024;15:1464092.
Abstract

ZHENG F, Wang Z, Dong Q, Li S, et al
Prognostic Significance and Immune Landscape of an Efferocytosis-Related Gene Signature in Bladder Cancer.
Biochem Genet. 2024 Sep 23. doi: 10.1007/s10528-024-10924.
Abstract

WANG L, Chen SY, Yang JW, Li KP, et al
Perioperative and functional outcomes of single-port versus multi-port robotic-assisted radical cystectomy: evidence-based on controlled studies.
J Robot Surg. 2024;18:344.
Abstract

SIDDHARTHA R, Goel A, Singhai A, Garg M, et al
Matrix Metalloproteinases -2 and -9, Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor and CD105- Micro-Vessel Density are Predictive Markers of Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer Subtypes.
Biochem Genet. 2024 Sep 23. doi: 10.1007/s10528-024-10921.
Abstract

ZHAO X, Yu X, Li W, Chen Z, et al
CDK6 as a Biomarker for Immunotherapy, Drug Sensitivity, and Prognosis in Bladder Cancer: Bioinformatics and Immunohistochemical Analysis.
Int J Med Sci. 2024;21:2414-2429.
Abstract

REN J, Mo Z, Deng X, Ren M, et al
TPH1 inhibits bladder tumorigenesis by targeting HIF-1alpha pathway in bladder cancer.
Asian Biomed (Res Rev News). 2024;18:171-179.
Abstract

DA SILVA AE, Leite NP, Smaidi K, Hidaka AK, et al
Mini nutritional assessment as a screening tool for muscle-invasive bladder cancer patients: A cross-sectional study in a high-volume center.
Bladder (San Franc). 2024;11:e21200002.
Abstract

LIU Z, Huang C, Mao X, Mi J, et al
Single cell RNA-Sequencing Reveals Mast Cells Enhance Mononuclear Phagocytes Infiltration in Bladder Cancer Microenvironment.
J Cancer. 2024;15:5672-5690.
Abstract

CAO K, Shi H, Wu B, Lv Z, et al
Identification of ECM and EMT relevant genes involved in the progression of bladder cancer through bioinformatics analysis.
Am J Clin Exp Urol. 2024;12:183-193.
Abstract

Retraction: miR-203 suppresses bladder cancer cell growth and targets twist1.
Oncol Res. 2024;32:1693-1694.
Abstract

HUDKINS RL, Allen E, Balcer A, Hoffman ID, et al
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia.
J Med Chem. 2024;67:16737-16756.
Abstract

ZHANG X, Mei W, Guo D, Sun J, et al
Preparation of photo-controlled release ROS-responsive Ce6/elemene co-loaded liposomes and study on the effect on enhancing apoptosis of NMIBC.
Biomed Pharmacother. 2024;179:117398.
Abstract

APOLO AB, Bellmunt J, Cordes L, Gupta S, et al
The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.
ESMO Open. 2024;9:103725.
Abstract

RODRIGUEZ-VIDA A, Valderrama BP, Castellano D, Pinto A, et al
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.
ESMO Open. 2024;9:103690.
Abstract

BAEKELANDT L, Akand M, VAN DEN Broeck T, Gevaert T, et al
Transforming UTUC diagnostics: the potential of bladder Epicheck(R) in clinical practice.
Minerva Urol Nephrol. 2024;76:654-656.
Abstract

MATSUBARA N, Miura Y, Nishiyama H, Taoka R, et al
Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations.
Int J Clin Oncol. 2024;29:1516-1527.
Abstract

GOTO T, Yasui M, Teramoto Y, Nagata Y, et al
Latrophilin-3 as a downstream effector of the androgen receptor induces urothelial tumorigenesis.
Mol Carcinog. 2024;63:1847-1854.
Abstract

QUINN C, Harding K, Schlein LJ, Korchia J, et al
It's not always histiocytic sarcoma: Immunocytochemistry to identify two unusual tumors in a Bernese Mountain dog.
Vet Clin Pathol. 2024;53:309-314.
Abstract

OSE H, Nakamura A, Nukaya T, Sofue T, et al
p53 and Vimentin Double Immunostaining to Differentiate between High-Grade Urothelial Carcinoma Cells and Benign Atypical Cells.
Acta Cytol. 2024;68:359-367.
Abstract

HANG JF, Ou YC, Yang WL, Tsao TY, et al
Evaluating Urine Cytology Slide Digitization Efficiency: A Comparative Study Using an Artificial Intelligence-Based Heuristic Scanning Simulation and Multiple Z-Plane Scanning.
Acta Cytol. 2024;68:342-350.
Abstract

CERRATO C, Crocerossa F, Marchioni M, Giannarini G, et al
Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis.
Eur Urol Oncol. 2024;7:1005-1014.
Abstract

BEN-DAVID R, Tillu N, Cumarasamy S, Alerasool P, et al
Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy.
Eur Urol Oncol. 2024;7:1105-1112.
Abstract

ZHANG GN, Susnik B, Paulsen EJ, Lyons LL, et al
Metastatic Pleomorphic Lobular Carcinoma of the Breast to the Urinary Bladder: A Report of 10 Cases and Assessment of TRPS1 in the Differential Diagnosis With Plasmacytoid Urothelial Carcinoma.
Arch Pathol Lab Med. 2024;148:1110-1118.
Abstract

BAHLBURG H, Hellmann T, Tully K, Butea-Bocu MC, et al
Psychosocial distress and quality of life in patients after radical cystectomy - one year follow-up in 842 German patients.
J Cancer Surviv. 2024;18:1600-1607.
Abstract

WANG Y, Song W, Feng C, Wu S, et al
Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.
J Transl Med. 2024;22:900.
Abstract

LORIOT Y, Kamal M, Syx L, Nicolle R, et al
The genomic and transcriptomic landscape of metastastic urothelial cancer.
Nat Commun. 2024;15:8603.
Abstract

LUO S, Wu Y, Yang R, Liu J, et al
Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence and progression of high-risk non-muscle-invasive b
Urol Oncol. 2024 Oct 4:S1078-1439(24)00666-5. doi: 10.1016/j.urolonc.2024.
Abstract

GURUNG J, Doykov M, Kostov G, Hristov B, et al
The expanding role of artificial intelligence in the histopathological diagnosis in urological oncology: a literature review.
Folia Med (Plovdiv). 2024;66:303-311.
Abstract

YANG T, Peng X, Huang X, Cao P, et al
COL6A1 Inhibits the Malignant Development of Bladder Cancer by Regulating FBN1.
Cell Biochem Biophys. 2024 Oct 4. doi: 10.1007/s12013-024-01573.
Abstract

ZHONG X, Li G, Zhu L
Dietary mineral intake and risk of bladder cancer: a systematic review and meta-analysis.
Eur J Cancer Prev. 2024 Sep 16. doi: 10.1097/CEJ.0000000000000922.
Abstract

WANG Y, Zhang Q
Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits in postoperative bladder cancer.
Sci Rep. 2024;14:22976.
Abstract

TOTEV TI, Ireland A, Shah A, Tardif-Samson A, et al
Overall burden and impact on health-related quality of life associated with intravesical treatment of patients with non-muscle invasive bladder cancer in the United States.
Curr Med Res Opin. 2024 Oct 3:1-13. doi: 10.1080/03007995.2024.2411424.
Abstract

FATTAHI MJ, Sedaghat F, Haghshenas MR, Ariafar A, et al
Two metabolic enzymes, LDH and FASN, serum levels in Bladder cancer patients.
Caspian J Intern Med. 2024;15:636-643.
Abstract

TYBURSKI P, Sikora J, Miedziaszczyk M, Niemir Z, et al
Acute tubulointerstitial nephritis induced by intravesical bacillus Calmette-Guerin: a rare case of acute kidney injury.
Eur Rev Med Pharmacol Sci. 2024;28:4290-4297.
Abstract

TEKE K, Yilmaz H, Baltaci S, Akgul M, et al
Analysis of risk factors for cancer-specific survival in neoadjuvant chemotherapy nonresponsive disease of muscle-invasive bladder cancer: A multicentre study from the Turkish Urooncology Association Bladder Tumor study group.
Urol Oncol. 2024 Sep 30:S1078-1439(24)00647.
Abstract

BAUMANN BC, Efstathiou JA
Adjuvant radiation therapy for locally advanced bladder cancer: A safe and promising emerging treatment option.
Int J Radiat Oncol Biol Phys. 2024 Sep 27:S0360-3016(24)03412.
Abstract

BURASCHI S, Xu SQ, Stefanello M, Moskalev I, et al
Correction: Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin.
Oncotarget. 2024;15:697-698.
Abstract

POLIMERA HV, Bhatia P, Wheelden M, Perimbeti S, et al
Management options for node-positive muscle-invasive bladder cancer.
Clin Adv Hematol Oncol. 2024;22:392-402.
Abstract

DIAZ R, Leonardi R, Murelli F, Fregatti P, et al
Comment to "An unusual "linitis plastica" like breast cancer bladder metastasis".
Arch Ital Urol Androl. 2024;96:12784.
Abstract

LU S, Gao X, Li X, Zhao H, et al
Niraparib Enhances and Synergizes with Ganglioside GD2 to Potentiate its Inhibitory Effect on Bladder Cancer Cells.
Comb Chem High Throughput Screen. 2024.
Abstract

BELL SD, Quinn AE, Spitzer TD, Voss BB, et al
Emerging molecular therapies in the treatment of bladder cancer.
Explor Target Antitumor Ther. 2024;5:1135-1154.
Abstract

GAO H, Qiu Y, Zheng X, Xu T, et al
Revealing the mechanisms of RAC3 in tumor aggressiveness, the immunotherapy response, and drug resistance in bladder cancer.
Front Oncol. 2024;14:1466319.
Abstract

HUANG J, Zhou D, Luo W, Liu Y, et al
Integrating oxidative-stress biomarkers into a precision oncology risk-stratification model for bladder cancer prognosis and therapy.
Front Cell Dev Biol. 2024;12:1453448.
Abstract

IBRAHIM M, Kim P, Marawar R, Avgerinos KI, et al
Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis.
J Prev Alzheimers Dis. 2024;11:1355-1362.
Abstract

SONG M, Han Y, Zhao Y, Lv J, et al
Association of autosomal mosaic chromosomal alterations with risk of bladder cancer in Chinese adults: a prospective cohort study.
Cell Death Dis. 2024;15:706.
Abstract

NAKAGAKI N, Komori M, Shimokama T, Iwama E, et al
Multiple lung cyst formation caused by metastatic bladder cancer.
Thorax. 2024 Sep 30:thorax-2023-220573. doi: 10.1136/thorax-2023-220573.
Abstract

HOLMSTEN K, Sjodahl G, Abrahamsson J, Bernardo C, et al
Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.
JCO Precis Oncol. 2024;8:e2400209.
Abstract

SHAN L, Liu W, Zhan Y
Retraction of: Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer.
Aging (Albany NY). 2024;16:12652-12653.
Abstract

TUO Z, Gao M, Jiang C, Zhang D, et al
Construction of M2 macrophage-related gene signature for predicting prognosis and revealing different immunotherapy response in bladder cancer patients.
Clin Transl Oncol. 2024 Sep 30. doi: 10.1007/s12094-024-03698.
Abstract

DUWE G, Wagner I, Banasiewicz KE, Frey LJ, et al
Radical cystectomy in patients aged < 80 years versus >/= 80 years: analysis of preoperative geriatric assessment scores in predicting postoperative morbidity and mortality.
World J Urol. 2024;42:552.
Abstract

XIANG G, Huang Y, Gan L, Wang L, et al
Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States.
Front Immunol. 2024;15:1426024.
Abstract

BURSIEWICZ W, Zlotkiewicz M, Krajewski W, Tupikowski K, et al
Long-term efficacy and safety of intravesical Bacillus Calmette-Guerin Moreau Polish substrain in the treatment of non-muscle invasive bladder cancer.
Cent European J Urol. 2024;77:196-202.
Abstract

WANG X, Jia Y, Wang D
Cathepsin C Promotes Tumorigenesis in Bladder Cancer by Activating the Wnt/beta-catenin Signalling Pathway.
Front Biosci (Landmark Ed). 2024;29:327.
Abstract

HSIAO CH, Lin YW, Liu CH, Nguyen HT, et al
Light-Driven Green-Fabricated Artificial Intelligence-Enabled Micro/Nanorobots for Multimodal Phototherapeutic Management of Bladder Cancer.
Adv Healthc Mater. 2024 Sep 29:e2402864. doi: 10.1002/adhm.202402864.
Abstract

GUO S, Su Q, Yang Z, Mo W, et al
Development and validation of a novel liquid-liquid phase separation gene signature for bladder cancer.
Sci Rep. 2024;14:22552.
Abstract

LIEDBERG F, Mariappan P, Gontero P
Clinical Implementation of Urinary Biomarkers for Surveillance of Non-muscle-invasive Bladder Cancer (NMIBC): Considerations from the European Association of Urology NMIBC Guideline Panel.
Eur Urol Oncol. 2024 Sep 28:S2588-9311(24)00221.
Abstract

KETTUNEN K, Mathlin J, Lamminen T, Laiho A, et al
Profiling steroid hormone landscape of bladder cancer reveals depletion of intratumoural androgens to castration levels: a cross-sectional study.
EBioMedicine. 2024;108:105359.
Abstract

MIRZAEE E, Novin K, Fadavi P, Soltani S, et al
Intravesical Gemcitabine for Non-Muscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure: A Prospective Study.
Asian Pac J Cancer Prev. 2024;25:3173-3177.
Abstract

YAMAMOTO A, Kawashima A, Sakai S, Mita M, et al
Serum D-asparagine concentration adjusted for eGFR could serve as a novel screening tool for urothelial carcinoma.
Biochem Biophys Res Commun. 2024;733:150701.
Abstract

LLOYD L
Gut microbiota influence bladder tumour development.
Nat Rev Urol. 2024;21:576.
Abstract

ISHIGAKI S, Kajio N, Yoshikawa N, Taguchi H, et al
The potential of interleukin-17 inhibitors treatment for reactive arthritis after transurethral resection of a bladder tumor and intravesical administration of bacillus calmette-guerin therapy.
Clin Rheumatol. 2024;43:3255-3256.
Abstract

VARVIL MS, Dos Santos AP
A review of the current standing of microRNA expression in canine urothelial carcinoma.
Am J Vet Res. 2024;85:ajvr.
Abstract

ALGABA F
The journey of determining PD-L1 expression in muscle-invasive urothelial carcinoma.
Actas Urol Esp (Engl Ed). 2024;48:553-554.
Abstract

ROVIELLO G, Santoni M, Sonpavde GP, Catalano M, et al
The evolving treatment landscape of metastatic urothelial cancer.
Nat Rev Urol. 2024;21:580-592.
Abstract

BOTA EC, Koumoundourou D, Ravazoula P, Zolota V, et al
A comprehensive analysis of GATA3 expression in carcinomas of various origins with emphasis on lung carcinomas.
Monaldi Arch Chest Dis. 2023;94.
Abstract

COSTA CERQUEIRA M, Silva A, Martins Sousa S, Pinto-Ribeiro F, et al
Chromene-based compounds as drug candidates for renal and bladder cancer therapy - A systematic review.
Bioorg Chem. 2024;153:107865.
Abstract

PRAYGOD TF, Li J, Li H, Tan W, et al
Identification of RNA-binding protein RBMS3 as a potential biomarker for immunotherapy in bladder cancer.
Cancer Biomark. 2024 Aug 4. doi: 10.3233/CBM-230489.
Abstract

LIU J, Luo Y, Chen S, Wang G, et al
Deubiquitylase USP52 Promotes Bladder Cancer Progression by Modulating Ferroptosis through Stabilizing SLC7A11/xCT.
Adv Sci (Weinh). 2024 Oct 11:e2403995. doi: 10.1002/advs.202403995.
Abstract

DAVIS NB, Kilari D, Kessler ER, Smelser WW, et al
Editorial: Bladder preservation options for bladder cancer.
Front Oncol. 2024;14:1493854.
Abstract

QIAO Y, Tian X, Li S, Niu H, et al
Identification and experimental validation of a sialylation-related long noncoding RNA signature for prognosis of bladder cancer.
BMC Urol. 2024;24:222.
Abstract

SEPEHRI S, Rezaee ME, Su ZT, Kates M, et al
Strategies to Improve Clinical Outcomes and Patient Experience Undergoing Transurethral Resection of Bladder Tumor.
Curr Urol Rep. 2024;26:13.
Abstract

ZHAOXUE L, Du H, Shao G, Wang G, et al
Sonodynamic Therapy for Intestinal Obstruction Caused by Intestinal Metastasis of Bladder Cancer: A Case Report.
Photodiagnosis Photodyn Ther. 2024 Oct 8:104354.
Abstract

MANI S
Gut microbiome and bladder cancer: A new link through nitrosamine metabolism.
Cell Host Microbe. 2024;32:1637-1639.
Abstract

CHAKRABORTY A, Hasler J, Handorf E, Anari F, et al
Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles.
Clin Genitourin Cancer. 2024;22:102218.
Abstract

LORUSSO V, Palmisano F, Piccinelli ML, Rossi RS, et al
Analysis of the Application of the Micrometric Substaging System to Predict Recurrence and Progression in a Cohort of Patients with pT1 High-Grade Non-Muscle Invasive Bladder Cancer.
Arch Esp Urol. 2024;77:843-849.
Abstract

LI Y, Zhu N, Ahmed M, Urbina J, et al
Three-dimensional computer vision for exploring heterogeneity in collective Cancer Invasion.
Sci Rep. 2024;14:23560.
Abstract

RIOU O, Hennequin C, Khalifa J, Sargos P, et al
News and prospects on radiotherapy for bladder cancer: Is trimodal therapy becoming the gold standard?
Cancer Radiother. 2024 Oct 8:S1278-3218(24)00147.
Abstract

REN C, Qian W
A Model Based on Automated Urinalysis Parameters for Urothelial Carcinoma Risk Stratification in Suspected Patients.
Clin Lab. 2024;70.
Abstract

D'ANDREA VD, Magnani CJ, Ernandez J, Bellmunt J, et al
Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer.
Curr Urol Rep. 2024;26:12.
Abstract

ZHANG Y, Wu J, Liang X
A basement membrane-related signature for prognosis and immunotherapy benefit in bladder cancer based on machine learning.
Discov Oncol. 2024;15:537.
Abstract

WANG T, Zhang X, Zhang GM
Commentary: Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis.
Front Oncol. 2024;14:1417921.
Abstract

ZHANG L, Chen Z, Sun G, Li C, et al
Dynamic landscape of m6A modifications and related post-transcriptional events in muscle-invasive bladder cancer.
J Transl Med. 2024;22:912.
Abstract

KATO M, Taoka R, Miki J, Saito R, et al
Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter study.
Int J Clin Oncol. 2024 Oct 9. doi: 10.1007/s10147-024-02636.
Abstract

CARBONELL E, Sierra A, Mercader C, Peradejordi M, et al
Intravenous indocyanine green to evaluate distal ureteral vascularity during robot-assisted radical cystectomy with intracorporeal urinary diversion.
World J Urol. 2024;42:568.
Abstract

ALI-EL-DEIN B, Abdelgawad M, Tarek M, Abdel-Rahim M, et al
Bladder cancer associated with elevated heavy metals: Investigation of probable carcinogenic pathways through mitochondrial dysfunction, oxidative stress and mitogen-activated protein kinase.
Urol Oncol. 2024 Oct 7:S1078-1439(24)00650-1. doi: 10.1016/j.urolonc.2024.
Abstract

AZZAROUALI S, Goudschaal K, Visser J, Bel A, et al
Cone-Beam Computed Tomography-Guided Online Adaptive Radiotherapy: Promising Results for Bladder Cancer Case.
Cureus. 2024;16:e68863.
Abstract

TRAN P, Rama Sai P, Prasad C, Do H, et al
Mixed neuroendocrine-nonneuroendocrine epithelial neoplasm of muscle invasive bladder cancer: a clinicopathologic case study.
J Surg Case Rep. 2024;2024:rjae612.
Abstract

SONG L, Xu Q, Chen R, Sun W, et al
KLF1 Activates RAC3 to Mediate Fatty Acid Synthesis and Enhance Cisplatin Resistance in Bladder Cancer Cells.
Am J Mens Health. 2024;18:15579883241273305.
Abstract

AZZAROUALI S, Goudschaal K, Visser J, Daniels L, et al
Minimizing human interference in an online fully automated daily adaptive radiotherapy workflow for bladder cancer.
Radiat Oncol. 2024;19:138.
Abstract

DE MAESENEER D, De Visschere P, Van den Broecke M, Delbare F, et al
Retrospective analysis of multiparametric MRI in predicting complete pathologic response of neo-adjuvant chemotherapy in bladder cancer.
BMC Med Imaging. 2024;24:268.
Abstract

YU Q, Xu S, Weng S, Ye L, et al
GREM1 may be a biological indicator and potential target of bladder cancer.
Sci Rep. 2024;14:23280.
Abstract

TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-arm multicenter
Int J Clin Oncol. 2024 Oct 7. doi: 10.1007/s10147-024-02638.
Abstract

LAI S, Liu J, Zhang G, Hu H, et al
ASO Author Refections: A Novel Prognostic Model Based on Muscle-Invasive Bladder Cancer Types.
Ann Surg Oncol. 2024 Oct 7. doi: 10.1245/s10434-024-16275.
Abstract

NIEGISCH G, Kramer M
[Current developments in urothelial carcinoma].
Urologie. 2024;63:975-976.
Abstract

ZHANG X, Tao X, Zhou Y, Shi G, et al
Comprehensive Analysis of the Significance of Breast Cancer Gene 1 (BRCA-1) in Bladder Cancer.
Cancer Manag Res. 2024;16:1305-1319.
Abstract

LI L, Ma X, Li Y
A Nomogram for Predicting Suicide Risk and Prognostic Factors in Bladder Cancer Patients Following Diagnosis: More Information Needed.
J Clin Nurs. 2024 Oct 6. doi: 10.1111/jocn.17447.
Abstract

LI JL, Xu Y, Xiang YS, Wu P, et al
Comparative analysis of amide proton transfer and diffusion-weighted imaging for assessing Ki-67, p53 and PD-L1 expression in bladder cancer.
Acad Radiol. 2024 Oct 5:S1076-6332(24)00692-5. doi: 10.1016/j.acra.2024.
Abstract

LV W, Lei X, Wang H, Wang T, et al
A modified model of PANoptosisto identify prognosis and immunotherapy response in bladder cancer.
Int J Biochem Cell Biol. 2024;176:106672.
Abstract

TAYLOR Z, Musallam S, Meyer K, Elkhashab I, et al
Tubeless ureteroenteric anastomosis in robot-assisted radical cystectomy with intracorporeal urinary diversion does not increase the risk of anastomotic stenosis or postoperative complications.
J Robot Surg. 2024;18:361.
Abstract

ZOU R, Lu J, Bai X, Yang Y, et al
The epigenetic-modified downregulation of LOXL1 protein mediates EMT in bladder epithelial cells exposed to benzo[a]pyrene and its metabolite BPDE.
Int Immunopharmacol. 2024;142.
Abstract

PAFFENHOLZ P, Zschabitz S
[Classical chemotherapy, immunotherapy, or adjuvant radiotherapy-how to improve the oncologic outcome of radical cystectomy?].
Urologie. 2024;63:994-1001.
Abstract

JIA D, Chen S
Environmental pollutants and bad bugs work hand in glove.
Trends Cancer. 2024;10:873-875.
Abstract

CASUSCELLI J, von Amsberg G, Retz M
[Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors].
Urologie. 2024;63:1002-1010.
Abstract

FILMAR S, Gross AJ, Tonus C, Hook S, et al
[Rare case of leiomyosarcoma of the urinary bladder in a young man].
Urologie. 2024;63:1028-1032.
Abstract

NETSCH C, Filmar S, Hook S, Rosenbaum C, et al
[Follow-up after urinary diversion].
Urologie. 2024;63:1050-1059.
Abstract

LOBO A, Collins K, Kaushal S, Acosta AM, et al
Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature.
Histopathology. 2024;85:748-759.
Abstract

TAKEDA K, Adeniran AJ, Levi AW, Tang H, et al
Cytomorphological characteristics of low-grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high-grade papillary urothelial carcinoma.
Cytopathology. 2024;35:724-732.
Abstract

MAIA A, Soares DM, Azevedo S, Pereira T, et al
Pembrolizumab-induced type 1 diabetes.
J Oncol Pharm Pract. 2024;30:1118-1121.
Abstract

LORIOT Y, Kalebasty AR, Flechon A, Jain RK, et al
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.
Future Oncol. 2024;20:1621-1631.
Abstract

BYTNAR JA, McGlynn KA, Kern SQ, Shriver CD, et al
Incidence rates of bladder and kidney cancers among US military servicemen: comparison with the rates in the general US population.
Eur J Cancer Prev. 2024;33:505-511.
Abstract

GAO W
Current opinions regarding the clinical utility of en bloc resection in the treatment of non-muscle invasive bladder cancer-a review of the literature.
Discov Oncol. 2024;15:574.
Abstract

AGRAWAL S, Naik N, Priyanka P
Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT).
J Gastrointest Cancer. 2024;56:7.
Abstract

CAO K, Zou Y, Zhang C, Zhang W, et al
A multicenter bladder cancer MRI dataset and baseline evaluation of federated learning in clinical application.
Sci Data. 2024;11:1147.
Abstract

PRASAD SK, Raza FS, Karna S, Hoq NM, et al
Epididymo-Orchitis Mimicking Malignancy Resulting From Intravesical Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer: An Attempt to Understand Pathophysiology, Diagnostic Challenges, Patients' Implications and Future Directions.
J Med Cases. 2024;15:354-358.
Abstract

ZHANG W, Zhang J, Zhang J, Chu J, et al
Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment.
J Nanobiotechnology. 2024;22:638.
Abstract

SIMON C, Jeyasinghe U, Shiferaw B
BCG-osis: a complication after intravesical BCG immunotherapy.
BMJ Case Rep. 2024;17:e261804.
Abstract

GUO Z, Li Z, Wang J, Jiang H, et al
Modeling bladder cancer in the laboratory: Insights from patient-derived organoids.
Biochim Biophys Acta Rev Cancer. 2024;1879:189199.
Abstract

KUPPANDA P, Hermans L, Uren A, Cotterill N, et al
National audit of patient reported experience of radical cystectomy for bladder cancer pathways.
BJUI Compass. 2024;5:961-968.
Abstract

DERRE L, Crettenand F, Grilo N, Stritt K, et al
The role of preoperative immunonutrition on morbidity and immune response after cystectomy: protocol of a multicenter randomized controlled trial (INCyst Trial).
Trials. 2024;25:687.
Abstract

O'LEARY K
Perioperative immunotherapy for bladder cancer.
Nat Med. 2024 Oct 16. doi: 10.1038/d41591-024-00074.
Abstract

HE Q, Xiao B, Tan Y, Wang J, et al
Integrated multicenter deep learning system for prognostic prediction in bladder cancer.
NPJ Precis Oncol. 2024;8:233.
Abstract

ZHONG Q, Shao L, Yao Y, Chen S, et al
Urine-based SERS and multivariate statistical analysis for identification of non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.
Anal Bioanal Chem. 2024 Oct 17. doi: 10.1007/s00216-024-05595.
Abstract

SATO T, Sano T, Adachi H, Ikeda Y, et al
Assessment of Clinicopathological Characteristics and Clinical Outcomes of Patients who Developed Non-Muscle-Invasive Bladder Cancer after Radiotherapy for Prostate Cancer: A Retrospective Multicenter Study.
Tohoku J Exp Med. 2024 Oct 17. doi: 10.1620/tjem.2024.
Abstract

SHAH A, Meedimale S, Kumar D, Sharma P, et al
Drug-induced acute febrile neutrophilic dermatosis (Sweet syndrome): A case report presented at Delhi State Cancer Institute.
J Cancer Res Ther. 2024;20:1605-1607.
Abstract

BEIJERT IJ, van den Burgt Y, Hentschel AE, Bosschieter J, et al
Bladder Cancer detection by urinary methylation markers GHSR/MAL: a validation study.
World J Urol. 2024;42:578.
Abstract

MYERS AA, Steinmetz AR, Kamat AM
The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care.
Expert Rev Anticancer Ther. 2024 Oct 18:1-6. doi: 10.1080/14737140.2024.2417768.
Abstract

[Expert consensus of multi-disciplinary collaboration on bladder-preserving treatment for bladder cancer in China (2024 edition)].
Zhonghua Zhong Liu Za Zhi. 2024;46:1-20.
Abstract

LILLESAND M, Kvikstad V, Gudlaugsson E, Skaland I, et al
Integrating Genetic Alterations and Histopathological Features for Enhanced Risk Stratification in Non-Muscle-Invasive Bladder Cancer.
Diagnostics (Basel). 2024;14:2137.
Abstract

ALOUINI S, Bakri Y
Para-Aortic Lymphadenectomy in Ovarian, Endometrial, Gastric, and Bladder Cancers: A Systematic Review of Randomized Controlled Trials.
Cancers (Basel). 2024;16:3394.
Abstract

BOLLMANN LM, Lange F, Hamacher A, Biermann L, et al
Triple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer.
Cancers (Basel). 2024;16:3374.
Abstract

SHEYBAEE MOGHADDAM F, Dwabe S, Mar N, Safdari L, et al
The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond.
Cancers (Basel). 2024;16:3361.
Abstract

GUERRERO-RAMOS F, Gonzalez-Padilla DA, Perez-Cadavid S, Garcia-Rojo E, et al
Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs.
Cancers (Basel). 2024;16:3330.
Abstract

HASSOUNEH Z, Kim ME, Bowman N, Rao M, et al
The Laws of Attraction: Chemokines as Critical Mediators in Cancer Progression and Immunotherapy Response in Bladder Cancer.
Cancers (Basel). 2024;16:3303.
Abstract

WINNICKA A, Brzeszczynska J, Saluk J, Wigner-Jeziorska P, et al
Nanomedicine in Bladder Cancer Therapy.
Int J Mol Sci. 2024;25:10388.
Abstract

NAGATA Y, Minato A, Aono H, Kimuro R, et al
Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Int J Mol Sci. 2024;25:10348.
Abstract

BANEGAS MP, O'Keeffe Rosetti M, Gilbert SM, Kwan ML, et al
Comparing direct medical care costs of patients with bladder cancer who received an ileal conduit vs. neobladder in the year following cystectomy.
Urol Oncol. 2024 Oct 14:S1078-1439(24)00672.
Abstract

NARAYAN VM, Tholomier C, Mokkapati S, Martini A, et al
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec.
Eur Urol Oncol. 2024 Oct 14:S2588-9311(24)00225.
Abstract

OZSAGIR YO, Ozsagir E, Dil E, Eren H, et al
Prognostic impact of EGFR expression and immunohistochemistry-based "molecular classification" in bladder cancer.
Ann Diagn Pathol. 2024;73:152380.
Abstract

DE ARRUDA CAMARGO GC, Oliveira G, Santos BNS, Roberto IM, et al
Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad(R) (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases.
Med Oncol. 2024;41:287.
Abstract

VASANTHARAJAN S, Wessel N, Thune I, Habberstad A, et al
[Not Available].
Tidsskr Nor Laegeforen. 2024;144.
Abstract

CARRIERE P, Alhalabi O, Gao J, Mohamad O, et al
Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer.
Clin Transl Radiat Oncol. 2024;49:100866.
Abstract

GOFRIT ON, Yutkin V, Duvdevani M, Hidas G, et al
Collagen fiber arrangement in the normal bladder lamina propria and their potential impact on the pathological substaging of bladder cancer stage T1.
Histol Histopathol. 2024 Sep 19:18817. doi: 10.14670.
Abstract

LOBO J, Zein-Sabatto B, Lal P, Netto GJ, et al
Digital and Computational Pathology Applications in Bladder Cancer: Novel Tools Addressing Clinically Pressing Needs.
Mod Pathol. 2024 Oct 12:100631. doi: 10.1016/j.modpat.2024.100631.
Abstract

LI S, Zheng F, Wang Z, Xiong S, et al
Integrated analysis of bulk and single-cell RNA-seq data reveals cell differentiation-related subtypes and a scoring system in bladder cancer.
J Cell Mol Med. 2024;28:e70111.
Abstract

PARRA M, Gerber BL, Pasquet A, Jamar F, et al
Jingle Bells: Bladder Cancer and Rare Endocardial Metastases, An Unexpected Early Recurrence and Diagnostic Conundrum.
Eur Heart J Cardiovasc Imaging. 2024 Oct 14:jeae261. doi: 10.1093.
Abstract

ZHANG Q, Fu S, Li X, Wang H, et al
STAT1 as a potential therapeutic target to treat bladder cancer.
Int J Clin Exp Pathol. 2024;17:298-307.
Abstract

WAN QK, Li TT, Liu BB, He B, et al
USP5 promotes tumor progression by stabilizing SLUG in bladder cancer.
Oncol Lett. 2024;28:572.
Abstract

LIANG PS, Shih HJ, Huang SH, Chen YZ, et al
Primary lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) in the urinary bladder mimicking recurrent urinary tract infection: a case report and literature review.
BMC Urol. 2024;24:223.
Abstract

CIANFLONE F, Mazzucato G, Rubilotta E, Orlando R, et al
Tumor location at trans-urethral resection is predictive of ipsilateral pelvic lymph-nodal metastases in patients undergoing radical cystectomy for bladder cancer.
Urol Oncol. 2024 Oct 11:S1078-1439(24)00679.
Abstract

KAMITANI R, Tanaka N, Anno T, Murakami T, et al
Tumor immune microenvironment dynamics and outcomes of prognosis in non-muscle-invasive bladder cancer.
Cancer Sci. 2024 Oct 11. doi: 10.1111/cas.16333.
Abstract

OKABE Y, Fukuhara Y, Matsuoka W, Nakamura N, et al
Identification of risk factors associated with oral 5-aminolevulinic acid induced adverse events in photodynamic diagnosis-transurethral resection of bladder tumor.
Photodiagnosis Photodyn Ther. 2024;49:104291.
Abstract

CHOUDHURY S, Ahmed S, Bose AGD, Ghosh D, et al
Transvesical blockade of the obturator nerve to prevent adductor contraction in transurethral resection of urinary bladder tumor.
Urologia. 2024;91:695-700.
Abstract

AKBULUT D, Whiting K, Teo MY, Tallman JE, et al
Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications.
Mod Pathol. 2024;37:100557.
Abstract

LEE JY, Lee YS, Tae JH, Chang IH, et al
Selection of Convolutional Neural Network Model for Bladder Tumor Classification of Cystoscopy Images and Comparison with Humans.
J Endourol. 2024;38:1036-1043.
Abstract

WONG R, Matulewicz RS, Talwar R, Shoenbill KA, et al
Increased tobacco taxation associated with decreased consumption and bladder cancer incidence.
Urol Pract. 2024 Oct 25:101097UPJ0000000000000743.
Abstract

SONG B, Wu P, Wan C, Sun Q, et al
Integrating single cell and bulk RNA sequencing data identifies RBM17 as a novel response biomarker for immunotherapy in bladder cancer.
Virchows Arch. 2024 Oct 25. doi: 10.1007/s00428-024-03952.
Abstract

UN H, Wusimanjiang W, Zhan W, Zhang X, et al
Understanding bladder cancer risk: Mendelian randomization analysis of immune cell and inflammatory factor influence.
Front Immunol. 2024;15:1460275.
Abstract

Retraction: long noncoding RNA ATB promotes proliferation, migration, and invasion in bladder cancer by suppressing microRNA-126.
Oncol Res. 2024;32:1819.
Abstract

WANG B, Shangguan W, Li W, Xie M, et al
Blautia coccoides and its metabolic products enhance the efficacy of bladder cancer immunotherapy by promoting CD8(+) T cell infiltration.
J Transl Med. 2024;22:964.
Abstract

SHALATA AT, Alksas A, Shehata M, Khater S, et al
Precise grading of non-muscle invasive bladder cancer with multi-scale pyramidal CNN.
Sci Rep. 2024;14:25131.
Abstract

LIU W, Wei C, He Q, Chen Z, et al
Author Correction: Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer.
Sci Rep. 2024;14:25244.
Abstract

LOBO N, Duan Z, Sood A, Zhao H, et al
Sex Disparity in Non-muscle-invasive Bladder Cancer: Pitfalls of Large Population-based Data Sets and Lessons from an Integrated Analysis.
Eur Urol Oncol. 2024 Oct 23:S2588-9311(24)00226.
Abstract

DADGAR-ZANKBAR L, Mokhtaryan M, Bafandeh E, Javanmard Z, et al
Microbiome and bladder cancer: the role of probiotics in treatment.
Future Microbiol. 2024 Oct 24:1-18. doi: 10.1080/17460913.2024.2414671.
Abstract

LIFA A, El Moudane A, Bounouar O, Boukhannous I, et al
Pyoperitoneum Revealing a Spontaneous Renal Forniceal Rupture Due to Bladder Cancer: A Case Report.
Cureus. 2024;16:e69976.
Abstract

ROMERO D
Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer.
Nat Rev Clin Oncol. 2024 Oct 23. doi: 10.1038/s41571-024-00961.
Abstract

SASAKI Y, Yamamoto Y, Fukuta K, Izumi K, et al
Cutaneous ureterostomy following robot-assisted radical cystectomy: a multicenter comparative study of transperitoneal versus retroperitoneal techniques.
World J Urol. 2024;42:591.
Abstract

DE OLIVEIRA VM, Malospirito CC, da Silva FB, Videira NB, et al
Exploring the molecular pathways of the activation process in PPARgamma recurrent bladder cancer mutants.
J Chem Phys. 2024;161:165102.
Abstract

LAI C, Hu Z, Hu J, Li Z, et al
Screening Model for Bladder Cancer Early Detection With Serum miRNAs Based on Machine Learning: A Mixed-Cohort Study Based on 16,189 Participants.
Cancer Med. 2024;13:e70338.
Abstract

NASERGHANDI A, Azizmohammad Looha M, Jameie M, Moradian Haft Cheshmeh Z, et al
Incidence trends, histological subtypes, and topographical distribution of bladder cancer in Iran: a study based on the Iranian National Cancer Registry during 2006-2015.
Front Oncol. 2024;14:1423968.
Abstract

LU X, Hu C, Duan L, Chen K, et al
Establishment of matched bladder cancer PDX and PDX-derived organoid model and evaluation of anti-tumor efficacy of abemaciclib.
Clin Transl Oncol. 2024 Oct 22. doi: 10.1007/s12094-024-03666.
Abstract

HOU X, Li N, Ruan L, Yao X, et al
Association between time to treatment and bladder cancer survival: a population-based analysis.
Transl Androl Urol. 2024;13:2079-2091.
Abstract

DAI X, Yu K, Wang H, Zhong R, et al
Construction and multiple validations of a robust ferroptosis-related prognostic model in bladder cancer: A comprehensive study.
Medicine (Baltimore). 2024;103:e40133.
Abstract

WANG H, Zheng Y, Zhang C, Li M, et al
Development and validation of a recurrence risk assessment model for high-grade bladder cancer based on TCGA and GEO.
Transl Cancer Res. 2024;13:4973-4984.
Abstract

ZHOU X, Liu Y, Lv Z, Shen C, et al
Construction and verification of an innovative immune-related and hallmark gene sets prognostic model for bladder cancer.
Transl Cancer Res. 2024;13:4639-4653.
Abstract

LIU R, Ma J, Zhang Y, Zhou Z, et al
Integrated transcriptome analysis of CSE1L regarding poor prognosis and immune infiltration in bladder urothelial carcinoma and experimental verification.
Front Immunol. 2024;15:1449251.
Abstract

ZHANG X, Xu J, Zhuang G, Wang Y, et al
Circular RNA TAF4B targeting MFN2 accelerates cell growth in bladder cancer through p27 depression and AKT activation.
Front Immunol. 2024;15:1477196.
Abstract

HE Y, Xu A, Xiao L, Yang Y, et al
Phosphorus Metabolism-Related Genes Serve as Novel Biomarkers for Predicting Prognosis in Bladder Cancer: A Bioinformatics Analysis.
Iran J Public Health. 2024;53:1935-1950.
Abstract

XU M, Li P, Wei J, Yan P, et al
Progress of fluorescence imaging in lymph node dissection surgery for prostate and bladder cancer.
Front Oncol. 2024;14:1395284.
Abstract

PIZARRO-MONDESIR M, Ramirez-Marcano C, Arriaga-Perry R, Rodriguez-Bury V, et al
Unusual Presentation of Bladder Cancer in a Young Male With Significant Tattoo Exposure: A Case Report.
Cureus. 2024;16:e69637.
Abstract

LU J, Zhou J, Liu Y, Li Y, et al
Treatment and survival of non-metastatic small cell carcinoma of the bladder from multiple centers in China.
Sci Rep. 2024;14:24652.
Abstract

OH EL, Redfern A, Hayne D
An evaluation of durvalumab across the spectrum of urothelial carcinoma.
Expert Rev Anticancer Ther. 2024;24:1101-1115.
Abstract

SHOJO K, Tanaka N, Murakami T, Anno T, et al
Multiplexed Spatial Imaging at the Single-Cell Level Reveals Mutually Exclusive Expression of B7 Family Proteins.
Lab Invest. 2024;104:102131.
Abstract

VLAJNIC T, Bubendorf L
[New edition of the Paris classification 2022: What is new?].
Pathologie (Heidelb). 2024;45:389-396.
Abstract

YASAR E, Uysal AI, Akarken I, Altiparmak B, et al
Obturator Nerve Block Performed Blinded Versus by Ultrasound-guidence for Transurethral Resection of Bladder Tumors: A Randomized Controlled Trial.
Urol J. 2024;21:356-360.
Abstract

DENG H, Ning J, Ruan Y, Yu W, et al
TNFRSF11B promotes the progression of bladder cancer through PI3K/AKT signaling pathway.
Mol Cell Probes. 2024 Oct 29:101989. doi: 10.1016/j.mcp.2024.101989.
Abstract

YAN L, Luo G, Han C, Meng J, et al
Exploring the oncogenic role of RGS19 in bladder cancer progression and prognosis.
Acta Histochem. 2024;126:152212.
Abstract

SHIN D, Kim C, Chae Y, Yun T, et al
Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog.
J Am Anim Hosp Assoc. 2024;60:275-279.
Abstract

SACHAN A, Nayyar R, Pethe S, Singh P, et al
A 3-arm randomized control trial to compare the efficacy of re-circulant hyperthermic intravesical chemotherapy versus conventional intravesical mitomycin C and BCG therapy for intermediate-risk non-muscle invasive bladder cancer.
World J Urol. 2024;42:609.
Abstract

ACHARD V, Huddart R
Chemoradiation therapy for Nonmetastatic Muscle-Invasive Bladder Cancer: Still the Only Bladder Preservation Treatment in 2024.
Int J Radiat Oncol Biol Phys. 2024 Sep 27:S0360-3016(24)03331.
Abstract

NADIMI PARASHKOUHI S, Karimzadeh I, Rezvani A, Abbasian H, et al
Cost-Utility Analysis of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy Regimen in Comparison With Gemcitabine and Cisplatin Chemotherapy Regimen in the Treatment of Patients With Muscle Invasive Bladder Cancer in Iran.
Value Health Reg Issues. 2024 Oct 30:101051. doi: 10.1016/j.vhri.2024.101051.
Abstract

GAYLIS FD, Emond B, Manceur AM, Tardif-Samson A, et al
Adherence to First-Line Intravesical Bacillus Calmette-Guerin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.
J Health Econ Outcomes Res. 2024;11:109-117.
Abstract

TIAN J, Gao M, Zhu J, Xu H, et al
Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis.
Theranostics. 2024;14:6692-6707.
Abstract

LI M, Cui Y, Qi Q, Liu J, et al
SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1.
Theranostics. 2024;14:6543-6559.
Abstract

LI Y, Zhang Y, Feng N, Yu F, et al
Three-in-One Nanozyme for Radiosensitization of Bladder Cancer.
Int J Nanomedicine. 2024;19:10873-10883.
Abstract

HUANG J, Luo Y, Wang Y, Wang S, et al
Silencing CCT3 induces ferroptosis through the NOD1-NF-kappaB signaling pathway in bladder cancer.
Sci Rep. 2024;14:26188.
Abstract

CHIANG TW, Chang LW, Chiang FF, Li JR, et al
Colon Cancer With Bladder Invasion: A Single Center Experience.
In Vivo. 2024;38:2990-3001.
Abstract

IGUCHI R, Inoue K
Distal preservation and retrograde resection of the anterior vaginal wall in female robot-assisted radical cystectomy.
Asian J Endosc Surg. 2025;18:e13399.
Abstract

MACKENZIE NJ, Zimmermann K, Nicholls C, Perera MP, et al
Altered immunophenotypic expression in the peripheral bladder cancer immune landscape.
Immunol Cell Biol. 2024 Oct 30. doi: 10.1111/imcb.12829.
Abstract

RUSSELL B, Hagberg O, Haggstrom C, Holmberg L, et al
The difficulty of studying the association between pathway delays and survival in cancer - an example from bladder cancer.
Scand J Urol. 2024;59:181-184.
Abstract

LIU GL, Luo H, Liang DD, Zhong L, et al
Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Tumor Immune Infiltration in Bladder Cancer.
Recent Pat Anticancer Drug Discov. 2024.
Abstract

LONG C, Shi H, Li J, Chen L, et al
The diagnostic accuracy of urine-derived exosomes for bladder cancer: a systematic review and meta-analysis.
World J Surg Oncol. 2024;22:285.
Abstract

LI Y, Piao C, Kong C
Stearoyl CoA desaturase inhibition can effectively induce apoptosis in bladder cancer stem cells.
Cancer Cell Int. 2024;24:357.
Abstract

JIAO P, Wu S, Yang R, Ni X, et al
Deep Learning Predicts Lymphovascular Invasion Status in Muscle Invasive Bladder Cancer Histopathology.
Ann Surg Oncol. 2024 Oct 29. doi: 10.1245/s10434-024-16422.
Abstract

TAKEUCHI M, Higaki A, Kojima Y, Ono K, et al
Diagnostic significance of peritumoral enhancement in distinguishing between muscle-invasive and non-muscle-invasive bladder cancer.
Abdom Radiol (NY). 2024 Oct 30. doi: 10.1007/s00261-024-04658.
Abstract

SHI X, Zheng W, He B, Huang L, et al
UPLC-Q-TOF/MS-based urine metabolomics for the diagnosis and staging of bladder cancer.
Clin Chim Acta. 2024 Oct 27:120022. doi: 10.1016/j.cca.2024.120022.
Abstract

AMMAR E, Al-Mudallal N, Abbas SM
Cytotoxic Effect of Stenotrophomonas maltophilia Isolated from Prostate and Bladder Cancer Patients in Iraq.
Asian Pac J Cancer Prev. 2024;25:3701-3705.
Abstract

MA G, Jia H, Li Z, Zhang X, et al
Gefitinib Reverses PD-L1-Mediated Immunosuppression Induced by long-term Glutamine blockade in Bladder Cancer.
Cancer Immunol Res. 2024 Oct 29. doi: 10.1158/2326-6066.CIR-24-0039.
Abstract

ZHANG W, Guo G, Li X, Lin J, et al
A bibliometric analysis of bladder cancer and microRNA research: Trends and advances from 2008 to 2022.
Medicine (Baltimore). 2024;103:e40289.
Abstract

YOU C, Zhu Y, Zhu J, Xu Z, et al
Strength in Numbers: A Giant NIR-II AIEgen with One-for-All Phototheranostic Features for Exceptional Orthotopic Bladder Cancer Treatment.
Angew Chem Int Ed Engl. 2024 Oct 29:e202417865. doi: 10.1002/anie.202417865.
Abstract

BRANZ A, Matek C, Lange F, Bahlinger V, et al
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance.
Front Immunol. 2024;15:1478196.
Abstract

HUANG A, Zhao Y, Guan F, Zhang H, et al
Performance of a HER2 testing algorithm tailored for urothelial bladder cancer: A Bi-centre study.
Comput Struct Biotechnol J. 2024;26:40-50.
Abstract

LIU C, Liu J, Liu G, Song Y, et al
Clitoria ternatea L. flower-derived anthocyanins and flavonoids inhibit bladder cancer growth by suppressing SREBP1 pathway-mediated fatty acid synthesis.
Acta Biochim Biophys Sin (Shanghai). 2024 Oct 29. doi: 10.3724/abbs.2024192.
Abstract

SHAN L, Xu H, Piao C, Liu Z, et al
Nomogram for the Pathological Complete Response After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients.
Ann Surg Oncol. 2024 Oct 28. doi: 10.1245/s10434-024-16429.
Abstract

TATENUMA T, Matsukawa T, Goto T, Jiang G, et al
GULP1 as a Downstream Effector of the Estrogen Receptor-beta Modulates Cisplatin Sensitivity in Bladder Cancer.
Cancer Genomics Proteomics. 2024;21:557-565.
Abstract

WU N, Wang J, Fan M, Liang Y, et al
Non-glycanated DeltaDCN isoform in muscle invasive bladder cancer mediates cancer stemness and gemcitabine resistance.
Cell Oncol (Dordr). 2024 Oct 28. doi: 10.1007/s13402-024-00998.
Abstract

WEI Z, Bai X, Xv Y, Chen SH, et al
A radiomics-based interpretable machine learning model to predict the HER2 status in bladder cancer: a multicenter study.
Insights Imaging. 2024;15:262.
Abstract

SOLEDER S, Gengenbacher N, Mogler C, Eckstein M, et al
Development of a novel immunocompetent murine tumor model for urothelial carcinoma using in vivo electroporation.
Sci Rep. 2024;14:25619.
Abstract

AN S, Shi L, Liu Y, Ren L, et al
Comparison of Extracorporeal and Intracorporeal Urinary Diversion after Robot-Assisted Radical Cystectomy for Bladder Cancer: A Meta-Analysis.
Am J Mens Health. 2024;18:15579883241274866.
Abstract

BUELL M, Hu B
Rapid onset severe hyperkalemia during robotic radical cystectomy: a case report.
Can J Urol. 2024;31:12026-12029.
Abstract

STEFFENS D, Koh C, Hirst N, Cole R, et al
Prehabilitation in patients undergoing bladder cancer surgery - A systematic review and meta-analysis.
Can J Urol. 2024;31:12004-12012.
Abstract

JOTATSU Y, Arbiser JL, Moriwaki M, Hirata Y, et al
Dibenzolium induces apoptosis and inhibits epithelial-mesenchymal transition (EMT) in bladder cancer cell lines.
Sci Rep. 2024;14:25501.
Abstract

BAANA M, Arkwazi M, Zhao Y, Ofagbor O, et al
Using artificial intelligence for bladder cancer detection during cystoscopy and its impact on clinical outcomes: a protocol for a systematic review and meta-analysis.
BMJ Open. 2024;14:e089125.
Abstract

ZHANG J, Xu H, He Y, Zheng X, et al
Inhibition of KDM4A restricts SQLE transcription and induces oxidative stress imbalance to suppress bladder cancer.
Redox Biol. 2024;77:103407.
Abstract

TURAL D, Arslan C, Selcukbiricik F, Olmez OF, et al
Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer.
Clin Genitourin Cancer. 2024;22:102228.
Abstract

GUO Y, Zhang Y, Mao S, Zhang W, et al
Risk of subsequent primary cancers in bladder cancer survivors.
Clin Exp Med. 2024;24:247.
Abstract

RUSSO F, Esposito S, Tripodi L, Pandolfo SD, et al
Insights into Porphyromonas somerae in Bladder Cancer Patients: Urinary Detection by ddPCR.
Microorganisms. 2024;12:2049.
Abstract

PURPUROWICZ P, Kaminski TW, Kordan W, Korzekwa A, et al
A Pilot Study of the Role of Semaphorin 4A (sema4A) and 3C (sema3C) in Non-Muscle-Invasive Bladder Cancer (NMIBC).
Biomedicines. 2024;12:2407.
Abstract

MAGRI V, Marino L, Del Giudice F, De Meo M, et al
Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients.
Biomedicines. 2024;12:2359.
Abstract

MIN K, Zheng CM, Kim S, Kim H, et al
Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment.
Int J Mol Sci. 2024;25:11157.
Abstract

DANISHUDDIN, Haque MA, Khan S, Kim JJ, et al
Molecular Landscape of Bladder Cancer: Key Genes, Transcription Factors, and Drug Interactions.
Int J Mol Sci. 2024;25:10997.
Abstract

GUPTA A, Verma S, Gupta S
Comparison between N-803 and Erdafitinib in Bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:3445.
Abstract

SUNNETCI KM, Oguz FE, Ekersular MN, Gulenc NG, et al
Comparative Bladder Cancer Tissues Prediction Using Vision Transformer.
J Imaging Inform Med. 2024 Oct 25. doi: 10.1007/s10278-024-01228.
Abstract

LI H, Sui Y, Tao Y, Cao J, et al
Coupling Habitat Radiomic Analysis with the Diversification of the Tumor ecosystem: Illuminating New Strategy in the Assessment of Postoperative Recurrence of Non-Muscle Invasive Bladder Cancer.
Acad Radiol. 2024 Oct 24:S1076-6332(24)00685-8. doi: 10.1016/j.acra.2024.
Abstract

SUN S, Li H, Liu S, Xie X, et al
Long noncoding RNA UCA1 inhibits epirubicin-induced apoptosis by activating PPARalpha-mediated lipid metabolism.
Exp Cell Res. 2024;442:114271.
Abstract

WEI W, Wang S, Hu M, Tong X, et al
Impact of multi-parameter images obtained from dual-energy CT on radiomics to predict pathological grading of bladder urothelial carcinoma.
Abdom Radiol (NY). 2024;49:4324-4333.
Abstract

BERTZ S, Bahlinger V, Lange F, Hartmann A, et al
[Muscle-invasive and metastatic urothelial carcinoma of the urinary bladder : Current state of histopathologic, molecular, and immunologic prognostic and predictive factors].
Pathologie (Heidelb). 2024;45:363-370.
Abstract

PARK JH, Kim M, Yoon J, Park I, et al
Tumor necrosis in magnetic resonance imaging predicts urothelial carcinoma with squamous differentiation in muscle-invasive bladder carcinoma.
Abdom Radiol (NY). 2024;49:4341-4351.
Abstract

BAHLINGER V, Stoehr R, Hartmann A, Hes O, et al
Small cell neuroendocrine carcinoma and poorly differentiated rhabdomyosarcomas of the urinary bladder in adults-A comparative analysis in favor of a common histogenesis.
Virchows Arch. 2024;485:615-623.
Abstract

DENG H, Ji G, Ma J, Cai J, et al
RNF19A inhibits bladder cancer progression by regulating ILK ubiquitination and inactivating the AKT/mTOR signalling pathway.
Biol Direct. 2024;19:102.
Abstract

XU H, Chen Y, Ye L, Zheng H, et al
[Application of Magnetic Resonance Imaging Report Combined With VI-RADS Bi-Parametric and Multi-Parametric Scoring Systems in Bladder Cancer Diagnosis].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024;55:1071-1077.
Abstract

DENG J, Zhang M, Yang M, Zhang P, et al
[Clinicopathological Features and Outcomes of Perioperative Treatment for Small Cell Carcinoma of the Bladder].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024;55:1078-1084.
Abstract

SHENG H, Gu J, Huang Y, Kolat D, et al
Cuproptosis-related signature predicts prognosis and indicates tumor immune infiltration in bladder cancer.
Transl Androl Urol. 2024;13:2280-2293.
Abstract

CHEN Z, Zhang Y, Chen T
Prognostic value of neutrophil to lymphocyte ratio for patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.
Front Oncol. 2024;14:1463173.
Abstract

HUANG J, Lin L, Mao D, Hua R, et al
Prognostic value of neutrophil-to-lymphocyte ratio in patients with non-muscle-invasive bladder cancer with intravesical Bacillus Calmette-Guerin immunotherapy: a systematic review and meta-analysis.
Front Immunol. 2024;15:1464635.
Abstract

FITZPATRICK M, Yankelevich GR, Drerup J, Grubb RL, et al
First Reported Case of Bronchoperitoneal Fistula From Bladder Cancer Metastasis Treated With the Novel Utilisation of an Endobronchial Valve.
Cureus. 2024;16:e71025.
Abstract

MONJARAS-AVILA CU, Luque-Badillo AC, Bacon JVM, Wyatt AW, et al
A novel approach to engineering three-dimensional bladder tumor models for drug testing.
Sci Rep. 2024;14:26883.
Abstract

HO JN, Byun SS, Kim D, Ryu H, et al
Dasatinib induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells.
Investig Clin Urol. 2024;65:593-602.
Abstract

MOTLAGHZADEH S, Tabatabaei F, Eshragh F, Tavakoli A, et al
Association of viral infection with bladder cancer: A systematic review and meta-analysis.
Pathol Res Pract. 2024;264:155633.
Abstract

KONTA S, Hashimoto K, Shindo T, Kobayashi K, et al
Ideal cystoscopic interval after nephroureterectomy in patients with upper tract urothelial carcinoma.
World J Urol. 2024;42:629.
Abstract

SCILIPOTI P, Moschini M, de Angelis M, Afferi L, et al
The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer.
World J Urol. 2024;42:630.
Abstract

ZOU Y, Yu J, Cai L, Chen C, et al
Prediction of muscular-invasive bladder cancer using multi-view fusion self-distillation model based on 3D T2-Weighted images.
Biomed Tech (Berl). 2024 Nov 6. doi: 10.1515/bmt-2024-0333.
Abstract

ZENG YK, Zhang KY, Xing JC, Li YB, et al
Pleomorphic rhabdomyosarcoma of the adult bladder: a case report.
J Med Case Rep. 2024;18:523.
Abstract

HU XC, Yu QY, Ding HP, Xiao F, et al
Exploration on the construction of a bladder cancer prognostic model based on disulfidptosis-related lncRNAs and its clinical significance.
Sci Rep. 2024;14:26751.
Abstract

IYER G, Tangen CM, Sarfaty M, Regazzi AM, et al
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.
JCO Precis Oncol. 2024;8:e2400287.
Abstract

WATANABE M, Kawamorita N, Shiraiwa T, Sato T, et al
Distant recurrence of non-muscle invasive bladder cancer 8 years after initial treatment.
IJU Case Rep. 2024;7:448-453.
Abstract

AKAND M, Jatsenko T, Muilwijk T, Gevaert T, et al
Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered -omics studies.
Front Oncol. 2024;14:1424293.
Abstract

DIAO M, Li Y, Gao Z, Wang C, et al
Comparison of prognosis after transurethral resection of bladder tumor between solitary and multiple bladder cancers.
Medicine (Baltimore). 2024;103:e40314.
Abstract

KIANMEHR S, Vahabirad M, Seghatoleslam A, Sadeghi E, et al
Prognostic Value of TGF-beta Expression in Bladder Cancer: A Systematic Review and Meta-analysis.
Urol Res Pract. 2024;50:148-153.
Abstract

KURAL S, Pathak AK, Singh S, Jain G, et al
Prospective Assessment of VI-RADS with Muscle Invasion in Urinary Bladder Cancer and Its Implication on Re-Resection/Restaging TURBT Patients.
Ann Surg Oncol. 2024 Nov 4. doi: 10.1245/s10434-024-16424.
Abstract

ZHANG Z, Wu Z, Shen C, Liu Z, et al
Establishing a Murine Superficial Bladder Cancer Model via an Intravesical Cell Administration Technique.
J Vis Exp. 2024;.
Abstract

BEEREN I, Koops C, van der Heijden AG, Aben KKH, et al
Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists.
Bladder Cancer. 2024;10:215-220.
Abstract

DE JONG JJ, de Jong FC, van der Made ACJ, van Casteren NJ, et al
A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer.
Bladder Cancer. 2024;10:233-242.
Abstract

SINGH P, Ballas L, Sonpavde GP, Chen RC, et al
Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer.
Bladder Cancer. 2024;10:199-213.
Abstract

GURRAM S, Rathi N
Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer.
Bladder Cancer. 2024;10:167-182.
Abstract

DING JY, Pan TT, Lu XJ, You XM, et al
Effects of peer-led education on knowledge, attitudes, practices of stoma care, and quality of life in bladder cancer patients after permanent ostomy.
Front Med (Lausanne). 2024;11:1431373.
Abstract

PENG L, Shang W, Guo P, He K, et al
Correction: Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Postinstillation: A Preclinical Study.
Mol Cancer Ther. 2024;23:1681.
Abstract

CHANG L, Xu X, Wu G, Cheng L, et al
Predicting Preoperative Pathologic Grades of Bladder Cancer Using Intravoxel Incoherent Motion and Amide Proton Transfer-Weighted Imaging.
Acad Radiol. 2023 Oct 26:S1076-6332(23)00533-0. doi: 10.1016/j.acra.2023.
Abstract

TAN WS, O'Donnell M, Li R, Kamat AM, et al
Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-inv
Eur Urol Oncol. 2023 Oct 26:S2588-9311(23)00225.
Abstract

OLIVER T, Ramiah D, Mmereki D, Hugo M, et al
Bladder cancer: a retrospective audit at a single radiation oncology unit of an academic hospital in Johannesburg, South Africa.
J Egypt Natl Canc Inst. 2024;36:34.
Abstract

XIE G, Qi T, Yao Y, Feng D, et al
MFAP3L predicts tumor microenvironment status, molecular subtypes and clinical benefit in patients with bladder cancer.
Sci Rep. 2024;14:26545.
Abstract

YANG H, Jin C, Li J, Zhang Z, et al
Causal relationship between bladder cancer and gut microbiota contributes to the gut-bladder axis: A two-sample Mendelian randomization study.
Urol Oncol. 2024 Nov 2:S1078-1439(24)00697-5. doi: 10.1016/j.urolonc.2024.
Abstract

HUA X, Xiang D, Xu J, Zhang S, et al
ISO-upregulated BECN1 specifically promotes LC3B-dependent autophagy and anticancer activity in invasive bladder cancer.
Transl Oncol. 2024;51:102178.
Abstract

KAWASAKI JAI, Pinheiro LCL, da Silva IM, Miqueloto CA, et al
BCL-2 and gamma-H2AX immunostaining profile in urothelial bladder cancer prognosis.
Pathol Res Pract. 2024;264:155680.
Abstract

RAUTIOLA J, Martini A, Mertens LS, Skokic V, et al
Outcomes after robot-assisted radical cystectomy with orthotopic neobladder in women.
World J Urol. 2024;42:617.
Abstract

HUANG H, Dai Z, Jiang Z, Li X, et al
Anti-PD-1 immunotherapy for the treatment of metastatic urothelial carcinoma in a kidney transplant recipient: a case report.
BMC Nephrol. 2024;25:390.
Abstract

CAO Y, Feng J, Zhang Q, Deng C, et al
Magnetic 3D macroporous MOF oriented urinary exosome metabolomics for early diagnosis of bladder cancer.
J Nanobiotechnology. 2024;22:671.
Abstract

HAN Z, Tang Y, Yi X, Li J, et al
Oncological outcomes of organ-sparing cystectomy versus standard radical cystectomy in male patients diagnosed with bladder cancer.
World J Urol. 2024;42:619.
Abstract

BARKER SJ, Soylu E, Allen BC, Auron M, et al
ACR Appropriateness Criteria(R) Pretreatment Staging of Urothelial Cancer: 2024 Update.
J Am Coll Radiol. 2024;21.
Abstract

DOS ANJOS OLIVEIRA E, Cunha Almeida T, Nicioli da Silva G
Oncogenic role of lncRNA SBF2-AS1 in bladder cancer.
Gene. 2024;935:149061.
Abstract

SONG YX, Peng Y, Qin CP, Xu T, et al
[Current applications and translational prospects of omics technologies in urothelial carcinoma].
Zhonghua Wai Ke Za Zhi. 2024;62:1058-1063.
Abstract

NGUYEN DD, Hooper WF, Liu W, Chu TR, et al
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.
Nature. 2024;635:219-228.
Abstract

GRAFF P, Pommier P, Minsat M, Crehange G, et al
[Practice-changing trials: Urological radiation oncology].
Cancer Radiother. 2024;28.
Abstract

MOTIE FM, Soltani Howyzeh M, Ghanbariasad A
Synergic effects of DL-limonene, R-limonene, and cisplatin on AKT, PI3K, and mTOR gene expression in MDA-MB-231 and 5637 cell lines.
Int J Biol Macromol. 2024;280.
Abstract

TIBURCIO-JUNIOR E, Carrazzoni PG, Tenorio-Filho F, Pontes NE, et al
Prolonged detection of BPV2 in urine and blood of papillomatosis-affected cattle not grazing bracken fern.
Vet Res Commun. 2024;48:4061-4065.
Abstract

SHARAN KC, Srinivasan R, Uppal R, Rohilla M, et al
Utility of UroVysion Fluorescence in situ Hybridization in Improving the Diagnostic Performance of Urine Cytology.
Acta Cytol. 2024;68:423-435.
Abstract

RUSSELL BM, Fein DEC, Bellmunt J
Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments.
ESMO Open. 2024;9:103985.
Abstract

SHANG B, Hu Z, Xie R, Wu J, et al
Predictive Value of Neutrophil Extracellular Traps in Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
Mol Carcinog. 2024 Nov 14. doi: 10.1002/mc.23844.
Abstract

KAYAMA E, Uemura M, Onagi A, Meguro S, et al
A Novel Gene Expression Scoring System Predicts Recurrence in Non-Muscle-Invasive Bladder Cancer Patients.
Cancer Med. 2024;13:e70349.
Abstract

ALEXANDER CE, Nathan A, Light A, Gao C, et al
Understanding the long-term impact of the COVID-19 pandemic on non-muscle-invasive bladder cancer outcomes: 12-Month follow-up data from the international, prospective COVIDSurg Cancer study.
BJUI Compass. 2024;5:1044-1051.
Abstract

HUGHES S, Nair R, Radia B, Mavuduru RS, et al
Indian consensus statements on the management of small renal masses, non-muscle invasive bladder cancer and high-risk/locally advanced prostate cancer.
BJUI Compass. 2024;5:1034-1043.
Abstract

DEOL ES, Nabavizadeh R, Lavoie RR, Dumbrava MG, et al
Role of B7-H3 in predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
BJUI Compass. 2024;5:1052-1058.
Abstract

MANNION L, Watson V, Mullassery V, Nair R, et al
Treatment preferences of patients with muscle invasive bladder cancer: A discrete choice experiment.
BJUI Compass. 2024;5:1059-1068.
Abstract

AVUDAIAPPAN AP, Prabhakar P, Siretskiy R, Renshaw A, et al
Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer.
BJUI Compass. 2024;5:1090-1094.
Abstract

MIYAKE M, Iemura Y, Oda Y, Miyamoto T, et al
Bladder preservation with concurrent chemoradiotherapy for muscle-invasive bladder cancer: Retrospective comparison of three regimens.
Bladder (San Franc). 2024;11:e21200009.
Abstract

PENG Y, Song Y, Qin C, Du Y, et al
Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer.
Hum Vaccin Immunother. 2024;20:2425529.
Abstract

HORI K, Yamada S, Murata K, Miyata H, et al
Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization.
Hum Vaccin Immunother. 2024;20:2414542.
Abstract

PRIHADI JC, Hengky A, Lionardi SK, Haruman SP, et al
Characteristics and outcomes in bladder Leiomyoma management: a systematic review of case reports and case series from the past 20 years.
BMC Urol. 2024;24:252.
Abstract

JIAO P, Zheng Q
ASO Author Reflections: How to Efficiently and Accurately Predict the Lymphovascular Invasion Status of Muscle-Invasive Bladder Cancer?
Ann Surg Oncol. 2024 Nov 13. doi: 10.1245/s10434-024-16538.
Abstract

HOU DY, Zhang NY, Zhang P, Li XP, et al
In vivo self-assembled bispecific fluorescence probe for early detection of bladder cancer and metastasis.
Sci Bull (Beijing). 2024 Oct 31:S2095-9273(24)00792.
Abstract

AMIRIAN H, Franco FB, Dabiri B, Alessandrino F, et al
Urologic Imaging of the Bladder: Cancers and Mimics.
Urol Clin North Am. 2025;52:111-124.
Abstract

KWON WA
FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.
J Korean Med Sci. 2024;39:e320.
Abstract

MILOWSKY MI
Toward Curing More Patients with Bladder Cancer - A New Perioperative Strategy.
N Engl J Med. 2024;391:1848-1849.
Abstract

DU S, Yang Y, Wu T, Zhang L, et al
Culture supernatant of Toxoplasma gondii tachyzoites inhibits the proliferation and metastasis of bladder cancer cells.
Oncol Lett. 2024;29:12.
Abstract

SINGH A, Gali KV, Pai V, Hegde P, et al
A diagnostic challenge: Eosinophilic cystitis masquerading as bladder cancer with seminal vesicle invasion.
Asian J Urol. 2024;11:669-670.
Abstract

AHMADI N, Shafee H, Moudi E
Prediction of recurrence risk in patients with non-muscle-invasive bladder cancer.
Asian J Urol. 2024;11:625-632.
Abstract

WAHEED A, Gul MH, Wardak AB, Raja HAA, et al
Nogapendekin alfa inbakicept-PMLN: first approval milestone for BCG-unresponsive noninvasive bladder cancer: editorial.
Ann Med Surg (Lond). 2024;86:6386-6388.
Abstract

WANG Y, Zhao Y, Liu Q, Yang J, et al
Identifying functional cuproptosis-related long non-coding RNAs in patients with bladder cancer.
Transl Cancer Res. 2024;13:5178-5189.
Abstract

STORMOEN DR, Lehn S, Mouw KW, Szallasi Z, et al
Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.
Sci Rep. 2024;14:27448.
Abstract

THOMAS KR, Joshua C, Ibilibor C
Psychological Distress in Bladder Cancer Patients: A Systematic Review.
Cancer Med. 2024;13:e70345.
Abstract

HEARD JR, Ahdoot M, Theodorescu D, Mitra AP, et al
Biomarkers of treatment response in bladder cancer.
Expert Rev Mol Diagn. 2024 Nov 13:1-13. doi: 10.1080/14737159.2024.2428747.
Abstract

WATANABE A, Ogawa Y, Saeki M, Nagata T, et al
Different Patterns of Platelet Count Fluctuation in Response to Various Anticancer Chemotherapies among Patient with Bladder Cancer.
Case Rep Oncol. 2024;17:1277-1281.
Abstract

XIAO Z, Liu X, Wang Y, Jiang S, et al
Comprehensive analysis of single-cell and bulk RNA sequencing reveals postoperative progression markers for non-muscle invasive bladder cancer and predicts responses to immunotherapy.
Discov Oncol. 2024;15:649.
Abstract

LIU B, Wang K, Li Q, Xiao Z, et al
Engineered VNP20009 expressing IL-15&15Ralpha augments anti-tumor immunity for bladder cancer treatment.
Biomaterials. 2024;315:122951.
Abstract

LI S, Shi Y, Dong H, Guo H, et al
Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.
Cancer Med. 2024;13:e70368.
Abstract

LIU L, He JH, Xiao Y
Risk Factors of Suicide After Bladder Cancer Diagnosis and More Information to Development Nomogram.
J Clin Nurs. 2024 Nov 11. doi: 10.1111/jocn.17539.
Abstract

HAMADA K, Nagumo Y, Kandori S, Isoda B, et al
Phospholipase D2 downregulates interleukin-1beta secretion from tumor-associated macrophages to suppress bladder cancer progression.
Cancer Sci. 2024 Nov 11. doi: 10.1111/cas.16393.
Abstract

CAO J, Chen S, Wang J, Fan X, et al
Transcription factor PRRX1-activated ANXA6 facilitates EGFR-PKCalpha complex formation and enhances cisplatin sensitivity in bladder cancer.
Life Sci. 2024;359:123228.
Abstract

GUO W, Zhao S, Yan K, Fan Y, et al
The potential of ESCO2 as a prognostic and immunotherapeutic marker of pan-cancer and its role in anti-PD1 treatment of bladder cancer.
Oncology. 2024 Nov 11:1-26. doi: 10.1159/000542188.
Abstract

KURAL S, Kumar L
ASO Author Reflections: Reevaluating Muscle Invasion in Bladder Cancer: The Role of VI-RADS in Guiding Re-resections/ Re-stage TURBT.
Ann Surg Oncol. 2024 Nov 11. doi: 10.1245/s10434-024-16475.
Abstract

PERSHUKOV IV
[Drug-Eluting Stents - a Panacea for Everyone or Not? Commentary on the Paper <>].
Kardiologiia. 2024;64:74-76.
Abstract

POTIEVSKAYA VI, Choronenko VE, Loenko VB, Rerberg AG, et al
[Perioperative Myocardial Infarction and Successful Revascularization in Patient With Primary Metasynchronic Rectal, Gastric and Bladder Cancer].
Kardiologiia. 2024;64:68-73.
Abstract

TANG Y, Li S, Zhu L, Yao L, et al
Improve clinical feature-based bladder cancer survival prediction models through integration with gene expression profiles and machine learning techniques.
Heliyon. 2024;10:e38242.
Abstract

LI Y, Shi P, Ding Y, Yao Z, et al
Single cell analysis identified a basal cell transition state associated with the development and progression of bladder cancer.
J Transl Med. 2024;22:1010.
Abstract

FAN L, Guo D, Zhu C, Gao C, et al
LRRC45 accelerates bladder cancer development and ferroptosis inhibition via stabilizing NRF2 by competitively KEAP1 interaction.
Free Radic Biol Med. 2024 Nov 8:S0891-5849(24)01023.
Abstract

LI R, Villa NY, Yu X, Johnson JO, et al
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.
Nat Med. 2024 Nov 9. doi: 10.1038/s41591-024-03324.
Abstract

WANG G, Peng T, Chen L, Xiong K, et al
Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin beta1 localization.
Commun Biol. 2024;7:1476.
Abstract

SPAGNUOLO C, Mautone F, Meola AMI, Moccia S, et al
Synergistic Combination of Quercetin and Mafosfamide in Treatment of Bladder Cancer Cells.
Molecules. 2024;29:5176.
Abstract

CARBONELL E, Mercader C, Alfambra H, Narvaez P, et al
The Role of Bladder-Washing Cytology as an Adjunctive Method to Cystoscopy During Follow-Up for Low-Grade TaT1 Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:3708.
Abstract

AKAND M, Veys R, Ost D, Vander Eeckt K, et al
Cohort Profile: VZNKUL-NMIBC Quality Indicators Program: A Flemish Prospective Cohort to Evaluate the Quality Indicators in the Treatment of Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2024;16:3653.
Abstract

LAN K, Zhang Y, Xu Q, Zhang Y, et al
Pyroptosis-related biotargets and network mechanisms of juglone against bladder cancer: An integrated bioinformatics and multiple machine learning.
Asian J Surg. 2024 Nov 7:S1015-9584(24)02345.
Abstract

RICO L, Maqueda M, Blas L, Contreras P, et al
Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture.
BMJ Case Rep. 2024;17:e259977.
Abstract

YONEZAKI S, Shimizu MS, Ota T, Ozasa S, et al
Multiple Arterial Aneurysms in a Patient with Spondylitis Following Intravesical Bacillus Calmette-Guerin Administration for Bladder Cancer: A Case Report.
J Infect Chemother. 2024 Nov 6:S1341-321X(24)00296.
Abstract

NARGIS N, Sens DA, Mehus AA
Knockdown of Keratin 6 Within Arsenite-Transformed Human Urothelial Cells Decreases Basal/Squamous Expression, Inhibits Growth, and Increases Cisplatin Sensitivity.
Cells. 2024;13:1803.
Abstract

ZHANG X, Peng P, Bao LW, Zhang AQ, et al
Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression by Stabilizing c-MYC.
Cells. 2024;13:1798.
Abstract

KLEIN C, Mebroukine S, Madery M, Moisand A, et al
Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target.
Cells. 2024;13:1779.
Abstract

WANG S, Yan X, Lan W, Wang Y, et al
Genetic Alterations in Chromatin Regulatory Genes in Upper Tract Urothelial Carcinoma and Urothelial Bladder Cancer.
Cancer Med. 2024;13:e70398.
Abstract

JIAO P, Yang R, Liu Y, Fu S, et al
Deep learning-based computed tomography urography image analysis for prediction of HER2 status in bladder cancer.
J Cancer. 2024;15:6336-6344.
Abstract

FEGHALY C, Challita R, Hadir HB, Mobayed T, et al
Bladder Cancer Treatments in the Age of Personalized Medicine: A Comprehensive Review of Potential Radiosensitivity Biomarkers.
Biomark Insights. 2024;19:11772719241297168.
Abstract

GORDON NS, McGuigan EK, Ondasova M, Knight J, et al
Comparison and combination of mutation and methylation-based urine tests for bladder cancer detection.
Biomark Res. 2024;12:133.
Abstract

GOYAL S, Periasamy K, Dey T, Vias P, et al
Adjuvant Radiotherapy in Bladder Cancers: A Dosimetric Study Focusing on Ileal Conduit Sparing.
Clin Oncol (R Coll Radiol). 2024;37:103654.
Abstract

SCILIPOTI P, Moschini M, de Angelis M, Longoni M, et al
Risk of Metachronous Upper Tract Urothelial Carcinoma After Ureteral Stenting in Patients With Bladder Cancer.
Clin Genitourin Cancer. 2024;22:102241.
Abstract

UHRBRAND CG, Obad DS, Jensen BT, Jensen JB, et al
Effect of intraoperative methadone in robot-assisted cystectomy on postoperative opioid requirements: A randomized clinical trial.
Acta Anaesthesiol Scand. 2025;69:e14545.
Abstract

HUANG S, Jia K, Shen C, Chen H, et al
[Analysis of Clinicopathological Characteristics and Factors Affecting the Prognosis of Patients With Resectable Sarcomatoid Carcinoma of the Bladder].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024;55:1085-1091.
Abstract

TANG H, Liu X, Ke J, Tang Y, et al
New perspectives of exosomes in urologic malignancies - Mainly focus on biomarkers and tumor microenvironment.
Pathol Res Pract. 2024;263:155645.
Abstract

KHAZAMIPOUR N, Oo HZ, Al-Nakouzi N, Marzban M, et al
Transient CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors.
EMBO Mol Med. 2024;16:2775-2794.
Abstract

BOLEK H, Yazgan SC, Yekeduz E, Urun Y, et al
Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma.
Oncologist. 2024;29:999-1002.
Abstract

MA M, Li X, Jing M, Zhang P, et al
Enhanced Tumor-Targeted Delivery of Arginine-Rich Peptides via a Positive Feedback Loop Orchestrated by Piezo1/integrin beta1 Signaling Axis.
Adv Sci (Weinh). 2024;11:e2409081.
Abstract

ETO S, Kato D, Saeki K, Iguchi T, et al
Comprehensive Analysis of the Tumour Immune Microenvironment in Canine Urothelial Carcinoma Reveals Immunosuppressive Mechanisms Induced by the COX-Prostanoid Cascade.
Vet Comp Oncol. 2024;22:500-512.
Abstract

PARK JY, Yu J, Kim CS, Baek JW, et al
Transcutaneous electrical nerve stimulation and catheter-related bladder discomfort following transurethral resection of bladder tumour: A randomised controlled trial.
Eur J Anaesthesiol. 2024;41:821-830.
Abstract

CHEN C, Zhang Y, Lin Y, Shen C, et al
The prognostic significance and immune characteristics of bone morphogenetic proteins (BMPs) family: A pan-cancer multi-omics analysis.
Technol Health Care. 2024;32:4123-4175.
Abstract

PIRAS A, D'Aviero A, Sanfratello A, Boldrini L, et al
Stereotactic Radiotherapy for Penile Metastasis: Case Report and Systematic Literature Review.
Oncol Res Treat. 2024;47:565-572.
Abstract

CERSOSIMO RJ
Targeted and immunotherapy for the management of advanced urothelial carcinoma of the bladder.
Am J Health Syst Pharm. 2024;81:1109-1123.
Abstract

YU R, Cai L, Gong Y, Sun X, et al
MRI-Based Machine Learning Radiomics for Preoperative Assessment of Human Epidermal Growth Factor Receptor 2 Status in Urothelial Bladder Carcinoma.
J Magn Reson Imaging. 2024 Mar 8. doi: 10.1002/jmri.29342.
Abstract

MA X, Zhang Q, He L, Liu X, et al
Artificial intelligence application in the diagnosis and treatment of bladder cancer: advance, challenges, and opportunities.
Front Oncol. 2024;14:1487676.
Abstract

HASSOUNEH Z, Huang G, Zhang N, Rao M, et al
Commentary: On the Emerging Role of Innate Lymphoid Cells in Bladder Cancer.
J Cancer Immunol (Wilmington). 2024;6:125-134.
Abstract

XIAO Y, Xu D, Bao E, Liu Z, et al
Identification of inflammation related gene signatures for bladder cancer prognosis prediction.
Sci Rep. 2024;14:28867.
Abstract

DAI C, Li Q, Wang L, Zhang J, et al
FENDRR represses Bladder Cancer Cell Proliferation, Stemness, Migration, Invasion, and EMT Process by Targeting miR-18a-5p/AFF4 Axis.
Biochem Genet. 2024 Nov 21. doi: 10.1007/s10528-024-10944.
Abstract

AQERROUT M, Mharrach I, Anouar Tadlaoui K, Laraqui A, et al
Adenomatous Polyposis Coli (APC) Promoter Gene Methylation in Urine-Derived DNA: A Non-invasive Biomarker for Early Bladder Cancer Detection and Tumor Aggressiveness.
Cureus. 2024;16:e72055.
Abstract

LUO Y, Wei S, Yang J, Tan Z, et al
Nomogram for predicting all-cause mortality and cancer-specific mortality after TURBT for non-muscle-invasive bladder cancer.
Sci Rep. 2024;14:28759.
Abstract

LEYDERMAN M, Chandrasekar T, Grivas P, Li R, et al
Metastasis development in non-muscle-invasive bladder cancer.
Nat Rev Urol. 2024 Nov 20. doi: 10.1038/s41585-024-00963.
Abstract

BEIJERT IJ, Wever BMM, Hentschel AE, van den Burgt Y, et al
Bladder cancer detection in urine by novel methylation markers.
Sci Rep. 2024;14:28705.
Abstract

POPOV S V, Guseinov R G, Pomeshkin E V, Skryabin O N, et al
[Comparative study of thulium and holmium laser in non-muscle invasive bladder cancer].
Urologiia. 2024;:81-86.
Abstract

LOS M S, Makov P S, Ukharsky A V
[Studers operation is a fight for the quality of life of the patient].
Urologiia. 2024;:93-97.
Abstract

BAZAEV V V, Setdikova G R, Shibaev A N, Podoinitsin A A, et al
[The case of neuroectodermal pelvic tumor with bladder invasion].
Urologiia. 2024;:87-92.
Abstract

ABOYAN I A, Grigoriev N A, Pacus S M, Shiranov K A, et al
[Endoscopic treatment of obliteration of the ureteral orifice after transurethral resection of bladder tumor. Rendez-vous technique].
Urologiia. 2024;:10-13.
Abstract

DYMOV A M, Lee Yu A, Korchagin M P, Dzharimok A R, et al
[BCG-therapy for non-muscle-invasive bladder cancer: overview of the current trends].
Urologiia. 2024;:116-120.
Abstract

DARENKOV S P, Pronkin E A, Musaev I E, Novikov V A, et al
[En bloc transurethral resection for non-muscle invasive bladder cancer].
Urologiia. 2024;:83-87.
Abstract

KOBAYASHI K, Fujii N, Shimizu K, Hitaka Y, et al
Comparative analysis of oncological outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer utilizing propensity score matching.
Jpn J Clin Oncol. 2024 Nov 20:hyae164. doi: 10.1093.
Abstract

YUCEL C, Dumanli E, Karabacak MC, Akbay EK, et al
Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Muscle-Invasive Bladder Cancer after Radical Cystectomy.
Urol J. 2024 Nov 16. doi: 10.22037/uj.v21i.8266.
Abstract

TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
Correction to: Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-a
Int J Clin Oncol. 2024 Nov 19. doi: 10.1007/s10147-024-02654.
Abstract

YUDOVICH MS, Alzubaidi AN, Raman JD
Artificial Intelligence can Facilitate Application of Risk Stratification Algorithms to Bladder Cancer Patient Case Scenarios.
Clin Med Insights Oncol. 2024;18:11795549241296781.
Abstract

GOUDSCHAAL K, Azzarouali S, Visser J, Admiraal M, et al
Clinical implementation of RTT-only CBCT-guided online adaptive focal radiotherapy for bladder cancer.
Clin Transl Radiat Oncol. 2024;50:100884.
Abstract

STEINMETZ AR, Pierce M, Martini A, Tholomier C, et al
Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon alpha gene therapy in a murine bladder cancer model.
Front Immunol. 2024;15:1387229.
Abstract

YANG T, Luo W, Yu J, Zhang H, et al
Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis.
Front Immunol. 2024;15:1481296.
Abstract

LIU C, Ge H, Shen C, Hu D, et al
NOTCH3 promotes malignant progression of bladder cancer by directly regulating SPP1 and activating PI3K/AKT pathway.
Cell Death Dis. 2024;15:840.
Abstract

WANG KJ, Ye SZ, Jia XL, Wang KY, et al
RON receptor tyrosine kinase as a critical determinant in promoting tumorigenic behaviors of bladder cancer cells through regulating MMP12 and HIF-2alpha pathways.
Cell Death Dis. 2024;15:844.
Abstract

TRIMARCHI R, Migliaccio N, Bucolo GM, Abate C, et al
Spectral CT for non-invasive evaluation of bladder cancer grade.
Abdom Radiol (NY). 2024 Nov 19. doi: 10.1007/s00261-024-04683.
Abstract

HUANG Z, Zhang W, Huang K, Feng J, et al
Determination of serum vitamin D in patients with renal, bladder, and prostate cancer by ultra-performance liquid chromatography-tandem mass spectrometry.
Neoplasma. 2024;71:463-472.
Abstract

HENGKY A, Lionardi SK, Kusumajaya C
Can artificial intelligence aid the urologists in detecting bladder cancer?
Indian J Urol. 2024;40:221-228.
Abstract

KAPOOR VK
How I Manage My Patients with Gall Bladder Cancer?
Indian J Surg Oncol. 2024;15:652-660.
Abstract

YU Y, Zhang C, Chen H, Zhang J, et al
Efficacy and safety analysis of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer.
Front Immunol. 2024;15:1479743.
Abstract

ABUHASANEIN S, Radmann J, Jahnson S, Kjolhede H, et al
Diagnostic Performance of GeneXpert BC as a Triage Test for Patients Presenting with Macroscopic Hematuria Suspicious for Urinary Bladder Cancer: A Multicenter Prospective Case-Control Study.
Eur Urol Open Sci. 2024;70:158-166.
Abstract

ROUANNE M, Chen N, Mariuzza DL, Li F, et al
Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy.
bioRxiv [Preprint]. 2024 Oct 29:2024.10.24.620122.
Abstract

NASELLI A, Pirola GM, Castellani D
Bacillus Calmette-Guerin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice.
Res Rep Urol. 2024;16:299-305.
Abstract

ZHENG L, Wang J, Han S, Zhong L, et al
The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.
J Exp Clin Cancer Res. 2024;43:303.
Abstract

ISLAM MA, Mubashshira S, Rahman MM, Kabir Y, et al
Contribution of ERCC2 rs13181 (Lys751Gln) and rs1799793 (Asp312Asn) polymorphisms to the risk of bladder cancer in Bangladesh.
Cancer Genet. 2024;288-289:126-132.
Abstract

ZHAO F, Xie H, Guan Y, Teng J, et al
A redox-related lncRNA signature in bladder cancer.
Sci Rep. 2024;14:28323.
Abstract

D'ANDREA D, Mostafid H, Gontero P, Shariat S, et al
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guerin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.
Eur Urol Oncol. 2024 Nov 12:S2588-9311(24)00242.
Abstract

CHUNG Y, Lee S, Jeong BC, Ku JH, et al
Risk factors for urinary retention after robot-assisted radical cystectomy with orthotopic neobladder diversion: a multicenter study.
J Robot Surg. 2024;19:1.
Abstract

KIM JM, Park S
Pitfalls of frozen section diagnosis in ureter margin evaluation of plasmacytoid urothelial carcinoma of urinary bladder.
BMC Urol. 2024;24:254.
Abstract

CHOI H, Jeong SH, Simo C, Bakenecker A, et al
Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy.
Nat Commun. 2024;15:9934.
Abstract

TAKEUCHI M, Higaki A, Kojima Y, Ono K, et al
Comparative analysis of image quality and diagnostic performance among SS-EPI, MS-EPI, and rFOV DWI in bladder cancer.
Jpn J Radiol. 2024 Nov 16. doi: 10.1007/s11604-024-01694.
Abstract

LI C, Yuan H, Chen J, Shang K, et al
The oncogenic functions of SPARCL1 in bladder cancer.
J Cell Mol Med. 2024;28:e70196.
Abstract

SLOTMAN E, Richters A, Fransen HP, Smilde TJ, et al
Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns.
Urol Oncol. 2024 Nov 14:S1078-1439(24)00705.
Abstract

KADOURI Y, Lakssir J, Elaboudi A, El Sayegh H, et al
A challenging case of a multiple large stones in enterocystoplasty: a case report.
Pan Afr Med J. 2024;48:116.
Abstract

GU Y, Ly A, Rodriguez S, Zhang H, et al
PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers.
Cell Rep Med. 2024;5:101824.
Abstract

ZHENG Z, Zhang S, Liu Y, Han Z, et al
Mechanobiology studies of bladder tumor cells using laterally squeezing microfluidic flow cytometry.
Talanta. 2025;282:127090.
Abstract

GU Y, Wang J, Luo Z, Luo X, et al
Multiwavelength Surface-Enhanced Raman Scattering Fingerprints of Human Urine for Cancer Diagnosis.
ACS Sens. 2024;9:5999-6010.
Abstract

MEGURO S, Johmura Y, Wang TW, Kawakami S, et al
Preexisting senescent fibroblasts in the aged bladder create a tumor-permissive niche through CXCL12 secretion.
Nat Aging. 2024;4:1582-1597.
Abstract

GRIFFIN J, Hartmann A, Comperat E
Variation in cystectomy pathology reporting practice-results from an international survey of 212 pathologists.
Virchows Arch. 2024;485:879-888.
Abstract

AKBAS P, Bektas S, Yazici G
The association between variant histology and prognostic, histomorphological and clinical aspects of bladder urothelial carcinoma.
Ann Diagn Pathol. 2024;73:152373.
Abstract

PINARD A, Chen C, Van Ziffle J, Simko JP, et al
Next-generation sequencing has diagnostic utility in challenging small/flat urothelial lesions.
Ann Diagn Pathol. 2024;73:152370.
Abstract

GRAJALES V, Lin JY, Sharbaugh D, Pere M, et al
Factors influencing readmission patterns following radical cystectomy: An analysis of social determinants and discharge outcomes.
Urol Oncol. 2024;42:449.
Abstract

FONTES MS
A global view of the challenges and limitations of precision medicine for genitourinary cancers.
Urol Oncol. 2024;42:389-391.
Abstract

YILMAZ F, Sagir S
Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: Should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method?
Urol Oncol. 2024;42:450.
Abstract

MAHMOUDPOUR SH, Knott C, Kearney M, Russo L, et al
Factors associated with receipt of systemic anticancer treatment for locally advanced or metastatic urothelial carcinoma in England: a population-based study.
Urol Oncol. 2024;42:451.
Abstract

DAHMEN AS, Lazarovich A, Nusbaum DJ, Katebian B, et al
The impact of metabolic syndrome on short term radical cystectomy complications.
Urol Oncol. 2024;42:450.
Abstract

KUMBHAM S, Rahman KMM, Bosmajian C, Bist G, et al
Enhancing PDT efficacy in NMIBC: Efflux inhibitor mediated improvement of PpIX levels and efficacy of the combination of PpIX-PDT and SO-cleavable prodrugs.
Photochem Photobiol. 2024;100:1636-1646.
Abstract

T O'DWYER R, Jiang DM, Kitchlu A, Coulombe AM, et al
Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy.
Future Oncol. 2024;20:2889-2899.
Abstract

GALEA LA, Batrouney A, Flynn M, Christie M, et al
POU2F3-expressing intraepithelial small-cell carcinoma with mixed small-cell carcinoma and conventional-type urothelial carcinoma of the urinary bladder.
Virchows Arch. 2024;485:947-952.
Abstract

RAHMAN KMM, Bist G, Kumbham S, Foster BA, et al
Mitochondrial targeting improves the selectivity of singlet-oxygen cleavable prodrugs in NMIBC treatment.
Photochem Photobiol. 2024;100:1622-1635.
Abstract

FONTES MS, de Almeida DVP, Carcano F, Lages P, et al
Precision medicine for urothelial carcinoma: An international perspective.
Urol Oncol. 2024;42:402-410.
Abstract

XU Z, Wu Y, Bai Y, Chen X, et al
Identification of tumor-antigen signatures and immune subtypes for mRNA vaccine selection in muscle-invasive bladder cancer.
Surgery. 2024 Nov 28:108926. doi: 10.1016/j.surg.2024.
Abstract

ZHOU J, Zhang L, Wu H, Gao SL, et al
Ferroptosis-related lncRNA AL136084.3 is associated with NUPR1 in bladder cancer.
Discov Oncol. 2024;15:730.
Abstract

RASHAD AH, Abdel Hady HH, Assem A, Mohamed ME, et al
Identification of Molecular Subgroups of Muscle-Invasive Urothelial Bladder Cancer and Their Impact on Treatment Outcome.
Asian Pac J Cancer Prev. 2024;25:3953-3965.
Abstract

RAZMI M, Saeednejad Zanjani L, Rahimi M, Sajed R, et al
Nuclear Expression of Dynamin 2 Is Associated With Tumor Aggressiveness in Bladder Cancer Patients: A Bioinformatics and Experimental Approach.
Cancer Rep (Hoboken). 2024;7:e2133.
Abstract

BASHARAT S, Sajjad A, Javaid F, Khan M, et al
EVALUATION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXPRESSION IN UROTHELIAL CARCINOMA: A POSSIBLE PROGNOSTIC ROLE.
J Ayub Med Coll Abbottabad. 2024;36:274-278.
Abstract

DENG D, Xiao J, Liu J, Li H, et al
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer.
J Hematol Oncol. 2024;17:117.
Abstract

KEUM C, Yeom H, Noh TI, Yi SY, et al
Diagnosis of early-stage bladder cancer via unprocessed urine samples at the point of care.
Nat Biomed Eng. 2024 Nov 28. doi: 10.1038/s41551-024-01298.
Abstract

LI Z, Li J, Cao Q, Shen T, et al
Transcription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer.
J Biol Chem. 2024 Nov 26:108024. doi: 10.1016/j.jbc.2024.108024.
Abstract

JEONG MS, Baek SW, Yang GE, Mun JY, et al
Chemoresistance-Motility Signature of Molecular Evolution to Chemotherapy in Non-Muscle-Invasive Bladder Cancer and Its Clinical Implications.
Cancer Lett. 2024 Nov 26:217339. doi: 10.1016/j.canlet.2024.217339.
Abstract

MA Y, Sun Y, Guo H, Yang R, et al
Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies.
Front Immunol. 2024;15:1418131.
Abstract

LI X, Qian B, Chen X, Shen M, et al
The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets.
Front Immunol. 2024;15:1464327.
Abstract

WU L, Zhu K, Sun Y, Li T, et al
Nucleolar protein 3 promotes proliferation of bladder cancer cells through the PI3K-Akt pathway.
World J Surg Oncol. 2024;22:316.
Abstract

YAN X, Li Q, Xiao S, Chen J, et al
Sulfasalazine-loaded nanoframes: A new frontier in bladder cancer therapy through ferroptosis induction.
Colloids Surf B Biointerfaces. 2024;246:114394.
Abstract

BAO Q, Li Y, Chen Y, Zheng J, et al
Transcriptome-Based Network Analysis Related to Histone Deacetylase Genes and Identified EMP1 as a Potential Biomarker for Prognosis in Bladder Cancer.
Clin Genitourin Cancer. 2024;23:102262.
Abstract

GOFRIT ON, Goldberg SN, Lorber A, Duvdevani M, et al
Quantifying treatment burden: the patient burden score a study of 758 patients across three clinical urologic scenarios.
World J Urol. 2024;42:650.
Abstract

LIU LY, Tian L, Gao LH, Cui HJ, et al
E2F8 facilitates malignant phenotypes of muscle-invasive bladder cancer via increasing MCM7 expression.
Biochem Cell Biol. 2024 Nov 27. doi: 10.1139/bcb-2024-0083.
Abstract

SHARMA A, Raghavendra RT, Biswal D, Yadav P, et al
Rationale of restaging transurethral resection of bladder tumor in patients with nonmuscle invasive bladder cancer in the current era.
Urol Ann. 2024;16:288-291.
Abstract

MASSARO M, Ciani R, Grossi G, Cavallaro G, et al
Halloysite Nanotube-Based Delivery of Pyrazolo[3,4-d]pyrimidine Derivatives for Prostate and Bladder Cancer Treatment.
Pharmaceutics. 2024;16:1428.
Abstract

PIRAMIDE F, Sica M, Fondello G, Mesterca G, et al
Use of Multiparametric and Biparametric Magnetic Resonance Imaging in Bladder Cancer Staging: Prospective Observational Study and Analysis of Radiologist Learning Curve.
J Clin Med. 2024;13:6955.
Abstract

BESSA-GONCALVES M, Bras JP, Jesus TT, Prazeres H, et al
TERTmonitor Efficacy and Performance in Detecting Mutations by Droplet Digital PCR.
Genes (Basel). 2024;15:1424.
Abstract

MITIUSHKINA NV, Tiurin VI, Anuskina AA, Bordovskaya NA, et al
Use of 3' Rapid Amplification of cDNA Ends (3' RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas.
Int J Mol Sci. 2024;25:12126.
Abstract

MLYNARCZYK G, Miklosz A, Chabowski A, Baranowski M, et al
Urothelial Urinary Bladder Cancer Is Characterized by Stage-Dependent Aberrations in Metabolism of Bioactive Sphingolipids.
Int J Mol Sci. 2024;25:11889.
Abstract

CROITOR A, Dema V, Latcu S, Bardan R, et al
Clinical and Pathological Characteristics of Bladder Cancer in Patients Aged 18-45 Undergoing Transurethral Resection of Bladder Tumor.
Biomedicines. 2024;12:2449.
Abstract

HASSOUNEH Z, Noel ODV, Ji N, Kim ME, et al
Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer.
Cancers (Basel). 2024;16:3875.
Abstract

CANO BARBADILLA T, Alvarez Perez M, Prieto Cuadra JD, Dawid de Vera MT, et al
The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder Cancer.
Diagnostics (Basel). 2024;14:2501.
Abstract

ABOU CHAKRA M, Packiam VT, McElree IM, Mott SL, et al
The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer.
Urol Oncol. 2024 Nov 25:S1078-1439(24)00692.
Abstract

HE Y, Xiang L, Yuan J, Yan H, et al
Lactylation Modification as a Promoter of Bladder Cancer: Insights from Multi-Omics Analysis.
Curr Issues Mol Biol. 2024;46:12866-12885.
Abstract

TAYLOR J, Patel S, Gaitonde K, Greene K, et al
The Management of Non-Muscle-Invasive Bladder Cancer in a Veteran Patient Population: Issues and Recommendations.
Curr Oncol. 2024;31:6686-6698.
Abstract

LERNER SP, Tangen C, Svatek RS, Daneshmand S, et al
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
N Engl J Med. 2024;391:1206-1216.
Abstract

SHI T, Yu D, Xu Y, Huang X, et al
Analysis of postoperative complications in bladder cancer patients.
Open Med (Wars). 2024;19:20241069.
Abstract

LU X, Ge LP, Liu Z, Zhu Y, et al
CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer.
Front Oncol. 2024;14:1498579.
Abstract

LI M, Varble NA, Gurram S, Long D, et al
Bladder image stitching algorithm for navigation and referencing using a standard cystoscope.
Sci Rep. 2024;14:29168.
Abstract

STEINER L, Eldh M, Offens A, Veerman RE, et al
Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer.
Cancer Lett. 2024;609:217352.
Abstract

PORAV-HODADE D, Big SA, Barbos VI, Gherle B, et al
Extraperitoneal Open Radical Cystectomy: A New Standard in Frail Patients with Muscle-Invasive Bladder Cancer?
Clin Pract. 2024;14:2559-2567.
Abstract

SHAO Z, Wu G, Tang Y, Hou P, et al
Aptamer-Gadolinium Conjugates for Targeted Magnetic Resonance Imaging of Early-Stage Bladder Cancer.
Anal Chem. 2024 Nov 25. doi: 10.1021/acs.analchem.4c03659.
Abstract

GUO J, Zhang Y, He L, Wang X, et al
Prognostic features of bladder cancer based on five neddylation-related genes.
Am J Clin Exp Urol. 2024;12:240-254.
Abstract

DINH TJ, Rogg M, Cosenza-Contreras M, Li M, et al
Proteomic analysis of non-muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment.
J Pathol. 2024 Nov 25. doi: 10.1002/path.6367.
Abstract

WU X, Zhao Z, Yu W, Liu S, et al
Single-Cell Multiomics Identifies Glycan Epitope LacNAc as a Potential Cell-Surface Effector Marker of Peripheral T Cells in Bladder Cancer Patients.
ACS Chem Biol. 2024 Nov 24. doi: 10.1021/acschembio.4c00635.
Abstract

TASDEMIR MN, Eryuruk U, Oguz U, Tok B, et al
The role of multiparametric magnetic resonance imaging in the differentiation of low- and high-grade non-muscle invasive bladder cancer.
Diagn Interv Radiol. 2024 Nov 25. doi: 10.4274/dir.2024.243004.
Abstract

GAO W, Lou Z
Single center evaluation of sensitivity and specificity of CellDetect assay in early bladder cancer patients.
Sci Rep. 2024;14:29099.
Abstract

ISALI I, Almassi N, Nizam A, Campbell R, et al
State of the Art: The Microbiome in Bladder Cancer.
Urol Oncol. 2024 Nov 23:S1078-1439(24)00724.
Abstract

ROUMIGUIE M, Leon P, Xylinas E, Allory Y, et al
French AFU Cancer Committee Guidelines - Update 2024-2026: Non-muscle invasive bladder cancer (NMIBC).
Fr J Urol. 2024;34:102742.
Abstract

ROUMIGUIE M, Marcq G, Neuzillet Y, Bajeot AS, et al
French AFU Cancer Committee Guidelines - Update 2024-2026: Muscle-invasive bladder cancer (MIBC).
Fr J Urol. 2024;34:102741.
Abstract

SUARTZ CV, Fradet V, Toren P, Ribeiro-Filho LA, et al
Reevaluating the Role of Extended Pelvic Lymphadenectomy in Muscle-Invasive Bladder Cancer: Insights From SWOG S1011 and LEA AB 25-02 Trials.
Clin Genitourin Cancer. 2024;23:102249.
Abstract

SONG DM, Feng K, Luo WF, Lv DS, et al
Predicting survival in bladder cancer with a novel apoptotic gene-related prognostic model.
Discov Oncol. 2024;15:702.
Abstract

LI D, Wu L, Qi L, Yu Q, et al
Pseudouridine synthase 7 (PUS7) affects the prognosis and immune modulation of patients with bladder cancer.
Asian J Surg. 2024 Nov 22:S1015-9584(24)02557.
Abstract

BAUDELIN C, Sargos P, Dinart D, Hennequin C, et al
Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trials.
Crit Rev Oncol Hematol. 2024;205:104557.
Abstract

ARIAFAR A, Mansourabadi Z, Alipoor H, Faghih Z, et al
Gamma-delta T Cells in Bladder Cancer Draining Lymph Nodes.
Iran J Immunol. 2024;21.
Abstract

YAN Y, Huang Z, Zhu Z, Wang Y, et al
IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer.
Cancer Cell Int. 2024;24:386.
Abstract

ZHANG J, Liu S, Wu M, Shi W, et al
Clinical significance and expression of SLC35F6 in bladder urothelial carcinoma.
Diagn Pathol. 2024;19:150.
Abstract

MATSUKAWA A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, et al
Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies.
Eur Urol Focus. 2024 Nov 21:S2405-4569(24)00244.
Abstract

BRASSART C, Coutte A, Wallet J, Meyer E, et al
Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study.
Cancer Radiother. 2024 Nov 21:S1278-3218(24)00169.
Abstract

TRIVEDI H, Kay H, Reines K, Hartzell J, et al
Efficacy of Inpatient, Evidence-Based Tobacco Use Treatment of Patients With Bladder Cancer After Radical Cystectomy.
Clin Genitourin Cancer. 2024;23:102252.
Abstract

YANG YX, Ye GC, Xiang JC, Luo KD, et al
Differential Analysis of Surgical Treatment Modalities in T2N0M0 Bladder Cancer Patients: A Novel Propensity Score-Based Cohort Study.
Clin Genitourin Cancer. 2024;23:102257.
Abstract

GUO C, Xiong X, Zhao X, Li Y, et al
Superhydrophilic Fluorinated Polymer Probe for Zero-Background (19)F MRI with Adaptable Targeting Ability.
ACS Appl Mater Interfaces. 2024;16:65319-65327.
Abstract

GRIVAS P, Barata P, Moon H, Gupta S, et al
Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study.
Clin Genitourin Cancer. 2024;22:102238.
Abstract

SEYEDIN SN, Harada GK, Garemanian E, Rafizadeh D, et al
Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma.
Clin Genitourin Cancer. 2024;22:102243.
Abstract

HARA T, Teishima J, Okamura Y, Suzuki K, et al
Appearance of New Lesions Associate With Poor Prognosis in Pembrolizumab-Treated Urothelial Carcinoma.
Clin Genitourin Cancer. 2024;22:102236.
Abstract

REIKE MJ, Raggi D, Mercinelli C, Cigliola A, et al
Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study.
Clin Genitourin Cancer. 2024;22:102214.
Abstract

MURALI A, Philips MR, Patidar S, Shree S, et al
Total extra-peritoneal approach to radical cystectomy with ureterostomy: A novel technique for the elderly and frail.
Urol Oncol. 2025;43:61.
Abstract

DAHMEN AS, Nusbaum DJ, Lazarovich A, Fialkoff J, et al
Trends in the use of immediate postoperative intravesical chemotherapy following transurethral resection of bladder tumors.
Urol Oncol. 2025;43:62.
Abstract

DE ANGELIS M, Jannello LMI, Siech C, Baudo A, et al
Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma.
Urol Oncol. 2025;43:62.
Abstract

LIVERINGHOUSE C, Sim AJ, Zhang J, Jain RK, et al
A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder.
Clin Genitourin Cancer. 2024;22:102222.
Abstract

STECCA C, Abdeljalil O, Sridhar SS
Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study.
Clin Genitourin Cancer. 2024;22:102215.
Abstract

COTILLAS EA, Bernardo C, Veerla S, Liedberg F, et al
A Versatile and Upgraded Version of the LundTax Classification Algorithm Applied to Independent Cohorts.
J Mol Diagn. 2024;26:1081-1101.
Abstract

SWEIS RF, Gajate P, Morales-Barrera R, Lee JL, et al
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.
JAMA Oncol. 2024;10:1565-1570.
Abstract

GUILBERT A, Lebret T, Oudard S, Audenet F, et al
Real-world evaluation of nivolumab utilization in adjuvant treatment of localized muscle-invasive urothelial carcinoma.
Fr J Urol. 2024;34:102744.
Abstract

SUZUKI S, Gi M, Kobayashi T, Miyoshi N, et al
Urinary bladder carcinogenic potential of 4,4'-methylenebis(2-chloroaniline) in humanized-liver mice.
Toxicol Sci. 2024;202:210-219.
Abstract

ARTILES MEDINA A, Minguez Ojeda C, Subiela Henriquez JD, Muriel Garcia A, et al
Nomograms to Appraise The Risk of Chronic Kidney Disease After Radical Cystectomy: Shifting The Focus to Prevention.
Clin Genitourin Cancer. 2024;22:102205.
Abstract

BEN-DAVID R, Lidagoster S, Geduldig J, Kolanukuduru KP, et al
The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysis.
Urol Oncol. 2025;43:66.
Abstract

KOBAYASHI K, Matsumoto H, Sakano S, Yamamoto M, et al
Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching.
Clin Genitourin Cancer. 2024;22:102212.
Abstract

YU N, Xu C, Jiang Y, Liu D, et al
Characteristics of Abdominal Fat Based on CT Measurements to Predict Early Recurrence After Initial Surgery of NMIBC in Stage Ta/T1.
Clin Genitourin Cancer. 2024;22:102199.
Abstract

YASUDA Y, Numao N, Urasaki T, Oki R, et al
Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution.
Int J Clin Oncol. 2024;29:1925-1930.
Abstract

ZUO W, Zhang J, Xu L, Xiong G, et al
Clinical, Prognosis, and Treatment Effect Features Analysis of Metachronous and Synchronous UTUC and BUC.
Clin Genitourin Cancer. 2024;22:102192.
Abstract

ULLAH A, Lee KT, Chaudhury H, Yasinzai AQK, et al
Prognostic Nomogram, Demographics and Comparative Analysis of Urinary Bladder Small Cell and Large Cell Neuroendocrine Carcinoma.
Clin Genitourin Cancer. 2024;22:102183.
Abstract

MASUDA C, Onishi S, Yorozu K, Kurasawa M, et al
PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model.
Clin Exp Metastasis. 2024;41:909-924.
Abstract

ORSINI A, Bignante G, Lasorsa F, Bologna E, et al
Urachal Carcinoma: Insights From a National Database.
Clin Genitourin Cancer. 2024;22:102175.
Abstract

VECCIA A, Brusa D, Treccani L, Malandra S, et al
Radical cystectomy with stentless urinary diversion: A systematic review and meta-analysis of comparative studies.
Urol Oncol. 2025;43:54-60.
Abstract

KOLL FJ, Weers L, Weigert A, Banek S, et al
Histopathologic, Molecular, and Clinical Profiling of Lymphoepithelioma-like Carcinoma of the Bladder.
Mod Pathol. 2024;37:100588.
Abstract

ZENNAMI K, Sumitomo M, Nukaya T, Takenaka M, et al
Impact of Urethra-Preserving Surgery During Radical Cystectomy: An Optimal Urethral Management in the Robotic Era.
Clin Genitourin Cancer. 2024;22:102146.
Abstract

ABOU CHAAYA C, Ourfali S, Marchand C, Merienne C, et al
Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC.
Fr J Urol. 2024;34:102699.
Abstract

YANG GE, Kim MH, Jeong MS, Lee SY, et al
Association between PDCD6-VNTR polymorphism and urinary cancer susceptibility.
Genes Genomics. 2024;46:1281-1291.
Abstract

HERZBERG H, Babaoof R, Marom R, Veredgorn Y, et al
Sterile Water Versus Glycine in Transurethral Resection of Bladder Tumors-Immunogenic and Clinical Implications.
Eur Urol Focus. 2024;10:796-804.
Abstract

KHALATBARI F, Moafi-Madani M, Amin A
Mixed-Grade Urothelial Carcinoma: Insights Into Clinical Behavior and Prognostic Implications Compared to Pure Low-Grade and High-Grade Urothelial Carcinomas.
Arch Pathol Lab Med. 2024;148:1352-1357.
Abstract

CONTIERI R, Martini A, Mertens LS, Giannatempo P, et al
The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma.
Eur Urol Focus. 2024;10:662-665.
Abstract

HASSLER MR, Moedlagl V, Hindinger H, Krauter J, et al
Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy.
Eur Urol Focus. 2024;10:779-787.
Abstract

PALKOWSKI T, Bibeau F, Thiery-Vuillemin A, Kleinclauss F, et al
High-Risk Non-Muscle Invasive Bladder Cancer: outcomes of patients who cannot benefit from Standard of Care.
Fr J Urol. 2024 Dec 3:102838. doi: 10.1016/j.fjurol.2024.102838.
Abstract

TERZI E, Oz-Bedir BE, Ercan E, Ozdemir-Sanci T, et al
beta-Arbutin and cisplatin: A combined approach to modulating apoptosis, cell viability, and migration in bladder cancer cells.
Toxicol In Vitro. 2024 Dec 3:105985. doi: 10.1016/j.tiv.2024.105985.
Abstract

HU HY, Hu SY, Yang M, Hu Y, et al
Hu similarity coefficient: a clinically oriented metric to evaluate contour accuracy in radiation therapy.
Sci Rep. 2024;14:30215.
Abstract

SILVEIRA BM, Amparo TR, Seibert JB, Almeida TC, et al
Hydromethanolic fraction from Abatia americana (Salicaceae) inhibits T24 bladder cancer cell line and the bacterium Listeria monocytogenes with high selectivity.
Nat Prod Res. 2024 Dec 5:1-5. doi: 10.1080/14786419.2024.2435536.
Abstract

NISHIMURA Y, Oki Y, Nonomura D, Matsuzaki K, et al
[A Case of Secondary Extramammary Paget's Disease Developed at 11 Years after Cystectomy].
Hinyokika Kiyo. 2024;70:335-341.
Abstract

DE SOUSA NETO PI, Pinto VBP, Pianco EDS, Gomes ML, et al
The role of microRNAs in non-invasive diagnosis of bladder cancer: a systematic review.
Einstein (Sao Paulo). 2024;22:eRW0611.
Abstract

SADHUKHAN P, Feng M, Illingworth EJ, Sloma I, et al
YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/ STAT3 pathway and CXCL deregulation.
J Clin Invest. 2024 Nov 21:e171164. doi: 10.1172/JCI171164.
Abstract

CAO N, Cheng F, Zhou J, Liu N, et al
Identification and construction of prognostic clusters and risk-prognosis model based on aging-immune related genes in bladder cancer.
Discov Oncol. 2024;15:742.
Abstract

GABRIEL PE, Ganesan V, Krishnan J, Autorino R, et al
Pure open versus robotic radical cystectomy with intracorporeal urinary diversion: a propensity matched analysis.
World J Urol. 2024;43:13.
Abstract

ROMUNDSTAD L, Raeder J
Does methadone offer any benefits for analgesia over morphine after bladder cancer surgery?
Acta Anaesthesiol Scand. 2025;69:e14552.
Abstract

YANG X, Zheng H, Huang J, Liu Y, et al
Co-inhibition of PGF and VEGFA enhances the effectiveness of immunotherapy in bladder cancer.
Int J Med Sci. 2024;21:2870-2882.
Abstract

ZOU J, Xu B, Luo P, Chen T, et al
Non-coding RNAs in bladder cancer, a bridge between gut microbiota and host?
Front Immunol. 2024;15:1482765.
Abstract

NARA T, Numakura K, Kikuchi A, Sekine Y, et al
[Four Cases of Bladder Cancer in Young Patients with Severe Motor and Intellectual Disabilities].
Hinyokika Kiyo. 2024;70:227-231.
Abstract

TUCCI FA, Pennisi R, Rigiracciolo DC, Filippone MG, et al
Loss of NUMB drives aggressive bladder cancer via a RHOA/ROCK/YAP signaling axis.
Nat Commun. 2024;15:10378.
Abstract

CRUPI E, Costa de Padua T, Marandino L, Fallara G, et al
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review.
JCO Precis Oncol. 2024;8:e2400470.
Abstract

FERRO M, Tataru OS, Fallara G, Fiori C, et al
Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guerin response among bladder cancer patients: a novel machine-learning approach.
Minerva Urol Nephrol. 2024 Dec 3. doi: 10.23736/S2724-6051.24.05876.
Abstract

DALL CP, Liu X, Faraj KS, Srivastava A, et al
Hospital Quality and Racial Differences in Outcomes After Genitourinary Cancer Surgery.
Cancer Med. 2024;13:e70436.
Abstract

YANG E, Ji L, Zhang X, Jing S, et al
Identification of a Novel Mesenchymal Stem Cell-Related Signature for Predicting the Prognosis and Therapeutic Responses of Bladder Cancer.
Stem Cells Int. 2024;2024:6064671.
Abstract

ZHANG Z, Liu F, Yu Y, Xie F, et al
Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosis.
PeerJ. 2024;12:e18530.
Abstract

LI L, Guo Y, Wang C, Chang R, et al
[High expression of miR-204-5p promotes malignant behaviors of bladder cancer cells by negatively regulating RAB22A].
Nan Fang Yi Ke Da Xue Xue Bao. 2024;44:2235-2242.
Abstract

A two-phase point-of-care diagnostic device for bladder cancer.
Nat Biomed Eng. 2024 Dec 2. doi: 10.1038/s41551-024-01301.
Abstract

CAMPBELL T, Hunt TC, Li A, Cheng Z, et al
Analysis of Genitourinary Rhabdomyosarcoma in Phase 3 clinical trials.
World J Urol. 2024;43:6.
Abstract

RETRACTION: Upregulation of LncRNA SnoRNA Host Gene 6 Regulates NUAK Family SnF1-like Kinase-1 Expression by Competitively Binding MicroRNA-125b and Interacting with Snail1/2 in Bladder Cancer.
J Cell Biochem. 2024 Dec 1:e30676. doi: 10.1002/jcb.30676.
Abstract

MALSHY K, Steidle M, Tabayoyong W, Messing EM, et al
Letter to the Editor: Risk of Metachronous Upper Tract Urothelial Carcinoma After Ureteral Stenting in Patients With Bladder Cancer.
Clin Genitourin Cancer. 2024;23:102263.
Abstract

WU L, Yang E, Zhang Y, Yin B, et al
An immune-related lncRNA signature for predicting overall survival and chemotherapy sensitivity in bladder cancer patients.
Asian J Surg. 2024 Nov 29:S1015-9584(24)02515.
Abstract

LIU B, Chen M, Liang Y, Mei Z, et al
ZC3H13 promotes autophagy in bladder cancer through m6A methylation modification of PJA2 and ubiquitination of KSR1.
Hum Cell. 2024;38:23.
Abstract

MYERS AA, Fang AM, Moussa MJ, Hwang H, et al
Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder.
ESMO Open. 2024;9:103964.
Abstract

DAN W, Fan Y, Wang Y, Hou T, et al
The Tumor Suppressor TPD52-Governed Endoplasmic Reticulum Stress is Modulated by APC(Cdc20).
Adv Sci (Weinh). 2024;11:e2405441.
Abstract

HUANG SY, Yu TS, Lin JH, Liu WH, et al
Stable laminar shear stress induces G1 cell cycle arrest and autophagy in urothelial carcinoma by a torque sensor-coupled cone-and-plate device.
Eur J Cell Biol. 2024;103:151451.
Abstract

WANG X, Zhang P, Yan J, Huang J, et al
SIRT6 deficiency impairs the deacetylation and ubiquitination of UHRF1 to strengthen glycolysis and lactate secretion in bladder cancer.
Cell Biosci. 2024;14:153.
Abstract

SEVKO A, Prevosto C, Ragavan S, Domingos-Pereira S, et al
Immunomonitoring in bladder cancer: a short report on stability of leukocytes and proteins in refrigerated urine samples.
BMC Urol. 2024;24:276.
Abstract

PICHLER R, Fritz J, Maier S, Hassler MR, et al
Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer.
Cancer Immunol Immunother. 2024;74:30.
Abstract

CHO M, Chang H, Kim JH
Integration of bulk and single-cell RNA-seq reveals prognostic gene signatures in patients with bladder cancer treated with immune checkpoint inhibitors.
Cancer Immunol Immunother. 2024;74:28.
Abstract

WU MH, Zhang MH, Hu XD, Fan HX, et al
Proteome-wide Mendelian randomization and therapeutic targets for bladder cancer.
BMC Urol. 2024;24:273.
Abstract

KHOSROBEIGI A, Sichani MM, Rangraz-Jeddi F, Gharakhani DD, et al
A novel smartphone application for bladder cancer management (BCM App): Design, development, and usability evaluation.
J Educ Health Promot. 2024;13:375.
Abstract

PARK SY
Corrigendum to "Computed tomography-based prediction model for identifying patients with high probability of non-muscle-invasive bladder cancer" [Abdominal Radiology (2024) 49:163-172.].
Abdom Radiol (NY). 2024 Dec 19. doi: 10.1007/s00261-024-04763.
Abstract

LIU S, Feng C, Tan L, Zhang D, et al
Single-cell dissection of multifocal bladder cancer reveals malignant and immune cells variation between primary and recurrent tumor lesions.
Commun Biol. 2024;7:1659.
Abstract

HU X, Li G, Kong C, Liu L, et al
Fluorinated chitosan mediated transepithelial delivery of sanguinarine-loaded platinum (IV) prodrug for intravesical instillation therapy of muscle-invasive bladder cancer.
J Control Release. 2024 Dec 17:S0168-3659(24)00866.
Abstract

TASSINARI E, Danielli L, Marchetti A, Rosellini M, et al
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes.
Hum Vaccin Immunother. 2025;21:2440165.
Abstract

EL SAFTAWY E, Aboulhoda BE, Alghamdi MA, Abd Elkhalek MA, et al
Heterogeneity of modulatory immune microenvironment in bladder cancer.
Tissue Cell. 2024;93:102679.
Abstract

NAKAGAWA R, Izumi K, Hiratsuka K, Inaba T, et al
Tumor-associated macrophages promote bladder cancer metastasis through the CCL20-CCR6 axis.
Neoplasia. 2024;60:101103.
Abstract

CANIZO CG, Guerrero-Ramos F, Perez Escavy M, Lodewijk I, et al
Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer.
Oncoimmunology. 2025;14:2438291.
Abstract

WANG YF, Li XG
Application of cryoablation in animal models of bladder and muscle-invasive bladder cancer: a narrative review of current status and future perspectives.
Quant Imaging Med Surg. 2024;14:9653-9666.
Abstract

SEO HK, Jung EH, Song G
Exploring radiotherapy combined with a radiosensitizer for Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
Transl Androl Urol. 2024;13:2354-2357.
Abstract

GUO L, Chen N, Qiu M, Yang J, et al
Immunogenic cell death-related signature predicts prognosis and immunotherapy efficacy in bladder cancer.
Transl Cancer Res. 2024;13:5801-5814.
Abstract

SOLTANI-TEHRANI AM, Kumar A, Pohar KS
Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.
Transl Cancer Res. 2024;13:6489-6502.
Abstract

PATEL M, Moore K, Lichtbroun BL, Stephenson RD, et al
Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review.
Transl Cancer Res. 2024;13:6413-6429.
Abstract

MORGAN D, Berggren KL, Millington G, Smith H, et al
Loss of MK2 Enhances Radiation-Mediated Apoptosis in Bladder Cancer.
World J Oncol. 2024;15:871-881.
Abstract

ZHAO J, Zhang Q, Zhu C, Yuqi W, et al
Prognostic feature based on androgen-responsive genes in bladder cancer and screening for potential targeted drugs.
BioData Min. 2024;17:59.
Abstract

ZHAO Y, Qiu W, Weng X, Gu C, et al
ALK + anaplastic large cell lymphoma involving the bladder: case report and review of the literature.
Diagn Pathol. 2024;19:157.
Abstract

TU CC, Hsieh TH, Chu CY, Lin YC, et al
Targeting PPARgamma via SIAH1/2-mediated ubiquitin-proteasomal degradation as a new therapeutic approach in luminal-type bladder cancer.
Cell Death Dis. 2024;15:908.
Abstract

TAYLOR J, Kamat AM, Annapureddy D, Khene ZE, et al
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guerin in Patients with Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer.
Eur Urol Oncol. 2024 Dec 17:S2588-9311(24)00288.
Abstract

LIEDBERG F, Xylinas E, Gontero P
Reply to Laila Schneidewind, Fabian P. Stangl, Jennifer Kranz, and Gernot Bonkat's Letter to Editor re: Fredrik Liedberg, Evanguelos Xylinas, Paolo Gontero. Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guerin Instillations for Bladder C
Eur Urol Focus. 2024 Dec 17:S2405-4569(24)00260.
Abstract

SCILIPOTI P, Moschini M, Briganti A
Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma.
Cell Rep Med. 2024;5:101873.
Abstract

ZHENG J, Zhang A, Du Q, Li C, et al
Synergistic photoinduction of ferroptosis and apoptosis by a mitochondria-targeted iridium complex for bladder cancer therapy.
J Colloid Interface Sci. 2024;683.
Abstract

ZHOU Z, Chai Y, Li Y, Zhang Y, et al
Lipid metabolism subtypes reflects the prognosis and immune profiles of bladder cancer patients by NMF clustering and building related signature.
Discov Oncol. 2024;15:796.
Abstract

PORSERUD A, Aly M, Steinertz H, Rydwik E, et al
Exercise in primary care after robot-assisted radical cystectomy for urinary bladder cancer - effects on postoperative complications: a secondary analysis of a randomised controlled trial.
Scand J Urol. 2024;59:193-199.
Abstract

ZHAO Z, Jia H, Sun Z, Li Y, et al
A new perspective on macrophage-targeted drug research: the potential of KDELR2 in bladder cancer immunotherapy.
Front Immunol. 2024;15:1485109.
Abstract

ZHAO T, He J, Zhang L, Li H, et al
A multimodal deep-learning model based on multichannel CT radiomics for predicting pathological grade of bladder cancer.
Abdom Radiol (NY). 2024 Dec 18. doi: 10.1007/s00261-024-04748.
Abstract

LIU K, Zhao H, Chen X, Wu H, et al
Association Between Hypoglycemia Agents and Long-term Survival Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin Immunotherapy.
Eur Urol Oncol. 2024 Dec 16:S2588-9311(24)00284.
Abstract

YING W, Zhao Y, He Y, Deng Y, et al
Exosomal miR-184 facilitates bladder cancer progression by targeting AKR1C3 and inducing immune escape via IRF2-CXCL10 axis.
Biochim Biophys Acta Mol Basis Dis. 2024;1871:167627.
Abstract

CHENG J, Wang L, Wang W, Liang H, et al
HSPE1 Inhibits Bladder Cancer Ferroptosis via a Glutathione-Dependent Mechanism by Suppressing GPX4.
Am J Mens Health. 2024;18:15579883241306904.
Abstract

PALETTA P, Mosconi P, Colombo C, Dossena E, et al
[Not Available].
Recenti Prog Med. 2024;115:630-631.
Abstract

HAN L, Yang H, Jiang X, Zhou Z, et al
Prognostic model based on disulfidptosis-related lncRNAs for predicting survival and therapeutic response in bladder cancer.
Front Immunol. 2024;15:1512203.
Abstract

NIE W, Jiang Y, Yao L, Zhu X, et al
Prediction of bladder cancer prognosis and immune microenvironment assessment using machine learning and deep learning models.
Heliyon. 2024;10:e39327.
Abstract

OLEYNIKOVA NA, Sycheva IN, Mikhailov IA, Zhestkov IA, et al
[Patterns of CAF expression in tumors of the genitourinary system].
Arkh Patol. 2024;86:28-35.
Abstract

HOU DY, You Q, Zhang P, Li XP, et al
Cascade-Activatable Nanoprodrug System Augments Sonochemotherapy of Bladder Cancer.
ACS Nano. 2024 Dec 17. doi: 10.1021/acsnano.4c12967.
Abstract

JASZEK N, Bogdanowicz A, Siwiec J, Starownik R, et al
Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.
J Clin Med. 2024;13:7159.
Abstract

KIM J, Ham WS, Koo KC, Lee J, et al
Evaluation of the Diagnostic Efficacy of the AI-Based Software INF-M01 in Detecting Suspicious Areas of Bladder Cancer Using Cystoscopy Images.
J Clin Med. 2024;13:7110.
Abstract

BACH-GRIERA M, Hernandez A, Julian E
Mycobacteria Treatment Inhibits Bladder Cancer Cell Migration, Invasion, and Anchorage-Independent Growth.
Int J Mol Sci. 2024;25:12997.
Abstract

MIKOLASKOVA I, Zvarik M, Szaboova K, Tibenska E, et al
Association of Sympathovagal Imbalance with Increased Inflammation and Impaired Adaptive Immunity in Bladder Cancer Patients.
Int J Mol Sci. 2024;25:12765.
Abstract

RUIZ-LORENTE I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, et al
Exploring the Immunoresponse in Bladder Cancer Immunotherapy.
Cells. 2024;13:1937.
Abstract

YILDIRIM M
Content-Based Image Retrieval and Image Classification System for Early Prediction of Bladder Cancer.
Diagnostics (Basel). 2024;14:2637.
Abstract

PIGNOT G, Barthelemy P, Borchiellini D
Sex Disparities in Bladder Cancer Diagnosis and Treatment.
Cancers (Basel). 2024;16:4100.
Abstract

LIAO K, Li J, He C, Peng J, et al
N6-methyladenosine-modified SRD5A3, identified by IGF2BP3, sustains cisplatin resistance in bladder cancer.
Hum Cell. 2024;38:30.
Abstract

YANG Q, Yuan W, Zhao T, Jiao Y, et al
Magnetic-Powered Spora Lygodii Microrobots Loaded with Doxorubicin for Active and Targeted Therapy of Bladder Cancer.
Drug Des Devel Ther. 2024;18:5841-5851.
Abstract

AHANGAR M, Mahjoubi F, Mowla SJ
Bladder cancer biomarkers: current approaches and future directions.
Front Oncol. 2024;14:1453278.
Abstract

ZHANG Y, Peng L, Zhang Y, Li H, et al
Clinical efficacy and safety of organ-sparing cystectomy: a systematic review and meta-analysis.
PeerJ. 2024;12:e18427.
Abstract

GUO L, Zhao Y, Bai X, Wang X, et al
RRM2 Is a Putative Biomarker and Promotes Bladder Cancer Progression via PI3K/AKT/mTOR Pathway.
J Cell Physiol. 2024 Dec 16:e31501. doi: 10.1002/jcp.31501.
Abstract

AGRAWAL S, Kapoor V, Rahul R, Singh A, et al
A Randomized Study of Consolidation Chemoradiation (CTRT) versus Observation after first line chemotherapy (CT) in Advanced Gall bladder Cancers (GBC):RACE-GB study.
Int J Radiat Oncol Biol Phys. 2024 Dec 13:S0360-3016(24)03706.
Abstract

YANKELEVICH GR, Moreland K, Swancutt MM, Grubb RL, et al
Illuminating the use of photodynamic therapy in urologic oncology.
Can J Urol. 2024;31:12035-12044.
Abstract

SCHNEIDEWIND L, Stangl FP, Kranz J, Bonkat G, et al
Re: Fredrik Liedberg, Evanguelos Xylinas, Paolo Gontero. Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guerin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box? Eur Urol Focus. In press. https:/
Eur Urol Focus. 2024 Dec 13:S2405-4569(24)00258.
Abstract

RAGGI D, Huddart RA
Transformative or transitional? Deciphering the role of NIAGARA in shaping future practice.
Med. 2024;5:1456-1458.
Abstract

MITTAL K, Joshi M
Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward.
Med. 2024;5:1449-1451.
Abstract

CHEN W, Wu S, Chen Y, Li W, et al
USP20 mediates malignant phenotypic changes in bladder cancer through direct interactions with YAP1.
Neoplasia. 2024;60:101102.
Abstract

JOHNSON AM, Johnson A, Hines RB, Zhu X, et al
Racial differences in carcinoma-in-situ and non-muscle-invasive bladder cancer mortality: Accounting for insurance status, black segregation, and neighborhood poverty.
Cancer Epidemiol. 2024;94:102728.
Abstract

DENG M, Zhou Z, Chen J, Li X, et al
Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer.
Adv Sci (Weinh). 2024 Dec 10:e2408599. doi: 10.1002/advs.202408599.
Abstract

YU A, Fu L, Jing L, Wang Y, et al
Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis.
Cell Death Differ. 2024 Dec 13. doi: 10.1038/s41418-024-01434.
Abstract

CONTIERI R, Claps F, Hurle R, Buffi NM, et al
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy.
Urol Oncol. 2024 Dec 12:S1078-1439(24)00748.
Abstract

CARBUNARU S, Neshatvar Y, Do H, Murray K, et al
Survival After Radical Cystectomy for Bladder Cancer: Development of a Fair Machine Learning Model.
JMIR Med Inform. 2024;12:e63289.
Abstract

WANG P, Jiang N, Zhong J, Chen Q, et al
IFI27 enhances bladder cancer immunotherapy response by modulating regulatory T cell enrichment.
J Cancer. 2024;15:6616-6630.
Abstract

YANG S, Jian J, Zhao X, Wang L, et al
Causal Association of Adipose Tissue with Bladder Cancer and the Mediating Effects of Circulating Metabolites: A Mendelian Randomization Study.
J Cancer. 2024;15:6521-6530.
Abstract

GORBOKON N, Wossner N, Ahlburg V, Plage H, et al
Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer.
J Pathol Clin Res. 2025;11:e70012.
Abstract

APOSTOLSKI D, Roitner F
Gastric Outlet Obstruction as a First Symptom of a Non-Muscle Invasive Bladder Cancer (NMIBC) Progression-A Case Report.
Cancer Rep (Hoboken). 2024;7:e70077.
Abstract

ZHU L, Xiao F, Hou Y, Huang S, et al
Identification of anoikis-related molecular patterns and the novel risk model to predict prognosis, tumor microenvironment infiltration and immunotherapy response in bladder cancer.
Front Immunol. 2024;15:1491808.
Abstract

ZHUANG J, Zhou M, Yu H, Zhou R, et al
CircFAM64A(3) promoted bladder cancer proliferation and inhibited CD8 + T cell via sponging to miR-149-5p and activated IL-6/JAK/STAT pathway.
Int Immunopharmacol. 2025;145:113762.
Abstract

MOODY KA, Iofel SS, Clements MB
Health-Related Quality of Life Across the Spectrum of Bladder Cancer: A Current Review.
Curr Urol Rep. 2024;26:21.
Abstract

WU Y, Meng Z, Bao Y, Zhao X, et al
Association between family functioning and delay in seeking medical care of Chinese bladder cancer patients: the mediating effect of coping styles.
Support Care Cancer. 2024;33:15.
Abstract

ZHANG ZR, Liu MQ, Ji Y, Xiao D, et al
Sotorasib inhibits ubiquitination degradation of TXNIP and suppresses glucose metabolism in KRAS(G12C) mutant bladder cancer.
Am J Cancer Res. 2024;14:5251-5268.
Abstract

XIANG Y, Wen Z, Yang M, Lyu H, et al
Case report: A rare case of renal tuberculosis combined with bladder cancer.
Front Oncol. 2024;14:1423744.
Abstract

WU X, Sheng X
Molecular subtyping in urothelial carcinoma treatment.
Cancer Cell. 2024;42:1993-1996.
Abstract

EOM KY, Mann B, Halpern MT
Integrated care among patients with kidney or urinary bladder cancer: An NCI patterns-of-care analysis.
Urol Oncol. 2024 Dec 9:S1078-1439(24)00745-2. doi: 10.1016/j.urolonc.2024.
Abstract

YAO D, Yu W, Ma X, Tian J, et al
A novel necroptosis-related genes signature to predict prognosis and treatment response in bladder cancer.
Front Mol Biosci. 2024;11:1493411.
Abstract

HARADA GK, Seyedin SN, Heutlinger O, Azizi A, et al
A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy.
Adv Radiat Oncol. 2024;10:101671.
Abstract

JIA Y, Wu K, Li X
Association between tumor size and prognosis in bladder cancer: novel classifications and insights from a SEER database analysis.
Front Surg. 2024;11:1489832.
Abstract

TRUONG A, Liu J, Ni C, Yashar S, et al
Chilblain lupus erythematosus associated with erdafitinib therapy in a patient with metastatic bladder cancer.
JAAD Case Rep. 2024;54:62-65.
Abstract

HU W, Zhou Z, Zou F, Huang Y, et al
Harnessing Natural Pollen as Sustained-Release, Mucoadhesive, and Biosafe Drug Microcapsules for Intravesical Instillation in Bladder Cancer Treatment.
Small. 2024 Dec 9:e2406351. doi: 10.1002/smll.202406351.
Abstract

LV Y, Song B, Yang G, Wang Y, et al
In Situ Transformable Nanoparticle Effectively Suppresses Bladder Cancer by Damaging Mitochondria and Blocking Mitochondrial Autophagy Flux.
Adv Sci (Weinh). 2024 Dec 9:e2409425. doi: 10.1002/advs.202409425.
Abstract

LIU Z, Pu X
Orosomucoid 1 interacts with S100A12 and activates ERK signalling to expedite the advancement of bladder cancer.
Cell Adh Migr. 2025;19:1-11.
Abstract

WANG JF, Wang JS, Liu Y, Ji B, et al
Knockdown of integrin beta1 inhibits proliferation and promotes apoptosis in bladder cancer cells.
Biofactors. 2024 Dec 7. doi: 10.1002/biof.2150.
Abstract

CAO Z, Yan R, Chen J, She M, et al
Water-Soluble Fluorescent Sensors for Quantification of Trace Cisplatin in Body Fluids from Clinical Cancer Patients.
J Am Chem Soc. 2024;146:33651-33662.
Abstract

HAMIDI H, Senbabaoglu Y, Beig N, Roels J, et al
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.
Cancer Cell. 2024;42:2098-2112.
Abstract

ROHENA-RIVERA K, You S, Kim M, Billet S, et al
Targeting ketone body metabolism in mitigating gemcitabine resistance.
JCI Insight. 2024;9:e177840.
Abstract

TIAN Y, Ren C, Shi L, Guo Z, et al
Surgical treatment of urachal adenocarcinoma with lung metastasis: A case report and literature review.
Thorac Cancer. 2024;15:2509-2513.
Abstract

KAVAS G, Celik B
Reclassification of Urinary Cytology according to the Paris System for Reporting Urinary Cytology Correlation with Histological Diagnosis.
Acta Cytol. 2024;68:544-554.
Abstract

DI BELLO F, Siech C, de Angelis M, Rodriguez Penaranda N, et al
Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients.
Ann Surg Oncol. 2025;32:583-588.
Abstract

BREAU RH, Lavallee LT, Cagiannos I, Momoli F, et al
Tranexamic Acid During Radical Cystectomy: A Randomized Clinical Trial.
JAMA Surg. 2024;159:1355-1363.
Abstract

SAMARA M, Thodou E, Apostolopoulou C, Vlachostergios PJ, et al
Evaluation of a Cytology-Molecular Co-Test in Liquid-Based Cytology-Processed Urine for Defining Indeterminate Categories of the Paris System.
Acta Cytol. 2024;68:532-543.
Abstract

PARK K, Kim EJ, Kim JY, Kim H, et al
Four versus six cycles of platinum-based chemotherapy for advanced Urothelial carcinoma in the era of immune checkpoint inhibitors: A retrospective cohort study (FOCUS, KCSG-GU23-08).
Curr Probl Cancer. 2024;53:101149.
Abstract

SINGH A, Khan AA, Ahluwalia C, Ahuja S, et al
Diagnostic Accuracy of the Second Edition of the Paris System for Reporting High-Grade Urothelial Carcinoma in Urinary Cytology.
Acta Cytol. 2024;68:525-531.
Abstract

SHAH MS, Hochberg AR, Prebay ZJ, Shah YB, et al
Stent vs Stentless Ileal Conduits After Radical Cystectomy: Is There a Difference in Early Postoperative Outcomes?
Urol Pract. 2025;12:139-146.
Abstract

COEN JJ, Rodgers JP, Saylor PJ, Lee CT, et al
Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial.
Int J Radiat Oncol Biol Phys. 2025;121:153-161.
Abstract

CHANG SJ, Chen WT, Chai CY
Arsenic-induced disruption of circadian rhythms and glutamine anaplerosis in human urothelial carcinoma.
J Trace Elem Med Biol. 2024;86:127507.
Abstract

JEONG HJ, Kang YJ, Choo MS, Jeong SJ, et al
Excluding confusable diseases in patients with presumptive diagnosis of interstitial cystitis: A large patient cohort study.
Int J Gynaecol Obstet. 2025;168:369-376.
Abstract

NAKAGAWA R, Izumi K, Toriumi R, Aoyama S, et al
Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma.
Jpn J Clin Oncol. 2024;54:1329-1335.
Abstract

HAFEEZ S, Warren-Oseni K, Jones K, Mohammed K, et al
Bladder Tumor-Focused Adaptive Radiation Therapy: Clinical Outcomes of a Phase I Dose Escalation Study.
Int J Radiat Oncol Biol Phys. 2025;121:165-175.
Abstract

WONG CH, Ko IC, Leung DK, Yuen SK, et al
Safety and Efficacy of Immediate Hyperthermic Intravesical Chemotherapy Following Transurethral Resection of Bladder Tumour (I-HIVEC).
Eur Urol Oncol. 2024;7:1171-1174.
Abstract

SUBIELA JD, Krajewski W, Gonzalez-Padilla DA, Laszkiewicz J, et al
Unlocking the Potential of Adequate Bacillus Calmette-Guerin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
Eur Urol Oncol. 2024;7:1367-1375.
Abstract

LEE YT, Chen CC, Chao H, Chang CC, et al
Planned Abscopal Effect with Concurrent Pembrolizumab and Ablative Radiotherapy to Pulmonary Metastasis: A Case Report and Review of the Literature.
Curr Oncol. 2024;31:7787-7792.
Abstract

BAZZI N, Jaber S, Saad WA, Al Hassan S, et al
Cutaneous Metastasis of Bladder Cancer: A Systematic Review.
Cureus. 2024;16:e74439.
Abstract

YU Z, Tan G, Yu C, Chen Y, et al
Targeting LncRNA ADAMTS9-AS1 is a Promising Therapeutic Strategy to Inhibit the Progression of Bladder Cancer.
Discov Med. 2024;36:2454-2464.
Abstract

NOUH MR, Ezz Eldin O
Precise vesical wall staging of bladder cancer in the era of precision medicine: has it been fulfilled?
Abdom Radiol (NY). 2024 Dec 27. doi: 10.1007/s00261-024-04786.
Abstract

TING HK, Dou YC, Lin YH, Chen TM, et al
Pyr3 inhibits cell viability and PKCalpha activity to suppress migration in human bladder cancer cells.
Eur J Pharmacol. 2024 Dec 24:177235. doi: 10.1016/j.ejphar.2024.177235.
Abstract

FINATI M, Fanelli A, Cinelli F, Schiavone N, et al
Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series.
World J Urol. 2024;43:47.
Abstract

TSENG WH, Chiang TY, Ho CH, Huang SK, et al
Navigating the obesity paradox in bladder cancer prognosis-insights from the Taiwan National Health Insurance System Database.
Front Nutr. 2024;11:1433632.
Abstract

NAGUIB EM, Ismail EF, Badran DI, Sherief MH, et al
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer.
J Egypt Natl Canc Inst. 2024;36:42.
Abstract

CAO Y, Wang S, Ma J, Long M, et al
Mechanistic insights into SIRT7 and EZH2 regulation of cisplatin resistance in bladder cancer cells.
Cell Death Dis. 2024;15:931.
Abstract

BEIGREZAEI S, Dianati M, Salehi-Abargouei A, Fararouei M, et al
The association between animal protein, plant protein, and their substitution with bladder cancer risk: a pooled analysis of 10 cohort studies.
Eur J Nutr. 2024;64:55.
Abstract

BREMBILLA G, Basile G, Cosenza M, Giganti F, et al
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI.
Radiology. 2024;313:e233020.
Abstract

WANG Y, Zhu J, Liu S, Sun Z, et al
CRISPR-Cas13a Targeting the FGFR3-TACC3 Fusion Gene Inhibits Proliferation of Bladder Cancer Cells in vitro and in vivo.
Onco Targets Ther. 2024;17:1197-1207.
Abstract

LEMBERGER U, Ernhofer B, Krieger S, Bruchbacher A, et al
Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Eur Urol Open Sci. 2024;71:38-48.
Abstract

REN S, Lu Y, Zhang G, Xie K, et al
Integration of Graph Neural Networks and multi-omics analysis identify the predictive factor and key gene for immunotherapy response and prognosis of bladder cancer.
J Transl Med. 2024;22:1141.
Abstract

RABIEN A, Rong D, Rabenhorst S, Schlomm T, et al
Diagnostic performance of Uromonitor and TERTpm ddPCR urine tests for the non-invasive detection of bladder cancer.
Sci Rep. 2024;14:30617.
Abstract

ZHAO X, Qi X, Liu D, Che X, et al
A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System.
Int J Nanomedicine. 2024;19:13461-13483.
Abstract

HUANG Y, Xu M, Ma X, Wang W, et al
Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess.
Front Pharmacol. 2024;15:1503154.
Abstract

ZHANG J, He J, Qiang Z, Zhang J, et al
Methyltransferase like 13 promotes malignant behaviors of bladder cancer cells through targeting PI3K/ATK signaling pathway.
Open Life Sci. 2024;19:20220981.
Abstract

LI J, Jiang Y, Ma M, Wang L, et al
IGF2BP2 Shapes the Tumor Microenvironment by Regulating Monocyte and Macrophage Recruitment in Bladder Cancer.
Cancer Med. 2024;13:e70506.
Abstract

HONDA H, Matsuo T, Mori S, Araki K, et al
[Risk Factor of Cutaneous Symptoms Associated with Enfortumab Vedotin for Urothelial Carcinoma].
Hinyokika Kiyo. 2024;70:361-366.
Abstract

KOTHA NV, Kumar A, Riviere P, Nelson TJ, et al
Patterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2024;23:102229.
Abstract

MINATO A, Yoshii M, Watanabe S, Moriya R, et al
Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer.
Jpn J Clin Oncol. 2024 Dec 22:hyae183. doi: 10.1093.
Abstract

YU X, Wang C, Wang L, Pang Y, et al
Impact of ERAS on Hysteromyomectomy: A Study on Anxiety, Depression, and Ovarian Function.
Altern Ther Health Med. 2024;30:249-255.
Abstract

ONER M, Lin E, Chiu KY, Chen MC, et al
p35/CDK5 Regulates Bladder Cancer Proliferation and Migration and Promotes Higher Tumor Grade and Poor Survival Rate in Patients With Bladder Cancer.
Anticancer Res. 2024;44:543-553.
Abstract

YU SH, Wang CY, Wang SS, Li JR, et al
Comparing Clinical Efficacy of Different Bacillus Calmette-Guerin Strains in Patients With T1 High Grade Bladder Cancer.
Anticancer Res. 2024;44:1299-1307.
Abstract

SHINDO T, Hashimoto K, Takahashi A, Miyamoto S, et al
Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Anticancer Res. 2024;44:1271-1279.
Abstract

SATO R, Watanabe K, Matsushita Y, Watanabe H, et al
Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
Anticancer Res. 2024;44:1417-1423.
Abstract

FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
Anticancer Res. 2024;44:1675-1681.
Abstract

CHEN CH, Chen YC, Chang YC, Hung CH, et al
Taurine Rescues Cancer-induced Atrophy in Human Skeletal Muscle Cells via Ameliorating the Inflammatory Tumor Microenvironment.
Anticancer Res. 2024;44:1963-1971.
Abstract

KOBATAKE K, Ikeda K, Kohada Y, Tasaka R, et al
Muscle-Invasive Bladder Cancer With Hydronephrosis Exhibits a High Frequency of Mutations in Fibroblast Growth Factor Receptor 3 Gene.
Anticancer Res. 2024;44:1947-1954.
Abstract

HUBER F, Wolf I, Storz J, Schultze-Seemann S, et al
Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer.
Anticancer Res. 2024;44:1837-1844.
Abstract

FUKUOKAYA W, Akazawa K, Kimura T
Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
Anticancer Res. 2024;44:2117-2123.
Abstract

FUCHIZAWA H, Ando K, Motoi N, Iizuka T, et al
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-gamma-induced Apoptosis in Urothelial Cancer.
Anticancer Res. 2024;44:1925-1930.
Abstract

ZEKAN D, Hogan T, Jackson B, Jackson G, et al
The Novel Platinum Analog Dicycloplatin Provides Reliable Growth Inhibition of Urothelial Carcinoma Cells In Vitro.
Anticancer Res. 2024;44:3243-3254.
Abstract

SATO M, Sato T, Hozumi C, Han Q, et al
[(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
Anticancer Res. 2024;44:3891-3898.
Abstract

DIONESE M, Bimbatti D, Pierantoni F, Lai E, et al
Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy.
Anticancer Res. 2024;44:4379-4386.
Abstract

JARADAT JH, Idrissi YA, Saeed A
HOOK3 Amplification in Bladder Urothelial Carcinoma: Insights from Gene Expression and Survival Analysis.
Anticancer Res. 2024;44:5175-5185.
Abstract

YIM A, Alberto M, Sharma V, Green A, et al
Near-infrared spectroscopy as a novel method of ex vivo bladder cancer tissue characterisation.
BJU Int. 2024 Jan 18. doi: 10.1111/bju.16226.
Abstract

Significant advances in chemotherapy for both urothelial and renal cancer.
BJU Int. 2024;133:122-123.
Abstract

KLEMM J, Fisch M, Laukhtina E, Dahlem R, et al
Continent diversion is losing its momentum: a nationwide trend analysis from Germany 2005-2021.
BJU Int. 2024;133:154-157.
Abstract

LU SM, Zhang Y, Dong XT, Wang JL, et al
Microchip for detection of cell-free DNA in urine to help identify patients with bladder cancer.
BJU Int. 2024 Jan 30. doi: 10.1111/bju.16271.
Abstract

CONTIERI R, Tan WS, Grajales V, Hensley PJ, et al
Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
BJU Int. 2024 Feb 19. doi: 10.1111/bju.16293.
Abstract

HAAS M, Engelmann SU, Mayr R, Gossler C, et al
A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer.
BJU Int. 2024 Feb 26. doi: 10.1111/bju.16298.
Abstract

TEMPO JA, Sii S, Ischia J, Bolton DM, et al
Lessons from a population-based bladder cancer registry: exploring why survival is not improving.
BJU Int. 2024 Feb 26. doi: 10.1111/bju.16286.
Abstract

VON DEIMLING M, Mertens LS, Furrer M, Li R, et al
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319.
Abstract

HAYNE D, Ong K, Swarbrick N, McCombie SP, et al
The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
BJU Int. 2024 Mar 12. doi: 10.1111/bju.16325.
Abstract

DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al
Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
BJU Int. 2024 Mar 18. doi: 10.1111/bju.16333.
Abstract

LOBO N, Uthayanan L, Uribe-Lewis S, Issa R, et al
Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study.
BJU Int. 2024;133:474-479.
Abstract

LAUKHTINA E, Gontero P, Babjuk M, Moschini M, et al
Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer.
BJU Int. 2024 Apr 16. doi: 10.1111/bju.16371.
Abstract

DITONNO F, Veccia A, Montanaro F, Pettenuzzo G, et al
Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
BJU Int. 2024 Apr 15. doi: 10.1111/bju.16366.
Abstract

LONGONI M, Scilipoti P, Re C, Rosiello G, et al
Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
BJU Int. 2024 Apr 15. doi: 10.1111/bju.16363.
Abstract

VAN KESSEL CS, Palma CA, Solomon MJ, Leslie S, et al
Comparison of urological outcomes and quality of life after pelvic exenteration: partial vs radical cystectomy.
BJU Int. 2024;133 Suppl 4:53-63.
Abstract

BOTROS A, Rival PM, Page F, Davis ID, et al
Quality of transurethral resection of bladder tumour documentation: implications for non-muscle-invasive bladder cancer risk stratification and management.
BJU Int. 2024;133 Suppl 4:7-10.
Abstract

SARI MOTLAGH R, Ghoreifi A, Yanagisawa T, Kawada T, et al
Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis.
BJU Int. 2024 Apr 24. doi: 10.1111/bju.16364.
Abstract

BREE KK, Janes JL, Hensley PJ, Srinivasan A, et al
Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system.
BJU Int. 2024 Apr 29. doi: 10.1111/bju.16380.
Abstract

HAAS M, Kriegmair MC, Breyer J, Sikic D, et al
Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert(R) BC Monitor.
BJU Int. 2024 May 8. doi: 10.1111/bju.16389.
Abstract

PELLEGRINO F, Martini A, Falagario UG, Rautiola J, et al
How can we reduce morbidity after robot-assisted radical cystectomy with intracorporeal neobladder? A report on postoperative complications by the European Association of Urology Robotic Urology Section Scientific Working Group.
BJU Int. 2024;133:673-677.
Abstract

FINOCCHIARO A, Paciotti M, Contieri R, Fasulo V, et al
Assessing long-term upgrade risks in recurrent low-grade non-muscle-invasive bladder cancer, can we deintensify the treatment?
BJU Int. 2024 May 22. doi: 10.1111/bju.16406.
Abstract

Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
BJU Int. 2024;134:4-5.
Abstract

PELLEGRINO F, Scilipoti P, Rosiello G, Longoni M, et al
Long-term functional outcomes after robot-assisted radical cystectomy with intracorporeal ileal orthotopic neobladder.
BJU Int. 2024;134:48-50.
Abstract

TUDERTI G, Mastroianni R, Anceschi U, Bove AM, et al
Learning curve for intracorporeal robotic Padua ileal bladder: 10-year functional assessment from a high-volume single-centre series.
BJU Int. 2024;134:103-109.
Abstract

MYERS AA, Tan WS, de Groot J, Westney OL, et al
'Case of the Month' from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder.
BJU Int. 2024;134:45-47.
Abstract

TAGUCHI S, Kawai T, Nakagawa T, Kume H, et al
Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
BJU Int. 2024;134:43-44.
Abstract

AN X, Xue C, Chen M, Ni M, et al
Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma.
BJU Int. 2024;134:63-71.
Abstract

WOLFF I, Kravchuk AP, Wirtz RM, Schlomm T, et al
Real-world performance of Uromonitor(R) in urothelial bladder cancer detection: a multicentric trial.
BJU Int. 2024 Jun 24. doi: 10.1111/bju.16450.
Abstract

FLAMMIA RS, Tuderti G, Bologna E, Minore A, et al
Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
BJU Int. 2024 Jun 24. doi: 10.1111/bju.16440.
Abstract

ANTONELLI L, Wendel-Garcia PD, Deforth M, Afferi L, et al
Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding.
BJU Int. 2024 Jul 3. doi: 10.1111/bju.16444.
Abstract

REMMELINK MJ, Rip Y, Nieuwenhuijzen JA, Ket JCF, et al
Advanced optical imaging techniques for bladder cancer detection and diagnosis: a systematic review.
BJU Int. 2024 Jul 17. doi: 10.1111/bju.16471.
Abstract

HOLMBERG L, Skogmar S, Garmo H, Hagberg O, et al
Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations.
BJU Int. 2024;134:229-238.
Abstract

MATSUDA A, Taoka R, Miki J, Saito R, et al
Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
BJU Int. 2024;134:207-218.
Abstract

CHAKRA MA, Lassila R, El Beayni N, Mott SL, et al
Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naive non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel.
BJU Int. 2024 Jul 31. doi: 10.1111/bju.16486.
Abstract

SU ZT, Florissi IS, Mahon KM, Li T, et al
Varying the intensity of cystoscopic surveillance for high-risk non-muscle-invasive bladder cancer.
BJU Int. 2024 Aug 29. doi: 10.1111/bju.16521.
Abstract

TAYLOR JI, Kamat AM, O'Donnell MA, Annapureddy D, et al
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.
BJU Int. 2024 Aug 25. doi: 10.1111/bju.16509.
Abstract

VACCARO C, Dewulf K, Richter K, Branger N, et al
Fully sexual-sparing robot-assisted cystectomy: a step-by-step surgical technique.
BJU Int. 2024;134:501-503.
Abstract

ZENNAMI K, Kusaka M, Tomozawa S, Toda F, et al
Impact of an enhanced recovery protocol in frail patients after intracorporeal urinary diversion.
BJU Int. 2024;134:426-433.
Abstract

D'ANDREA D, Soria F, Moschini M, Laukhtina E, et al
Addition of neoadjuvant chemotherapy to a 'quadrifecta' composite in radical cystectomy.
BJU Int. 2024;134:459-464.
Abstract

AFFERI L, Spahn M, Hayoz S, Strebel RT, et al
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
BJU Int. 2024;134:388-397.
Abstract

LIU K, Nicoletti R, Zhao H, Chen X, et al
The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer.
BJU Int. 2024 Sep 10. doi: 10.1111/bju.16493.
Abstract

CONROY S, Jubber I, Noon AP, Rosario DJ, et al
Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.
BJU Int. 2024 Sep 26. doi: 10.1111/bju.16516.
Abstract

MAISCH P, Hwang EC, Kim K, Narayan VM, et al
Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review.
BJU Int. 2024;134:541-550.
Abstract

RIEGER C, Schluchtermann J, Storz E, Kastner L, et al
Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC.
BJU Int. 2024;134:582-588.
Abstract

DEL GIUDICE F, Vestri A, Fegatelli DA, Husch T, et al
VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol.
BJU Int. 2024 Oct 13. doi: 10.1111/bju.16531.
Abstract

GABRIEL PE, Pinar U, Lenfant L, Parra J, et al
Comparative effectiveness of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy for bladder cancer.
BJU Int. 2024 Oct 21. doi: 10.1111/bju.16565.
Abstract

LONE Z, Shin D, Nowacki A, Campbell RA, et al
Body morphometry may predict parastomal hernia following radical cystectomy with ileal conduit.
BJU Int. 2024;134:841-847.
Abstract

DE JONG JJ, Proudfoot JA, Daneshmand S, Svatek RS, et al
A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy.
BJU Int. 2024 Nov 1. doi: 10.1111/bju.16572.
Abstract

DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.
BJU Int. 2024 Oct 27. doi: 10.1111/bju.16571.
Abstract

PACIOTTI M, Diana P, Gallioli A, De Groote R, et al
International consensus panel for transurethral resection of bladder tumours metrics: assessment of face and content validity.
BJU Int. 2024;134:932-938.
Abstract

GUO AA, Zeng K, Bushati Y, Kim P, et al
Cardiopulmonary exercise testing prior to radical cystectomy: a systematic review and meta-analysis.
BJU Int. 2024;134 Suppl 2:22-29.
Abstract

AKDEMIR E, Stuiver MM, van de Kamp MW, der Hulst JB, et al
Long-term quality of life in patients with bladder cancer following radical cystectomy.
BJU Int. 2024 Dec 1. doi: 10.1111/bju.16610.
Abstract

LONGONI M, Di Bello F, Rodriguez Penaranda N, Falkenbach F, et al
Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer.
BJU Int. 2024 Dec 12. doi: 10.1111/bju.16622.
Abstract

HAILE ES, Lone Z, Shin D, Nowacki AS, et al
Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function.
BJU Int. 2024 Dec 9. doi: 10.1111/bju.16606.
Abstract

PFAIL J, Capellan J, Passarelli R, Kaldany A, et al
National Surgical Quality Improvement Program audit of contemporary perioperative care for radical cystectomy.
BJU Int. 2025;135:140-147.
Abstract

JOHN JB, Collins M, Eames S, O'Flynn K, et al
The carbon footprint of the perioperative transurethral resection of bladder tumour pathway.
BJU Int. 2025;135:78-87.
Abstract

SU X, Jin K, Guo Q, Xu Z, et al
Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer.
Br J Cancer. 2024 Jan 11. doi: 10.1038/s41416-023-02572.
Abstract

ZHANG L, Zhang R, Jin D, Zhang T, et al
Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer.
Br J Cancer. 2024 Feb 8. doi: 10.1038/s41416-024-02598.
Abstract

FONT A, Mellado B, Climent MA, Virizuela JA, et al
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
Br J Cancer. 2024;130:434-441.
Abstract

OUYANG Y, Zhong W, Xu P, Wang B, et al
Tumor-associated neutrophils suppress CD8(+) T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis.
Br J Cancer. 2024;130:880-891.
Abstract

JONES RJ, Crabb SJ, Linch M, Birtle AJ, et al
Systemic anticancer therapy for urothelial carcinoma: UK oncologists' perspective.
Br J Cancer. 2024;130:897-907.
Abstract

LU JL, Ye YL, Zheng DD, Shi XY, et al
Temporal dynamics of immune cell patterns in bladder cancer patients receiving Bacillus Calmette-Guerin therapy.
Br J Cancer. 2024 Oct 31. doi: 10.1038/s41416-024-02883.
Abstract

ALEMAN A, Adrien L, Lopez-Serra L, Cordon-Cardo C, et al
Editorial Expression of Concern: Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays.
Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02903.
Abstract

PEIPERT JD, Chang J, Li S, di Pietro A, et al
Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBlSI-18) in patients with advanced urothelial cancer.
Cancer. 2024;130:31-40.
Abstract

NIERENGARTEN MB
Major advancements in first-line treatments for advanced urothelial cancer.
Cancer. 2024;130:333-334.
Abstract

MARTINI DJ, Case KB, Gratz D, Pellegrini K, et al
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.
Cancer. 2024 Jul 3. doi: 10.1002/cncr.35465.
Abstract

NIERENGARTEN MB
New standard of care for bladder cancer.
Cancer. 2024;130:2407.
Abstract

NIERENGARTEN MB
Promising new treatment shows potential for high-risk bladder cancer.
Cancer. 2024;130:3075.
Abstract

NATHAN KK, Follmer KM, Nash MG, Wolff EM, et al
The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient-centered trial.
Cancer. 2024 Oct 14. doi: 10.1002/cncr.35600.
Abstract

BRIGGS LG, Parke SC, Beck KL, Sinha D, et al
Prehabilitative/rehabilitative exercise, nutrition, and psychological support for bladder cancer: A scoping review of randomized clinical trials.
Cancer. 2024 Nov 2. doi: 10.1002/cncr.35608.
Abstract

BERGEROT CD, Schmitz KH, Crane TE, Klaassen Z, et al
Comprehensive care for patients with bladder cancer: Addressing the interplay of physical, nutritional, and emotional well-being.
Cancer. 2024 Nov 28. doi: 10.1002/cncr.35670.
Abstract

HOSNI S, Kilian V, Klumper N, Gabbia D, et al
Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
Cancer Res. 2024;84:725-740.
Abstract

JONES RT, Scholtes M, Goodspeed A, Akbarzadeh M, et al
NPEPPS Is a Druggable Driver of Platinum Resistance.
Cancer Res. 2024;84:1699-1718.
Abstract

ZENG Y, Luo Y, Zhao K, Liu S, et al
m6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis.
Cancer Res. 2024 Jul 24. doi: 10.1158/0008-5472.CAN-23-3703.
Abstract

YANG Y, Suhasini AN, Jiang Z, Liu N, et al
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants.
Cancer Res. 2024;84:2169-2180.
Abstract

KELLER PJ, Adams EJ, Wu R, Cote A, et al
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.
Cancer Res. 2024;84:2501-2517.
Abstract

CUI C, Zhang H, Yang C, Yin M, et al
Inhibition of JNK Signaling Overcomes Cancer-Associated Fibroblast-Mediated Immunosuppression and Enhances the Efficacy of Immunotherapy in Bladder Cancer.
Cancer Res. 2024 Sep 18. doi: 10.1158/0008-5472.CAN-24-0940.
Abstract

PRABAGAR MG, McQueney M, Bommireddy V, Siegel R, et al
THE STING AGONIST VB-85247 INDUCES DURABLE ANTITUMOR IMMUNE RESPONSES BY INTRAVESICAL ADMINISTRATION IN A NON-MUSCLE INVASIVE BLADDER CANCER.
Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-24-1022.
Abstract

PAN J, Xie X, Sheng J, Ju C, et al
Construction and identification of lncRNA/circRNA-coregulated ceRNA networks in gemcitabine-resistant bladder carcinoma.
Carcinogenesis. 2023;44:847-858.
Abstract

PETRYLAK DP, Eigl BJ, George S, Heath EI, et al
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
Clin Cancer Res. 2024;30:63-73.
Abstract

MAGUIRE WF, Lee D, Weinstock C, Gao X, et al
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
Clin Cancer Res. 2024;30:2011-2016.
Abstract

BALASOORIYA ER, Wu Q, Ellis H, Zhen Y, et al
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
Clin Cancer Res. 2024;30:2181-2192.
Abstract

CHELUSHKIN MA, van Dorp J, van Wilpe S, Seignette IM, et al
Platinum-based chemotherapy induces opposing effects on immunotherapy response-related spatial and stromal biomarkers in the bladder cancer microenvironment.
Clin Cancer Res. 2024 Jul 24. doi: 10.1158/1078-0432.CCR-24-0724.
Abstract

ZANG J, Shahatiaili A, Cai MC, Jin D, et al
Genomic profiling and immune phenotyping of neuroendocrine bladder cancer.
Clin Cancer Res. 2024 Sep 3. doi: 10.1158/1078-0432.CCR-24-1277.
Abstract

EISNER JR, de Jong FC, Shibata Y, Mayhew GM, et al
Characterization of Fibroblast Growth Factor Receptor Alterations and Activation in Patients with High-Risk Non-Muscle Invasive Bladder Cancer.
Clin Cancer Res. 2024 Sep 26. doi: 10.1158/1078-0432.CCR-24-2015.
Abstract

BRAVE MH, Maguire WF, Weinstock C, Zhang H, et al
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
Clin Cancer Res. 2024;30:4815-4821.
Abstract

FLECHON A, Morales-Barrera R, Powles T, Alva A, et al
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
Clin Cancer Res. 2024;30:5353-5364.
Abstract

COLBERT L, Jia Y, Sharma A, Hu J, et al
FDA Approval Summary: Nadofaragene firadenovec-vncg for bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
Clin Cancer Res. 2024 Dec 20. doi: 10.1158/1078-0432.CCR-24-2812.
Abstract

MENG XY, Zhou XH, Li S, Shi MJ, et al
Machine Learning-Based Detection of Bladder Cancer by Urine cfDNA Fragmentation Hotspots that Capture Cancer-Associated Molecular Features.
Clin Chem. 2024 Oct 21:hvae156. doi: 10.1093.
Abstract

CALLERIS G, von Deimling M, Kesch C, Soria F, et al
Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology.
Curr Opin Urol. 2024 Mar 1. doi: 10.1097/MOU.0000000000001170.
Abstract

ENGLINGER B
Molecular research in bladder cancer.
Curr Opin Urol. 2024 Apr 12. doi: 10.1097/MOU.0000000000001181.
Abstract

NOSSING C, Herek P, Shariat SF, Berger W, et al
Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.
Curr Opin Urol. 2024 Apr 11. doi: 10.1097/MOU.0000000000001177.
Abstract

ABUFARAJ M, Al Karmi J, Bdeir A
Is there a role for metastasis-directed therapy in bladder cancer?
Curr Opin Urol. 2024 Apr 5. doi: 10.1097/MOU.0000000000001174.
Abstract

ERTL I, Shariat SF, Berger W, Englinger B, et al
Preclinical models for bladder cancer therapy research.
Curr Opin Urol. 2024 Apr 17. doi: 10.1097/MOU.0000000000001182.
Abstract

GRAUSENBURGER R, Herek P, Shariat SF, Englinger B, et al
Recent contributions of single-cell and spatial profiling to the understanding of bladder cancer.
Curr Opin Urol. 2024 Apr 23. doi: 10.1097/MOU.0000000000001183.
Abstract

OBIREDDY SR, Lai WF
Advances in preclinical approaches for intravesical therapy of bladder cancer.
Curr Opin Urol. 2024 May 17. doi: 10.1097/MOU.0000000000001186.
Abstract

FAZEKAS T, Miszczyk M, Matsukawa A, Nyirady P, et al
Defining oligometastatic state in uro-oncological cancers.
Curr Opin Urol. 2024;34:261-265.
Abstract

XIA L, Daneshmand S
Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer?
Curr Opin Urol. 2024 Aug 20. doi: 10.1097/MOU.0000000000001213.
Abstract

LAUKHTINA E, Moschini M, Teoh JY, Shariat SF, et al
Bladder sparing options for muscle-invasive bladder cancer.
Curr Opin Urol. 2024 Sep 3. doi: 10.1097/MOU.0000000000001220.
Abstract

KURNOT JA, Kaye DR
Reducing financial toxicity in bladder cancer care.
Curr Opin Urol. 2024 Sep 2. doi: 10.1097/MOU.0000000000001218.
Abstract

LAUKHTINA E, Moschini M, Teoh JY, Shariat SF, et al
Perioperative platform for muscle-invasive bladder cancer trials: designs and endpoints.
Curr Opin Urol. 2024 Sep 12. doi: 10.1097/MOU.0000000000001228.
Abstract

PFAIL J, Lichtbroun B, Golombos DM, Jang TL, et al
The role of radical cystectomy and lymphadenectomy in the management of bladder cancer with clinically positive lymph node involvement.
Curr Opin Urol. 2024 Sep 26. doi: 10.1097/MOU.0000000000001230.
Abstract

GROBET-JEANDIN E, Roupret M, Seisen T
Novel intravesical therapies and delivery systems for the management of bladder cancer.
Curr Opin Urol. 2024 Oct 8. doi: 10.1097/MOU.0000000000001232.
Abstract

PASTORINO GL, Mercinelli C, Necchi A
The role of MRI in muscle-invasive bladder cancer: an update from the last two years.
Curr Opin Urol. 2024 Nov 12. doi: 10.1097/MOU.0000000000001249.
Abstract

BEN-DAVID R, Mehrazin R, Attalla K, Wiklund P, et al
Tumor-informed circulating tumor DNA in urothelial carcinoma: a promising novel biomarker.
Curr Opin Urol. 2024;34:464-470.
Abstract

HONG H, Qu Y
Letter re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
Eur J Cancer. 2024;207:114173.
Abstract

OZBAY MF, Ilhan Y
Letter Re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
Eur J Cancer. 2024;210:114254.
Abstract

YOLMO P, Siemens DR, Koti M
Predicting Response in TIME and Space: Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
Eur Urol. 2023 Dec 23:S0302-2838(23)03296-7. doi: 10.1016/j.eururo.2023.
Abstract

KIM SK, Byun YJ, Park SH, Piao XM, et al
A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer.
Eur Urol. 2024 Jan 11:S0302-2838(24)00001-0. doi: 10.1016/j.eururo.2024.
Abstract

PEDERZOLI F, Riba M, Venegoni C, Marandino L, et al
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer.
Eur Urol. 2024 Jan 5:S0302-2838(23)03341-9. doi: 10.1016/j.eururo.2023.
Abstract

NAOUN N, Loriot Y
Towards Tailored Adjuvant Therapy in Bladder Urothelial Carcinoma: How Should We Fit Each Size?
Eur Urol. 2024;85:123-124.
Abstract

SRIDHAR SS, Powles T, Climent Duran MA, Park SH, et al
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Eur Urol. 2024;85:154-163.
Abstract

POWLES T, Assaf ZJ, Degaonkar V, Grivas P, et al
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
Eur Urol. 2024;85:114-122.
Abstract

BINHUMAID FS, Goel A, Gordon NS, Abbotts B, et al
Circulating Tumour Dna Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients.
Eur Urol. 2024 Jan 31:S0302-2838(24)00017-4. doi: 10.1016/j.eururo.2024.
Abstract

SHARIAT SF, Laukhtina E
Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S, Izadmehr S, et al. Nat Med 2023;29:2825-34.
Eur Urol. 2024 Feb 14:S0302-2838(24)00066-6. doi: 10.1016/j.eururo.2024.
Abstract

FENG YN, Xie GY, Xiao L
Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95-108.
Eur Urol. 2023;84:e145.
Abstract

PEDERSEN GL, Mogensen K, Rosthoj S, Hermann GG, et al
Reply to Deng-Xiong Li, De-Chao Feng, and Shi Deng's Letter to the Editor re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Blad
Eur Urol. 2023;84:e154.
Abstract

LI DX, Feng DC, Deng S
Re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-gui
Eur Urol. 2023;84:e152-e153.
Abstract

MOSCHINI M, Necchi A, Montorsi F
Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Eur Urol. 2024 Feb 17:S0302-2838(24)00068-X. doi: 10.1016/j.eururo.2023.
Abstract

VAN DER KWAST TH, Bubendorf L, Cheng L
International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer: Main Conclusions and Recommendations.
Eur Urol. 2024 Feb 26:S0302-2838(24)00080-0. doi: 10.1016/j.eururo.2024.
Abstract

GUPTA S, Necchi A
LEAP-011 in Urothelial Cancer. Unraveling the Puzzle: Combination or Cohort?
Eur Urol. 2024;85:239-241.
Abstract

HUELSTER HL, Gould B, Schiftan EA, Camperlengo L, et al
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.
Eur Urol. 2024;85:283-292.
Abstract

MATSUBARA N, de Wit R, Balar AV, Siefker-Radtke AO, et al
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Eur Urol. 2024;85:229-238.
Abstract

HEER R, Tan WS, Gravestock P, Vadiveloo T, et al
Reply to Arnulf Stenzl, Morgan Roupret, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193-4.
Eur Urol. 2024;85:309-312.
Abstract

CAVILLON A, Pouessel D, Houede N, Mathevet F, et al
Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.
Eur Urol. 2024;85:293-300.
Abstract

ALFRED WITJES J, Bruins HM, Carrion A, Cathomas R, et al
Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31].
Eur Urol. 2024 Mar 15:S0302-2838(24)02194-8. doi: 10.1016/j.eururo.2024.
Abstract

LIEDBERG F, Bobjer J
Re: Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data.
Eur Urol. 2024;85:392.
Abstract

LINSCOTT JA, Meeks JJ, Dyrskjot L, Li R, et al
The Elusive Horizon: Biomarkers in Urothelial Carcinoma.
Eur Urol. 2024;85:317-319.
Abstract

DAHM P, Ergun O, Sathianathen N
Re: Pramit Khetrapal, Joanna Kae Ling Wong, Wei Phin Tan, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Contr
Eur Urol. 2024;85:e116.
Abstract

PIRAMIDE F, Turri F, Amparore D, Fallara G, et al
Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes.
Eur Urol. 2024;85:348-360.
Abstract

COX A, Klumper N, Stein J, Sikic D, et al
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
Eur Urol. 2024;85:328-332.
Abstract

DUQUESNE I, de la Taille A
Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol. 2024 Mar 26:S0302-2838(24)02206-1. doi: 10.1016/j.eururo.2024.
Abstract

ZHOU Y, D'Andrea VD, Shanmugam SP, Stelter I, et al
Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.
Eur Urol. 2024 Mar 23:S0302-2838(24)02231-0. doi: 10.1016/j.eururo.2024.
Abstract

BABJUK M
Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol. 2024 Apr 9:S0302-2838(24)02262-0. doi: 10.1016/j.eururo.2024.
Abstract

ST-LAURENT MP, Black PC
Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder Cancer by Abrogating Immunosuppression.
Eur Urol. 2024 Apr 12:S0302-2838(24)02259-0. doi: 10.1016/j.eururo.2024.
Abstract

THALMANN GN
Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Surgery: All Is in the Eye of the Beholder.
Eur Urol. 2024;85:431-432.
Abstract

MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial.
Eur Urol. 2024;85:422-430.
Abstract

ABSOLOM K, Rogers Z, Catto JWF, Bottomley S, et al
Decision Regret Regarding Treatment Choices 1 Year After a New Diagnosis of Bladder Cancer.
Eur Urol. 2024 May 11:S0302-2838(24)02346-7. doi: 10.1016/j.eururo.2024.
Abstract

TILGENER C, Bedke J
Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Eur Urol. 2024;85:591-592.
Abstract

ROSENBERG JE, Mamtani R, Sonpavde GP, Loriot Y, et al
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
Eur Urol. 2024;85:574-585.
Abstract

BABJUK M
Can an En Bloc Technique Improve Outcomes of Endoscopic Surgery for Non-muscle-invasive Bladder Cancer?
Eur Urol. 2024 May 25:S0302-2838(24)02382-0. doi: 10.1016/j.eururo.2024.
Abstract

MYERS AA, Tan WS, Grajales V, Hwang H, et al
Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guerin Have an Effect?
Eur Urol. 2024 Jun 14:S0302-2838(24)02409-6. doi: 10.1016/j.eururo.2024.
Abstract

DEBATIN NF, Bady E, Mandelkow T, Huang Z, et al
Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer.
Eur Urol. 2024;86:42-51.
Abstract

PLIMACK ER, Tangen C, Plets M, Kokate R, et al
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.
Eur Urol. 2024 Jul 12:S0302-2838(24)02453-9. doi: 10.1016/j.eururo.2024.
Abstract

YUEN-CHUN TEOH J, Cheng CH, Tsang CF, Kai-Man Li J, et al
Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial.
Eur Urol. 2024;86:103-111.
Abstract

BECCIA V, Pinterpe G, Iacovelli R
Re: Thomas Powles, Zoe June Assaf, Viraj Degaonkar, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol 2024;85:1
Eur Urol. 2024;86:e44-e45.
Abstract

DRAKE MJ, Birder LA
Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.
Eur Urol. 2024;86:183-184.
Abstract

MANCON S, Ofner H, D'Andrea D
Re: Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-year Outcomes from a Randomized Controlled Trial.
Eur Urol. 2024;86:186-187.
Abstract

DE JONG JJ, Lotan Y, Boormans JL
Re: EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
Eur Urol. 2024 Aug 10:S0302-2838(24)02511-9. doi: 10.1016/j.eururo.2024.
Abstract

COLOMBEL M
Re: Predicting Non-muscle Invasive Bladder Cancer Outcomes Using Artificial Intelligence: A Systematic Review Using APPRAISE-AI.
Eur Urol. 2024 Aug 21:S0302-2838(24)02521-1. doi: 10.1016/j.eururo.2024.
Abstract

BROOKMAN-MAY SD, Kamat AM, May M
Re: Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
Eur Urol. 2024 Aug 19:S0302-2838(24)02553-3. doi: 10.1016/j.eururo.2024.
Abstract

GONTERO P, Birtle A, Capoun O, Comperat E, et al
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update.
Eur Urol. 2024 Aug 17:S0302-2838(24)02514-4. doi: 10.1016/j.eururo.2024.
Abstract

MERRILL NM, Kaffenberger SD, Bao L, Vandecan N, et al
Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.
Eur Urol. 2024 Aug 17:S0302-2838(24)02408-4. doi: 10.1016/j.eururo.2024.
Abstract

COMPERAT E, Wasinger G, Klager J
Re: Metastasis and Recurrence Patterns in the Molecular Subtypes of Urothelial Bladder Cancer.
Eur Urol. 2024 Aug 17:S0302-2838(24)02518-1. doi: 10.1016/j.eururo.2024.
Abstract

BEIJERT IJ, Hagberg O, Gardmark T, Holmberg L, et al
The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non-muscle-invasive Bladder Cancer.
Eur Urol. 2024 Aug 28:S0302-2838(24)02528-4. doi: 10.1016/j.eururo.2024.
Abstract

PLAGE H, Dressler FF, Fendler A
Patient-derived Models: A Promising Frontier in Testing the Efficacy of Drugs for Bladder Cancer.
Eur Urol. 2024 Aug 25:S0302-2838(24)02556-9. doi: 10.1016/j.eururo.2024.
Abstract

LI R, Hensley PJ, Gupta S, Al-Ahmadie H, et al
Bladder-sparing Therapy for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.
Eur Urol. 2024 Aug 24:S0302-2838(24)02516-8. doi: 10.1016/j.eururo.2024.
Abstract

CATALANO M, Santoni M, Roviello G
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Eur Urol. 2024;86:283.
Abstract

CHEN DC, AlSaffar H, Graefen H, Perera S, et al
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Eur Urol. 2024;86:282-283.
Abstract

KLUMPER N, Vera-Badillo FE, Eckstein M, Hadaschik B, et al
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Eur Urol. 2024;86:280-281.
Abstract

ZHOU W, Zu X, Hu J
Re: Srikala S. Sridhar, Thomas Powles, Miguel. A. Climent Duran, et al. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. Eur Ur
Eur Urol. 2024;86:e96.
Abstract

NORDENTOFT I, Lindskrog SV, Birkenkamp-Demtroder K, Gonzalez S, et al
Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
Eur Urol. 2024;86:301-311.
Abstract

MUNOZ-LOPEZ C, Rathi N, Campbell SC
Predicting Renal Function following Nephroureterectomy can Impact Timing of Systemic Chemotherapy.
Eur Urol. 2024;86:378-379.
Abstract

PANEBIANCO V, Briganti A, Efstathiou J, Galgano S, et al
The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee.
Eur Urol. 2024 Sep 23:S0302-2838(24)02606-X. doi: 10.1016/j.eururo.2024.
Abstract

GAKIS G
Re: Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer.
Eur Urol. 2024 Oct 1:S0302-2838(24)02619-8. doi: 10.1016/j.eururo.2024.
Abstract

SHARIAT SF
Navigating the Challenges of BCG-Unresponsive Non-muscle-invasive Bladder Cancer: Insights and Future Directions.
Eur Urol. 2024 Oct 7:S0302-2838(24)02620-4. doi: 10.1016/j.eururo.2024.
Abstract

HUDDART R, Hafeez S, Griffin C, Choudhury A, et al
Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial.
Eur Urol. 2024 Sep 24:S0302-2838(24)02596-X. doi: 10.1016/j.eururo.2024.
Abstract

MYERS AA, Kamat AM
Reply to Christopher Guske, Seyed Behzad Jazayeri, and Roger Li's Letter to the Editor re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Gueri
Eur Urol. 2024 Oct 15:S0302-2838(24)02642-3. doi: 10.1016/j.eururo.2024.
Abstract

GUSKE C, Jazayeri SB, Li R
Re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guerin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027.
Eur Urol. 2024 Oct 14:S0302-2838(24)02638-1. doi: 10.1016/j.eururo.2024.
Abstract

AFFERI L, Cimadamore A, Gallioli A, Pradere B, et al
Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.
Eur Urol. 2025;87:1-4.
Abstract

ATALLAH A, Grossman A, Nauman RW, Pare JF, et al
Systemic versus localized Bacillus Calmette Guerin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
Int J Cancer. 2024 Mar 14. doi: 10.1002/ijc.34897.
Abstract

DI BELLO F, Siech C, Jannello LMI, de Angelis M, et al
Contemporary survival in metastatic bladder cancer patients: A population-based study.
Int J Cancer. 2024 Jul 3. doi: 10.1002/ijc.35077.
Abstract

NESIC M, Rasmussen MH, Henriksen TV, Demuth C, et al
Beyond basics: Key mutation selection features for successful tumor-informed ctDNA detection.
Int J Cancer. 2024;155:925-933.
Abstract

SHARMA A, Kumari L, Ratre BK, Khan MA, et al
Effect of anesthetic technique on antitumor immunity in patients undergoing surgery for gall bladder cancer: A prospective randomized comparative study.
Int J Cancer. 2024 Oct 9. doi: 10.1002/ijc.35179.
Abstract

KIEBACH J, Beeren I, Aben KKH, Witjes JA, et al
Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer.
Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35250.
Abstract

MANN J, Niedermayer K, Krautstrunk J, Abbey L, et al
Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse.
Int J Cancer. 2025;156:389-402.
Abstract

XU M, Gu M, Zhou J, Da J, et al
[Retracted] Interaction of YAP1 and mTOR promotes bladder cancer progression.
Int J Oncol. 2024;64:50.
Abstract

THI TN, Thanh HD, Nguyen VT, Kwon SY, et al
Complement regulatory protein CD46 promotes bladder cancer metastasis through activation of MMP9.
Int J Oncol. 2024;65:71.
Abstract

TSAI TF, Hwang TI, Chen PC, Chen YC, et al
Hyperthermia reduces cancer cell invasion and combats chemoresistance and immune evasion in human bladder cancer.
Int J Oncol. 2024;65:116.
Abstract

NAKAMOTO T, Yoshida T
Response to Comment: Future goals of upper tract urothelial carcinoma endoscopic management.
Int J Urol. 2024;31:90.
Abstract

MORI K, Yanagisawa T, Fukuokaya W, Iwatani K, et al
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
Int J Urol. 2024;31:25-31.
Abstract

KIKUCHI E, Ng CF, Kitamura H, Ku JH, et al
Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific.
Int J Urol. 2024;31:32-38.
Abstract

JUE JS, Alameddine M, Armenakas NA
Future goals of upper tract urothelial carcinoma endoscopic management.
Int J Urol. 2024;31:89.
Abstract

UKIMURA O
Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
Abstract

TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
Abstract

NAGAKAWA S, Shiota M, Takamatsu D, Tsukahara S, et al
Clinical features and oncological outcomes of bladder cancer microsatellite instability.
Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15370.
Abstract

KONDO T
Editorial Comment to Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
Int J Urol. 2024;31:133.
Abstract

SUHARA Y, Urabe F, Yoshihara K, Kurawaki S, et al
Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
Int J Urol. 2024;31:125-132.
Abstract

MORI K, Hatakeyama S, Enokida H, Miyake H, et al
Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
Int J Urol. 2024;31:194-207.
Abstract

ISHIKAWA Y, Tanaka H, Fujiwara M, Nakamura Y, et al
Incidence and predictors of intraoperative hypotension during transurethral bladder tumor resection with oral 5-aminolevulinic acid.
Int J Urol. 2024;31:238-244.
Abstract

MATSUKAWA A, Morizane S, Shimizu R, Teraoka S, et al
Chronic kidney disease and Charlson comorbidity index predict complications after robot-assisted radical cystectomy: A single-center study in Japan.
Int J Urol. 2024;31:231-237.
Abstract

SAKURA Y, Yamashita R, Notsu A, Usui K, et al
Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification.
Int J Urol. 2024 Apr 12. doi: 10.1111/iju.15465.
Abstract

LUO HL
Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
Int J Urol. 2024;31:421.
Abstract

TAOKA R, Sugimoto M
Editorial Comment on Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
Int J Urol. 2024;31:418-419.
Abstract

HIYAMA Y
Editorial comment to Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
Int J Urol. 2024;31:437.
Abstract

URABE F
Letter to the Editor Re: Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
Int J Urol. 2024;31:420.
Abstract

HAYAKAWA N, Kikuchi E
Editorial comment to "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
Int J Urol. 2024;31:402-403.
Abstract

SAZUKA T
Editorial Comment on "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
Int J Urol. 2024;31:401-402.
Abstract

TAGUCHI S
Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
Int J Urol. 2024;31:348.
Abstract

SOWANTHIP D, Zennami K, Bejrananda T, Nukaya T, et al
Older versus younger patients in robot-assisted radical cystectomy with intracorporeal ileal conduit comparing safety and clinical outcomes.
Int J Urol. 2024;31:370-378.
Abstract

KAMEI J, Endo K, Yamazaki M, Sugihara T, et al
Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
Int J Urol. 2024;31:430-437.
Abstract

SASAHARA T, Yanagisawa T, Sugaya S, Hisakane A, et al
Prognostic factors for overall survival in clinical node-positive patients with upper tract urothelial carcinoma.
Int J Urol. 2024;31:386-393.
Abstract

YU TY, Wang HJ, Sung MT, Chuang YC, et al
Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
Int J Urol. 2024;31:410-418.
Abstract

NAKANO J, Urabe F, Kiuchi Y, Takamizawa S, et al
The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study.
Int J Urol. 2024;31:394-401.
Abstract

URABE F, Ito K, Kimura T
Letter to the Editor Re: Balancing diagnostic advancements with cardiovascular considerations in 5-aminolevulinic acid use for bladder tumors.
Int J Urol. 2024;31:452.
Abstract

KAWAI T, Matsuyama H, Kobayashi K, Ikeda A, et al
Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).
Int J Urol. 2024 May 2. doi: 10.1111/iju.15483.
Abstract

MIYAKE M, Nishimura N, Nakahama T, Nishimoto K, et al
Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474.
Abstract

SHIOTA M, Nagakawa S, Tsukahara S, Matsumoto T, et al
Independent validation of genetic risk model to progression after intravesical bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer.
Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15484.
Abstract

MIYAKE M
Editorial Comment from Dr Miyake to Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node
Int J Urol. 2024 May 3. doi: 10.1111/iju.15487.
Abstract

KONDO T
Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Int J Urol. 2024;31:560-561.
Abstract

ISHIHARA H, Takagi T
Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Int J Urol. 2024;31:559-560.
Abstract

KITA Y, Otsuka H, Ito K, Hara T, et al
Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Int J Urol. 2024;31:552-559.
Abstract

TANAKA T, Yamasaki K, Nofuji S, Maehana T, et al
Development and preliminary evaluation of a novel procedure for creation of an ileal conduit stoma aimed at preventing parastomal hernia.
Int J Urol. 2024;31:512-518.
Abstract

HAYAKAWA N, Kikuchi E
Editorial Comment on "Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification
Int J Urol. 2024 May 16. doi: 10.1111/iju.15495.
Abstract

MITSUI Y, Okawa M, Hori S, Uetani M, et al
Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
Int J Urol. 2024 May 31. doi: 10.1111/iju.15509.
Abstract

MIKI J, Fukuokaya W, Taoka R, Saito R, et al
Oncological outcomes of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: A nationwide multi-institutional study.
Int J Urol. 2024 May 31. doi: 10.1111/iju.15505.
Abstract

FU H, Hillman E, Talluri S, Liang L, et al
Comparison of the perioperative outcomes of using the Firefly system with indocyanine green during robotic-assisted cystectomy with urinary diversion.
Int J Urol. 2024;31:646-652.
Abstract

HARA T, Matsushita Y, Harada K, Fujimoto N, et al
Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.
Int J Urol. 2024;31:696-698.
Abstract

UEMURA K, Ito H, Jikuya R, Kondo T, et al
Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
Int J Urol. 2024;31:678-684.
Abstract

NAKAGAWA R, Izumi K, Toriumi R, Aoyama S, et al
Does radical cystectomy have a better prognosis than bladder conservative treatment in the real world?
Int J Urol. 2024;31:628-636.
Abstract

HATTORI Y, Fujiwara T, Hagimoto H, Kokubun H, et al
Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Int J Urol. 2024 Jul 3. doi: 10.1111/iju.15524.
Abstract

YASUDA Y, Numao N, Fujiwara R, Takemura K, et al
Surgical outcomes and predictive value for major complications of robot-assisted radical cystectomy of real-world data in a single institution in Japan.
Int J Urol. 2024;31:724-729.
Abstract

ASAKAWA K, Waratani M, Massey O, Holbrook T, et al
Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.
Int J Urol. 2024;31:730-738.
Abstract

URABE F, Suzuki H, Iwatani K, Kimura T, et al
Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15537.
Abstract

KIKUCHI E, Hayakawa N
Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15541.
Abstract

GIUDICE GC, Sonpavde GP
Editorial Comment on "Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey".
Int J Urol. 2024;31:943-944.
Abstract

CHENG LJ, Kim J, Mukherjee A, Milloy N, et al
Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey.
Int J Urol. 2024;31:933-943.
Abstract

SHINDO T
Editorial Comment to J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
Int J Urol. 2024;31:867-868.
Abstract

KIKUCHI E, Hayakawa N, Nakayama M, Uno M, et al
J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
Int J Urol. 2024;31:859-867.
Abstract

TAOKA R, Sugimoto M
A surgical checklist for optimizing the quality and outcomes of transurethral resection of bladder tumors: A literature review.
Int J Urol. 2024;31:846-851.
Abstract

NOHARA T, Takimoto A, Shinzawa R, Kurauchi D, et al
Comprehensive analysis of perioperative hypotension in photodynamic diagnosis-assisted transurethral resection of bladder tumor with 5-aminolevulinic acid.
Int J Urol. 2024;31:891-898.
Abstract

YAMANE H, Morizane S, Honda M, Muraoka K, et al
Preoperative risk stratification models after radical cystectomy for bladder cancer: A multi-center study.
Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15560.
Abstract

FUKUOKAYA W, Miki J, Taoka R, Saito R, et al
Development and validation of a model to predict the outcomes of radical cystectomy in patients with bladder cancer.
Int J Urol. 2024 Sep 18. doi: 10.1111/iju.15585.
Abstract

HARA T, Suzuki K, Okada K, Chiba K, et al
Comparative clinical trials with a novel approach: Utilizing the shiny method for investigational urothelial carcinoma therapies.
Int J Urol. 2024;31:1168-1170.
Abstract

NAKAMURA Y, Ishikawa Y, Kobayashi M, Fujiwara M, et al
Location-specific diagnostic efficiency of photodynamic diagnosis-guided biopsy in bladder mapping biopsies.
Int J Urol. 2024;31:1263-1268.
Abstract

YOSHIDA S, Maezawa Y, Ishihara K, Inoue N, et al
Outcomes and prognostic factors in patients with synchronous and metachronous oligometastatic urothelial carcinoma with visceral metastases.
Int J Urol. 2024;31:1234-1240.
Abstract

PALERMO G, Bizzarri FP, Scarciglia E, Sacco E, et al
The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score-matched study.
Int J Urol. 2024;31:1423-1428.
Abstract

SASAKI Y, Fukuta K, Kadoriku F, Daizumoto K, et al
Retroperitoneal cutaneous ureterostomy following radical cystectomy: A multicenter comparative study of robotic versus open surgery.
Int J Urol. 2024;31:1408-1413.
Abstract

MORIZANE S, Miki J, Shimbo M, Kanno T, et al
Japanese expert consensus on the standardization of robot-assisted pelvic lymph node dissection in urological surgery: Extent of pelvic lymph node and surgical technique.
Int J Urol. 2024;31:1300-1310.
Abstract

TAOKA R, Fujimoto K, Inoue K, Tsuzuki T, et al
Accuracy of photodynamic diagnosis for non-muscle-invasive bladder cancer: Exploratory analysis of anatomical locations and tumor types using data from a prospective, single-arm, multicenter phase III trial.
Int J Urol. 2024 Dec 13. doi: 10.1111/iju.15653.
Abstract

NAKAMURA Y, Yoshida S, Arita Y, Takeshita R, et al
The need for a second transurethral resection in high-risk non-muscle-invasive bladder cancer based on the Vesicle Imaging-Reporting and Data System.
Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15638.
Abstract

WU J, Cheng X, Yang H, Xiao S, et al
Geriatric nutritional risk index as a prognostic factor in elderly patients with non-muscle-invasive bladder cancer: a propensity score-matched study.
Int Urol Nephrol. 2024 Jan 4. doi: 10.1007/s11255-023-03905.
Abstract

SAITO T, Matsumoto K, Tanaka N, Fukumoto K, et al
Prognostic impact of tumor ureteral invasion on recurrence after radical cystectomy.
Int Urol Nephrol. 2024;56:129-135.
Abstract

KACZMAREK K, Plage H, Furlano K, Hofbauer S, et al
Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.
Int Urol Nephrol. 2024;56:499-508.
Abstract

BAHADORI A, Bray G, Rukin N
Secondary tumours in orthotopic neobladder using isolated gut segment post radical cystectomy for urothelial carcinoma: a systematic review.
Int Urol Nephrol. 2024;56:519-525.
Abstract

WANG S, Wei Z, Shu H, Xu Y, et al
Early diagnosis and prognostic potential of RAC3 in bladder tumor.
Int Urol Nephrol. 2024;56:475-482.
Abstract

BRISUDA A, Hornak J, Zemlickova B, Hacek J, et al
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study.
Int Urol Nephrol. 2024 Feb 8. doi: 10.1007/s11255-023-03924.
Abstract

LI Y, Xu H, Lin T, Zhang J, et al
Preoperative low plasma creatine kinase levels predict worse survival outcomes in bladder cancer after radical cystectomy.
Int Urol Nephrol. 2024 Feb 5. doi: 10.1007/s11255-024-03957.
Abstract

KOBERLE B, Usanova S, Piee-Staffa A, Heinicke U, et al
Strong apoptotic response of testis tumor cells following cisplatin treatment.
Int Urol Nephrol. 2023 Oct 27. doi: 10.1007/s11255-023-03825.
Abstract

ZHAI H, Wang Y, Chen Z, Wang Z, et al
Clinicopathological characteristics, surgical treatments, and oncological outcomes of localized primary unifocal urothelial carcinoma involving the ureterovesical junction.
Int Urol Nephrol. 2024;56:941-955.
Abstract

MOEEN AM, Hameed DA, Mostafa MG, Shaban SH, et al
Lymphadenectomy before and after radical cystectomy: does this affect the radicality? A prospective randomized comparative study.
Int Urol Nephrol. 2024;56:965-972.
Abstract

LI B, Lin Y, Yang Y, Wang Z, et al
Patients with periodontitis might increase the risk of urologic cancers: a bidirectional two-sample Mendelian randomization study.
Int Urol Nephrol. 2024;56:1243-1251.
Abstract

JAKUS D, Solic I, Borovac JA, Situm M, et al
The influence of the initial clinical presentation of upper tract urothelial carcinoma on histopathological tumor features.
Int Urol Nephrol. 2024;56:1335-1341.
Abstract

SILVA MEDEIROS M, Botelho de Carvalho LA, Alves M, Papoila A, et al
Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.
Int Urol Nephrol. 2024 Mar 26. doi: 10.1007/s11255-024-03971.
Abstract

BERNARDINO RM, Wettstein M, Garisto J, Fleshner NE, et al
Editorial comment to the paper: RE: low cubilin/myeloperoxidase's ratio as a promising biomarker for prognosis of high grade T1 bladder cancer.
Int Urol Nephrol. 2024 Apr 2. doi: 10.1007/s11255-024-04035.
Abstract

ZHU W, Wu L, Xie W, Zhang G, et al
Comparison of morbidity and mortality after radical cystectomy between individuals older and younger than 80 years: a systematic review and meta-analysis.
Int Urol Nephrol. 2024;56:1525-1535.
Abstract

DAVID J, Pathak RA
Editorial comment for "Surgeon-administered regional nerve blocks during radical cystectomy: a feasibility study".
Int Urol Nephrol. 2024;56:1937-1938.
Abstract

YAN T, Zhou W, Li C
Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer.
Int Urol Nephrol. 2024 May 24. doi: 10.1007/s11255-024-04086.
Abstract

LIANG H, Sun H, Chen J
A modified ureteroileal anastomosis can reduce ureteroileal anastomotic stricture after ileal conduit.
Int Urol Nephrol. 2024;56:2235-2241.
Abstract

REFUGIA JM, Thakker PU, Roebuck E, Brownstead HA, et al
Surgeon-administered regional nerve blocks during radical cystectomy: a feasibility study.
Int Urol Nephrol. 2024;56:2227-2234.
Abstract

XIONG Y, Zhao T, Li C
Application value of extreme flexion and abduction hip combined with stirrup-shaped multifunctional leg frame in blocking obturator nerve reflex in transurethral resection of bladder tumor.
Int Urol Nephrol. 2024;56:2503-2511.
Abstract

LUO Q, Xu L, Lin C, Chao H, et al
The clinical study of urinary flow parameters after drag-and-bond anastomosis for ileal orthotopic neobladder reconstruction.
Int Urol Nephrol. 2024;56:2615-2621.
Abstract

KAYRA MV, Deniz ME, Ozer C, Guvel S, et al
Estimation of Physiologic Ability and Surgical Stress (E-PASS) predicts postoperative complications after radical cystectomy.
Int Urol Nephrol. 2024;56:3743-3749.
Abstract

IVANIC D, Dug H, Jagodic S, Delibegovic S, et al
Preoperative neutrophil-to-lymphocyte ratio (NLR) value as a predictor of recurrence of non-muscle-invasive bladder cancer.
Int Urol Nephrol. 2024 Nov 27. doi: 10.1007/s11255-024-04297.
Abstract

SEVEN I, Akturk Esen S, Sekmek S, Karahan I, et al
Clinicopathological features and treatment outcomes of urothelial carcinoma variant histologies and non-urothelial bladder cancers.
Int Urol Nephrol. 2024 Dec 27. doi: 10.1007/s11255-024-04341.
Abstract

SHENG X, Wang L, He Z, Shi Y, et al
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
J Clin Oncol. 2024;42:1391-1402.
Abstract

KLUMPER N, Tran NK, Zschabitz S, Hahn O, et al
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
J Clin Oncol. 2024;42:2446-2455.
Abstract

MERCINELLI C, Moschini M, Cigliola A, Mattorre B, et al
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer.
J Clin Oncol. 2024 Sep 6:JCO2400576. doi: 10.1200/JCO.24.00576.
Abstract

DAHL DM, Rodgers JP, Shipley WU, Michaelson MD, et al
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
J Clin Oncol. 2024 Sep 3:JCO2302510. doi: 10.1200/JCO.23.02510.
Abstract

MARCQ G, Kool R, Dragomir A, Kulkarni GS, et al
Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis.
J Clin Oncol. 2024 Oct 3:JCO2302718. doi: 10.1200/JCO.23.02718.
Abstract

GEYNISMAN DM, Abbosh PH, Ross E, Zibelman MR, et al
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
J Clin Oncol. 2024 Dec 16:JCO2401214. doi: 10.1200/JCO-24-01214.
Abstract

GALSKY MD, Witjes JA, Gschwend JE, Milowsky MI, et al
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
J Clin Oncol. 2025;43:15-21.
Abstract

WEISS K, Abimbola O, Mueller D, Basak R, et al
Feasibility, Acceptability, and Outcomes of a Mobile Health Tool for Radical Cystectomy Recovery.
J Urol. 2024;211:266-275.
Abstract

HOLZBEIERLEIN JM, Bixler BR, Buckley DI, Chang SS, et al
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
J Urol. 2024 Jan 24:101097JU0000000000003846. doi: 10.1097/JU.0000000000003846.
Abstract

KAY H, Matulewicz RS, Bjurlin MA
Clearing the Smoke: Underreporting of Smoking Status in Food and Drug Administration-Approved Bladder Cancer Therapeutic Trials.
J Urol. 2024 Feb 1:101097JU0000000000003853. doi: 10.1097/JU.0000000000003853.
Abstract

MONTORSI F, Moschini M, Gandaglia G, Briganti A, et al
Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATL
J Urol. 2024;211:482-483.
Abstract

GILL IS, Desai MM, Cacciamani GE, Khandekar A, et al
Robotic Radical Cystectomy for Bladder Cancer: The Way Forward.
J Urol. 2024;211:476-480.
Abstract

BOCHNER BH, Kamat AM, Bivalacqua TJ
Open vs Robotic Cystectomy: Case Closed?
J Urol. 2024;211:473-475.
Abstract

ALLORY Y, Culine S, Krucker C, Fontugne J, et al
Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.
J Urol. 2024;211:564-574.
Abstract

KAY H, Silver SN, Smith AB, Basak R, et al
Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health Related Quality of Life Measures: An Assessment of the Comparative Effectiveness of Survivorship Health in Bladder Cancer (CEASE-BC) Study.
J Urol. 2024 Apr 11:101097JU0000000000003964. doi: 10.1097/JU.0000000000003964.
Abstract

HOLZBEIERLEIN J, Bixler BR, Buckley DI, Chang SS, et al
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO GUIDELINE (2017; Amended 2020, 2024).
J Urol. 2024 Apr 25:101097JU0000000000003981. doi: 10.1097/JU.0000000000003981.
Abstract

KARABURUN MC, Kuz ED, Akpinar C, Obaid K, et al
Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guerin Therapy?
J Urol. 2024 May 1:101097JU0000000000003990. doi: 10.1097/JU.0000000000003990.
Abstract

NARAYAN VM, Boorjian SA, Alemozaffar M, Konety BR, et al
Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial.
J Urol. 2024 May 5:101097JU0000000000004020. doi: 10.1097/JU.0000000000004020.
Abstract

DJALADAT H, Ghoreifi A, Tejura T, Miranda G, et al
Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial.
J Urol. 2024;211:743-753.
Abstract

KASEB H, Leslie SW, Soon-Sutton TL, Aeddula NR, et al
The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guerin in Treating Nonmuscle-Invasive Bladder Cancer.
J Urol. 2024 Jun 7:101097JU0000000000004070. doi: 10.1097/JU.0000000000004070.
Abstract

LAZAROVICH A, Dahmen AS, Modi PK, Agarawal PK, et al
Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
J Urol. 2024;212:236-237.
Abstract

LOTAN Y, Daneshmand S, Shore N, Black P, et al
A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial.
J Urol. 2024;212:41-51.
Abstract

PATEL SH, Gabrielson AT, Chan S, Schwartz D, et al
A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin?Naive Nonmuscle-Invasive Urothelial Carcinoma of the Bladder.
J Urol. 2024;212:95-103.
Abstract

CHANG SS
Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
J Urol. 2024 Apr 22:101097JU0000000000003900. doi: 10.1097/JU.0000000000003900.
Abstract

MEEKS JJ
Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
J Urol. 2024 Jun 19:101097JU0000000000004097. doi: 10.1097/JU.0000000000004097.
Abstract

LINSCOTT J, Li R
Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
J Urol. 2024 Jun 24:101097JU0000000000004122. doi: 10.1097/JU.0000000000004122.
Abstract

DINNEY CPN, Narayan VM
Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
J Urol. 2024 Jul 5:101097JU0000000000004128. doi: 10.1097/JU.0000000000004128.
Abstract

CHANG SS
Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
J Urol. 2024 May 17:101097JU0000000000004018. doi: 10.1097/JU.0000000000004018.
Abstract

HALSTUCH D, Kool R, Marcq G, Breau RH, et al
The Impact of Histologic Subtypes on Clinical Outcomes After Radiation-Based Therapy for Muscle-Invasive Bladder Cancer.
J Urol. 2024 Jul 25:101097JU0000000000004160. doi: 10.1097/JU.0000000000004160.
Abstract

ANDERSON CB
What Is the Future of Cystoscopy for Detecting Urothelial Carcinoma?
J Urol. 2024;212:399-400.
Abstract

Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guerin Therapy? Erratum.
J Urol. 2024;212:641.
Abstract

PASSARELLI R, Ghodoussipour S, Packiam VT
Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
J Urol. 2024;212:622-623.
Abstract

CHANG SS
Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
J Urol. 2024 Jun 17:101097JU0000000000004092. doi: 10.1097/JU.0000000000004092.
Abstract

GHOREIFI A, Daneshmand S
Technical Considerations to Minimize False-Positive Findings in Blue Light Cystoscopy for Non-muscle-invasive Bladder Cancer.
J Urol. 2024 Sep 16:101097JU0000000000004250. doi: 10.1097/JU.0000000000004250.
Abstract

WU Y, Zhang Z
Letter: The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guerin in Treating Nonmuscle-Invasive Bladder Cancer.
J Urol. 2024 Sep 27:101097JU0000000000004248. doi: 10.1097/JU.0000000000004248.
Abstract

CHRISTOPH SOERENSEN SJ, Schmidt B, Thomas IC, Montez-Rath ME, et al
An Automated Electronic Health Record Score to Estimate Length of Stay and Readmission in Patients Undergoing Radical Cystectomy for Bladder Cancer.
J Urol. 2024 Oct 2:101097JU0000000000004262. doi: 10.1097/JU.0000000000004262.
Abstract

PETERSEN E, Holt S, Browning A, Cavanaugh D, et al
Characterizing Psychological Resources and Resilience in Patients With Bladder Cancer: Associations With Frailty and Quality of Life.
J Urol. 2024 Sep 30:101097JU0000000000004257. doi: 10.1097/JU.0000000000004257.
Abstract

LOTAN Y, Krishna V, Abuzeid WM, Launer B, et al
Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort.
J Urol. 2024 Oct 9:101097JU0000000000004278. doi: 10.1097/JU.0000000000004278.
Abstract

CHANG SS
Urological Oncology: Bladder, Penis, and Urethra Cancer, and Basic Principles of Oncology.
J Urol. 2024 Jul 25:101097JU0000000000004120. doi: 10.1097/JU.0000000000004120.
Abstract

PRASAD SM, Shishkov D, Mihaylov NV, Khuskivadze A, et al
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).
J Urol. 2024 Oct 24:101097JU0000000000004296. doi: 10.1097/JU.0000000000004296.
Abstract

VILLEGAS E, Lajkosz K, Din S, Kuk C, et al
Long-term recurrence risk, metastatic potential and length of cystoscopic surveillance of low-grade non-muscle invasive bladder cancer.
J Urol. 2024 Oct 29:101097JU0000000000004305. doi: 10.1097/JU.0000000000004305.
Abstract

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment: Erratum.
J Urol. 2024;212:936.
Abstract

RAMOS P, Bras JP, Dias C, Bessa-Goncalves M, et al
Uromonitor(R): Clinical Validation and Performance Assessment of a Urinary Biomarker within the Surveillance of Non-Muscle Invasive Bladder Cancer Patients.
J Urol. 2024 Nov 19:101097JU0000000000004335. doi: 10.1097/JU.0000000000004335.
Abstract

PIETZAK E, Anderson CB
What is the Standard of Care For Multifocal Low-Grade Bladder Cancer?
J Urol. 2024 Nov 18:101097JU0000000000004316. doi: 10.1097/JU.0000000000004316.
Abstract

ZHOU F, Deng Z, Shen D, Lu M, et al
DLGAP5 triggers proliferation and metastasis of bladder cancer by stabilizing E2F1 via USP11.
Oncogene. 2024 Jan 5. doi: 10.1038/s41388-023-02932.
Abstract

CAI H, Ke ZB, Chen JY, Li XD, et al
Ubiquitin-specific protease 5 promotes bladder cancer progression through stabilizing Twist1.
Oncogene. 2024 Jan 13. doi: 10.1038/s41388-023-02936.
Abstract

WANG X, Guo T, Niu L, Zheng B, et al
Engineered targeting OIP5 sensitizes bladder cancer to chemotherapy resistance via TRIP12-PPP1CB-YBX1 axis.
Oncogene. 2024 Aug 18. doi: 10.1038/s41388-024-03136.
Abstract

DU K, Luo Y, Zhang L, Zeng Y, et al
m(6)A modification of lipoyltransferase 1 inhibits bladder cancer progression by activating cuproptosis.
Oncogene. 2024 Aug 28. doi: 10.1038/s41388-024-03139.
Abstract

HUANG T, Fan L, Tang J, Chen S, et al
Advances in research on the carcinogenic mechanisms and therapeutic potential of YAP1 in bladder cancer (Review).
Oncol Rep. 2025;53:10.
Abstract

REIKE MJ, Reicherz A, Tully KH, Bahlburg H, et al
An empirical survey on the adaption of neoadjuvant chemotherapy in bladder cancer.
Urol Int. 2024 Jan 19. doi: 10.1159/000536321.
Abstract

BANEK S, Hoeh B, Cano Garcia C, Koll F, et al
Metastatic Squamous Cell Carcinoma of the Urinary Bladder: Urgent Call for New Therapies.
Urol Int. 2024;108:1-8.
Abstract

VOLZ Y, Trappmann R, Ebner B, Eismann L, et al
Upstaging after Transurethral Resection of the Bladder for Non-Muscle-Invasive Cancer of the Bladder: Who Is at Highest Risk?
Urol Int. 2024;108:42-48.
Abstract

DUAN H, Deng Z, Zou J, Zhang G, et al
The efficacy and safety of Hyperthermia intravesical chemotherapy in the treatment non-muscle invasive bladder cancer:A meta analysis.
Urol Int. 2024 Mar 20. doi: 10.1159/000538373.
Abstract

GARAZ R, Stuhler V, Stenzl A, Rottscholl R, et al
Hemangioma of the Urinary Bladder: A Brief Narrative Review of Their Diagnosis, Histology, and Treatment Options.
Urol Int. 2024;108:83-88.
Abstract

WALACH MT, Nitschke K, Gross-Weege M, Grosshans J, et al
Cyclin A2 Expression as Predictive Biomarker in Muscle-Invasive Upper Tract Urothelial Carcinoma.
Urol Int. 2024;108:128-136.
Abstract

CHO HJ, Chung HS, Hwang EC, Jung SI, et al
Music from noise-canceling headphones is beneficial against anxiety in male bladder cancer patients undergoing follow-up cystoscopy: A prospective randomized trial.
Urol Int. 2024 May 10. doi: 10.1159/000539312.
Abstract

OZCAN L, Polat EC, Baran C, Boylu A, et al
Systemic Inflammatory Index: A Promising Non-Invasive Marker for the Prediction of Response to Neoadjuvant Chemotherapy prior to Cystectomy.
Urol Int. 2024;108:226-233.
Abstract

BANEK S, Wenzel M, Lauer B, Le QC, et al
Real-World Evidence of Tumor and Patient Characteristics and Survival with Avelumab Maintenance after Chemotherapy for Advanced and Metastatic Urothelial Carcinoma.
Urol Int. 2024;108:285-291.
Abstract

SCHEPER V, Seitz AK, Kubler H, Kocot A, et al
A propensity-score based comparison regarding renal, functional and surgical outcome of continent cutaneous urinary diversions in patients with benign chronic bladder diseases and patients with bladder cancer.
Urol Int. 2024 Aug 16. doi: 10.1159/000540950.
Abstract

CARL N, Schmidt L, Buedenbender B, Blum AK, et al
Body image perception and social support are important predictors of quality of life in bladder cancer patients after cystectomy with urinary diversion.
Urol Int. 2024 Aug 30. doi: 10.1159/000541223.
Abstract

OZER MS, Incir C, Yildiz HA, Deger MD, et al
Comparison of tissue and urine microbiota in male, intervention naive patients with and without non-invasive bladder cancer.
Urol Int. 2024 Sep 21:1-13. doi: 10.1159/000541296.
Abstract

PYRGIDIS N, Schulz GB, Volz Y, Ebner B, et al
The Prognostic Value of Perioperative Platelet and Leukocyte Values in Patients Undergoing Radical Cystectomy: A Prospective Long-Term Cohort Study.
Urol Int. 2024;108:421-428.
Abstract

CHEN H, Wu M, Chen M
Evaluation of the Management of Urachal Carcinoma: A Single-Center Experience over 13 Years.
Urol Int. 2024;108:508-516.
Abstract

TULLY K, Bahlburg H, Reike MJ, Brehmer M, et al
Discrimination of T-stage using tumor weight and size - a potential approach to guide perioperative decision making in patients with bladder cancer.
Urol Int. 2024 Dec 16:1-15. doi: 10.1159/000543112.
Abstract

RICHARDS HL, Fortune DG, Lyons L, Curtin Y, et al
Patients' emotional talk during surveillance cystoscopy for non-muscle invasive bladder cancer - opportunities for improving communication.
Urology. 2023 Dec 29:S0090-4295(23)01116-0. doi: 10.1016/j.urology.2023.
Abstract

PETEINARIS A, Gkeka K, Katsakiori P, Tatanis V, et al
Replicating Florence Intracorporeal Neobladder Technique in Laparoscopic Radical Cystectomy: A Retrospective Study.
Urology. 2024;183:106-110.
Abstract

KIM AH, Ruel NH, Yamzon J, Zhumkhawala AA, et al
Indiana Pouch Continent Cutaneous Urinary Diversion After Robotic-assisted Radical Cystectomy: A 16-Year Experience.
Urology. 2024;183:e325-e327.
Abstract

MORRIS KE, Pappas TN
Malignancy in the public life: the story of Hubert Humphrey's bladder cancer.
Urology. 2024 Jan 31:S0090-4295(24)00017-7. doi: 10.1016/j.urology.2023.
Abstract

LIBLIK K, Queen JC, Touma NJ
Immune Checkpoint Inhibitors for Kidney and Bladder Cancer: Adrenotoxic Consequences.
Urology. 2024 Feb 29:S0090-4295(24)00129-8. doi: 10.1016/j.urology.2024.
Abstract

LEPOR H, Wiegand L, Patel K, Du W, et al
A Randomized Clinical Trial Evaluating Indigo Carmine as a Visualization Aid for Evaluating Ureteral Patency.
Urology. 2024;184:105-111.
Abstract

WEISS K, Abimbola O, Miller K, Kim WY, et al
Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report.
Urology. 2024;184:75-78.
Abstract

HUELSTER HL, Mason NT, Davaro F, Naqvi SMH, et al
Cost-Utility of Initial Management of High-grade T1 Bladder Cancer with Intravesical BCG vs Immediate Radical Cystectomy.
Urology. 2024 Mar 9:S0090-4295(24)00126-2. doi: 10.1016/j.urology.2024.
Abstract

SAHNI DS, Oberoi AS, Ramsaha S, Teahan S, et al
Incidence of Ureteroenteric Anastomotic Strictures After Robotic vs Open Cystectomy in Adults.
Urology. 2024;185:100-108.
Abstract

CARLTON CE, Christie AL, Prokesch BC, Chao TC, et al
Robotic simple cystectomy as a last resort for antibiotic-recalcitrant recurrent urinary tract infections in women.
Urology. 2024 Feb 21:S0090-4295(24)00108-0. doi: 10.1016/j.urology.2024.
Abstract

HARDESTY JK, Burns RT, Soyster ME, Jansen NE, et al
Female Bladder Dysfunction Following Boari Bladder Flap Ureteral Reconstruction.
Urology. 2024;186:31-35.
Abstract

EULE CJ, Warren A, Kuna EM, Callihan EB, et al
Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen.
Urology. 2024 Apr 27:S0090-4295(24)00306-6. doi: 10.1016/j.urology.2024.
Abstract

SEKAR RR, Irani S, Maganty A, Montgomery JS, et al
Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer.
Urology. 2024 May 17:S0090-4295(24)00359-5. doi: 10.1016/j.urology.2024.
Abstract

YU J, Wang CG, Zhang Y, Yang W, et al
A Novel Approach to Treatment with Antiangiogenic Agents in Adenocarcinoma of Urachal Origin.
Urology. 2024;187:121-122.
Abstract

BRANDT SB, Kingo PS, Laurberg JR, Lam GW, et al
Reply to Editorial comments on "Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature".
Urology. 2024;187:139.
Abstract

BRANDT SB, Kingo PS, Laurberg JR, Lam GW, et al
Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature.
Urology. 2024;187:131-136.
Abstract

LIN JS, Zhao LC
Editorial comments on "Definition of Benign Ureteroenteric Anastomotic Strictures in Ileal Conduits After Radical Cystectomy: Experience From a Single Center and Previously Published Literature".
Urology. 2024;187:137-138.
Abstract

MORAN M, Kim JE, Fu MZ, Ghodoussipour S, et al
Worsening Neobladder Incontinence in a Patient on Nivolumab Therapy.
Urology. 2024;187:92-93.
Abstract

CABRAL JD, Modi PK
Editorial Comment on "Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer".
Urology. 2024 Jun 20:S0090-4295(24)00469-2. doi: 10.1016/j.urology.2024.
Abstract

LIU WJ, Campbell RA, Michael PD, Wood A, et al
Clinical upstaging after neoadjuvant chemotherapy impacting eligibility for vaginal-sparing cystectomy: identifying bladder cancer patients who may benefit from interim imaging.
Urology. 2024 Jun 20:S0090-4295(24)00474-6. doi: 10.1016/j.urology.2024.
Abstract

REFUGIA JM, Roebuck E, Thakker P, Sandberg M, et al
Sequential Intravesical Chemotherapy for Treatment Naive, High-Risk Non-Muscle Invasive Bladder Cancer: Oncologic Outcomes, Tolerance, and Comparison to Contemporary Controls.
Urology. 2024 Jun 19:S0090-4295(24)00463-1. doi: 10.1016/j.urology.2024.
Abstract

CONNORS C, Wang D, Levy M, Ravivarapu KT, et al
Transurethral Resection of Bladder Tumor Outcomes Are Predicted by a 5-Item Frailty Index.
Urology. 2024;188:104-110.
Abstract

RICHARDS KA
Editorial comment on "Sequential intravesical chemotherapy for treatment naive, high-risk non-muscle invasive bladder cancer: oncologic outcomes, tolerance, and comparison to contemporary controls.
Urology. 2024 Jul 21:S0090-4295(24)00591-0. doi: 10.1016/j.urology.2024.
Abstract

KRONSTEDT S, Cathey J, Chiu CB, Saffati G, et al
Exposures and Bladder Cancer Risk Among Military Veterans: A Systematic Review and Meta-analysis.
Urology. 2024 Aug 15:S0090-4295(24)00659-9. doi: 10.1016/j.urology.2024.
Abstract

TABER C, Lee B, Djang R, Shone E, et al
Evaluating the Differences of Wound Related Complications in Robotically Assisted Radical Cystectomy vs Open Radical Cystectomy.
Urology. 2024;190:56-62.
Abstract

RICH JM, Sfakianos JP
Reply to Editorial Comment on "Thromboembolic Events After Robotic Radical Cystectomy: A Comparative Analysis of Extended and Limited Prophylaxis".
Urology. 2024;190:54-55.
Abstract

COWAN AN, Rosen GH
Editorial Comment on "Thromboembolic Events After Robotic Radical Cystectomy: A Comparative Analysis of Extended and Limited Prophylaxis".
Urology. 2024;190:53.
Abstract

RICH JM, Geduldig J, Elkun Y, Lavallee E, et al
Thromboembolic Events After Robotic Radical Cystectomy: A Comparative Analysis of Extended and Limited Prophylaxis.
Urology. 2024;190:46-52.
Abstract

KRONSTEDT S, Saffati G, Hinojosa-Gonzalez DE, Doppalapudi SK, et al
Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Urology. 2024 Sep 2:S0090-4295(24)00770-2. doi: 10.1016/j.urology.2024.
Abstract

FU H, Anele UA, Messer JC
Editorial Commentary on: "Exposures and Bladder Cancer Risk Among Military Veterans: A Systematic Review and Meta-analysis".
Urology. 2024 Sep 10:S0090-4295(24)00793-3. doi: 10.1016/j.urology.2024.
Abstract

DALL CP, Liu X, Faraj KS, Srivastava A, et al
Teaching Hospitals and Textbook Outcomes After Major Urologic Cancer Surgery.
Urology. 2024;191:64-70.
Abstract

AIZPURUA XP, Gardiner JIM, Popescu OB, Gonzalez EB, et al
A Systematic Review on the Current Landscape of T1 Bladder Cancer Substaging.
Urology. 2024 Oct 8:S0090-4295(24)00880-X. doi: 10.1016/j.urology.2024.
Abstract

OZDEMIR MS, Keskin ET, Savun M, Yuzkan S, et al
VI-RADS-Based Algorithm for Bladder Cancer Management Randomized Retrospective Study.
Urology. 2024 Oct 17:S0090-4295(24)00867-7. doi: 10.1016/j.urology.2024.
Abstract

SANKIN A, Dave P, Cherrill LR, Boucher RH, et al
Low-grade Urothelial Carcinoma Recurs at a Tempo that Naturally Accelerates Over Time.
Urology. 2024;193:166-172.
Abstract

SANCHEZ B C, Rickard M, Denburg A, Khondker A, et al
Bladder Embryonal Rhabdomyosarcoma Presenting in the Perinatal Period: Report of Two Consecutive Cases.
Urology. 2024;193:e85-e88.
Abstract

ABOU HEIDAR N, Mahmood AW, Khan M, Harrington G, et al
Does Ta Low-grade Urothelial Carcinoma of the Bladder With Focal High-grade Features Carry Worse Prognosis? The Roswell Park Comprehensive Cancer Center Experience.
Urology. 2024;193:136-142.
Abstract

LIU H, Jin L, Shi J
Incidence and risk factors for postoperative acute kidney injury after radical cystectomy for bladder cancer.
Urology. 2024 Nov 25:S0090-4295(24)01092-6. doi: 10.1016/j.urology.2024.
Abstract

ECKE TH, Meisl CJ, Schlomm T, Rabien A, et al
Performance of urinary markers in patients with suspicious cystoscopy during follow-up of recurrent non-muscle invasive bladder cancer: BTA stat(R), NMP22(R) BladderChek(R), UBC(R) Rapid Test, CancerCheck(R) UBC(R) rapid VISUAL, and uromonitor(R) in c
Urology. 2024 Dec 1:S0090-4295(24)01113-0. doi: 10.1016/j.urology.2024.
Abstract

ZENG E, Saucke M, Pati B, Rose A, et al
"...I Wish Someone Told Me About That...": A Qualitative Assessment of the Educational Needs of Patients Undergoing Cystectomy.
Urology. 2024;194:348-355.
Abstract

MEKAYTEN M, Tin AL, Sidhu A, Liso N, et al
Trans Oblique Ileal Conduit Technique Has a Low Risk of Parastomal Hernias.
Urology. 2024;194:241-246.
Abstract

JING S, Yang E, Luo Z, Zhang Y, et al
Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer.
BMC Cancer. 2024;24:127.
Abstract

PAN DL, Zhang LF, Li XJ, Zhang KP, et al
Feasibility and safety of laparoscopic radical cystectomy for male octogenarians with muscle-invasive bladder cancer.
BMC Cancer. 2024;24:159.
Abstract

VERGHOTE F, Van Praet C, Berquin C, Lumen N, et al
Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice.
BMC Cancer. 2024;24:160.
Abstract

ZHANG J, Yang M, Wei D, Zhang D, et al
The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
BMC Cancer. 2024;24:202.
Abstract

YANG M, Zhang J, Wei D, Yu T, et al
Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
BMC Cancer. 2024;24:196.
Abstract

HUANG LH, Chen CS, Li JR, Chiu KY, et al
The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.
BMC Cancer. 2024;24:247.
Abstract

LI X, Liang Z, Pan J, Zhang M, et al
Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer.
BMC Cancer. 2024;24:328.
Abstract

JI J, Zhang T, Zhu L, Yao Y, et al
Using machine learning to develop preoperative model for lymph node metastasis in patients with bladder urothelial carcinoma.
BMC Cancer. 2024;24:725.
Abstract

ZHANG X, Hong B, Li H, Zhao J, et al
Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer.
BMC Cancer. 2024;24:746.
Abstract

MENG H, Yang R, Lin Q, Du W, et al
Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b.
BMC Cancer. 2024;24:737.
Abstract

MOHAMED AH, Mohamed KA, Kayacan E, Nur Y, et al
Clinical characteristics and factors associated with survival rate of patients with non-muscle invasive bladder cancer attending at a Tertiary Hospital in Somalia.
BMC Cancer. 2024;24:839.
Abstract

CICIN I, Plimack ER, Gurney H, Leibowitz R, et al
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.
BMC Cancer. 2024;23.
Abstract

PORSERUD A, Karlsson P, Aly M, Rydwik E, et al
Effects of an exercise intervention in primary care after robot-assisted radical cystectomy for urinary bladder cancer: a randomised controlled trial.
BMC Cancer. 2024;24:891.
Abstract

IQBAL MS, Sardar N, Peng K, Almutairi LA, et al
Association between CYP1A2 gene variants -163 C/A (rs762551) and -3860 G/A (rs2069514) and bladder cancer susceptibility.
BMC Cancer. 2024;24:880.
Abstract

LIU R, Yang T, Huang J, Xiao Z, et al
Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
BMC Cancer. 2024;24:947.
Abstract

BOTROUS S, Elmaghraby A, Achy SE, Mustafa Y, et al
Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A.
BMC Cancer. 2024;24:971.
Abstract

HAO S, Yang Z, Wang G, Cai G, et al
Development of prognostic model incorporating a ferroptosis/cuproptosis-related signature and mutational landscape analysis in muscle-invasive bladder cancer.
BMC Cancer. 2024;24:958.
Abstract

CHEN D, Cao H, Zheng X, Wang H, et al
Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target.
BMC Cancer. 2024;24:1024.
Abstract

FAN Z, Liu Y, Wang X, Xu Y, et al
APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis.
BMC Cancer. 2024;24:1046.
Abstract

PALACKA P, Holickova A, Roska J, Makovicky P, et al
Prognostic value of nucleotide excision repair and translesion DNA synthesis proteins in muscle-infiltrating bladder carcinoma.
BMC Cancer. 2024;24:1103.
Abstract

SONG J, Sun X, Wang T, Li C, et al
Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.
BMC Cancer. 2024;24:1261.
Abstract

YAO Z, Li Y, Ding Y, Hou Y, et al
Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters >/=3cm compared to transurethral resection: a non-randomized controlled study.
BMC Cancer. 2024;24:1239.
Abstract

KARLSSON P, Nygren-Bonnier M, Torikka S, Porserud A, et al
Patients experiences of an exercise intervention in primary care following robot-assisted radical cystectomy due to bladder cancer: a qualitative study.
BMC Cancer. 2024;24:1306.
Abstract

FUKUMOTO W, Okamura S, Tamai M, Arima J, et al
Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.
BMC Cancer. 2024;24:1333.
Abstract

SCHUCK S, Loussikian P, Mebarki A, Malaab J, et al
Perceived unmet needs and impact on quality of life of patients living with advanced bladder cancer and their caregivers: results of a social media listening study conducted in five European countries.
BMC Cancer. 2024;24:1444.
Abstract

KVIKSTAD V, Lillesand M, Gudlaugsson E, Mangrud OM, et al
Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas.
PLoS One. 2024;19:e0297141.
Abstract

CHEN LC, Yang HJ, Yu BH, Lee MS, et al
Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
PLoS One. 2024;19:e0300391.
Abstract

Retraction: SATB1 Overexpression Regulates the Development and Progression in Bladder Cancer through EMT.
PLoS One. 2024;19:e0301572.
Abstract

PORTE F, Granghaud A, Chang J, Kearney M, et al
Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
PLoS One. 2024;19:e0302548.
Abstract

EMINAGA O, Lau H, Shkolyar E, Wardelmann E, et al
Deep learning identifies histopathologic changes in bladder cancers associated with smoke exposure status.
PLoS One. 2024;19:e0305135.
Abstract

ZENG X, Luo D, Zhang S, Cui Z, et al
High-dose radiation-induced immunogenic cell death of bladder cancer cells leads to dendritic cell activation.
PLoS One. 2024;19:e0307024.
Abstract

SHIN YS, Han K, Lee J, Han HH, et al
Lymphatic embolization for early post-operative lymphatic leakage after radical cystectomy for bladder cancer.
PLoS One. 2024;19:e0305240.
Abstract

MARQUES M, Tezier M, Tourret M, Cazenave L, et al
Risk factors for postoperative acute kidney injury after radical cystectomy for bladder cancer in the era of ERAS protocols: A retrospective observational study.
PLoS One. 2024;19:e0309549.
Abstract

CHEONG H, Yoo Y, Sung SH, Park S, et al
Prognostic value of isolated tumor cells and micrometastasis of lymph nodes in invasive urinary bladder cancer.
PLoS One. 2024;19:e0302445.
Abstract

JING W, Wang G, Cui Z, Li X, et al
Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression.
Proc Natl Acad Sci U S A. 2024;121:e2312855121.
Abstract

ARMANETTI P, Locatelli I, Venegoni C, Alchera E, et al
Gold nanorod-assisted theranostic solution for nonvisible residual disease in bladder cancer.
Proc Natl Acad Sci U S A. 2024;121:e2411583121.
Abstract

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.

;